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Globally, snakebite envenoming (SBE) kills in excess of 100,000 people annually and causes 
sequalae to over 450,000. Improvements to treatment, and even much of our understanding 
of the pathologies surrounding snakebite have gone little improved in over a century. This 
thesis aims to uncover more of the mysteries surrounding SBE and outline methodologies for 
the improvement of diagnostics for snakebites. Clinicians are crippled by a lack of reliable 
diagnostical tools and have nothing by which to treat any of the underlying conditions 
associated with SBE. Here we aim to answer two questions, what are these underlying 
conditions and are future therapeutics likely to be efficacious; and can toxin-specific antibodies 
be developed to identify venom components and diagnose SBE?  To answer the first, we 
focus on venom-induced muscle damage and oxidative stress through characterising 
collagenolytic activities of snake venom metalloproteases (SVMP) and methaemoglobin 
production respectively (methaemoglobin is a toxic product of the oxidation of haemoglobin). 
This latter effect, was found to be a potential result of a wide range of venoms and particularly 
pronounced in an Elapid, Naja nigricollis, challenging the assumption that this effect is only 
seen in viper venoms. In addition to this, the route by which SVMPs induce permanent skeletal 
muscle damage was elucidated via the purification of a P-III SVMP and its treatment in skeletal 
muscles of mice. The three causative factors contributing to the prevention of muscle 
regeneration seen were found to be 1. destruction of collagen and a range of other basement 
membrane components, 2. Damage of blood capillaries causing delayed macrophage 
infiltration and blockade of blood supply to the affected regions, and 3. reduced proliferation, 
migration and abundance of satellite cells, thereby preventing the muscle regeneration. The 
use of matrix metalloprotease inhibitors, marimastat and batimastat were found to inhibit a P-
I SVMP. The administration of such therapeutics requires careful diagnosis, and thus our 
second focus was developing means by which to detect snake venoms in victims. The use of 
a sequence-structure-function and phylogenetic approach in synthesising peptides from which 
to make toxin-specific antibodies showed some promise but yielded ineffectual antibodies for 
use in the two-site immunoassay they were designed for. Using antibodies instead raised 
against purified toxins was more successful, allowing the development of relatively specific 
two-site enzyme-linked immunosorbent assays and lateral flow assays. Together, this study 
forms a solid basis in order to characterise SBE in more detail and develop diagnostic 
platforms using novel strategies to not only improve the diagnosis and treatment of snakebites 
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1.1 Definition of snakebite envenoming 
Snakebite is the product of bites from approximately 4,000 species of snakes. It can lead to 
psychological trauma, infections, bleeding and other undesirable effects, but only a certain 
proportion of these bites will involve envenomation [1]. Less than 20% of the snake species 
found globally are venomous, and bites from these species can lead to Snakebite 
Envenomation (SBE). SBE involves much more serious pathologies and frequently results in 
death [2]. Even in the case of bites from venomous species, outcomes ranging from dry bites, 
where no venom is injected, to full envenomations, with the injection of all venom available in 
the glands, can occur, leading to a broad range of pathologies. 
SBE kills an estimated 100,000 people or more every year [3], causes physical and 
psychological trauma to many more and is now receiving unprecedented attention from the 
media and research funders. SBE is nevertheless likely to remain a hugely distressing and 
common disease in the rural tropics for many decades to come.  
It is the rapid injection of the most toxicologically complex, naturally occurring cocktail 
on earth and associated with such a diverse range of effects that animal-derived antivenom 
treatments have been very difficult to improve upon. The lack of education, protective clothing 
and effective antivenoms all also contribute to this dire state of affairs [4]. Clinicians feel 
somewhat powerless, without protocols or any diagnostical methods and treatment does, to a 
large extent, depend upon the individual clinician’s experience with bites and somewhat trial 
and error approaches from their past. Clinicians recognise antivenoms inefficacy at treating 
the local effects and are unequivocally in need of adjunctive treatments for the reduction of 
mortality, permanent physical disabilities, disfigurement and other SBE associated morbidity 
[5]. Snake venoms are hugely diverse arsenals, and the result of millennia of evolution with 
natural selection guiding snake venoms to both kill their prey and begin digestion from within 




components from ten major toxin families, each eliciting a range of effects [7]. The full variety 
of effects induced by each family is far from being understood, but the future of therapeutics 
which must target morbidity as well as mortality, depends upon understanding exactly which 
systems a venom can attack, and how best this can be prevented or ameliorated. 
 
1.2 Generalised pathology of SBE 
After injection from venom glands via fangs, venom is typically deposited in the 
interstitial fluid, where the non-locally acting components slowly travel through the lymphatic 
system (aided in some cases by hyaluronidases in the venom cleaving the hyaluronic acid of 
the interstitial fluid) before reaching the blood stream [1]. The vast range of effects can then 
be grouped loosely into systemic haemotoxic and neurotoxic effects and local cytotoxicity. 
Viper venoms are typically a combination of both haemotoxic and cytotoxic components: upon 
reaching the blood, haemotoxic venoms act on vessels and the blood itself, collagenolytic 
enzymes begin cleaving blood vessels and causing haemorrhaging (snake venom 
metalloproteases [SVMPs]). Simultaneously, a range of compounds will start affecting the 
blood directly, both inhibiting or activating platelets (disintegrins, snake venom serine 
proteases [SVSPs], cysteine rich secretory proteins [CRiSPs], L-amino acid oxidases [LAAO], 
phospholipase A2 [PLA2]) cleaving fibrinogen to cause unstable clots (SVMP and SVSP) and 
making the blood uncoagulable – intensifying haemorrhaging – and lysing red blood cells to 
release haemoglobin (PLA2 and three finger toxins [3FTX]), and then oxidising this to form the 
toxic hypoxic compound methaemoglobin (LAAO and others). The consequential reduction in 
circulating blood causes hypotension and can at the extreme cause hypovolemic shock and 
heart failure [4]. This is frequently combined with cytotoxic effects involving venom 
components attacking the muscle and other tissues which are exposed following 
haemorrhaging or surrounding the bite site. The basement membrane of muscle fibres and 




muscle regeneration [8, 9]. The lack of blood supply from the haemotoxic effects then further 
exacerbate this cytotoxicity [10].  
This is in contrast to elapid envenomation, which, while frequently involving some 
degree of haemotoxic/cytotoxic effects, more typically centre on neurotoxicity. Following the 
slow release from the lymphatic system to the blood, their, largely non-enzymatic components, 
primarily target synapses (PLA2, 3FTX and kunitz type peptides), preventing nerve 
transmission and frequently paralysing victims of bites [11].  
This highlights the huge complexity of SBE, which despite being considered one 
disease, gives rise to a range of different disorders. SBE is recognised as a neglected tropical 
disease (NTD), but by comparison to other NTDs it has many more impediments to treatment: 
it has a much greater range of causative toxins; just one far more antiquated treatment option; 
and almost no diagnostical methods by which to not only improve treatment, but also allow 
the collection of more robust epidemiological data – which is currently lacking [2].  
 
1.3 Toxic synergy of methaemoglobin production as a result of SBE 
An incomplete understanding of all the underlying pathophysiology of SBE mean there 
are no therapies yet to be considered realistic alternatives to antivenom. Local to the bite, 
many venoms will have such destructive effects on the vasculature in the tissues they enter, 
that antivenoms are unable to reach the areas in need and fail to ameliorate the hypoxia, local 
tissue damage and other secondary effects [12]. One compounding factor to the cytotoxic 
nature of many venoms is methaemoglobin production. The generation of this toxic 
haemoglobin species is currently associated with few (mostly viper) venoms [13, 14] but is 
actually the result of a large range of both viper and elapid venoms [15]. This production of 
such a toxic compound can exacerbate hypoxia from haemorrhage induced ischaemia and 
cause oxidative stress, particularly at the bite site where the majority of necrosis and local 




means of ameliorating the effect [13, 16]. However, melatonin is also associated with lowering 
of the blood pressure [17] and has the potential to act in synergy with hypotensive venom 
toxins, intensified by haemorrhaging caused by SVMPs and increasing the chances of 
hypovolemic shock occurring. Therefore, the safe administration of melatonin is likely to rely 
on specific diagnosis in order to rule out envenoming from hypotensive venoms. This effect 
on haemoglobin is also likely to add significantly to local hypoxic conditions, adding to delayed 
muscle regeneration and furthering the cell death and necrosis common to the tissues local 
to the bite site. Muscles already starved of oxygen from haemorrhaging of vasculature and 
ischaemia are provided with an oxidised and unrelinquishing haemoglobin species, that 
promotes oxidative stress in already necrotic and dying tissues.  
 
1.4 Delays in muscle regeneration following SBE 
The effects of venoms on muscles can be attributed to three main toxin families, PLA2, 
3FTXs and SVMPs. As pore forming molecules the myotoxic nature of PLA2s and 3FTXs is 
rapid depolarisation of myocytes, effecting the myofibres without effecting the basement 
membrane (BM) surrounding them [18]. The BM is an essential element skeletal muscle and 
provides the medium for satellite cell functionality and consequential successful muscle 
regeneration [19] (see Figure 1). Satellite cells are the multipotent precursors to myocytes 
which move to sites of damage before proliferating and differentiating into renewed muscle 
[20]. This causes PLA2 and 3FTX induced muscle damage to undergo much faster 
regeneration than SVMP-induced muscle damage, due not only to the destruction of collagen 
and other muscular basement membrane components by SVMPs, but also haemorrhaging 





Figure 1. Schematic showing normal skeletal muscle regeneration. Taken from Gutierrez 
et al. (2018) [23]. After muscle damage and consequential necrosis, an inflammatory response 
is triggered involving an influx of resident immune cells including neutrophils and 
macrophages to clear necrotic debris. Resident multipotent satellite cells are then activated 
and replicate, regenerating the damaged muscle fibre. Under viperid envenoming, 
haemorrhaging prevents leucocyte efficacy and damage to the basement membrane prevents 
normal satellite cell function thereby hindering regeneration. 
Secondary to a venom’s directly myotoxic actions on the BM, can be the haemorrhagic and 
consequently ischaemic and hypoxic conditions which can in themselves cause cytotoxicity 
through the lack of toxin clearance, reduction in nutrients and oxygen, and lack of debris 
clearance by macrophages [22]. Therefore, SVMPs are a key target when addressing the local 
effects of snakebite in order to ensure functioning vasculature through which a healthy blood 
supply can pass and if necessary, drugs can be administered. A range of potential small 
molecular therapeutics (SMTs) targeting SVMPs have been proposed, though none are yet to 
have been approved for clinical usage.  
 
Suggested future therapeutics combatting SVMP related cyto- and haemotoxic effects 
are currently limited to two groups: the metal chelators, for example EDTA [24], which are able 
to chelate the zinc found within SVMPs - an ion which is essential to their function; and the 
matrix metalloprotease inhibitors (MMPis), which mimic the natural substrate of 




endogenous metalloproteases has implications for their use in vivo, however there is a 
growing body of evidence suggesting such SMTs could significantly ameliorate the 
haemorrhagic and collagenolytic effects of the SVMPs – which may outweigh any negative 
effects on endogenous proteins. This would reduce ischemia, hypoxia and other SVMP-
associated local effects. The significant homogeneity between SVMPs and endogenous 
matrix metalloproteases mean these are also inhibited by these compounds. The MMPis have 
been associated with a decrease in vascular growth and the other endogenous functions of 
these proteases [26]. Therefore, care must be taken when administering such drugs and 
ascertaining the state of envenomation by an SVMP-containing venom is essential before 
administration of potentially detrimental compounds [2]. 
1.5 Current state and necessity of diagnosis in treating SBE 
Diagnostical devices for snakebite envenoming are virtually non-existent. Given the 
lack of diversity in treatments, with typically only one polyvalent antivenom available in a 
region, some scientists deem the development of such products unnecessary. However, in 
the future, alternative treatments will become available.  
In order to facilitate the toxin-specific approaches that most of these future therapeutics 
are currently focussed on, cheap, indicative, point-of-care devices are in need of development. 
This will not only take the onus off clinicians making the right decision on treatment, but 
prevent drug wastage and unnecessary hospital bills [2]. This can potentially inform on the 
exact species in some locations and indicate toxin-specific treatments where available.  
By furthering our understanding of some of the lesser known effects of venoms and 
assessing the ability of available drugs to ameliorate the negative effects we can rapidly 
alleviate some of the morbidity associated with SBE. The use of drugs will undoubtedly have 
consequences on physiology, some of which may not be beneficial, therefore benefits should 




administration, only when certain that perceived benefits are justified and that the drug 
indicated will be beneficial to the victim of that specific envenomation. 
 
1.5 Summary 
In this thesis SBE is shown to be an incredibly complex malady, particularly when compared 
to other neglected tropical diseases. Clinicians feel somewhat powerless, in part due to rarely 
having an understanding of the offending snake species, how much venom has been injected 
and therefore what to expect from a given envenomation. SBE also has underlying and 
currently untreated side effects, including methaemoglobin production and associated 
hypoxia. The production of which we show to be common amongst snake venoms. 
Methaemoglobin is likely to exacerbate local tissue damage and muscle regeneration. The 
musculature is already damaged due to a range of myotoxic venom components, and 
regeneration is known to be delayed in SVMP-containing venoms. We found this delayed 
regeneration to be a result of basement membrane destruction which has consequences for 
satellite cell mobility and efficacy – an essential aspect to effective regeneration. This is unlike 
smaller pore forming myotoxins which allow muscles to regenerate with relative ease and 
pace. We found metalloprotease inhibitors and chelators to effectively prevent the 
collagenolytic activity of a P-I SVMP in vitro, suggesting these compounds could aid in the 
amelioration of SVMP-induced long-term skeletal muscle damage. Finally, we show two 
possible methods for developing simple point of care devices indicating the presence of 
specific toxins. These can be developed using purified proteins, or peptides based on 
conserved regions of proteins and immediately feed into protocols, indicating antivenom, as 
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Conclusion of this chapter 
Snakebite envenoming is one of the most complex of the neglected tropical diseases. The 
diversity in toxicological profiles and resulting pathologies is unprecedented in other diseases 
and clinicians are somewhat powerless in diagnosing and treating it. Currently, polyvalent 
antivenoms are the only treatment option and aim at preventing the life-threatening aspects 
of envenomation but have few effects on the local tissue damage and morbidity associated 
with snakebite. An added issue is that diagnosis is usually based on symptoms, making the 
rapid administration of antivenom (which is essential to minimising local effects and minimising 
risk of death) a rare occurrence. There are however a range of emerging therapies as both 
adjunctive and alternative treatments to antivenom, but the commonality of adverse effects -
such as unwanted inhibition of endogenous proteins - make proper diagnosis a necessity 
before administering potentially harmful drugs. Such diagnostical tools are in desperate need 
of development as none are currently commercially available in the areas most in need.  
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Abstract: Snakebite envenoming (SBE) is a priority neglected tropical disease, which kills in excess 
of 100,000 people per year. Additionally, many millions of survivors also suffer through disabilities 
and long-term health consequences. The only treatment for SBE, antivenom, has a number of major 
associated problems, not least, adverse reactions and limited availability. This emphasises the 
necessity for urgent improvements to the management of this disease. Administration of antivenom 
is too frequently based on symptomatology, which results in wasting crucial time. The majority of 
SBE-affected regions rely on broad-spectrum polyvalent antivenoms that have a low content of case-
specific efficacious immunoglobulins. Research into small molecular therapeutics such as 
varespladib/methyl-varespladib (PLA2 inhibitors) and batimastat/marimastat (metalloprotease 
inhibitors) suggest that such adjunctive treatments could be hugely beneficial to victims. Progress 
into toxin-specific monoclonal antibodies as well as alternative binding scaffolds such as aptamers 
hold much promise for future treatment strategies. SBE is not implicit during snakebite, due to 
venom metering. Thus, the delay between bite and symptom presentation is critical and when 
symptoms appear it may often already be too late to effectively treat SBE. The development of 
reliable diagnostical tools could therefore initiate a paradigm shift in the treatment of SBE. While 
the complete eradication of SBE is an impossibility, mitigation is in the pipeline, with new 
treatments and diagnostics rapidly emerging. Here we critically review the urgent necessity for the 
development of diagnostic tools and improved therapeutics to mitigate the deaths and disabilities 
caused by SBE. 
Keywords: snakebite envenoming (SBE); venom; diagnostics; therapeutics; toxin neutralisation; 
neglected tropical disease 
Key Contribution: This review highlights the key factors contributing to the gross mortality and 
morbidity associated with snakebite envenoming. The current research taking place to overcome 
this complex disease and the urgent need to develop improved diagnostics and therapeutics for 
snakebites are also discussed. 
 
1. Introduction 
Snakebite envenomation (SBE) is a life threatening and traumatising affliction that is 
unequivocally associated with the world’s most impoverished people [1]. Mortalities from SBE are 
concentrated in the rural tropics where snakes are in abundance and the agricultural work force is 
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poorly protected. The limited recognition of the scale of the crisis by health authorities around the 
globe afforded SBE a place on the World Health Organisation’s list of neglected tropical diseases in 
2009 (NTD). This was followed by a contentious removal before again being reinstated in 2017 and 
quickly being made a priority NTD [2,3]. The confusion surrounding SBE as an NTD is somewhat 
justified: SBE is not limited to the tropics and all other NTDs are caused by pathogens entering the 
body: protozoa, helminths, bacteria and viruses [4]. Thus, the causative agents are easier to identify 
and study by comparison to the diversity of pathologies associated with SBE. Indeed, Australia 
classes snakebite as a non-intentional injury rather than a disease, but with an average of two deaths 
a year, it is unlike the crisis seen in more impoverished countries [5]. The extent of SBE taking place 
every year is estimated to be between 1.8–2.7 million [6]. The actual deaths from SBE are purported 
to be between 81,000–137,000 [7] and nearly 50,000 of these deaths are estimated to take place in India 
alone [8].There are a further 8,000 in Pakistan and 6,000 in Bangladesh [9], while in the Americas 
despite 60,000 snakebites taking place annually, deaths are estimated to only be in the hundreds [10]. 
While shocking, the deaths frequently hide a potentially greater issue, which is the disability and 
consequential loss to the economic workforce. Delays in seeking medical assistance are common, and 
postponements for just a couple of days can lead to gangrene, compartmental syndrome and 
amputation [11]. Surviving SBE can also have mental health implications, with survivors seeing a 
three-fold increase in depressive disorders compared to the general population [12]. Post-traumatic 
stress disorder also occurred in a further 20% of SBE victims surveyed in Sri Lanka [12]. In West 
Africa, the disability-adjusted life years (years lost due to disability or early death) from SBE are 
estimated to be over 300,000 [13]. These figures are ever increasing, due to past data suffering from 
flaws from under-reporting and victims avoiding hospitals for cheaper and more convenient 
traditional herbalists. 
This staggering epidemiology is unsurprising when compared to more typical diseases. The 
marked difference between SBE and many of the other NTDs is the diversity involved in the range 
of associated toxins seen globally. Cholera, for example, (not limited to the tropics and therefore 
sometimes ignored as an NTD), like SBE causes many thousands of deaths every year (Table 1). 
Cholera has such a dramatic effect on its victims primarily through one toxin (cholera toxin/CT) 
released by strains of the Vibrio cholerae bacteria. CT triggers a cascade of events which culminate in 
an influx of salts and water into the intestine, causing the diarrhoea that aids in transmission of the 
disease to others, and leaves victims to die by dehydration [14]. The disease is the result of one toxin, 
from one species of bacteria, with one simple and effective treatment. The nematode infections 
(shown in Table 1) are all a result of roundworms, which have evolved to inhabit the gastrointestinal 
tract of humans. Despite resulting from a range of species, the same anti-helminthic drugs can easily 
treat this disorder [15]. In stark contrast, SBE can be the result of bites from hundreds of different 
snake species, each possessing a multitude of different toxin profiles and leading to a vast array of 
different pathologies [16]. Treatment is consequently far more complex than the rehydration required 
to beat the majority of cholera infections [17], and simple prophylactics required to prevent many of 
the other NTDs (Table 1) [18]. SBE has proved to be an incredibly complex disease to accurately 
diagnose and treat appropriately. 
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Table 1. A comparison of snakebite envenomation (SBE) alongside other traditional major neglected tropical diseases. Sorted based on deaths. Adapted and updated 
from Hotez et al. (2007) [19]. 
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Neurotoxicity and paralysis or 
cardiovascular toxicity and 
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amputation. 
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Fang marks, local tissue damage, 
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Venoms are essentially cocktails of toxic and non-toxic components: proteins, peptides, metal 
ions and small organic molecules, including nucleotides, secreted by animals to predate on or defend 
against other animals. In snakes, venom is a modified form of saliva produced from a pair of 
venomous glands and delivered by fangs, and found in species from a number of taxa. All venomous 
reptiles have been grouped in a clade called Toxicofera, within which, another clade, Caenophidia 
holds all the venomous snakes (Figure 1). The strictly venomous families are Elapidae (elapids) that 
includes the snakes with fixed front fangs e.g., cobras, kraits, mambas, taipans and sea snakes 
(sometimes grouped in the subfamily, Hydrophiinae) amongst others; and Viperidae (vipers) which 
have hinged front fangs allowing longer fangs and deeper tissue penetration. The vipers are further 
divided into two subfamilies, Viperinae (the true vipers, e.g., Gaboon viper and European adder) and 
Crotalinae (the pit vipers, e.g., rattlesnakes and lanceheads). Additionally, two other families contain 
venomous species, although the majority of these families are made up of non-venomous snakes. The 
first is Colubridae (colubrids), a loose grouping containing over half of described snake species with 
reported deaths arising from at least five species: the boomslang (Dispholidus typus); twig snake 
(Thelotornis capensis); tiger keelback (Rhabdophis tigrinus); South American green racer (Philodryas 
offersii) and Peruvian slender snake (Tachymenis peruviana) [29], though many others have potentially 
occurred. The second mixed family is Lamprophiidae (lamprophiids), which contains several 
venomous (e.g., Atractaspidinae) and non-venomous subfamilies, of note is the genus Atractaspis: the 
stiletto snakes or burrowing asps [16,30,31]. Venomous bites from Atractaspis occur across most of 
sub-Saharan Africa (and some western Asian counties) and occasionally cause fatalities [32] due in 
part to a lack of specific antivenom over most of the genus’ range. The majority of lethal bites are, 
however, almost exclusively from members of Viperidae and Elapidae families [33]. The impact of 
these two families can be oversimplified as largely neurotoxic in the case of elapid bites and 
haemotoxic in the case of viper bites. Flaccid paralysis and respiratory failure often result from elapid 
bites. Hypovolemic shock (the loss of >20% blood) leading to heart failure [34,35] alongside acute 
kidney injury [36] are potential causes of death in viper bites. However, there are some vipers that 
rely on neurotoxic components, such as the atypical South American rattlesnake (Crotalus durissus 
terrificus) the venom of which contains crotoxin, and Russell’s viper, Daboia russelii, which contains 
U1-viperitoxin-Dr1a [37]. Both of these viperid neurotoxins are pre-synaptically active neurotoxic 
phospholipase A2 (PLA2) [38] which are generally seen more commonly in elapid venoms (other 
neurotoxic viper venoms are known [39–41]). Elapids are also not without their exceptions to the rule, 
in particular the Australian elapids for which the cause of death is frequently cardiac arrest, and 
coagulopathy is also common due to the high proportion of prothrombin activators in their venoms 
[5,42,43].  
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Figure 1. Phylogenetic tree adapted from Reyes-Velasco et al. (2014) [44]. Shows the Caenophidia, a 
clade including all venomous snakes. The skull diagrams were adapted from published images 
[45,46]. Number of species and genera were taken from the reptile database [47]. 
2. The Complexity of Snake Venoms 
One of the major difficulties in treating snakebites is the hugely diverse geographic and 
taxonomic nature of venomous snakes and the consequential variability of venoms [48–50]. Many of 
the 680 or so venomous species of snakes are further split into subspecies each with added levels of 
diversity in venom compositions to their congeners [51]. As well as this, many undiscovered cryptic 
species may also exist providing yet further diversity of venom and undiscovered venom 
components [52]. The variation in venom between these subspecies leads to differences in 
symptomatology [53] as well as varying levels of antivenom efficacy [54]. Therefore, a thorough 
knowledge of serpentine systematics is crucial for effective treatment of snakebites [55]. Despite their 
differences, snake venoms do have many similarities. They are all complex mixtures of hydrolytic 
enzymes, biologically active non-enzymatic proteins and peptides—these are responsible for the 
spectrum of their toxic effects (Figure 2) [16].  
24
Toxins 2019, 11, 363 7 of 29 
 
 
Figure 2. Generalised effects of viper and elapid snakebite envenomation and toxins causing these 
effects. Inspired by Gutiérrez et al. (2017) [16]. Abbreviations: PLA2—Phospholipase A2, SVMP—
Snake venom metalloprotease, G2PLA2—Group 2 PLA2, SVSP – Snake venom serine protease, 
CRiSPs—Cysteine rich secretory proteins, Snaclecs—Snake c-type lectins, 3FTXs—Three finger 
toxins, SBE—snakebite envenoming, BM—basement membrane. 
A large number of protein families exist within snake venoms: there are four dominant protein 
families (phospholipase A2, metalloproteases, serine proteases, and three-finger toxins), and six 
secondary protein families (Cysteine-rich secretory proteins, L-amino acid oxidases, kunitz peptides, 
C-type lectins, disintegrins and natriuretic peptides) as well as over 36 rarer protein families [56]. 
These dominant and secondary families form the bulk of snake venoms and are largely to blame for 
the incredibly broad symptomatology and pathology associated with SBE (Table 2). 
Table 2. The major enzymatic (grey) and non-enzymatic (blue) proteins found in snake venoms and 
their primary functions. The table was adapted from Warrell (2010) [30] and abundance data were 
created using data from 132 snake species (42 members of Elapidae, 20 Viperinae and 65 Crotalinae). 
These data were provided in Tasoulin & Isbister (2017) [56] and data were used with the authors’ 
permission. 
Venom Component 
Approximate Abundance (% 
(±SD)) Major Described Functions 
Elapidae  Viperinae Crotalinae 
Phospholipase A2 
(PLA2) 31 (±24) 22 (±17) 22 (±20) 
Presynaptic neurotoxicity (β-neurotoxins), 
membrane phospholipolysis, haemolysis, 
myotoxicity, necrosis and 




3 (±3) 35 (±20) 36 (±20) Haemorrhaging, fibrin(ogen)olytic activity, 
endothelial damage and myotoxicity 
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Snake venom serine 
protease (SVSP) 
1 (±1) 12 (±9) 16 (±14) Hypotension, fibrin(ogen)olytic activity and 
bleeding 
L-amino acid oxidase 
(LAAO) 1 (±2) 2 (±2) 5 (±4) 
Apoptosis, oedema, cytotoxicity via products 
and anticoagulant effects via inhibition factor 
IX 
Three-finger toxin 
(3FTX) 55 (±27) NA NA 
Postsynaptic neurotoxicity via binding of 
cholinergic receptors (α-neurotoxins), 
cardiotoxicity, myotoxicity and cytotoxicity 
Kunitz type serine 
protease inhibitors 
(KSPi) 
4 (±10) 3 (±6) NA 
Neurotoxicity via binding of voltage gated 
potassium channels or anticoagulopathic 




2 (±3) 4 (±4) 2 (±2) Smooth muscle inhibition via blocking of calcium channels 
Natriuretic peptides 1 (±1) 1 (±3) 7 (±9) Promote excretion of sodium by kidneys 
causing hypotension and cardiotoxicity  
Snake C-type lectins 
(Snaclec) 
NA 9 (±6) 6 (±8) Platelet inhibition and activation via an array 
of receptors 
Disintegrin NA 6 (±5) 2 (±4) Binding of integrins causing inhibition of 
platelet aggregation 
2.1. Enzymatic Components 
PLA2 are a group of esterolytic enzymes present in snake venoms that typically catalyse the 
breakdown of glycerophospholipids, the main component of biological membranes, into 
lysophospholipids and a fatty acid (which may be involved with the oxidisation of haemoglobin [57]). 
However, within snake venoms, many members of this group have lost most of their enzymatic 
activity and instead bind to various receptors. The snake venom PLA2s are split into two groups, 
group I PLA2s are found predominantly in elapid and some colubrid snakes, while group II are found 
only within Viperidae. Group I are generally β-neurotoxins which act pre-synaptically, sometimes 
binding to voltage gated potassium channels [58], although multiple mechanisms exist [59,60]. After 
binding, neurotoxic PLA2s can sometimes hydrolyze nerve terminal phospholipids causing 
permanent neurotoxicity [61]. This has the effect of causing paralysis, while group II PLA2s tend to 
act cytotoxically, predominantly as myotoxins, causing myonecrosis via the disruption of the plasma 
membrane [62]. Sometimes after hydrolysing membrane phospholipids, non-enzymatic PLA2 
homologues cause damage to the sarcolemma via hydrophobic interactions [63]. PLA2s have further 
diverse pharmacological functions, however, haemotoxicity [64], postsynaptic neurotoxicity as well 
as the inhibition and activation of platelet aggregation, cardiotoxicity and anticoagulant effects have 
also been reported [65,66].  
Snake venom metalloproteases (SVMPs) are the most abundant venom enzymes in vipers (also 
present to a lesser extent in elapids), and include both coagulants (e.g., activation of prothrombin or 
factor X), and anticoagulants (comprising of integrin shedding and fibrinolytic enzymes [67]). 
Importantly, they also frequently induce haemorrhaging due to hydrolysis of the endothelial cell 
basement membrane components around blood capillaries [68]. These also affect muscle fibres 
impairing their regeneration [69]. These enzymes are in themselves a highly diverse family, and are 
separated into four groups depending on the domains present: P-I/Group I comprise just a 
metalloprotease domain, present in all groups. In the venom gland it exists as a zymogen with a pro-
peptide domain that is cleaved before activation; P-II/Group II has an additional disintegrin domain, 
which have been found to be liberated as free disintegrins after processing in some venoms [70]; P-
III/Group III has additional disintegrin-like and Cysteine rich domains and P-IV as P-III but with two 
C-type lectin-like domains attached via disulphide bonds [52,71]. These additional domains afford 
SVMPs a wide variety of different functions. For example, the disintegrin domains bind integrins 
blocking their functions in platelets and endothelial cells [72] and have the potential to bind the 
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integrins in muscle cells, colocalising and exacerbating myotoxic effects [69]. Cysteine-rich domains 
have also been found to inhibit collagen induced platelet aggregation as well as to play a key role in 
the onset of inflammation [73]. Finally, C-type lectin-like domains, which amongst other functions of 
SVMPs, are involved in the activation of platelets by the clustering of tyrosine kinase dependent 
receptors [74]. 
Snake venom serine proteases (SVSPs) mainly affect the haemostasis of victims by proteolytically 
degrading the blood components (e.g., fibrinogen) as well as modulating various coagulatory factors 
(e.g., factor V and plasminogen) [75]. Despite the variety of processes SVSPs can affect, the primary 
function of the majority of studied SVSPs is to cleave fibrinogen, promoting coagulation, but they can 
also prevent coagulation through dysfibrinogenemia. These are called ‘thrombin-like’ enzymes due 
to their mimicking of thrombin’s primary function, although SVSPs rarely activate factor XIII which 
thrombin does in order to cross-link the soluble fibrin clot into an insoluble clot [76]. There are 
additional SVSPs described as ‘kallikrein-like’ (bradykinin releasing and blood vessel dilating) 
[77,78], factor V activators (consequently prothrombin activating) [79] and platelet aggregators (via 
cleavage of protease activated receptors PAR1 & PAR4 [80]) that cause alterations in blood pressure 
or cause blood to clot [81]. Anticoagulant SVSPs also exist with some found to activate protein C, a 
proenzyme involved in negatively regulating the coagulation cascade via inactivation of factors V 
and VIII [82,83], and degrading blood clots by conversion of plasminogen to plasmin.  
L-amino acid oxidases (LAAOs) are not an abundant enzyme family, they are, however, found 
fairly ubiquitously in both elapid and viper venoms [56]. They are glycoproteinaceous flavoenzymes 
and catalyse the oxidative deamination of L-amino acids. This produces an α-keto acid, ammonia 
and hydrogen peroxide, all of which can have cytotoxic effects. The hydrogen peroxide produced 
may additionally lead to the oxidation of haemoglobin seen as a result of some viper venoms [84,85]. 
They may also induce oedema [86] and apoptosis [87], as well as acting as anti-coagulants via the 
inhibition of factor IX [88]. These enzymes are, however, still poorly understood, and thought to play 
some roles in the stabilisation of venom components within the gland or ducts [89] or aid in digestion. 
Other enzymes found in much lower quantities in venoms include; acetylcholinesterase, a serine 
hydrolase which functions synaptically, hydrolysing the neurotransmitter acetylcholine [90]; and 
hyaluronidases which are known as the spreading factors [91] due to their facilitation of the diffusion 
of other toxins across the body tissues as well as causing oedema via hydrolysing the hyaluronic acid 
barrier in the interstitial space [92]. The remaining groups of venom enzymes are thought to be 
involved more in digestion rather than the immobilisation of prey, and are consequently considered 
non-toxic by many researchers [93]. However, ignoring the hidden functions of these “non-toxic” 
components could be imprudent, for example, the ability of nucleases to liberate purines (adenosine 
in particular) which can act as multifunctional toxins [94].  
2.2. Non-Enzymatic Components 
As well as enzymes, there are also a whole host of non-enzymatic venom components, which 
carry out a variety of different functions. Three-finger toxins are characterised by a three-finger fold 
made up of three loops which protrude from a hydrophobic core [95]. They are found predominantly 
in elapid venoms, some viper venoms (only via transcriptomics [96]) and also certain colubrid 
venoms [97,98]. Despite their common structure, they bind to many different receptors and elicit a 
variety of biological effects [99]. They are typically neuro- or cytotoxic-. The α-neurotoxins, one 
important group of three finger toxins, bind post-synaptically, to nicotinic acetylcholine receptors 
found in the skeletal muscle of vertebrates [98], blocking neuromuscular transmission, causing flaccid 
paralysis and respiratory failure in some cases [100]. Three-finger toxins also include κ-bungarotoxins 
and haditoxin which operate similarly to the α-neurotoxins [99]; as well as acetylcholinesterase 
inhibitors—the fasciculins of the Dendroaspis genus [101]; cytolytic, ion pore forming cardiotoxins 
(cytolysins) found in cobra venoms [102] and L-type calcium channel blockers and platelet 
aggregation inhibiting three-finger toxins as well [99].  
Cysteine-rich secretory proteins (CRISPs) are single chain polypeptides widely distributed within 
venoms, and have been found in the venoms of all the three main families of venomous snakes [68] 
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as well as in some lizard venoms [103]. Like three-finger toxins, CRISPs have a scaffold that is highly 
conserved and is stabilised via disulphide linkages and exert a wide range of pharmacological 
activities. Helothermine, a CRISP isolated from the venom of the lizard, Heloderma horridum horridum 
has been found to block calcium [104] and potassium [105] currents in neurons and to lower body 
temperature in mice [106]. CRISPs have also been documented to inhibit smooth muscle contraction 
via the blocking of Ca2+ channels [107,108] and to block cyclic nucleotide gated ion channels which 
are significant in many modes of sensory transduction [106]. 
Kunitz-type proteinase inhibitors are small proteins that are found in a range of viper and elapid 
venoms [109]. While some act to inhibit serine proteases, others have been found to block a large 
range of ion channels despite high homology. One notable neurotoxic group of Kunitz peptides are 
called the dendrotoxins, and form the largest component of mamba (Dendroaspis spp.) venoms before 
α-neurotoxins [110]. These proteins have no protease activity and instead interact with voltage gated 
potassium channels [110,111]. This potentiates the effect of acetylcholine, facilitating its release at the 
presynaptic nerve terminal causing excitation resulting in involuntary muscle contractions [112]. 
Synergism between components within venoms is well known [110,113], and some PLA2s are even 
known to act as heterodimers with Kunitz peptides potentiating their combined effects as in β-
bungarotoxin from Bungarus multicinctus [114] and MitTX from Micrurus tener tener [115]. 
In mammalian systems, C-type lectins typically bind to calcium and sugar residues. However, 
in snake venoms they are known as Snake C-type lectin-like proteins or snaclecs and they rarely have 
the binding loop responsible for this mammalian function but instead bind to a variety of receptors 
on platelets [74], as well as coagulation factors IX/X [116] and endothelial cells [117]. They have been 
reported to both inhibit [118] and activate [119] via a number of receptors on platelets including α2β1, 
GPIb, GPVI and CLEC-2 [89,120], sometimes causing thrombocytopenia as a result [16,74].  
The disintegrins are a family of polypeptides present in viper venoms, some of which are released 
from SVMPs while others have independent genes. The majority of disintegrins rely on an RGD (Arg-
Gly-Asp) motif, (a tripeptide recognised and used by integrins in cell membrane binding) to inhibit 
integrin function. Disintegrins are not to be confused with the disintegrin-like domains within certain 
metalloproteases which instead rely on an ECD (Glu-Cys-Asp) motif [72]. They inhibit collagen 
induced platelet activation via integrin α2β1 [121] and can competitively inhibit the binding of 
collagen to the α1 domain of α1β1 [122] along with targets on a wide range of other disintegrins [123]. 
They are predominantly potent inhibitors of platelet aggregation [67], acting primarily upon integrin 
αIIbβ3, the fibrinogen receptor. Others that do not inhibit platelet aggregation have also been 
characterised [124].  
Natriuretic peptides have been found in both elapid and viper venoms, although they are found 
in much higher abundance in viper venoms, occasionally making up as much as 30% of venoms such 
as within the bushmasters; Lachesis genus [125]. These peptides promote natriuresis, that is to say the 
excretion of sodium into urine by the kidneys, which affects inotropic (speed and force of 
contractions) and lusitropic (rate of relaxation) myocardial actions, as well as promoting vasodilation 
causing hypotension [126,127]. 
There are many other non-enzymatic venom components which have been described as minor 
protein families [56] these include bradykinin-potentiating peptides (BPPs) which both inhibit 
angiotensin converting enzyme as well as cleaving bradykinin giving potent hypotensive effects 
[128]. The presence of growth factors including nerve growth factor (NGF) and endothelial growth 
factor (EGF) in venom is poorly understood but may be involved in prey incapacitation, with NGFs 
purportedly causing mast cells to release a mass of chemical mediators and increasing vascular 
permeability aiding the dispersal of other venom toxins [129]. There are an additional 40 or more rare 
and unique protein families [56]. These rare families frequently exert only mild, if any, toxic effects 
such as the lipocalins whose function is currently unknown [130]. Others of these families have 
extremely limited taxonomic distribution within snake venoms such as the sarafotoxins, which are a 
toxic form of the vasoconstrictive endothelins and are only found in the Atractaspis genus [95,131]. 
Small basic myotoxic peptides (also referred to as defensins [56]) which are found in a limited number 
of Crotalus spp. induce muscle spasms and necrosis [16,30] and other proteins such as waglerin which 
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is a neurotoxin found only in Tropidolaemus spp. [40]. Venoms are all associated with such different 
toxin combinations which in some cases work synergistically causing SBE to be an incredibly complex 
disease to treat.  
Hence, the currently accepted antivenom therapy has numerous drawbacks, and thus, novel 
strategies are being employed worldwide to improve the treatment of this disease. Real 
improvements to the treatment will to some extent depend upon better diagnostic methods. 
3. Antivenom (Anti-Snake Venom/Venin/ASV) and Its Associated Problems 
Antivenom is the only effective and accepted treatment for systemic SBE yet to stand up to 
rigorous scientific testing and has single-handedly saved the lives of those suffering SBE for over a 
century [132].  
Despite this, there are a number of major problems associated with antivenom: poor stability in 
liquid form, adverse reactions, often poor efficacy and great difficulties associated with production, 
which is frequently too expensive for those most in need. Antivenoms are made via the hyper-
immunisation of an animal, typically large mammals e.g., horses and rare instances of manufacturers 
using sheep and donkeys [133]. The size of these animals means that large volumes of plasma can be 
collected, allowing larger volumes of antivenom to be generated [134]. This is produced by exposing 
the animal’s immune system to a single venom leading to the creation of monovalent/monospecific 
antivenoms, or multiple venoms to produce polyvalent/polyspecific antivenoms. The animal’s 
immune system responds by raising antibodies (particularly immunoglobulin G [IgG] in mammals) 
that bind specifically to immunogenic antigens present in the venom/s [135]. The plasma is then 
separated from the blood by centrifugation or sedimentation procedures and erythrocytes can then 
be reinfused into the animal [132]. Further purification then occasionally takes place to reduce non-
immunoglobulin serum proteins in some antivenoms (CroFab) reducing non-selective effects. Non-
specific immunoglobulins are sometimes also removed via affinity chromatography, and digestion 
by pepsin or papain is sometimes used to remove the Fc regions resulting in F(ab’)2 or Fab fragments 
respectively which are used by the majority of western antivenom producers, though whole IgG is 
also used [133].  
3.1. Reproducibility Issues Associated with Antivenom Production  
In reality, antivenoms are challenging to produce. Not only do the very same species causing 
the life-threatening bites have to be milked for their venoms—a high risk task for the personnel 
involved, but this toxic secretion then has to be injected into an animal at a safe (non-lethal) dose or 
detoxified in a way so as not to lose immunogenicity. These aforementioned issues cause antivenom 
generation to be inherently problematic, and can cause stress for the animal, the upkeep of which is 
already expensive without stress threatening poor immune responses and consequential yields of 
antivenom [136,137]. The process of production is not only extremely time consuming with low 
yields, but is also associated with huge batch-to-batch variability [138,139], unsurprising when 
injecting venoms, which vary greatly, into animals, whose immune systems will have hugely varied 
responses to the antigen. In order to mitigate these difficulties it is suggested that pooled venoms 
from at least 20–50 specimens from the same geographical location are used [132]. These can, where 
available, be compared to national reference venoms for quality control and undergo biochemical 
characterisation (SDS-PAGE, HPLC, enzymatic activities, etc.) as evidence of consistency. 
Antivenoms are prepared from pooled plasma/serum and then require rigorous testing to find the 
median effective dose (ED50), i.e., the volume of antivenom required to protect 50% of a population 
injected with the venom [132]. 
3.2. Relative Instability of Antivenom  
The instability of liquid antivenom reduces its availability in the remote regions of developing 
countries where it is most needed and lyophilised preparations are problematic. In liquid form, 
antivenom requires preservatives, as well as, and more problematically, refrigeration at between 4 
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°C and 6 °C to maintain its potency. Lyophilised or freeze-dried products are also available, but to 
minimise cost and maximise ease of use, some are distributed in liquid form [140]. Moreover, warmer 
temperatures can lead to the formation of protein aggregates in liquid antivenom, which increase the 
chances of adverse reactions [141]. The relative instability results in antivenom being sold with expiry 
dates and warnings for avoiding the use of antivenom that has undergone multiple freeze-thaw 
cycles, despite there being some evidence that neither of these have significant effects on antivenom 
efficacy [142]. Where antivenom shortages have been identified, such as for the North American Coral 
Snake antivenom, shelf life extension programs (SLEP) have validated stability over that predicted 
extending their usage period [143]. This prevents the local distribution of antivenom and contributes 
to over two thirds of snakebite victims preferentially choosing traditional healers over hospital 
treatment in several parts of the world, where snakebite is a major concern [144]. 
There have also been some studies suggesting that as well as being less prone to triggering 
adverse reactions, camelid immunoglobulins may belong to a more thermally stable subclass of IgGs 
[145] which could help to overcome the need for refrigeration [146]. Despite improved 
thermostability, this study was not really designed to replicate the variation in temperature that 
antivenom would undergo over the course of several years in a tropical country. 
3.3. Adverse Reactions to Antivenom 
Antivenom invariably contains immunogenic proteins, which activate the immune system of 
patients, and causes them to suffer from adverse reactions. These are split into two types: acute 
(anaphylactoid or pyrogenic) and delayed ‘serum’ sickness (now plasma as most antivenoms are 
plasma-derived) type reactions [147]. Early reactions may be triggered immediately but can take up 
to an hour for onset of the symptoms. They are associated with mild symptoms such as urticaria 
(hives), coughing, vomiting, diarrhoea, headaches and nausea, though severe systemic anaphylaxis 
can also develop, and is associated with bronchospasm, hypotension and angioedema [148]. 
Pyrogenic reactions may also occur in response to endotoxins from bacterial contaminants of the 
antivenom [149]. They are characterised by fever, vasodilation, reduction in blood pressure and 
shaking chills. Late reactions usually occur several days after the initial dose of antivenom and are a 
form of type III hypersensitivity, which is caused by a build-up of immune complexes inadequately 
cleared by the immune system [149]. They give similar symptoms to early reactions, but additional 
symptoms include joint pain, adenopathy, albuminuria and rare cases of encephalopathy. 
Anaphylactic reactions are frequently treated successfully using prophylactic drugs such as 
adrenaline and hydrocortisone [150] which serves to reduce capillary permeability and 
bronchospasm in people suffering from early adverse reactions [148].  
The frequency and nature of adverse reactions depends in part on the level of antivenom 
purification. Crude first generation antivenom has caused adverse reactions in up to 54% of patients 
[151], but it can be affinity purified to produce second generation antivenoms (pure immunoglobulin 
mixes without any plasma proteins), consisting of just the whole immunoglobulins (IgG), which some 
studies have found to decrease adverse reactions to less than 25% of patients [152].  
By removing the Fc (fragment crystallisable, or tail) regions of these antibodies enzymatically 
with pepsin or papain, third generation antivenoms are created. The use of papain breaks the hinge 
regions resulting in Fab fragments (these portions bind the toxin epitopes) [153] while pepsin will 
initially leave the hinge region intact forming F(ab’)2 fragments, although prolonged digestion could 
result in Fv fragments (fragments containing the variable region) which may only bind to antigens 
temporarily [154]. The removal of Fc regions is assumed to result in fewer adverse reactions [16], with 
Fab causing only minor adverse reactions when compared to IgG or F(ab’)2 [154].  
Indeed, despite all the stages of purification, complete neutralisation by antivenom is rarely 
achieved [155] and a large percentage of IgG found in antivenom may not be therapeutically useful 
[146]. In addition to the enhanced stability of camelid immunoglobulins mentioned above [156,157], 
their immunoglobulins lack the light chains that are present in ovine and equine antibodies [158] and 
have also been found to bind to epitopes not bound by other mammalian IgGs [159]. However, all 
these developments into antivenom over the years still fail to address two of the treatment’s biggest 
30
Toxins 2019, 11, 363 13 of 29 
 
drawbacks: stability and cost, which together seriously limit the availability of antivenoms to those 
most in need. 
3.4. Expense of Antivenom 
In addition to animal maintenance, when the level of immunoglobulin purification increases, 
the price of treatment also increases. Although the more expensive and effective generations of 
antivenoms are of some use in the western world where they are mostly affordable, in third world 
countries where snakebites are most prevalent, these extortionate antivenoms can cause victims to be 
financially as well as physically crippled from a snakebite, the financial burden of which can often 
extend to their friends and family [160]. In India, treatment can cost up to US$5000, more than double 
India’s GDP per capita and representative of over ten years salary for a typical farm worker [160]. 
Likewise in the USA, treatment (including antivenom) costing as much as US$153,000 has been 
reported [161] though more expensive treatments are likely to have taken place. This does not mean 
it is impossible to make a cheap antivenom, as an effective antivenom is reported to have been 
developed from a Nigeria/UK collaboration that is available at just US$40 per treatment, at which 
price antivenom is considered one of the most cost effective treatments in the world [136]. However, 
after the expense of clinical trials and hospital charges, treatment in some countries may have cost 
1000 times the production cost of one vial of antivenom [161].  
The majority of snakebites occur in rural settings, these are areas far from the hospitals and 
where electricity is required for refrigerating and administering antivenom [30]. The instability of 
antivenom means that keeping supplies in the unrefrigerated but most needed regions is impossible, 
and even if it were possible, the difficulty of administration combined with high probability of 
adverse reactions would render it of little use to untrained individuals without adequate tertiary care 
facilities. The dosage is complex, with hugely different mean effective doses depending on venoms 
targeted and quantity of venom delivered. Mean effective doses from 47 mL [162] to 180 mL [163] of 
antivenom have been reported and there is some evidence that larger doses can be less effective [164]. 
There are frequently drugs co-administered with antivenom such as broad-spectrum antibiotics to 
treat wound infections around the bite site which may occur due to the oral flora present in the 
mouths of snakes being introduced into bite victims [165,166], which may also lead to sepsis if 
untreated. There is also growing evidence that venom glands from many species contain a viable 
microbiome which may directly contribute to wound infection [167]. 
Such an expensive and complex medicine will always be difficult to distribute widely enough to 
give protection to the millions of people living alongside potentially deadly snakes. The dangerously 
low supplies of antivenom have been described as a ‘crisis’ [168] and available supplies are 
insufficient in both quantity and quality with limited—if any—preclinical assessment data available 
[137]. A more practical alternative therapeutic approach would therefore be of great merit, 
particularly to the developing world. Preventative measures such as wearing rubber boots [169] 
when harvesting and sleeping under mosquito nets [170] are also important to reduce reliance on 
therapy alone, though the purchase and distribution to all those in need is unrealistic. 
Despite the issues with antivenom, as of yet it is the only medicine proven in the treatment of 
SBE in humans. The cases where it has been ineffective should not detract from its ability to save 
people even in the late stages of envenomation [171]. Indeed many of the problems arising from the 
use of antivenom can be minimised by adhering to the WHO guidelines for the management of 
snakebite [148]. Guidelines which could also serve to reduce the administration of dangerously large 
doses of antivenom, with reports of doses of 200 vials or two litres of antivenom in some rare cases 
[172].  
4. Diagnosis of Snakebites  
For a long time, the diagnosis of snakebites has relied almost entirely on the symptomatology as 
well as a detailed clinical history of the symptoms, and of the offending snake. For rapid assessment, 
five brief questions to help with this have been described [16]: 
1. Where were you bitten? Leading to examination of bite site. 
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2. When were you bitten? In recent bites symptoms may be absent.  
3. What were you doing when you were bitten? Activity may be diagnostical. 
4. Where is the snake that bit you or what did it look like? Actual snake or photo can aid 
in diagnosis. 
5. How are you feeling now? Check for further symptoms of envenoming. 
In some situations, notably bites from the Bungarus genus, victims may wake paralysed as this 
genus frequently bites people indoors, at ground level, during the night [173]. In these sorts of 
situations there is no way of verbally confirming a bite and clinical or laboratory diagnosis have to 
be employed. Improvements to snakebite diagnostics would not only rule out administration of 
antivenom in cases of dry bites and bites from species not covered by the antivenom or non-
venomous but may also begin to quantify the scale of envenoming and quantity of antivenom 
required, as well as paving the way to more case-specific treatments. 
4.1. Clinical Diagnosis  
The clinical symptoms to be seen first in viper envenomation are blistering, swelling, bleeding, 
necrosis and pain. While the first signs of neurotoxicity from elapid envenomation is ptosis caused 
by ophthalmoplegia (paralysis of facial and extraocular muscles) which can descend into cyanosis 
and a decrease in ventilatory capacity in the run up to flaccid paralysis. Further diagnosis relies on 
the presence of multiple markers, and systemic envenoming can be confirmed by peripheral 
neutrophil leucocytosis (an increase in the number of neutrophils in response to the venom), or 
abnormal haematocrit (ratio of red blood cells to blood) which can be an indicator of haemorrhaging 
(low haematocrit) or haemoconcentration due to plasma leakage from increased permeability of 
capillaries (high haematocrit) [16]. Incoagulable blood after bites from vipers, certain elapids and 
colubrids have caused the 20-min whole blood clotting test to be the mainstay of snakebite 
diagnostics for decades. This involves leaving a small sample of victim’s blood in a glass tube for 20 
min and then ascertaining whether it has clotted. This can be a good indicator of consumption 
coagulopathy and usually the presence of procoagulant [30] proteins in the venom of the offending 
snake [173,174]. Despite being worthy of acting as a diagnostical tool in some settings [175], it is 
primitive and there are instances of it providing false information [174] and hence, better diagnostics 
are undoubtedly required [176]. 
4.2. Venom Detection Kits 
The Australian Commonwealth serums laboratory snake venom detection kit (CSL-SVDK) [177] 
which relies on an enzyme-linked immunoassay procedure is currently the only SBE detection device 
commercially available. This kit is less of a snake identification device than a tool for matching one 
of Australia’s five monovalent antivenoms—Tiger snake (Notechis), Brown snake (Pseudonaja), Black 
snake (Pseudechis), Death adder (Acanthophis) or Taipan (Oxyuranus)—to the envenomation. For 
example, the tiger snake immunotype will also neutralise a range of other species including Lowland 
Copperhead (Austrelaps superbus) as well as some Pseudechis, Tropidechis and Hoplocephalus species 
[177]. The major problem with snakebite diagnostics is the cross reactivity seen between venoms, as 
some of the proteins in each venom overlap, detection devices are rarely species specific and will 
detect a range of species when using immunological techniques. This problem is especially evident 
with the CSL-SVDK which has been recorded giving false positives with bites from species 
considered completely non-venomous [178,179]. More specific molecular methods are being 
developed, but are inappropriate as point of care devices, although potentially beneficial in 
corroborating reliability in more appropriate point of care devices [180]. The production of lateral 
flow assays (LFA) which can quickly and qualitatively differentiate between bites allowing more 
specific antivenoms to be used is necessary. Research is well under way on the use of lateral flow 
devices to detect snakebites, and a device capable of differentiating between Indian cobra, Naja naja 
and Russel’s Viper, Daboia russelii, envenomation in India has been developed [181]. Similarly, in 
Taiwan an LFA device to detect either haemorrhagic bites (Trimeresurus stejnegeri & Protobothrops 
mucrosquamatus) or neurotoxic bites (Bungarus multicinctus and Naja atra) and discriminating between 
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which of the two bivalent Taiwanese antivenoms to use has also been reported [182], which is 
progress from the enzyme-linked immunosorbent assay currently in use and single band LFA 
previously reported [183].  
4.3. Improving the Diagnosis of SBE  
A large percentage of snakebites are considered dry bites; where a venomous species has 
delivered no venom or bites from non-venomous species. Alternatively, bites from venomous species 
with a venom that has mild or non-lethal effects on humans, but has instead evolved to defeat 
amphibian, reptilian, icthian or avian prey can lead to confusion regarding the state of envenomation 
[184]. These bites may still be presented to hospitals, using antivenoms unnecessarily, taking hospital 
beds and the time of healthcare professionals. A basic device simply able to differentiate between 
someone suffering a life-threatening bite or a dry bite would therefore provide confidence for 
clinicians including the less experienced personnel in rural regions and overcome the problems 
associated with lack of experience in administration of antivenom. A simple device may enable 
victims to confirm SBE and seek prompt hospital treatment instead of resorting to traditional healers. 
In the case of true envenoming, that is to say the injection of a potentially life-threatening venom, 
immediate transfer to hospital and administration of the correct antivenom saves countless lives [16]. 
However, choosing the correct antivenom is frequently not an option, as there is often only one 
choice. In many of the problem areas the antivenom used is polyvalent; in India an antivenom raised 
against the ‘Big Four’—Indian Cobra (Naja naja), Russell’s Viper (Daboia russelii), Indian krait 
(Bungarus caeruleus) and Saw-scaled viper (Echis carinatus)—is used [185]. Similarly, the most widely 
used antivenom in Africa is polyvalent (SAVP) and is raised against 11 species: Black mamba 
(Dendroaspis polylepis), Green mamba (Dendroaspis angusticeps), Jameson's mamba (Dendroaspis 
jamesoni), Cape cobra (Naja nivea), Snouted cobra (Aspidelaps lubricus), Egyptian cobra (Naja haje), 
Forest cobra (Naja melanoleuca), Gaboon viper (Bitis gabonica), Mozambique spitting cobra (Naja 
mossambica), Puff adder (Bitis aerietans) and Rinkhals (Haemachatus hemachatus) [186], meaning a small 
fraction of the antibodies is specific for each snake bite. With typically just one choice of antivenom, 
clinicians have the binary choice of whether or not to administer the only antivenom available. A 
point of care test would prevent unwarranted and wasteful administration of this life-saving 
medicine, which despite new antivenoms being produced is still in very short supply (~2.5% of 
projected needs) [187]. It could also enable doctors to become less reliant on presented symptoms, 
and to be more conclusive in identifying the offending snake, depending on a device’s specificity for 
different taxa (families, genera, species, etc.). After the development of diagnostical devices, the many 
emerging possibilities for alternative treatments can be used with confidence and reliable 
epidemiological data can be gathered, allowing more rational distribution of antivenoms or novel 
treatments. 
5. Future Treatment Approaches for SBE 
Current animal-derived antivenoms are clearly antiquated, as are the huge number of ineffective 
herbal remedies still used and sought around the world [188] but the difficulties in evolving from 
this treatment are endless. That said, around the world a lot of research into future strategies is taking 
place and they have been reviewed in detail [189–192] as have the design considerations [193] which 
should be carefully considered by health care authorities before plunging forwards with unrealistic 
solutions. The majority can be split into small molecular inhibitors and protein or nucleic acid-based 
technologies. 
5.1. Small Molecular Therapeutics (SMTs) 
As mentioned previously, a large proportion of venoms (particularly viperidae) are made up of 
enzymatic components, with specific active sites, that frequently depend on just three amino acids—
the catalytic triad. Therefore, compounds that can block this site prevent the enzymatic function of 
that venom component. A number of different small molecular therapeutics have been causing 
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excitement in recent years. The use of such compounds can be expedited by molecular docking 
studies and promising results have been obtained in this manner [194]. The foremost SMTs are 
varespladib and its orally available prodrug methyl-varespladib which are repurposed drugs for 
treating acute coronary syndrome, which shows potent inhibition of the secreted PLA2 found in a 
range of snake venoms [195]. Although an inhibitor of just one venom enzyme family, it has been 
shown to improve survival in a large range of experimental envenomations. This has been shown to 
inhibit the anticoagulant and haemorrhagic aspects [196,197], as well as the myotoxicity caused by 
Group I and II PLA2 [198]. As has been previously noted, however, many snake venoms are devoid 
of PLA2 (notable is the black mamba Dendroaspis polylepis, with <0.1% PLA2 [110]), and varespladib is 
unlikely to be efficacious against bites from these species [190]. The second most abundant enzymatic 
group after PLA2 are the SVMPs (see Table 2), for which the matrix metalloprotease inhibitor 
batimastat and orally available prodrug marimastat have been shown to effectively abrogate the 
haemorrhagic and necrotic effects of these enzymes [194,199]. Both these SMTs, varespladib and 
batimastat/marimastat have side-effects however, significantly increasing the incidence of 
myocardial infarction [200] and inhibiting vascular growth [201], respectively. This causes 
unnecessary administration to be inadvisable and corroboratory diagnostics to be an important first 
step prior to administration. Acetylcholinesterase inhibitors such as neostigmine and atropine have 
also come under investigation with promising results in reducing mortality from some elapid venoms 
[202–204]. Nanoparticles (particles <100 nm) are also under investigation [205], and C60 fullerine (a 
spheroidal carbon molecule) has shown some antivenom properties in an insect model [206] although 
of course this is a far cry from the mammalian system involved in human SBE. 
5.2. Protein, Peptide and Oligomer Based Technologies 
In addition to antivenoms, other large biomolecular therapies are being investigated. 
Monoclonal human single chain variable fragments (scFvs) [207] as well as full monoclonal human 
IgGs [112] (known to have longer half-lives and different Fc-dependent effector functions) have also 
both been developed. Fewer adverse reactions and promises of cost competitivity [208] indicate these 
technologies could be key in the inhibition of various components of snake venoms in the future. This 
research has highlighted the huge potential of recombinantly expressed oligoclonal mixtures in the 
neutralisation of venom toxins [112]. The large size of these molecules is a double-edged sword, 
however, and although their half-lives are prolonged compared to small molecules, their speed of 
distribution is reduced. Thus, reduced tissue penetration impacts the ability to reach areas affected 
by the tissue damage and necrosis associated with viper bites [209]. The single domain antibodies 
(sdAb), specifically those based on heavy chain variable domains, have begun to receive some 
attention. This research has predominantly focused on the VHH fragments from camelids 
(nanobodies). These nanobodies are small, specific, stable and show high affinity for their epitopes 
making them a promising lead in potential future antivenoms [210]. The possibility of further 
improving their thermostability is also interesting [211]. Diabodies which are antibody-based dimers 
which bind antigens divalently and are composed of two single chain fragments [212], have been 
shown to neutralise neurotoxins [213] and benefit from retaining the benefits of an IgG molecule—
with two binding sites, but being approximately one third of the size.  
The use of aptamers, which are short sequences of DNA or RNA that bind to specific targets also 
show promise and have been shown to inhibit toxins from cone snails [214] as well as α-bungarotoxin 
and cardiotoxins [215]. Research is also being carried out on a large range of alternative binding 
scaffolds (AbScaffs) which due to low cost of production, high stability and engineerability could 
play a key role in future therapeutics for SBE [216]. 
A number of ABScaff proteins have been put forward as having potential in venom toxin 
neutralisation including affimers based on phytocystatins; adnectins (monobodies) based on a 
fibronectin domain and affibodies based on an Fc-binding staphylococcal domain, amongst many 
others [216]. Although yet to be put to use as antivenoms, these ABScaffs hold huge potential. They 
mostly rely on diversifiable loop regions, the insertion of peptide or nucleotide sequences into which 
allow molecular recognition and flexibility in binding regions. The major problem with these 
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scaffolds arises with their very short half-lives and all suffering from rapid clearance by the kidneys. 
The in vivo half-life of aptamers can be as low as two minutes [217] though PEG-ylation can increase 
this as can fusion to antibodies [218] which has the potential to increase half-lives and turn these 
scaffolds into realistic treatments. Such PEG-ylation and fusion to larger molecules defeats their 
foremost advantage: their small size, and would inevitably have cost implications.  
The Fc domains found on antibodies are markers, allowing these proteins to be recycled back 
into the blood stream: proteins not possessing this region required for interaction with the neonatal 
Fc receptor are subjected to catabolism via lysosomal degradation [219,220], therefore, conjugation of 
promising ABScaffs to Fc domains has the potential to increase the half-lives of lead compounds. 
6. Diagnostics Feeding into Treatment 
Improved diagnostics are essential in not only differentiating between diverse venoms but 
allowing clinicians to act before symptoms of SBE develop and expediting the use of standard 
protocols rather than being forced to rely on their own judgement as is too frequently the case [172]. 
Hence, simple diagnostics would boost the production of more specific treatments. At the animal-
derived antivenom level: monovalent, bivalent and genus specific antivenoms could be produced 
and used with confidence. Family specific detection devices, differentiating between a viper and 
elapid bite, could allow the two major polyvalent antivenoms (for Africa and India) to be divided, at 
least by family. The ‘Big Four’ antivenom could become two bivalent antivenoms; with one raised 
against saw-scaled viper, E. carinatus, and Russell’s viper, D. russelii, venoms and the other against 
Indian cobra, N. naja, and Indian krait, B. caeruleus venoms. Similarly, African antivenoms could 
potentially be split into an elapid and viper antivenom. This would mean a higher proportion of each 
vial would be specific to the family-specific envenomation effects suffered by the patient.  
Increasing advancement of kits able to detect specific toxins, could allow the envenoming species 
to be inferred, allowing treatments to begin targeting toxins present in the blood and those local 
toxins associated with the bite from a species. The cheap and heat stable SMTs could be made 
available locally in areas of high risk, allowing pre-hospital adjunctive treatments to be administered 
after ascertaining envenomation that could lower risk of paralysis and tissue damage [189]. Further 
surveillance and secondary treatment at hospital may then be sought, with more specific monoclonal, 
ABScaff or any other improved treatments administered (Figure 3). 
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Figure 3. Comparison of current and future events involved in the diagnosis and treatment of 
snakebite envenoming. 
7. Conclusion 
SBE continues to be one of the most neglected tropical diseases, associated with one of the largest 
annual burdens of all the NTDs (over 1 million people in sub-Saharan Africa alone [221]) and one of 
the highest mortality rates. We need novel strategies in the diagnosis and treatment of SBE. Although 
they are required, are they realistic? Improved diagnosis involves fewer hurdles and will have a 
direct impact on patient outcomes, but the development and licencing of a superior therapy to treat 
snakebites other than antivenom will take time. The World Health Organisation’s SBE working group 
has recently been developing a new strategy “WHO snakebite envenoming road map” [222] which 
aims primarily to augment antivenom production, the only available treatment for snakebite. The 
stockpiling of antivenoms by the WHO will increase affordability and access to this lifesaving drug 
worldwide while scientists continue to improve potential future therapies. However, diagnostics are 
in immediate need of improvement to prevent inappropriate administration of a drug which in much 
of its range is a precious resource [137]. The strategy appreciates that a focus on new treatments and 
effective diagnosis also needs to be made and that the acceleration of preclinical and clinical testing 
of treatments such as Varespladib may well improve hospital survival [222]. 
With climate change, the overlap between humans and venomous snakes seems likely to 
increase, as tropical margins also increase [223]. Added to which, poor waste management and the 
unrelenting rise of rodents alongside the continued expansion of humans into snake territory 
promises to support the rise of SBE throughout the Anthropocene unless something is done. 
Understanding the risk factors contributing to SBE is already leading to simple and cheap methods 
of prevention such as wearing boots and sleeping under mosquito nets. This needs to continue as we 
need to learn to live alongside the natural world, working with it rather than against it; for example, 
despite the dangers of electricity, it has become an essential part of our life. Similarly, even though 
SBE is dangerous, we have to learn to live with snakes to maintain natural biodiversity. While the 
complete eradication of SBE would require an impossible and unethical worldwide extermination of 
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all venomous snake species, the disease can be mitigated. Reducing predators like this will bring 
further problems from increased pest species and disease vectors. The SBE working group has a 
strategy that has the potential to carry out its promise of halving deaths by 2030 [222], by which time 
a non-animal-derived antivenom might just have been approved. Although with reports of drug 
development and approval taking over 15 years and costing up to USD$12 billion, this is by no means 
a foregone conclusion [224]. Novel strategies are undoubtedly emerging and are indeed required if 
this disease is ever to cease being a frequently deadly medical emergency. 
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Conclusion of this chapter 
This chapter analyses the views of South Indian clinicians who come into regular contact with 
snakebite victims. They typically expect to see an increase in cases over the rainy season and 
all treated patients using polyvalent antivenom, with an initial dose of ten vials. Shockingly, 
200 vials were used in one instance, a dosage associated with almost certain adverse effects, 
and highly unlikely to be necessary. The majority of clinicians found identifying the snake of 
importance, though others indicated that due to the lack of specific treatments knowledge of 
the snake was unnecessary. They highlighted the need for diagnostical methods to be 
developed and more efficacious treatments to be made available to them. More efficacious 
treatment will require a better understanding of all the underlying effects, particularly 
surrounding local tissue damage, oxidative stress and the resulting permanent sequelae.  
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a b s t r a c t
Snakebites cause death, disability and economic devastation to their victims, people who live almost
exclusively in rural areas. Annually an estimated two million venomous bites cause as many as 100,000
deaths worldwide as well as hundreds of thousands of deformities and amputations. Recent studies
suggest that India has the highest incidence of snakebite and associated deaths worldwide. In this study,
we interviewed 25 hospital-based clinicians who regularly treat snakebites in Tamil Nadu, India, in order
to gauge their opinions and views on the diagnostic tools and treatment methods available at that time,
the difficulties encountered in treating snakebites and improvements to snakebite management pro-
tocols they deem necessary. Clinicians identified the improvement of community education, training of
medical personnel, development of standard treatment protocols and improved medication as priorities
for the immediate future.
© 2017 Elsevier Ltd. All rights reserved.
1. Introduction
Snakebites are one of the major neglected tropical medical
challenges affecting rural populations worldwide with several
million bites (White, 2000) and around 100,000 deaths each year
(Kasturiratne et al., 2008). India is one of the countries where snake
envenomation is most prevalent, however snakebites in this
country are poorly characterised (White, 2000; Kasturiratne et al.,
2008; Chippaux, 1998; Warrell, 2010; Vaiyapuri et al., 2013). The
medically important snakes in India are considered to be the ‘big
four’: the Russell's viper (Daboia russelii), saw-scaled viper (Echis
carinatus), Indian cobra (Naja naja) and the common krait (Bun-
garus caeruleus), although other medically important snakes have
also been reported (Kochar et al., 2007; Simpson and Norris, 2007;
Sharma et al., 2008; Joseph et al., 2007).
The complexity of snake venoms and their combined action in
victims pose considerable challenges to the treatment of bites.
Currently, the only available treatment in rural India is polyvalent
anti-snake venom (ASV) raised in either horses or sheep against the
venoms of the big four. The efficacy of this ASV against the venom of
snakes that are not one of the big four and big four individuals from
different geographical locations is unclear. Moreover, the adminis-
tration of ASV from horses and sheep regularly leads to dangerous
anaphylactic reactions and problems relating to hypersensitivity
that can last for several days. In India, there are no specific diag-
nostic tools to confirm snakebite occurrence in victims or to identify
the source snake species or family. There is therefore a need to
improve diagnostic methods for snakebites, allowing the family of
the offending snake to be known, appropriate quantities of ASV to
be delivered and the dangers associated with the administration of
ASV by inexperienced individuals to be minimised.
In order to better understand the available diagnostic tech-
niques, treatment methods, difficulties encountered in treating
snakebites and improvements required to current protocols, we
conducted face to face interviews with clinicians who regularly
treat snakebites and present their views in this article.
2. Methods
This study was conducted along with a population survey aimed
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at understanding snakebite incidence and its socio-economic im-
pacts on the rural population of Tamil Nadu, India (Vaiyapuri et al.,
2013). Interviews were conducted with 25 clinicians based in 20
private multi-specialty hospitals in the Indian state of Tamil Nadu.
All the clinicians interviewed had been treating snakebites for at
least six years and nine had more than 20 years of experience. A
standard questionnaire was used to collect their views on snakebite
incidence, diagnosis and treatment. The School of Biological Sci-
ences Ethical Committee review panel at the University of Reading
approved this study and the questionnaire. After obtaining written
consent, the interviews were recorded either in the local language
or in English and later translated by the authors. The appropriate-
ness of translationwas checked prior to the interviews. The authors
performed the interviews and all data were anonymised prior to
analysis.
3. Results and discussion
The clinicians in private hospitals were interviewed between
2010 and 2012 to gauge their opinions about current management
and treatment of snakebites, the difficulties they have experienced
and their views on how snakebite treatment could be improved in
the future. On average, each clinician interviewed, evaluated and
treated 50 snakebite victims per year with some of the referral
hospital physicians seeing more than 100 victims each year
(Table 1). Seventy-five percent of clinicians reported an increase in
hospitalised snakebite cases during the rainy seasons, an observa-
tion that was stable over the years, while 25% observed no seasonal
variations. In all cases, the clinical examination included analysing
symptoms such as vomiting, nausea, bleeding gums, swelling/
infection/bleeding at the bite site, and other physical symptoms. All
the clinicians attempted to find out the time of bite, snake species
and treatments received either from traditional healers or other
medical professionals.
Following whole blood clotting time (WBCT) test and clinical
observations, all clinicians used polyvalent ASV to treat the bites.
Typically, treatment would start with ten vials of ASV, but as many
as 200 vials were used in some cases (Table 1). The typical cost for a
single vial was Rs 400-550. Antibiotics and anti-histamine were the
most common additional treatments reported, and the duration of
a patients stay in hospital ranged from 2 days up to 35 days during
this treatment (Table 1). The clinicians estimated the cost of
treatment to range from Rs 5,000 to Rs 200,000. We found 67% of
clinicians to consider identification of the offending snake impor-
tant in order to determine whether it was likely to have more
haemotoxic or neurotoxic effects. The remaining clinicians felt that
identifying the snake was unimportant; mainly due to the lack of
species-specific treatment.
The clinicians reported a range of time intervals between the
snakebite and the arrival of a victim at hospital. Forty percent of
victims arrived within 30 min and a further 30% of victims arrived
within a few hours of the bite (Table 1). Many also commented that
some patients (approximately 30%) did not come to hospital until
several days after the bite due to treatments sought from locally
available traditional healers. Delays in arrival were considered to
lead to increased envenomation effects and complications, partic-
ularly pulmonary bleeding, renal failure, necrosis, septicaemia,
cerebral bleeding and respiratory failure. In some cases, the delay in
obtaining correct treatments resulted in severe complications
leading to surgery to remove or graft the affected areas. Despite
this, less than five per cent of envenomed patients died in hospitals.
Clinicians were frequently unable to save the lives of snakebite
victims who had cerebral bleeding and pulmonary bleeding, and
this was associated with 80% mortality due to increased compli-
cations. When clinicians were asked to report any unusual snake-
bite cases, two reported early morning neuroparalytic syndrome.
The clinicians infused ASV assuming that this may have been due to
a krait bite, and the victims recovered after 24 h and confirmed that
they had suffered from snakebite.
Clinicians were asked for their opinions on the treatments
currently available and their views on how snakebite prevention
and management could be improved in the future. Each, without
exception, emphasized that current treatments lack efficacy since
knowledge of the snakebite is normally limited, with nothing
known about the species or dose of venom the victim is suffering
from. They also suggested that diagnostic methods for snakebites
should be improved to aid in the identification of snakebite,
particularly in the case of krait bites. The clinicians recommended
that tools must be developed to analyse the pharmacokinetics of
venom activity in victims, and tomonitor the rate of its release from
the bite site into circulation. Developing appropriate diagnostic
tools to identify specific snakebites would improve snakebite
treatment.
Eighty percent of clinicians interviewed considered the use of
polyvalent ASV to be a satisfactory approach, although considered
improvements desirable, particularly to reduce side effects. We
found 70% of clinicians to also recommend further ASV purification,
which could reduce anaphylactic reactions in response to con-
taminants such as albumin and endotoxins. A few clinicians also
recommended the introduction of monovalent ASV, although
confident identification of snake species would be necessary for
this to be effective. Clinicians unanimously recommended that a
standard protocol should be made available and followed. This has
been recommended by others (Alirol et al., 2010; Gutierrez et al.,
2006) and there are recently updated (2016) WHO guidelines
which can be found at apps.searo.who.int/PDS_DOCS/B5255.pdf
and should be made available to all clinicians coming into regular
contact with snakebite victims the world over, as there is a clear
Table 1
Summary of clinicians' interview on complications associated with the diagnosis and treatment of snakebites.
Complications associated with the diagnosis and treatment of snakebites
Number of years involved in treating snakebites 6 - >30 years
Number of patients seen in each hospital 20 - 150 cases/year
Seasonal variations in snakebites Most of the bites occurred in rainy seasons
Preclinical diagnostic methods Vomiting, nausea, bleeding, swelling, infections at the bite site and first aid received
Main treatment method ASV
Number of vials used for treatment Minimum 10 and maximum up to 200
Costs of ASV Rs 400 - Rs 550/vial
Additional treatment options Broad spectrum antibiotics, anti-histamines and blood or plasma transfusion
Hospital stay during treatment Minimum 2 days and maximum 35 days
Treatment costs Minimum Rs 5,000 to maximum Rs 200,000 (went up to Rs 1,000,000 when surgery was required)
Extreme complications seen with snakebites Pulmonary bleeding, cerebral bleeding, acute renal failure and uncontrolled breathing
Percentage of victims that died in hospitals 0-<5%
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lack of knowledge in this area, as displayed by the delivery of up to
200 vials of ASV in some cases (Table 1). Even in private hospitals,
clinicians found there to be no snakebite protocols available. The
production and circulation of protocols could at the very least
prevent such dangerous over-doses and wastage of ASV.
Half of the clinicians recommended that the government should
raise awareness of the dangers of snakebite among the general
population, suggesting the use of advertisements in the local media
and awareness camps in rural areas. Several clinicians wanted to
see better training for those working in rural areas in order to avoid
the unnecessary use of ASV for non-venomous bites and to enable
local practitioners to treat the victims with confidence rather than
referring them to distant hospitals. The clinicians also suggested
that snakebite management should be introduced into the curric-
ulum for medical students.
When asked what advice they had given to victims, clinicians
reported to have given guidance about prevention of future bites by
wearing protective clothing, particularly shoes, taking extra care
when outside, and that patients should avoid home treatments and
instead go straight to hospital. These preventivemeasures have also
been suggested by other researchers (Warrell, 2010; Alirol et al.,
2010), and the WHO's latest guidelines for the management of
snakebite in South East Asia recognise that community education is
the best approach to prevent snakebites (WHO, 2016).
4. Conclusions
In summary, this study emphasizes the difficulties associated
with the currently followed diagnostic and treatment methods
from the clinicians' point of view. This highlights that there is a
need to develop specific diagnostic tools for the confirmation of
venomous snakebites and identification of the source snake family.
Research should be initiated to develop monovalent ASV to specific
snake species, or may be bivalent ASV for the viper and elapid sides
of the big four. We believe that this article could help the govern-
ment officials in Tamil Nadu and India, as well as researchers
working in this area to understand the complications associated
with snakebites and to design strategies to improve the diagnosis
and treatment of snakebites in India.
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3. Aims and objectives of experimental chapters 
 
1. Impact of Naja nigricollis Venom on the Production of Methaemoglobin  
Hypothesis: Snake venoms can oxidise haemoglobin to produce toxic 
methaemoglobin. 
Aims: Ascertain the ability for venoms to oxidise haemoglobin, assess the diversity of 
snake venoms showing potential for oxidising haemoglobin to methaemoglobin and 
establish whether this is a proteolytic effect 
Experimental system: Full wavelength scans using haemoglobin peaks and 
methaemoglobin peaks to assess approximate scale of oxidation 
Chapter connection: This is likely to be a compounding factor to a range of the pathologies 
associated with snakebite envenomation. This effect will be most prominent at the local bite 
site, exacerbating skeletal muscle regeneration and potentially having similar effects on 
myoglobin. 
 
2. Mechanisms underpinning the permanent muscle damage induced by snake 
venom metalloprotease  
Hypothesis: Snake venom metalloproteases cause attenuated regeneration via direct 
effects on the basement membrane 
Aims: Uncover the exact mechanisms by which snake venom metalloproteases cause 
muscle damage and impair regeneration compared to pore-forming three-finger toxins 
Experimental system: protein purification and characterisation in vitro, injection of 




Chapter connection: Muscle damage is a common side effect of snakebite envenomation 
(especially from vipers). The proposed matrix metalloprotease inhibitors batimastat and 
marimastat are one potential option to mitigate this. 
3. Effects of batimastat and marimastat on a group I metalloprotease from the 
venom of Crotalus atrox  
Hypothesis: Commercially available inhibitors can prevent the collagenolytic effects of a P-I 
snake venom metalloprotease in vitro 
Aims: Characterise a P-I snake venom metalloprotease and assess the ability for proposed 
inhibitors and chelators to abrogate its collagenolytic effects 
Experimental system: protein purification and characterisation of inhibitors in vitro; enzymatic 
and ex vivo cell-based assays  
Chapter connection: Proposed adjunctive or alternative therapies such as matrix 
metalloprotease inhibitors (to counteract SVMPs) or melatonin (against oxidative stress and 
methaemoglobin) are likely to be effective in certain envenomations. However, in the case of 
dry bites, or bites from species whose effects are exacerbated by these compounds, they may 
do more harm than good. Therefore, diagnostic tools need to be developed and made 
available to ensure administration only when beneficial. 
4. The detection of snake venom serine proteases using a peptide-based 
approach 
Hypothesis: Using multiple sequence alignment to identify conserved regions in proteins can 
allow the production of toxin-specific antibodies for detection of venoms 
Aims: Develop antibodies with which to detect snake venom serine proteases based on 
specific regions of the toxin 
Experimental system: injection of synthetic KLH-conjugated peptides into sheep; antibody 




Chapter connection: Synthetic peptides are one possible means of developing toxin specific 
antibodies, but the artificial choosing of epitopes may have caused issues with steric 
hindrance. Therefore, the use of whole proteins to develop toxin-specific antibodies may 
provide sufficient epitopes for two-site assays to be possible, allowing for development into a 
lateral flow assay configuration. 
5. Toxin-specific antibodies for the detection of snake venom metalloproteases 
in clinical samples obtained from snakebite victims 
Hypothesis: Purified proteins from venom can be used in the production of antibodies for 
broad ranging detection of viper venoms 
Aims: Purify proteins and develop antibodies with which to detect snake venom 
metalloproteases in two-site assays and lateral flow assays 
Experimental system: protein purification; enzyme linked immunosorbent assays (ELISA) 
and lateral flow assays (LFA) 
Chapter connection: Whole purified proteins provide a means by which to develop antibodies 
specific to that group of proteins and diagnose envenomations including this group of toxins. 
This could indicate treatment with adjunctive small molecular therapeutics, the rapid 
administration with which would reduce muscle damage, haemorrhaging, ischaemia and 
hypoxia. Over time such protocols for the treatment of snakebites will decrease morbidity 
among envenomations and prevent unnecessary administration of drugs and any 
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Conclusion of this chapter 
Part of the high morbidity associated with snakebites is the lack of proper understanding of all 
of the pathologies which can be caused by SBE. This chapter looks at the oxidation of 
haemoglobin to methaemoglobin with a range of snake venoms and hopes to highlight this as 
a common side effect of envenomation. The hypoxia and oxidative stress caused by 
methaemoglobin production will undoubtedly exacerbate local tissue damage and cause 
further detriment in muscle and other tissues already suffering from the direct action of various 
toxins as well as haemorrhage induced ischaemia and lack of blood flow. Added to which, the 
potential for this effect to also be present in myoglobin - the muscular oxygen storage protein 
- is likely to add to the extensive muscle damage associated with snakebites from certain 
species. Melatonin is one suggested treatment for this condition but will rely on accurate 
diagnosis to ensure efficacious administration. 
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Abstract: Snakebite envenomation is an affliction currently estimated to be killing upwards of 100,000
people annually. Snakebite is associated with a diverse pathophysiology due to the magnitude
of variation in venom composition that is observed worldwide. The haemolytic (i.e., lysis of red
blood cells) actions of snake venoms are well documented, although the direct impact of venoms on
haemoglobin is not fully understood. Here we report on the varied ability of a multitude of snake
venoms to oxidise haemoglobin into methaemoglobin. Moreover, our results demonstrate that the
venom of an elapid, the black necked spitting cobra, Naja nigricollis, oxidises oxyhaemoglobin (Fe2+)
into methaemoglobin (Fe3+) in a time- and concentration-dependent manner that is unparalleled
within the 47 viper and elapid venoms evaluated. The treatment of venom with a reducing agent,
dithiothreitol (DTT) is observed to potentiate this effect at higher concentrations, and the use of
denatured venom demonstrates that this effect is dependent upon the heat-sensitive proteinaceous
elements of the venom. Together, our results suggest that Naja nigricollis venom appears to promote
methaemoglobin production to a degree that is rare within the Elapidae family, and this activity
appears to be independent of proteolytic activities of venom components on haemoglobin.
Keywords: Snakebite; venom; methaemoglobin; haemoglobin; neglected tropical disease; spitting cobra
Key Contribution: We demonstrate the impact of Naja nigricollis (the black necked spitting cobra)
venom in the oxidation of haemoglobin to methaemoglobin, which is a toxic species capable of
causing a range of additional issues to envenomed victims.
1. Introduction
Snakebite envenomation is considered to be a major neglected tropical disease. It is estimated
to affect nearly five million people and result in approximately 100,000 deaths annually [1]. It is a
crisis that predominantly impacts upon people living in rural areas of developing nations, and can
induce major socio-economic ramifications [2,3]. Despite the significant impact on the health and
well-being of humans, much remains unknown about the different toxic proteins and peptides that
are the major components of snake venoms [4]. Venomous snakes have been classified into several
Toxins 2018, 10, 539; doi:10.3390/toxins10120539 www.mdpi.com/journal/toxins
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families and sub families, but the vast majority of deaths occur as a result of bites from those found in
Viperidae (Vipers) and Elapidae (Elapids). These two families are very different; vipers are typically
ambush predators that inject a venom composed mainly of large proteins that predominantly affect
haemostasis, while elapids are generally more active hunters, with venoms containing fewer of these
haemotoxic components but instead dominated by neurotoxic and cytotoxic proteins and peptides [5].
Thus elapids are less commonly associated with haemostatic disturbances.
A range of biological activities have been found to be induced by snake venom components,
with many of these proteins targeting the blood, haemostasis and cardiovascular system [6,7]. Serine
proteases and metalloproteases are the most abundant proteins found in viper venoms and they exhibit
various haemotoxic effects. Metalloproteases are able to affect the basement membrane of blood vessels
via collagenolytic activity [8], and several other venom components inhibit or activate platelets by
different mechanisms [9–11]. As well as interacting with platelets and blood vessels, many venom
proteins affect the blood coagulation cascade via coagulatory or anti-coagulatory effects [12]. An array
of different proteins capable of causing haemolysis also exist within snake venoms, for example,
the enzymatic phospholipase A2 (PLA2) which directly cleave the phospholipid bilayer, and the
hydrophobic three-finger toxins, which can bind to the cell membrane to promote lysis [13]. Indeed,
haemolysis can take place to such a degree that haemolytic anaemia has developed in some recorded
cases of snakebites [14]. Haemolysis is a well-known effect of several snake venoms, although their
direct effects on red blood cells (RBCs) and their components are not fully understood, especially given
the oxidative stress typically observed as a secondary effect of certain snake bites [15–17].
In addition to natural intra- or extravascular haemolysis (approximately 10% of RBCs will lyse
as a consequence of wear and tear) and direct lysis by venom components, haemolysis also takes
place as a result of the venom-induced local tissue damage which produces reactive oxygen (ROS)
and nitrogen species that contribute to oxidative damage and further lysis of cells [16]. The release of
haemoglobin (Hb) into the plasma following haemolysis triggers inflammation and oxidative stress as
well as impairing endothelial function. Excessive plasma Hb levels is called haemoglobinemia and it
can induce extreme nitric oxide consumption and clinical sequelae including haemolysis-associated
vasculopathies and endothelial dysfunction [18]. Free plasma Hb is bound rapidly by haptoglobin
in order to inhibit its oxidative activity, and this complex is rapidly removed by the mononuclear
phagocytic system, particularly the spleen [19]. After plasma haptoglobin is saturated, the excessive
Hb is filtered out by the kidneys. Frequently, during envenomation these organs are already under
pressure due to decreased renal blood flow as a result of ischaemia, thrombotic microangiopathy and
rhabdomyolysis. These in turn cause myoglobin deposits in renal tubules [4] and together lead to
acute kidney injury, which is a main systemic complication and is frequently the cause of death in
viper bites [20].
RBCs are essential for the transportation of oxygen to the tissues and delivery of CO2 (or dissolved
HCO3 ) to the lungs; they are entirely dependent upon the oxygen transport protein, Hb. This protein
relies on a prosthetic ferrous (Fe2+) haem group, the ferric oxidation of which renders the protein
(termed as methaemoglobin (MetHb)) unable to transport oxygen (Fe3+), a process which has already
been observed in specific snake venoms [21]. This process takes place at a very low rate naturally,
and MetHb is maintained at <1% by rapid reduction to the ferrous form, a process catalysed by the enzyme
methaemoglobin reductase [22]. Through this reaction, a superoxide free radical is generated but is quickly
dismutated via the enzyme superoxide dismutase forming H2O2 and O2 [23]. Methaemoglobinemia occurs
when the levels of MetHb occur above 2% and serious neurological and cardiovascular symptoms can
develop as a result of hypoxia with levels of approximately 15% and above [24].
Venom-induced oxidative stress appears to be an effect of envenomation that anti-snake venom
(ASV) (the only available treatment for snakebite envenoming) fails to ameliorate [25], and may actually
exacerbate [21]. These effects are reduced by the co-administration of melatonin, an anti-oxidant agent,
along with ASV, and there is evidence to suggest a reduction in methaemoglobinemia as a result [16,21].
However, the scale of oxidative stress and other effects of venom components on the functions of RBCs
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and Hb are yet to be studied in detail. Here, we report the screening of a large number of snake venoms
and specifically characterise the effect of the venom of Naja nigricollis (N. nigricollis) to determine its
impact on the production of MetHb.
2. Results
2.1. A Range of Snake Venoms Induce the Oxidation of Hb
The ability of venoms to oxidise Hb into MetHb has been reported within the family of
Viperidae [15–17,26]. Here, we screened 47 different viper (30) and elapid (17) venoms from the
targeted venom discovery array for the cardiovascular system (T-VDACV) in order to determine the
impact of these on MetHb production. The venoms (0.2 mg/mL) were mixed with an equal volume
of ovine Hb (the supernatant of lysed ovine RBCs) and incubated for 16 h prior to measuring the
absorbance at 500 nm and 630 nm (i.e., absorbance maxima for MetHb). An overnight period of
16 h was used in the experiments in order to determine the maximum impact of venom on MetHb
production. The data suggest that Hb oxidising activity is common among several viper venoms
but this is a rare phenomenon for an elapid snake venom (Figure 1). Notably, the large increase in
absorbance observed in many viper venoms was only evident in the venom of one elapid, N. nigricollis.
As this is a unique feature observed in N. nigricollis venom, we have analysed this effect in greater detail.
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Figure 1. Impact of T-VDACV venom array on MetHb production. Whole snake venoms (0.2 mg/mL)
from the T-VDACV array (Venomtech Limited, UK) targeting the cardiovascular system were dispensed
into 96-well micro titre plates, mixed with an equal volume of ovine Hb, and incubated at 37  C for 16 h.
The absorbance was measured at 500 nm and 630 nm (i.e., the peaks typically observed for MetHb) by
spectrofluorimetry (FLUOstar Optima, BMG Labtech) at 16 h. Data represent mean ± SEM (n = 3), and the
p values (all the values were compared to the negative control [PBS]) were calculated by One-way ANOVA
followed by post-hoc Tukey’s test using GraphPad Prism (* p < 0.05, ** p < 0.01, and **** p < 0.0001).
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2.2. Naja Nigricollis Venom Is Significantly Increasing MetHb Production
To determine the effect of N. nigricollis venom on MetHb production, additional experiments were
performed using ovine Hb. N. nigricollis venom (10 mg/mL was used to achieve a maximum response)
was incubated with ovine Hb and the level of absorbance for Hb and MetHb was measured every 2 h for
16 h. The venom displayed a time-dependent decrease in absorbance at 540 nm and 570 nm (i.e., peaks
observed for Hb) with a corresponding time-dependent increase in absorbance at 500 nm and 630 nm
(i.e., peaks typical of MetHb) (Figure 2A,B). Similarly, the increasing concentrations of N. nigricollis
venom suggest that this venom-induced impact on MetHb production is also concentration-dependent
(Figure 2C,D). Therefore, an optimal concentration of 0.2 mg/mL venom was used in other experiments
in this study. Together these results suggest that the N. nigricollis venom is promoting the oxidation of
oxyhaemoglobin to MetHb in a time- and concentration-dependent manner.
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Figure 2. Time- and concentration-dependent changes in absorbance for MetHb over 16 h. Ovine Hb
was incubated with a control (PBS) (A) or N. nigricollis venom (10 mg/mL to achieve maximum MetHb
production) (B) at 37  C in a plate reader (PHERAStar, BMG Labtech). The absorbance between 400 nm
and 700 nm was measured every 2 h. The peaks typical of oxygenated Hb are at 540 nm and 570 nm,
and those of MetHb are at 500 nm and 630 nm. Furthermore, the N. nigricollis venom was serially
diluted from 1 mg/mL to 0.007 mg/mL and mixed with an equal volume of ovine Hb. It was then
incubated for 16 h at 37  C in a plate reader (FLUOStar Optima, BMG Labtech) and the absorbance
was measured every 2 h at 500 nm (C) and 630 nm (D). The traces shown are representative of three
separate experiments, and they were selected to clearly demonstrate the changes in absorbance for Hb
and MetHb over a period of 16 h.
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2.3. Heat-Denaturation of N. nigricollis Venom Reduces Its Effect on MetHb Production
In order to determine whether the ability of N. nigricollis venom on MetHb production is
dependent on proteins, this venom was heat-denatured prior to using in the assay. The venom
was incubated at two different temperatures, 65  C and 95  C for 10 min and then cooled to
room temperature prior to use in the assay with ovine Hb. Notably, the heat-denatured venom
exhibited significantly reduced MetHb production at 16 h (Figure 3A). This data suggest that MetHb
production may be mediated through proteins that are present in the venoms and they are sensitive to
heat denaturation.
Toxins 2018, 10, x FOR PEER REVIEW  5 of 12 
 
Figure 2. Time- and concentration-dependent changes in absorbance for MetHb over 16 h. Ovine Hb 
was incubated with a control (PBS) (A) or N. nigricollis venom (10 mg/mL to achieve maximum MetHb 
production) (B) at 37 °C in a plate reader (PHERAStar, BMG Labtech). The absorbance between 400 
nm and 700 nm was measured every 2 h. The peaks typical of oxygenated Hb are at 540 nm and 570 
nm, and those of MetHb are at 500 nm and 630 nm. Furthermore, the N. nigricollis venom was serially 
diluted from 1 mg/mL to 0.007 mg/mL and mixed with an equal volume of ovine Hb. It was then 
incubated for 16 h at 37 °C in a plate reader (FLUOStar Optima, BMG Labtech) and the absorbance 
was measured every 2 h at 500 nm (C) and 630 nm (D). The traces shown are representative of three 
separate experiments, and they were selected to clearly demonstrate the changes in absorbance for 
Hb and MetHb over a period of 16 h. 
2.3. Heat-Denaturation of N. nigricollis Venom Reduces Its Effect on MetHb Production 
In order to determine whether the ability of N. nigricollis venom on MetHb production is 
dependent on proteins, this venom was heat-denatured prior to using in the assay. The venom was 
incubated at two different temperatures, 65 °C and 95 °C for 10 min and then cooled to room 
temperature prior to use in the assay with ovine Hb. Notably, the heat-denatured venom exhibited 
significantly reduced MetHb production at 16 h (Figure 3A). This data suggest that MetHb 
production may be mediated through proteins that are present in the venoms and they are sensitive 
to heat denaturation. 
 
Figure 3. Effect of heat, proteolytic activity of venom and a reducing agent (DTT) on MetHb 
production. (A) N. nigricollis venom was heat treated at 65 °C or 95 °C for 10 min prior to cooling the 
venom to room temperature and mixing with ovine Hb. The level of absorbance at 500 nm and 630 
nm was measured after 16 h. (B) SDS-PAGE (Coomassie stained) gel showing the protein profile of 
Hb before (as a control) and after incubation with different concentrations of N. nigricollis venom for 
16 h. Lanes, MW—molecular weight marker, Lane 1 and 4: Venom (12 µg) + haemoglobin (3 µg). Lane 
2 and 5: Venom (6 µg) + haemoglobin (3 µg). Lane 3 and 6: Venom (3 µg) + haemoglobin (3 µg). Lanes 
1-3; after 16 h incubation and lanes 4–6; as controls at 0 h. Lane 7: N. nigricollis venom (3 µg) alone and 
Figure 3. Effect of heat, proteolytic activity of venom and a reducing agent (DTT) on MetHb production.
(A) N. nigricollis venom was heat treated at 65  C or 95  C for 10 min prior to cooling the venom to
room temperature and mixing with ovine Hb. The level of absorbance at 500 nm and 630 nm was
measured after 16 h. (B) SDS-PAGE (Coomassie stained) gel showing the protein profile of Hb before
(as a control) and after incubation with different concentrations of N. nigricollis venom for 16 h. Lanes,
MW—molecular weight marker, Lane 1 and 4: Venom (12 µg) + haemoglobin (3 µg). Lane 2 and 5:
Venom (6 µg) + haemoglobin (3 µg). Lane 3 and 6: Venom (3 µg) + haemoglobin (3 µg). Lanes 1-3;
after 16 h incubation and lanes 4–6; as controls at 0 h. Lane 7: N. nigricollis venom (3 µg) alone and Lane
8: Hb (3 µg) alone. The image shown is representative of three separate experiments. (C) N. nigricollis
venom was treated with various concentrations (0.5 mM, 1 mM or 5 mM) of reducing agent, DTT for
10 min prior to mixing with ovine Hb and incubating for another 16 h. The level of absorbance was
measured as shown above. Data represent mean ± SEM (n = 3). The p values shown were as calculated
by two-way ANOVA followed by post-hoc Tukey’s test using GraphPad Prism 7 (* p < 0.05, ** p < 0.01,
*** p < 0.001 and **** p < 0.0001). The heated (A) or DTT (C)-treated samples were all compared with
the respective positive controls (untreated venom), and the negative control used was PBS.
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2.4. N. nigricollis Venom Does Not Exert Direct Proteolytic Activity on Hb
To determine whether the MetHb production occurs due to proteolytic actions of N. nigricollis
venom on Hb, different concentrations of the venom were incubated with 3 µg Hb overnight along
with controls, and these samples were analysed by SDS-PAGE. As shown in Figure 3B, the venom does
not have any direct proteolytic activity on Hb as the bands for this protein are intact and unaffected
by increasing concentrations of venom over 16 h compared to the controls. These data suggest that
N. nigricollis venom-induced effects on MetHb production are not dependent on direct proteolytic
actions of this venom on Hb, although we cannot rule out the possibilities of the effects of this venom
on other components that regulate MetHb production.
2.5. A Reducing Agent Increases the N. nigricollis Venom-Induced MetHb Production
To assess the impact of a reducing agent on the N. nigricollis venom-induced production of MetHb,
1,4-dithiothreitol (DTT) was used in the assay. The venom was pre-treated with different concentrations
of DTT [we chose a range of concentrations (low to high) including 0.5 mM, 1 mM and 5 mM in
order to analyse the maximum impact of this reducing agent on venom-induced MetHb production]
and then incubated with ovine Hb. The presence of DTT failed to prevent the oxidation of Hb,
and indeed increased the production of MetHb at the highest concentration (5 mM), although at lower
concentrations this increase was not significant (Figure 3C). These data suggest that venom-induced
MetHb production is not diminished by reducing agents such as DTT.
3. Discussion
The proteins found within the snake venoms have a multitude of pharmacological actions
including direct effects on cells. These include cell lysis or blockade of their functions via binding to a
range of receptors and ion channels. They also affect the blood coagulation cascade that is required
for effective haemostasis and the cholinergic disruptions to nerve transmission [27,28]. Moreover, a
number of snake venoms have been reported to induce direct haemolysis and lead to ischemia [29,30].
In this study, we have investigated the effects of a selection of snake venoms on the oxidation of
Hb. Most of the snake venoms tested caused at least a minor increase of absorbance at the selected
wavelength maxima for MetHb, although the elapids’ absorption generally increased to a much lesser
extent than the vipers. Despite this, compared to the other viper and elapid venoms, the largest shift
observed was for the venom of an elapid, N. nigricollis.
In a previous study [21], Naja naja (Indian Cobra) venom was found to have a greater ability to
produce MetHb than two other Indian vipers (Echis carinatus and Daboia russelii). Those results are
inconsistent with the findings from this study where many of the viper venoms including Echis carinatus
had more pronounced effects than Naja naja venom. Although the reasons for these discrepancies are
not entirely clear, they have used human whole blood in their experiments, whereas we have used
ovine Hb. Therefore, their experiments may relate more to the ability of venoms to lyse RBCs (as Hb
would be much more accessible after lysis) than to directly oxidise Hb. We can postulate that single
or multiple venom components may act either directly on Hb or potentially on MetHb reductase to
prevent the equilibrium found under healthy natural conditions. A schematic diagram of our working
hypothetical model of the impact of venom components on the production of MetHb is shown in
Figure 4.
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Figure 4. A schematic diagram hypothesising the impact of venom on MetHb production. Haemolysis
(the lysing of RBCs) by phospholipase A2 (PLA2) and other venom components is a common effect
of snakebite envenoming. In a healthy human, the oxidation of Hb to MetHb is constantly combated
by an enzyme, MetHb reductase. After certain venomous snakebites, this equilibrium is shifted in
favour of MetHb, a toxic species that is also known to be pro-inflammatory. This shift may be a result
of the ROS, which is generated as a metabolite of L-amino acid deamination [via L-amino acid oxidases
(LAAO)] or lipid peroxidation (via PLA2) present in various venoms. The potential mechanisms for
venom-induced changes in MetHb production are shown in the figure as dotted magenta lines.
A previous study using Crotalus molossus nigrescens venom reported that high concentrations
of this venom cause some level of proteolytic degradation to Hb [26]. The same study postulated
that the venom’s conversion of Hb to MetHb is due to the oxidative stress induced by H2O2 which
is produced by venom LAAO [26]. It may be possible that following this, H2O2 then reacts with the
ferrous Hb producing further reactive species via the Fenton reaction [31]. However, N. nigricollis
is a snake with potently cytotoxic venom that lacks LAAOs and is composed largely of three-finger
toxins (73.3%) and PLA2 (21.9%) [32]. These proteins typically bind to cell membrane components
or directly affect the phospholipid bilayer which leads to cell lysis, although they have not been
documented interacting directly with Hb. The lack of LAAO and the abundance of PLA2 in N. nigricollis
venom supports the theory that the phospholipase activity could be indirectly causing this effect as
a result of its oxidative product, arachidonic acid. However, members of the genus Agkistrodon
screened for their Hb oxidising ability (Figure 1) were found to have little or no effects on Hb
despite having a high percentage (31–46%) of PLA2 [33], more than half of which are enzymatic [34].
There is a very small percentage of group III metalloproteases (2.4%) and cysteine-rich secretory
proteins (CRiSPs) (0.2%) found in N. nigricollis venom [32], components that are also found in
viper venoms and are more typically associated with this oxidative effect. The metalloproteases
cause multiple pathologies which contribute to oxidative stress including haemorrhage, thereby
inducing spontaneous haemolysis, liberating Hb and free iron. Metalloproteases are also able to
induce necrosis [35], releasing myoglobin which has implications on the redox balance. After the
degradation of the extra-cellular matrix by metalloproteases, damage-associated molecular patterns
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(DAMPs) are likely to be released, and these can induce further oxidative stress and inflammation [25].
Given the lack of proteases in N. nigricollis venom, the highly cytotoxic PLA2 found in this venom
is more likely to be the primary cause of this oxidation. Hydrolysis of the sn-2 acyl bond of plasma
membrane glycerophospholipids by PLA2 releases free fatty acids such as arachidonic acid as well
as lysophospholipids and lysophosphatidylcholine, and potentially toxic, ROS [25]. The increase
in polyunsaturated fatty acids has also been postulated to cause an increase in lipid peroxidation
following administration of a viper (Echis carinatus) venom, and it may be possible that similar
peroxidation takes place as a result of N. nigricollis venom.
The time- (Figure 2A,B) and concentration- (Figure 2C,D) dependent shift in the absorbance
of Hb/MetHb by N. nigricollis venom demonstrates that the components of this venom are able to
promote the oxidation of Hb. The increase in MetHb production observed over 16 h and at higher
venom concentrations suggests that this effect may increase over time in snakebite victims, and is
dependent on the volume of venom injected by the snake. The increase in MetHb production observed
with the venom that was treated with the highest concentration of DTT suggests that this effect is
actually improved by the addition of a redox reagent. However, at lower concentrations of DTT,
this increase was not observed. We originally hypothesised that the addition of a redox reagent
such as DTT would prevent the production of ROS, and consequently MetHb by taking the place of
antioxidants such as glutathione found naturally in the plasma [36]. The thiol groups of glutathione
act as reducing agents in order to prevent the damage to cellular components by ROS. Therefore,
the surprising increase in MetHb production with the highest concentration of DTT could be due to
the reduction of the tetrameric structure of Hb and consequently, its enhanced oxidation. The decrease
in activity seen with heat treatment of venom provides evidence to suggest that this effect may be
due to the proteins present in the venom. The incubation of venom with purified bovine Hb and
further analysis suggest that this effect is not a result of proteolytic degradation of the Hb. However,
the results of a previous study using a protease-rich viper venom show that high venom concentrations
can lead to proteolytic degradation of Hb. The SDS-PAGE presented here suffers from large protein
bands (~16 kDa) in the crude venom overlapping with the Hb monomer (16.1 kDa), although it is clear
that Hb is still present. Further investigation using non-reducing or native protein electrophoresis is
required to ascertain if there is any degree of proteolysis with N. nigricollis venom on Hb and to further
scrutinise the mechanism of action of this venom on MetHb production.
Venom-induced neurological and coagulation pathologies have long been the two major areas
of interest for scientists to investigate snakebite pathophysiology due to their prominence as the
most immediately life-threatening aspects of a snakebite. However, the morbidity is gaining interest
recently as estimates of as many as 15,000 people annually suffering amputations as a result of
snakebites in sub-Saharan Africa alone [37]. Hence, the disability adjusted life years (DALYs) and
loss to any snakebite-afflicted region’s work force are of serious importance. ASV is currently the
only therapy for snakebite envenoming [4], and while it is effective in saving lives when administered
appropriately, it frequently fails to address some of the long-term damage induced by snake venom
components. This includes myotoxicity and skeletal muscle damage [38,39] as well as oxidative
stress [25], which puts undue pressure on the body that is already suffering from an array of potentially
fatal venom-induced health consequences. Following haemolysis caused either directly by the lysis of
RBCs or as a result of ROS produced by venom components, Hb levels are elevated in the blood. As a
result, this reduces the oxygen-carrying ability of the blood and decreases its ability to meet the oxygen
demand of vital organs. Furthermore, the elevated levels of Hb cause a reduction in free-haptoglobin
levels and can overwhelm the mononuclear phagocytic system, the spleen and eventually the kidneys,
which may lead to acute kidney injury [40]. The additional complication of conversion to MetHb could
potentially allow this toxic Hb species to build up and affect the efficiency of the systems in place to
reduce free Hb. These complications to the blood would then undoubtedly have further effects on
haemostasis and exacerbate existing ischaemic areas, contributing in turn to tissue damage, necrosis
and long-term damage from snakebites.
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In conclusion, we have demonstrated that a wide variety of venoms possess Hb-modifying
activity among a range of viper and elapid snakes. From the venoms tested, we have observed a
significantly higher activity for N. nigricollis venom for the production of MetHb. This effect is likely
to be a result of proteins present in the venom, although further fractionation and characterisation
is required to identify the exact proteins causing these changes. Moreover, most of the experiments
performed in this study used ovine Hb due to availability. However, future experiments will be
performed using human RBCs and Hb. The clinical significance of venoms on MetHb production
and its contribution to envenomation will also be determined in the future. The work highlighting
co-administration of melatonin with ASV is worth pursuing further [21], and the use of antioxidants
in vivo could potentially be developed further to ascertain whether the oxidative stress can be reduced
using flavonoids and their derivatives [41]. Although it may be a less important effect of snakebite
envenomation than the immediately life-threatening elements, the reduction of oxidative stress on
internal organs and tissues following a snakebite is likely to improve recovery and potentially reduce
some of the long-term damage and morbidity as a result.
4. Materials and Methods
4.1. Materials
The cardiovascular targeted-venom discovery array (Catalogue code: T-VDACV) of whole snake
venoms was from Venomtech Limited (Sandwich, UK) and ovine blood was obtained from Envigo
(UK) Ltd. (Oxon, UK). Clear 96- and 384-well plates were purchased from Greiner (Gloucestershire,
UK), and DTT, purified bovine Hb, and all other chemicals were from Sigma Aldrich (Dorset, UK)
4.2. Ovine RBC Lysis and Hb Production
Ovine blood was lysed by the addition of two volumes of ultrapure water followed by
centrifugation (5000⇥ g), and the clear supernatant was collected and used in further assays as
ovine Hb. Although this supernatant is likely to have other components from RBCs, the presence
of a prominent Hb band was confirmed by SDS-PAGE prior to using this as a Hb source in further
functional assays.
4.3. Screening of Venoms for MetHb Producing Activity
The whole snake venoms from the T-VDACV array were diluted in 1⇥ PBS (Fisher Scientific,
Loughborough, UK) (0.2 mg/mL) and mixed with an equal volume of ovine Hb (diluted 1:2 in 1⇥ PBS)
with a final assay volume of 100 µL in a 96-well micro titre plate. These samples were then incubated at
37  C and the absorbance at 500 nm and 630 nm was measured at 16 h by spectrofluorimetry (FLUOstar
Optima, BMG Labtech, Aylesbury, UK).
4.4. Time- and Concentration-Dependent Effect of N. nigricollis Venom on MetHb Production
Ovine Hb diluted (1:2) in 1⇥ PBS was incubated with N. nigricollis venom (at 10 mg/mL or a
range of concentrations between 1 mg/mL and 0.007 mg/mL) or PBS (a negative control) in a 384-well
plate. Plates were incubated at 37  C in a plate reader (PHERAStar, BMG Labtech, Aylesbury, UK)
and the absorbance spectrum between 400 nm and 700 nm was measured at 2-h intervals over 16 h.
After this time, maximum Hb oxidisation appeared to be reached, and therefore, this time point
was chosen for other experiments in this study. Moreover, to determine the impact of heat and a
reducing agent, venom was heat-treated (65  C or 95  C in a dry bath) or treated with a reducing
agent, DTT (0.5 mM, 1 mM or 5 mM) prior to using them in assays. The temperatures (65  C or 95  C)
were determined based on our previous experience in denaturing venom proteins and using them
in functional assays. DTT was specifically selected as this is a less toxic and volatile compared to
 -mercaptoethanol; moreover, DTT prevents the reoxidisation of disulfide bonds in proteins.
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4.5. Sodium Dodecyl Sulfate-Polyacrylamide (SDS-PAGE) Gel Electrophoresis
The SDS-PAGE analysis was performed according to standard procedures as described
previously [42]. The samples were taken before and after incubating a range of concentrations of
venom with purified bovine Hb (Sigma Aldrich, Dorset, UK) at 37  C for 16 h. Samples taken prior
to 16-h incubation were used as controls to compare the impact of venom on Hb before and after the
incubation. These samples were mixed with reducing sample treatment buffer (Bio-Rad, Watford, UK)
and run on a pre-made (Bio-Rad, Watford, UK) 10% SDS-PAGE gel for 40 min at 150 constant volts.
Gels were then stained with Coomassie brilliant blue (Bio-Rad, Watford, UK) for approximately 1 h on
a rocker, before destaining overnight (10% acetic acid/10% methanol/80% H2O).
4.6. Statistical Analysis
All statistical analyses were performed using GraphPad Prism 7. p-Values were calculated using
one-way or two-way ANOVA followed by Tukey’s post-hoc multiple comparisons test.
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and C.W.; Formal Analysis, H.F.W., D.R., H.J.L. and S.V.; Investigation, P.H., A.B., L.C. and C.W.; Methodology,
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Abstract
Snakebite is a major neglected tropical health issue that affects over 5 million people world-
wide resulting in around 1.8 million envenomations and 100,000 deaths each year. Snake-
bite envenomation also causes innumerable morbidities, specifically loss of limbs as a result
of excessive tissue/muscle damage. Snake venom metalloproteases (SVMPs) are a pre-
dominant component of viper venoms, and are involved in the degradation of basement
membrane proteins (particularly collagen) surrounding the tissues around the bite site.
Although their collagenolytic properties have been established, the molecular mechanisms
through which SVMPs induce permanent muscle damage are poorly understood. Here, we
demonstrate the purification and characterisation of an SVMP from a viper (Crotalus atrox)
venom. Mass spectrometry analysis confirmed that this protein is most likely to be a group
III metalloprotease (showing high similarity to VAP2A) and has been referred to as CAMP
(Crotalus atrox metalloprotease). CAMP displays both collagenolytic and fibrinogenolytic
activities and inhibits CRP-XL-induced platelet aggregation. To determine its effects on
muscle damage, CAMP was administered into the tibialis anterior muscle of mice and its
actions were compared with cardiotoxin I (a three-finger toxin) from an elapid snake (Naja
pallida) venom. Extensive immunohistochemistry analyses revealed that CAMP significantly
damages skeletal muscles by attacking the collagen scaffold and other important basement
membrane proteins, and prevents their regeneration through disrupting the functions of sat-
ellite cells. In contrast, cardiotoxin I destroys skeletal muscle by damaging the plasma mem-
brane, but does not impact regeneration due to its inability to affect the extracellular matrix.
Overall, this study provides novel insights into the mechanisms through which SVMPs
induce permanent muscle damage.
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Snakebite is a major neglected tropical disease that affects thousands of people in the rural
areas of developing countries. As well as the deaths, snakebites result in a significant num-
ber of disabilities including permanent loss of limbs that alter the lifestyle of the victims.
Snake venom is a mixture of different proteins with diverse functions; one of these major
protein groups present in viper venoms are metalloproteases that primarily induce muscle
damage. The mechanisms behind the development of snakebite (metalloprotease)-
induced permanent muscle damage are poorly studied. Here, we have purified a metallo-
protease (CAMP) from the venom of the Western diamondback rattlesnake, and charac-
terised its function in mice. To determine the actions of CAMP in the development of
permanent muscle damage, it was injected into the muscle of mice in a parallel compari-
son with cardiotoxin I (from the venom of the Red spitting cobra). The effects of these
proteins on muscle regeneration were analysed at 5 and 10 days after injection. The results
demonstrate that through a combination of effects on the structural scaffolds surrounding
the tissues, blood vessels and regeneration, CAMP significantly affects the muscles,
thereby leading to permanent muscle damage.
Introduction
Snakebite envenomation is a recently reinstated neglected tropical disease [1] that causes
around 100,000 deaths annually [2, 3] and innumerable permanent disabilities predominantly
on the rural population living in the lower income regions of the world [4–6]. The significant
rate of mortality and morbidity occurs due to the difficulties associated with the treatment of
snakebites [7], which vary depending on the species [8], geographical location [9], age of the
offending snake [10, 11], the quantity of venom injected, correct diagnosis and mode of treat-
ment [12]. Snake venoms contain proteins and small peptides with diverse functional effects
[12]. Medically important snakes are generally found in two main families; Elapidae, a family
with venoms mainly composed of smaller, neurotoxic proteins such as phospholipase A2
(PLA2) and three finger toxins, and Viperidae, a family with generally larger proteins such as
serine and metalloproteases that primarily affect the cardiovascular and musculoskeletal sys-
tems. Snake venom serine proteases (SVSPs) mainly cause systemic envenomation effects such
as the alteration of blood pressure, activation or inhibition of coagulation factors and degrada-
tion of fibrinogen [13, 14]. However, snake venom metalloproteases (SVMPs) primarily
induce local envenomation effects such as swelling, necrosis and extensive tissue/muscle dam-
age as well as the activation of certain coagulation factors and degradation of fibrinogen.
SVMP-induced muscle damage is often difficult to treat due to the delay in obtaining appro-
priate medical treatment and poor outcome of anti-snake venom (ASV) treatment in the local
tissues [15, 16]. Hence, extensive tissue damage is frequently treated by fasciotomy, a surgical
procedure to remove the damaged tissues, cleaning the affected areas followed by skin graft or
amputation of affected limbs or fingers when fasciotomy fails to suffice [7]. This results in per-
manent disabilities for victims, and significantly affects their socio-economic status following
snakebites. For example, long term (persisting for over 13 years) musculoskeletal disabilities
were found in over 3% of snakebite victims in a rural population of Sri Lanka and of these over
15% had to undergo amputations [17].
Skeletal muscle is composed of myofibres surrounded by the collagen-rich basement mem-
brane. This tissue is imbued with a resident stem cell population called satellite cells (SCs),
located under that basement membrane (BM), which are able to regenerate a functional tissue
even after extensive damage [18]. The BM plays a key role in muscle repair by orientating the
Snake venom metalloprotease-induced permanent muscle damage
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regenerating myofibres, a process mediated by SCs and acting as a scaffold for fibres to grow
parallel to the existing fibres [19]. The majority of the direct myotoxic effects of venoms are
attributed to PLA2 [20]. They can induce either local or systemic effects depending on their
specificity to muscle cells (systemic effects) or a broader range of cells (local effects) through
hydrolysis of phospholipids in plasma membrane. Other myotoxic venom components
include sodium channel-blocking myotoxins [21] and muscle fibre depolarising cardiotoxins
[22]. SVMPs are enzymatic proteins that primarily attack the collagenous structures and vari-
ous other important components of BM to induce muscle damage. It has recently been
reported that SVMPs induce haemorrhage by cleaving components of the BM and extracellu-
lar matrix surrounding the smaller blood vessels [23] although as multi-domain proteins, they
are capable of binding to and cleaving a range of different proteins [24, 25].
SVMPs are generally classified into four groups based on the additional domains present in
their structure: PI/Group I—contains only a metalloprotease domain; PII/Group II—contains
a metalloprotease and disintegrin domain, and in some cases the disintegrin domain has been
reported to be processed and liberated as a free disintegrin; PIII/Group III—contains a metal-
loprotease, a disintegrin-like and cysteine-rich domains; PIV/Group IV—contains two lectin-
like domains connected by disulphide bonds to the other domains that are found in PIII
SVMPs [26]. Although disintegrin-like domains show high sequence identity to disintegrins,
they lack the typical RGD motif found in the venom disintegrins, which inhibit platelet aggre-
gation via selectively blocking integrins. Both disintegrin-like and cysteine-rich domains have
been found to inhibit collagen-induced platelet aggregation and induce early events of acute
inflammation [27]. Notably, disintegrin-like domains were reported to contain an ECD motif
that interacts with integrins and block their functions [28]. The non-proteinase domains play
key roles in determining the diverse pharmacological effects of PII, PIII and PIV classes of
SVMPs including the activation of coagulation factor X [29] and prothrombin [30] amongst
others. These domains have also been found to co-localise in muscles, facilitating the hydroly-
sis of collagen and other BM components by the metalloprotease domain and promoting its
accumulation in the BM [24], exerting haemotoxic activities. Moreover, SVMPs are also
known to cause ischaemia in the local tissues due to poor blood supply as a result of their hae-
motoxic effects [31], which may prevent phagocytic removal of necrotic debris and reduce the
supply of oxygen and nutrients needed for regeneration [32]. Given the complexity of their
actions, a better understanding of the molecular mechanisms through which SVMPs induce
permanent muscle damage may pave the way to the development of improved therapeutic
strategies for snakebites. In this study, we demonstrate novel insights into the mechanisms by
which a PIII/group III metalloprotease isolated from the venom of a North American viper,
the western diamondback rattlesnake, Crotalus atrox triggers permanent muscle damage. Our
results establish that this SVMP induces muscle damage and also prevents muscle regeneration
by acting on the BM, myofibres, blood supply and SCs.
Materials and methods
Materials
Lyophilised C. atrox venom was purchased from Sigma Aldrich (UK) and the purified Cardio-
toxin 1 (CTX), a three-finger toxin from the venom of Naja pallida was obtained from Latoxan
(France).
Protein purification
C. atrox venom (10mg) was dissolved in 1mL of 20mM Tris.HCl buffer (pH 7.6) and centri-
fuged at 5000g for 5 minutes before applying to a pre-made 1mL HiTrap™ Q HP Sepharose
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anion exchange column. Protein elution was performed at a rate of 1mL/min using 1M NaCl/
20mM Tris.HCl gradient (up to 60%) by an ÄKTA purifier system (GE Healthcare, UK) over
20 minutes. The collected fractions were analysed by SDS-PAGE using standard protocols as
described previously [33] and fractions with the protein of interest were pooled. The pooled
fractions were then concentrated using a Vivaspin centrifugal filter and applied to a gel filtra-
tion column (Superdex 75, 1.6cm x 70cm). Protein elution was performed at a rate of 1mL/
min using 20mM Tris.HCl (pH 7.6). Following SDS-PAGE analysis, the fractions containing
the protein of interest were pooled and concentrated before running through the same gel fil-
tration column again for further purification. Finally, the fractions containing the pure protein
were pooled, concentrated and stored at -80˚C until further use. Protein estimation was per-
formed using Coomassie plus protein assay reagent (ThermoFisher Scientific, UK) and bovine
serum albumin as standards.
Mass spectrometry
The purified protein was subjected to SDS-PAGE, and a gel section containing the pure pro-
tein was subjected to tryptic digestion and analysed by mass spectrometry at AltaBioscience
(Birmingham, UK). The extracted protein (10μg) from the gel slice was added to 100mM
ammonium bicarbonate (pH 8). This was then incubated with dithiothreitol (10mM) at 56˚C
for 30 minutes. After cooling to room temperature, the cysteine residues were alkylated using
iodoacetamide (50mM). Trypsin gold (Promega, UK) was subsequently added and the samples
were incubated overnight at 37˚C. The digested peptides were concentrated and separated
using an Ultimate 3000 HPLC series (Dionex, USA). Samples were then trapped on an
Acclaim PepMap 100 C18 LC column, 5um, 100A 300um i.d. x 5mm (Dionex, USA), then fur-
ther separated in Nano Series Standard Columns 75μm i.d. x 15 cm. This was packed with C18
PepMap100 (Dionex, USA) and a gradient from 3.2% - 44% (v/v) solvent B (0.1% formic acid
in acetonitrile) over 30 minutes was used to separate the peptides. The digested peptides were
eluted (300nL/min) using a triversa nanomate nanospray source (Advion Biosciences, USA)
into a LTQ Orbitrap Elite Mass Spectrometer (ThermoFisher Scientific, Germany). The MS
and MS/MS data were then searched against Uniprot using Sequest algorithm and the partial
sequence was then compared to the other similar protein sequences available in the protein
database.
Fibrinogenolytic assay
Human plasma fibrinogen (100μg/mL) was incubated with different concentrations of the
whole venom or the purified protein, and a small volume of digested samples were removed at
30, 60, 90 and 120 minutes and mixed with reducing sample treatment buffer [4% (w/v) SDS,
10% (v/v) β-mercaptoethanol, 20% (v/v) Glycerol and 50mM Tris.HCl, pH 6.8]. The samples
were then analysed by 10% SDS-PAGE and stained with Coomassie brilliant blue to determine
the fibrinogenolytic activity of venom and the purified protein.
Enzymatic assays
The metalloprotease activity of both C. atrox whole venom and the purified protein was
assessed using a fluorogenic substrate, DQ-gelatin (ThermoFisher Scientific, UK). Briefly, the
whole venom or purified protein (10μg/mL) was mixed in phosphate buffered saline (PBS, pH
7.4) with DQ gelatin (10μg/mL). The reaction mix was incubated at 37˚C and the level of fluo-
rescence was measured at 60 minutes using an excitation wavelength of 485nm and emission
wavelength of 520nm by spectrofluorimetry (FLUOstar OPTIMA, Germany).
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Similarly, the serine protease activity was measured using a selective substrate, Nα-Benzoyl-
L-Arginine-7-Amido-4-methylcoumarin hydrochloride (BAAMC) (Sigma Aldrich, UK). The
whole venom or the purified protein (10μg/mL) was incubated with BAAMC (2μM) at 37˚C
and the level of fluorescence was measured at an excitation wavelength of 380nm and emission
wavelength of 440nm by spectrofluorimetry.
Ethical statement
The University of Reading Research Ethics Committee has approved the procedures for blood
collection from healthy human volunteers and the consent forms used to obtain written con-
sent. Experiments with mice were performed in line with the principles and guidelines of the
British Home Office and the Animals (Scientific Procedures) Act 1986 (PPL70/7516). All the
procedures were approved by the University Research Ethics Committee (License number:
UREC 17/17).
Platelet aggregation
Human blood was obtained from healthy volunteers in vacutainers with 3.2% (w/v) sodium
citrate as an anti-coagulant and the platelet-rich plasma (PRP) was prepared as described pre-
viously [34–36]. Platelet aggregation assays were performed by optical aggregometry using
0.5μg/mL cross-linked collagen related peptide (CRP-XL) as an agonist in the presence and
absence of different concentrations of the purified protein.
Administration of CTX or the purified protein in mice
The C57BL/6 mice (8 weeks old) were obtained from Envigo, UK. Mice were anaesthetised
with 3.5% (v/v) isofluorane in oxygen before maintaining at 2% for the procedure. They were
then injected intramuscularly with 30μL of either PBS (undamaged control), 50μM CTX, and
8 or 16 μM of the purified protein into their right tibialis anterior muscle. Mice were then
allowed to recuperate for either 5 or 10 days before sacrificing by carbon dioxide asphyxiation
and cervical dislocation.
Dissection of tibialis anterior (TA) and extensor digitorum longus (EDL)
The TA muscles from mice were dissected, weighed and frozen on liquid nitrogen cooled iso-
pentane prior to storage at -80˚C. The EDL muscle was dissected from the undamaged contra-
lateral hind limb of experimental mice and immediately placed in a 2mg/mL collagenase solu-
tion (Sigma Aldrich, UK) and incubated at 37˚C with 5% CO2 for 2 hours to isolate the single
fibres as previously described [37].
Proliferation and migration of satellite cells
To determine the proliferation of SCs and myogenic differentiation, isolated single fibres were
cultured for up to 48 hours at 37˚C with 5% CO2 in single fibre culture medium (SFCM—
DMEM, 10% (v/v) horse serum, 1% (v/v) penicillin-streptomycin and 0.5% (v/v) chick embryo
extract) supplemented with either 0, 0.3, 1 or 3 μM of the purified protein prior to fixation in
2% (w/v) paraformaldehyde in PBS and maintained in PBS prior to immunocytochemistry.
The migration of muscle fibre SCs was analysed as described previously [37]. Briefly, the
isolated single fibres were cultured for 24 hours in SFCM before transferring to SFCM contain-
ing 0, 0.3, 1 or 3μM of the purified protein and monitoring by a phase contrast microscope at
37˚C with 5% CO2 using a 10X objective. A time-lapse video was captured at a rate of 1 frame
every 15 minutes for a 24-hour period and analysed to determine the rate of migration.
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Immunohistochemistry
The collected TA muscles were mounted in Tissue-TEK1OCT compound in an orientation
allowing the transverse sections of 13μm thickness to be obtained using a cryo microtome. The
tissue sections were incubated in permeabilisation buffer [20mM HEPES, 3mM MgCl2, 50mM
NaCl, 0.05% (w/v) sodium azide, 300mM sucrose and 0.5% (v/v) Triton X-100] for 15 minutes
at room temperature. To remove the excess permeabilisation buffer, 3 x 5 minute washes were
performed using PBS before the application of wash buffer [PBS with 5% fetal bovine serum
(v/v), 0.05% (v/v) Triton X-100] for 30 minutes at room temperature.
Primary antibodies were pre-blocked in wash buffer for 30 minutes prior to application
onto muscle sections overnight at 4˚C. In order to remove the primary antibodies, muscle sec-
tions were washed three times (5 minutes each) in wash buffer. The sections were then incu-
bated with species-specific secondary antibodies that were conjugated with Alexa Fluor 488 or
594. The secondary antibodies were pre-blocked in wash buffer for minimum of 30 minutes
before their application onto the slides and incubated for 1 hour in the dark at room tempera-
ture. Thereafter, the muscle sections were washed 3 x 5 minutes in PBS to remove the unbound
secondary antibodies. Finally, the slides were mounted in fluorescent mounting medium, and
the myonuclei were visualised using 4, 6-diamidino-2-phenylindole (DAPI) (2.5μg/mL). The
images of sections were obtained using a fluorescence microscope (Zeiss AxioImager) and
analysed using ImageJ. Macrophages were detected by F4.80 staining using the Vector Labora-
tories ImmPRESS Excel Staining Kit. A list of antibodies used in this study is provided in S1
Table.
Statistical analysis
All the statistical analyses were performed using GraphPad Prism 7 and the P-values were cal-
culated using one-way ANOVA followed by Dunnett’s post hoc multiple comparisons test.
Results
Protein purification and identification
In order to purify a protein with a molecular weight of around 50kDa (as predicted for group
III SVMPs) from the venom of C. atrox, a two-dimensional chromatography approach was
employed. Following the initial fractionation of venom via anion exchange chromatography
(Fig 1A and 1B), the selected fractions (14–18) with a highly abundant protein at approxi-
mately 50kDa were pooled and run through a gel filtration chromatography column (Fig 1C
and 1D). The fractions (62–67) were pooled and run through the same gel filtration column
again to refine the purification (Fig 1E and 1F). Finally, a pure protein with a molecular weight
of around 50kDa was isolated. Mass spectrometry characterisation of the tryptic digested pep-
tides of this protein and further Mascot analysis confirmed it to be a similar or identical pro-
tein to vascular apoptosis inducing proteins (VAP) such as VAP2, a protein with a molecular
weight of 55kDa (an identical molecular weight to the purified protein) [38], which is a group
III metalloprotease (Fig 1G). The identified peptide sequences of the purified protein covered
around 43% of the sequence of VAP2A (highlighted in red in Fig 1G). The purified protein has
been referred to as ‘CAMP’ to denote C. atrox metalloprotease throughout this article.
Fibrinogenolytic and collagenolytic activities of CAMP
By using fluorogenic substrates, the protease activity of CAMP was analysed in comparison to
the whole venom. CAMP displayed no serine protease activity as it failed to cleave a serine pro-
tease selective fluorogenic substrate, BAAMC although the whole venom displayed significant
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serine protease activity (Fig 2A). However, it showed high levels (similar to the whole venom)
of collagenolytic activity (Fig 2B). Furthermore, the ability of CAMP to digest fibrinogen was
analysed by incubating it with human plasma fibrinogen. The SDS-PAGE analysis of samples
that were taken at different points of incubation confirmed that CAMP is capable of cleaving
Aα and Bβ chains of fibrinogen although it was unable to cleave the γ chain (Fig 2C). The
digestion of fibrinogen with CAMP appears to be rapid as the levels of Aα and Bβ chains of
fibrinogen were reduced significantly as early as 30 minutes of incubation. These results cor-
roborate CAMP as an SVMP with collagenolytic and fibrinogenolytic activities, which may
affect the collagen in the BM around the local tissues at the bite site and fibrinogen in the
blood.
CAMP inhibits human platelet aggregation
The ability of CAMP to inhibit agonist-induced platelet activation was analysed using human
platelet-rich plasma (PRP) by optical aggregometry. The pre-treatment of human platelets
(PRP) with CAMP (50μg/mL) has significantly inhibited 0.5μg/mL CRP-XL-induced platelet
aggregation (Fig 2D and 2E). This data confirms the ability of CAMP to affect human platelet
activation.
CAMP induces haemorrhage and fluctuations in muscle size in mice
In order to determine the mechanisms through which SVMPs induce permanent muscle dam-
age, CAMP was used as a tool to determine its pathological effects in TA muscle of mice in
comparison with CTX. The intramuscular injection of CAMP induced haemorrhage in the
damaged muscles and thereby, caused swelling and increase in muscle weight after five days of
administration (Fig 3A and 3B). However, CTX did not induce haemorrhage or swelling
although the muscle weight was reduced compared to the controls at the same time point. In
contrast, after ten days of administration, muscle weight in CAMP-treated mice was decreased
similar to CTX-treated muscle (Fig 3A and 3C). These data demonstrate that CAMP is capable
of inducing haemorrhage and swelling and thereby, increases in muscle weight initially
although it decreases at a later time point.
Attenuated regeneration in CAMP-damaged muscle
We examined the cellular processes underpinning the morphology of skeletal muscle and
assessed muscle regeneration after damage induced by CAMP. Haematoxylin (H) and eosin
(E) staining facilitates the identification of cellular organisation within a tissue and also the
presence of fibres containing centrally located nuclei (CLN), which is an indicator of muscle
regeneration. Five days after tissue damage, muscles treated with CTX contained many large
fibres with CLN (Fig 4A). Furthermore, there were regions of high cell density between fibres
displaying CLN. In contrast, 5 days after CAMP damage the number of fibres with CLN was
less abundant and smaller than in CTX damaged muscle (Fig 4A and 4B). Additionally, there
were areas of sparsely populated regions between fibres. Ten days after CTX damage, large
Fig 1. Purification of CAMP from the venom of C. atrox. A, A chromatogram demonstrates the purification profile of 10mg of whole C. atrox
venom by anion exchange chromatography. B, a Coomassie stained gel displays the protein profile of whole C. atrox venom and fractions 11–18 of
anion exchange chromatography. A chromatogram (C) and Coomassie stained gel (D) show the purification profile of fractions 14–18 of anion
exchange chromatography by gel filtration. E, a chromatogram of the second step of gel filtration for fractions 62–67 from the previous step and (F)
a Coomassie stained gel shows the purified protein at approximately 50kDa. G, the tryptic digested samples of the purified protein were analysed by
mass spectrometry and the identified peptide sequences match (via Mascot search) with the known sequence of VAP2A (coverage 43%; the mass
spectrometry-identified peptide sequences of the purified protein are shown in red) and confirms that the purified protein is most likely to be VAP,
a group III metalloprotease. The purified protein was named as CAMP to represent C. atrox metalloprotease.
https://doi.org/10.1371/journal.pntd.0007041.g001
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Fig 2. The functional characterisation of CAMP. A, the serine protease activity of 10μg/mL whole venom or CAMP was analysed using a fluorogenic substrate, Nα-
Benzoyl-L-Arginine-7-Amido-4-methylcoumarin hydrochloride (BAAMC) by spectrofluorimetry. Similarly, (B) the metalloprotease activity of 10μg/mL whole venom
or CAMP was analysed using DQ-gelatin, a specific fluorogenic substrate for collagenolytic enzymes and the level of fluorescence was measured by spectrofluorimetry.
C, a Coomassie stained gel demonstrates the fibrinogenolytic activity of CAMP in comparison with whole C. atrox venom. Lanes, 1—undigested fibrinogen, 2—
fibrinogen incubated with whole venom (100μg/mL), fibrinogen incubated with CAMP (100μg/mL) after 30 (3), 60 (4) and 90 (5) minutes, fibrinogen incubated with
CAMP (50μg/mL) after 30 (6), 60 (7) and 90 (8) minutes, and CAMP alone (9). Representative aggregation traces (D) and data (E) demonstrate the impact of CAMP on
cross-linked collagen related peptide (CRP-XL)-induced human platelet (PRP) aggregation. Data represent mean ± S.D. (n = 3). The p values shown are as calculated by
One-way ANOVA followed by post hoc Tukey’s test using GraphPad Prism (⇤⇤p<0.01, ⇤⇤⇤p<0.001 and ⇤⇤⇤⇤p<0.0001).
https://doi.org/10.1371/journal.pntd.0007041.g002
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fibres with CLN were evident with very little space between muscle fibres (Fig 4C and 4D).
The fibres appeared to be regular in terms of shape and size, evidencing robust muscle regen-
eration. Whereas, at the same time point, muscle damaged with CAMP displayed smaller
fibres with CLN and inter-fibre regions populated with cells were prominent (Fig 4C and 4D).
Next, we documented the profile of dying muscle fibres, facilitating the infiltration of circulat-
ing immunoglobulins (Ig) into the damaged fibres. Five days after CTX injection, low density
of small calibre fibres displayed the infiltration by IgG (Fig 4E–4G). In contrast, at the same
time point, CAMP treatment resulted in not only a higher density of fibres with infiltrated
IgG, but they were also of larger size (Fig 4E–4G). By day 10, very few dying fibres were present
in CTX treated muscle, however dying fibres were prominent in CAMP treated muscles (Fig
4H and 4I). We then examined the presence of regenerating muscle fibres, facilitated through
the expression of embryonic myosin heavy chain protein (MYH3). Muscle regeneration was
clearly evident in muscles damaged by CTX at day 5 (Fig 4J and 4K). Large numbers of evenly
sized fibres expressing MYH3 featured in CTX-damaged tissue (Fig 4J and 4L). In contrast to
CTX treatment, the number of regenerating fibres in CAMP-treated muscle was lower and
when present were of heterogeneous size (Fig 4J–4L). By Day 10, the expression of MYH3 has
been cleared in CTX-damaged muscle and when present was in very large fibres (Fig 4M–4O).
In contrast, MYH3 expression was clearly evident at day 10 in CAMP-damaged muscle but in
smaller, non-uniform fibres (Fig 4M–4O). Next, we examined the impact of CAMP and CTX
on blood vessels through immunostaining with the endothelial cell specific antibody, CD31.
Fig 3. Macrostructure of tibialis anterior muscle after CAMP treatment. A, representative images of muscles treated with either CTX or CAMP for 5 or 10 days.
Quantification of TA weight at 5 (B) and 10 (C) days post administration. Scale bar represents 5 mm. Data represent mean ± S.D. (n = 5 for each cohort). The p values
shown are as calculated by One-way ANOVA followed by post hoc Tukey’s test using GraphPad Prism (⇤p<0.05, ⇤⇤p<0.01 and ⇤⇤⇤p<0.001).
https://doi.org/10.1371/journal.pntd.0007041.g003
Snake venom metalloprotease-induced permanent muscle damage
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007041 January 29, 2019 10 / 20
79
At both 5 and 10 days, the number of capillaries serving each regenerating fibre was greater in
the CTX treated sample compared to CAMP (Fig 4P–4S). Importantly, the number of capillar-
ies serving each regenerating fibre in the CTX treated sample was identical to the undamaged
sample. Moreover, the degree of macrophage infiltration into the damaged area was analysed,
as these cells are key to effective muscle regeneration. The density of macrophages in damaged
muscle was greater in the CTX treated muscle compared to CAMP at day 5 (Fig 4T and 4U).
However, by day 10, the situation was reversed; there was a greater density of macrophages in
the CAMP treated samples compared to CTX (Fig 4V and 4W).
CAMP extensively damages the extracellular matrix (ECM) surrounding
the myofibres
Efficient regeneration of skeletal muscle following acute damage is contingent on stem cells
capable of replacing damaged tissue and their highly ordered formation into myotubes/fibres,
a process orchestrated by the ECM. The organisation of collagen IV, a major BM component
of muscle fibres was analysed as described previously [39]. A thin circle of collagen IV sur-
rounding muscle fibre was evident 5 days after CTX treatment (Fig 5A). In contrast, at an
Fig 4. Analysis of tibialis anterior muscle regeneration after administration of CAMP or CTX. A, H and E staining of muscle identifying centrally located fibre nuclei
(CLN) (arrows) and (B) quantification of centrally located muscle fibre size 5 days post administration. C, H and E staining of muscle (arrows) and (D) quantification of
centrally located muscle fibre size 10 days post administration. E, intra-fibre IgG localisation for necrotic muscle fibres (arrows) and quantification of necrotic fibre
density (F) and size (G) 5 days post administration. H, intra-fibre IgG localisation for necrotic fibres (arrows) and (I) quantification of necrotic fibre density 10 days post
administration. J, identification of regenerating muscle fibres through the expression of MYH3 (arrows) and quantification of regenerating muscle fibre density (K) and
size (L) 5 days post administration. M, identification of regenerating muscle fibres through the expression of MYH3 (arrows) and quantification of regenerating muscle
fibre density (N) and size (O) 10 days post administration. P, Localisation of endothelial marker CD31 and (Q) quantification of capillaries per regenerating muscle fibre
5 days post administration. R, localisation of endothelial marker CD31 and (S) quantification of capillaries per regenerating muscle fibre 10 days post administration. T,
immunostaining with antibody F4/80 and (U) its density quantification in damaged region 5 days post administration. V, immunostaining with antibody F4/80 and (W)
its density quantification in damaged region 10 days post administration. Data represent mean ± S.D. (n = 5 for each cohort). The p values shown are as calculated by two-
tailed Student’s T test for independent variables using GraphPad Prism (⇤p<0.05, ⇤⇤p<0.01 and ⇤⇤⇤p<0.001).
https://doi.org/10.1371/journal.pntd.0007041.g004
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identical time after CAMP treatment, muscle displayed large irregular, thick depositions of
collagen IV (Fig 5A and 5B) but by day 10, the picture was even more polarised, as CTX-dam-
aged muscle showed a relatively normal distribution of collagen IV (Fig 5C and 5D). In con-
trast, very few fibres from CAMP-treated muscle (at day 10) displayed a ring of collagen IV,
and instead this protein was localised at thick foci (Fig 5C and 5D). A near-identical pattern
was documented for the distribution of laminin, another major component of the muscle fibre
ECM (Fig 5E–5H).
Furthermore, the impact of CTX and CAMP on molecules that are associated with linking
the contractile apparatus to the ECM was investigated. Dystrophin is normally localised under
the sarcolemma of mature muscle fibres. Its expression was evident around some of the larger
Fig 5. Immunohistochemical analysis of muscle extracellular matrix and associated proteins after tibialis anterior damage with CAMP or CTX. Localisation
(arrows) (A) and thickness (B) of collagen IV 5 days post administration. Similarly, localisation (arrows) (C) and thickness (D) of collagen IV 10 days post injury. Note:
CTX damaged tissues show circumferential collagen compared to foci in CAMP treatment. Localisation (arrows) (E) and thickness (F) of laminin 5 days post injury.
Localisation (arrows) (G) and thickness (H) of laminin 10 days post injury. I, localisation of dystrophin 5 days post injury (arrows). Note: dystrophin around centrally
located nuclei in CTX-treated muscle. In contrast, incomplete dystrophin domain around CAMP-damaged muscle. J, intensity of dystrophin 5 days post injury.
Localisation (arrows) (K) and intensity (L) of dystrophin 10 days post injury. M, localisation of nNOS 5 days post injury (no circumferential nNOS was detectable at day 5)
and (N) thickness of nNOS 5 days post injury. O, localisation of nNOS 10 days post administration (arrows). Note: circumferential nNOS was only detectable in CTX-
treated muscle and (P) intensity of nNOS 10 days post injury. Localisation of CAMP in damaged region at day 5 (Q) and 10 (R) (arrows). Data represent mean ± S.D.
(n = 5 for each cohort). The p values shown are as calculated by One-way ANOVA followed by post hoc Tukey’s test using GraphPad Prism (⇤p<0.05, ⇤⇤p<0.01 and
⇤⇤⇤p<0.001). CNT represents control.
https://doi.org/10.1371/journal.pntd.0007041.g005
Snake venom metalloprotease-induced permanent muscle damage
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007041 January 29, 2019 12 / 20
81
regenerating muscle fibres 5 days after CTX damage (Fig 5I). Whereas, very few fibres express-
ing dystrophin were detected at a similar time point in CAMP-treated muscles (Fig 5I). How-
ever, when present, the thickness of the dystrophin expression domain was similarly reduced
by the two treatments (Fig 5J). At day 10, most of the fibres from CTX-treated muscle dis-
played a continuum of dystrophin expression, although at a lower thickness compared to
undamaged tissue (Fig 5K and 5L). However, very few fibres with a ring of dystrophin were
present in CAMP-treated muscles at day 10 (Fig 5K). Furthermore, the domain, when present
was thinner than both control as well as CTX treated muscles (Fig 5L). Then, the distribution
of nNOS, a protein that localises to a sub-sacrolemmal position which is dependent on its
binding to dystrophin was assessed. At 5 days after treatment, very little nNOS was present in
either CTX or CAMP-damaged muscles (Fig 5M and 5N). By day 10, a thin band of nNOS was
evident in CTX-treated muscle but not in the muscle damaged by CAMP (Fig 5O and 5P).
Lastly, the muscles were analysed to determine the presence of remaining CAMP in damaged
tissues. The immunohistological profiling showed that CAMP was clearly present at both 5
and 10 days after its administration (Fig 5Q and 5R). These results show that CAMP treatment
damages not only the ECM of muscle fibres but also affects intracellular components that link
it to the contractile machinery.
CAMP affects the functions of satellite cells (SCs)
The role of SCs adjacent to the muscle fibres is critical for muscle regeneration. In order to
determine the impact of CAMP on SCs, we have isolated myofibres from intact EDL muscles
and exposed them to a range of concentrations of CAMP. As early as 24 hours after CAMP
treatment, it was evident that there was a concentration dependent disturbance to the collagen
component of the ECM around muscle fibres. A uniform layer of collagen expression was
detected in untreated fibres (Fig 6A). At the lower concentration, CAMP caused a localised
denuding of the myofibre (Fig 6B), whereas the higher concentration resulted in the absence
of collagen from most parts of the fibres and caused it to concentrate in specific locations (Fig
6C). The cell growth, proliferation and migration were monitored on the isolated single mus-
cle myofibres over a 48 hour time period. SCs were immunostained using the myogenic tran-
scription factors, Pax7 (uncommitted cells) and MyoD (activated cells) in order to monitor the
progression of cells through myogenesis. The concentrations of above 0.3μM of CAMP
induced hypercontraction, which is indicative of extensive fibre damage. At 0.3μM, viable
fibres were present, and revealed that CAMP significantly decreased the number of associated
SCs (Fig 6D). Furthermore, the number of SC clusters was reduced per fibre (Fig 6E), although
each cluster at the lower concentration had more cells than untreated fibres (Fig 6F). Analysis
of differentiation was only possible at the lowest concentration of CAMP (Fig 6G) as at higher
concentrations, hypercontraction prevented this analysis. The migration speed was calculated
between 24 and 48 hours and was found to decrease significantly as the concentration of
CAMP increased (Fig 6H). These data demonstrate that CAMP is able to affect both the prolif-
eration and migration of SCs but not the differentiation.
Discussion
The swelling and necrosis at the bite site as well as permanent muscle damage are common
effects of snakebite envenomation (particularly viper bites). These effects frequently lead to
amputation and therefore disable victims, which adds to their inability to earn money, and
exacerbates the poverty that is already experienced by the vast majority of snakebite victims
[4]. Here we have purified a metalloprotease from one of the most studied venomous snake
species, C. atrox. Although deaths from this snake are now uncommon, disfigurement is still a
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prevalent side effect for survivors. SVMPs are a predominant component in viper venoms that
are involved in inducing the local envenomation effects including muscle damage. The ability
of SVMPs to degrade collagen has been established, but its impact on permanent muscle dam-
age under in vivo settings has not been previously demonstrated in sufficient detail. Therefore,
Fig 6. CAMP treatment affects proliferation and migration of satellite cells. (A-C) Increasing concentrations of CAMP change the distribution of collagen IV. Satellite
cell proliferative characteristics following CAMP treatment were analysed. For example, satellite cell number per fibre (D), satellite cell clusters per fibre (E) and cluster
size per fibre (F) were quantified. G, myogenic characteristics of satellite cells following CAMP treatment. H, migration rate of satellite cells. Scale bar represents 20μm.
Data represent mean ± S.D. (n = 20 fibres for each cohort). The p values shown are as calculated by One-way ANOVA followed by post hoc Tukey’s test using GraphPad
Prism (⇤p<0.05, ⇤⇤p<0.01 and ⇤⇤⇤p<0.001). CNT represents control.
https://doi.org/10.1371/journal.pntd.0007041.g006
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we deployed a metalloprotease from the venom of C. atrox and analysed its impact on skeletal
muscle damage in comparison to a three-finger toxin, CTX from the venom of Naja pallida.
Mass spectrometry analysis of the purified protein suggests it to be a group III metalloprotease,
which possess a metalloprotease domain as well as a disintegrin-like and cysteine-rich domains
[40]. Based on the peptide sequences identified by the mass spectrometry, the purified protein is
likely to be VAP2 or one of its heterodimers; VAP2A or VAP2B, both of which are vascular apo-
ptosis inducing proteins (38) that are known to be haemorrhagic [41] and in the case of VAP2B
to inhibit collagen-induced platelet activation [42]. Due to the limited peptide sequences identi-
fied by mass spectrometry for the purified protein, we are unable to conclude whether the puri-
fied protein (CAMP) is identical to VAP2 or either of its heterodimers. CAMP was characterised
to be a collagenolytic and fibrinogenolytic enzyme. It also inhibited CRP-XL-induced platelet
aggregation; group III metalloproteases are known to interact with the integrin α2β1, binding to
the α2 subunit and causing the shedding of β1 subunits [43]. However, VAP2B (a protein
described from C. atrox) has been reported to inhibit collagen induced platelet aggregation by
binding to collagen [44], although whether the SECD sequence found in disintegrin-like
domains is able to bind CRP-XL in the same way, is unknown.
In order to determine the impact of SVMPs in stimulating permanent muscle damage, dif-
ferent concentrations of CAMP were administered in mice along with CTX and control
groups and the effects were analysed at five and ten days after the administration. We suggest
that this occurs at two levels; by breaking down the ECM which normally acts as a scaffold for
the formation of new muscle fibres and around existing blood vessels and secondly attenuating
properties of resident stem cells that are essential to effective tissue repair. SVMPs are known
for their collagenolytic activities and for targeting various components of the BM in the vascu-
lature and inducing haemorrhage [45]. In line with previous studies, here we demonstrate that
CAMP induces haemorrhage and affects the architecture of collagen and laminin. The destruc-
tion of the collagen based ECM may be the key to long-term tissue destruction wrought by
CAMP. The disintegrin-like and cysteine-rich domains have already been identified as essen-
tial to the haemorrhagic activity and ECM degradation attributed to the PIII metalloproteases
[46]. This is in contrast to myotoxic PLA2 and three-finger toxins that are well documented in
causing membrane permeabilisation and consequentially myonecrosis via the hydrolysis of
membrane phospholipids or imbedding directly into the membrane respectively [47–49]. Our
data emphasise that CAMP in comparison to CTX significantly hindered the regeneration of
skeletal muscle fibres most probably by disturbing the organisation of the ECM. The elevated
levels of necrosis seen five days after administration with CAMP improved after ten days,
although it was still evident. However, it must be noted that at day 10, the CTX treated muscles
had almost completely regenerated with healthy fibres. Moreover, very low levels of MYH3
were detected five days after CAMP treatment. In CTX-treated muscles, this marker of regen-
erating fibres was clearly evident and present at a high level. This indicates that the initiation
of the regeneration process was attenuated by CAMP in comparison to CTX. Muscle regenera-
tion is dependent on blood supply and clearance of damaged fibres. We show here that both
these cellular compartments are affected in a detrimental manner by CAMP. We found that
the number of capillaries serving each regenerating muscle fibre was smaller in CAMP treated
muscle compared to CTX. Importantly the number of capillaries serving each fibre in damaged
CTX muscle was the same as in undamaged regions. These results show that capillaries as well
as muscle fibres are damaged by CAMP whereas it is only the latter in CTX treated tissue.
Additionally, we show that there was a greater influx of macrophages into the CTX damaged
muscle compared to regions affected by CAMP. Furthermore, the density of macrophages
decreased in CTX treated muscle over time, attesting to regeneration. In contrast, the density
of macrophages in CAMP treated muscle was lower at day 5 compared to CTX, possibly
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indicating an attenuated clearance process. Importantly the density of macrophages did not
change in the CAMP treated muscle over 10 days suggesting on-going muscle damage.
Although the abundance of MYH3 increased in CAMP-treated muscles by day 10, its expres-
sion in CTX-injured muscles was almost undetectable, signifying advanced regeneration. This
was reflected in the appearance of dystrophin and nNOS at their normal sub-sarcolemmal
position. In keeping with the notion that CAMP treatment not only affects the degree of regen-
eration but also its timing, we showed that very few fibres expressed dystrophin in its normal
position and a significantly reduced expression of nNOS was observed even at day 10. Most
importantly we show that CAMP is still present at the site of injury even 10 days after its
administration and that it profoundly disorganises the ECM.
The single fibre experiments highlight another aspect to explain the attenuated muscle
regeneration following CAMP-mediated muscle damage. We demonstrate that the prolifera-
tion and migration of SCs was significantly reduced by CAMP treatment. Both of these factors
are key in promoting muscle regeneration. Therefore, CAMP may bring about permanent
impairment of muscle organisation and function by firstly destroying muscle fibres, secondly
breaking down the organisation of the ECM. This is required by the SCs in order to align and
fuse in a coordinated manner and lastly by diminishing the ability for SCs to expand their
numbers and migrate to the site of injury to enact efficient regeneration. It is clear that current
ASV treatment is not effective at preventing muscle damage. Although translating the results
of this study into therapeutics might be difficult, these will improve the understanding of
SVMP-induced permanent muscle damage. The ability of group III metalloproteases to bind
components of the BM and prolong muscle exposure to their myotoxic effects suggests a thera-
peutic agent that is capable of interacting with these enzymes and non-enzymatic domains and
preventing the longevity of these proteins in the area surrounding fibres may be able to speed
up the rate of regeneration considerably. Moreover, any drugs aimed at treating this aspect of
snakebite envenomation may struggle to reach it intravenously, and therefore, they may have
to be administered via multiple local injections considering the widespread damage to micro-
vasculature [32] and consequential lack of blood supply to affected tissues.
ASV is the only effective treatment for systemic envenoming, however local venom pathol-
ogy is largely unaffected by ASV when treatment is not immediately administered [50]. ASV is
composed of large immunoglobulins that appear to struggle to reach the areas affected by
SVMPs. The combination of small vessel destruction combined with BM cleavage results in a
poor blood supply and therefore weak neutralisation by intravenously administered ASV.
Local injections of ASV have also been found to be of no benefit to the snakebite victims [51].
However, there are a range of matrix metalloprotease inhibitors that have undergone testing
for their specificity to SVMPs and some promising compounds have been identified [52]. The
small molecule inhibitors aimed at the metalloprotease domain such as batimastat [53] have
been tested extensively and they were found to abrogate the haemorrhagic effects of venom if
administered immediately after envenoming. Given their haemorrhagic effects are largely
dependent upon collagen degradation, it is reasonable to postulate that this prevention of hae-
morrhagic effects may also apply to muscle damage. Moreover, metal chelating agents such as
EDTA have also been tested in vivo at non-toxic doses and found to prevent venom-induced
lethality [54].
The need for immediate administration is of course unrealistic with conventional ASV but
small stable inhibitors have the potential to be spread and made available to those in areas with
a high density of snakebites. Multiple local injections do bring the potential for delivery
directly to the bite site and administering to multiple sites may overcome the problematic
spread of drug through a site of damaged muscles and vessels. Future experiments should aim
to investigate the effect of these drugs on BM components, using both pre-incubation with
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drugs and post envenomation delivery models. Overall, the complete destruction or loss of a
range of BM and dystrophin-glycoprotein complex components as well as the effect of this
SVMP on muscle regeneration highlights the significant difficulties involved in treating the
necrosis and muscle damage associated with snakebite envenomation. Hence, this study pro-
vides greater insights into the understanding of SVMP-induced permanent muscle damage
and local snakebite envenomation effects.
Supporting information
S1 Table. The list of antibodies used in the immunohisto- and cytochemistry analyses.
(DOCX)
Author Contributions
Conceptualization: Robert Mitchell, Ketan Patel, Sakthivel Vaiyapuri.
Formal analysis: Harry F. Williams, Ben A. Mellows, Peggy Sfyri, Rajendran Vaiyapuri,
Henry Collins-Hooper, Antonios Matsakas.
Investigation: Harry F. Williams, Ben A. Mellows, Robert Mitchell, Peggy Sfyri, Harry J. Lay-
field, Maryam Salamah, Rajendran Vaiyapuri, Henry Collins-Hooper, Antonios Matsakas.
Methodology: Andrew B. Bicknell, Ketan Patel, Sakthivel Vaiyapuri.
Supervision: Andrew B. Bicknell, Antonios Matsakas, Ketan Patel, Sakthivel Vaiyapuri.
Visualization: Ketan Patel, Sakthivel Vaiyapuri.
Writing – original draft: Harry F. Williams, Ketan Patel, Sakthivel Vaiyapuri.
Writing – review & editing: Harry F. Williams, Ben A. Mellows, Robert Mitchell, Ketan Patel,
Sakthivel Vaiyapuri.
References
1. WHO. Neglected tropical diseases 2017 [Available from: http://www.who.int/neglected_diseases/
diseases/en/.
2. Kasturiratne A, Wickremasinghe AR, de Silva N, Gunawardena NK, Pathmeswaran A, Premaratna R,
et al. The global burden of snakebite: a literature analysis and modelling based on regional estimates of
envenoming and deaths. PLoS Med. 2008; 5(11):e218. https://doi.org/10.1371/journal.pmed.0050218
PMID: 18986210
3. Chippaux JP. Snake-bites: appraisal of the global situation. Bulletin of the World Health organization.
1998; 76(5):515. PMID: 9868843
4. Harrison RA, Hargreaves A, Wagstaff SC, Faragher B, Lalloo DG. Snake envenoming: a disease of
poverty. PLoS neglected tropical diseases. 2009; 3(12):e569. https://doi.org/10.1371/journal.pntd.
0000569 PMID: 20027216
5. Chippaux J-P. Estimate of the burden of snakebites in sub-Saharan Africa: a meta-analytic approach.
Toxicon. 2011; 57(4):586–99. https://doi.org/10.1016/j.toxicon.2010.12.022 PMID: 21223975
6. Vaiyapuri S, Vaiyapuri R, Ashokan R, Ramasamy K, Nattamaisundar K, Jeyaraj A, et al. Snakebite and
its socio-economic impact on the rural population of Tamil Nadu, India. PloS one. 2013; 8(11):e80090.
https://doi.org/10.1371/journal.pone.0080090 PMID: 24278244
7. Williams HF, Vaiyapuri R, Gajjeraman P, Hutchinson G, Gibbins JM, Bicknell AB, et al. Challenges in
diagnosing and treating snakebites in a rural population of Tamil Nadu, India: The views of clinicians.
Toxicon. 2017; 130:44–6. https://doi.org/10.1016/j.toxicon.2017.02.025 PMID: 28238804
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Abstract: As a painful and expensive cause of death for over 100,000 people predominantly in 
developing countries, snakebite envenomation is one of the most lethal of the neglected tropical 
diseases. It is also associated with an incredibly complex pathophysiology due to the vast number 
of different proteins and peptides found in the 600 or more venomous snake species around the 
world. Here, we report the purification and characterisation of a group I metalloprotease (CA2) from 
the venom of the western diamondback rattlesnake, Crotalus atrox and its sensitivity to matrix 
metalloprotease inhibitors such as batimastat and marimastat. CA2 shows high sequence homology 
to atroxase from the venom of C. atrox and exhibits collagenolytic, fibrinogenolytic, haemolytic and 
cytotoxic activities. It delays blood clotting and exerts a mild inhibitory effect on agonist-induced 
platelet aggregation. Its collagenolytic activity is largely inhibited by batimastat and marimastat as 
well as zinc chloride, while being partially potentiated by calcium chloride. This study demonstrates 
the impact of matrix metalloprotease inhibitors in the modulation of group I snake venom 
metalloprotease activities compared to the whole venoms. Through improved understanding of each 
of the components found within snake venoms and their sensitivity to small molecule inhibitors, we 
can pave the way to the development of improved treatment strategies with reduced side effects for 
snakebite envenoming. 




In 2017, snakebite envenomation (SBE) was reinstated to the list of neglected tropical 




million people worldwide per year, resulting in an estimated 80,000-137,000 deaths and 400,000 
amputations per year [4-6]. The distribution of these fatalities is primarily located in rural tropical 
areas, including some of the world’s poorest and most hospital deprived communities [2,7,8]. Prompt 
access to antivenom and appropriate medical facilities is crucial in order to protect the victims’ lives 
and from extensive injuries caused by snakebites in their limbs. The currently used antivenom is 
considered to be less effective in accessing the affected local areas and preventing the venom-
induced tissue damage. Hence, the development of small molecules that are able to neutralise the 
impact of venom components would be highly beneficial in treating SBE.      
 Snake venom is a complex mixture of bioactive proteins and peptides, which have evolved 
to assist in subduing and killing prey as quickly as possible, as well as having a secondary role in 
prey digestion [9]. The clinical effects of SBE range from mild local effects to more serious life 
threatening systemic complications depending on a variety of variables including the size, species 
and locality of snake [10,11], ontogeny [12,13], size and health of the victim and the total volume of 
venom injected [14]. Snake venoms are composed of both enzymatic and non-enzymatic 
components. The most abundant enzymatic components from viper venoms are the snake venom 
metalloproteases (SVMPs), serine proteases and phospholipase A2 (PLA2) [15]. Whereas non-
enzymatic components include three finger toxins, C-type lectins and disintegrins amongst many 
others. The western diamondback rattlesnake, Crotalus atrox (C. atrox) is a Crotaline or pit viper that 
belongs to the genus Crotalus. This is known as an aggressive snake and likely to be responsible for 
the majority of SBE fatalities in Northern Mexico. C. atrox venom has an abundance of two major 
protein families; SVMPs and serine proteases, which account for approximately 69.5% of the total 
protein content found within the venom [16].  
SVMPs are zinc-dependent enzymes that vary in molecular mass from approximately 20 kDa 
to 100 kDa and are responsible for the haemorrhagic effects characterised by envenomation from 
vipers [9,17]. SVMPs are classified into P-I to P-IV depending on their additional domains. The 
simplest class, P-I, contains only a metalloprotease domain; P-II contain a metalloprotease domain 
followed by a disintegrin domain. P-III consist of a metalloprotease domain, as well as disintegrin-like 
and cysteine-rich domains [18] and P-IV have the same groups as P-III along with two additional C-
type lectin like domains (snaclecs). SVMPs are known to play multiple roles including the degradation 
of collagen, laminin, fibrinogen, certain receptors and the basement membrane of muscles and blood 




molecule chemical inhibitors will aid in the development of improved therapeutic strategies for SBE 
or selectively for venom-induced tissue damage.   Endogenous matrix metalloproteases (MMPs) also 
exist in humans and are involved in, amongst many other things, angiogenesis, via the degradation 
of vascular basement membrane and remodelling of the extracellular matrix [19]. This facilitation of 
angiogenesis has made MMPs a key target of inhibition in the treatment of certain cancers which rely 
on angiogenesis to proliferate [20]. Two such MMP inhibitors (MMPI), batimastat and marimastat, 
despite failing in clinical trials against cancer in the 90s, show some evidence of being effective 
inhibitors of SVMPs [21-24]. 
SVMPs in C. atrox venom account for 49.7% of total venom; which breaks down further to 22.4% 
PI- SVMP and 27.3% PIII-SVMP. In order to determine the therapeutic potential of batimastat and 
marimastat against P-I SVMPs, here, we report the purification and functional characterisation of a 
P-I SVMP with a molecular weight of around 23kDa from the venom of C. atrox. The purified protein 
was inhibited by batimastat and marimastat as well as the whole C. atrox venom. These data will lead 
to the further evaluation of these molecules against the broad spectrum of pathological effects 
induced by SVMPs and venoms in general.  
2. Materials and Methods  
2.1 Protein purification 
Lyophilized C. atrox venom was purchased from Sigma Aldrich (UK). The lyophilized venom (50 
mg) was dissolved in 1 mL of 20 mM TRIS.HCI (pH 7.6) and after centrifugation at 5000 rpm for 5 
minutes the supernatant was applied to a 5 mL HiTrapÔ Sepharose (SP) HP cation exchange 
chromatography column (GE Healthcare, UK) and fractionated using an Akta Purifier (GE Healthcare, 
UK). Fractions were collected at a rate of 1 mL/min using 20 mM TRIS.HCl pH 7.6 (Buffer A) and 20 
mM TRIS.HCl pH 7.6 + 1 M NaCl (Buffer B) using a gradient reaching 60% buffer B over 20 minutes 
(gradient 20). UNICORN v3 software was used to run the Akta Purifier system. Fractions were 
immediately put on ice to prevent protein denaturation. A small aliquot was taken from each peak to 
undergo a Bradford protein assay and sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) analysis using standard protocols. The Bradford Protein assay was run according to the 
manufacturers protocol (ThermoScientific, USA). The intensity of the colour change from brown to 
blue was measured at 600 nm using an Emax spectrophotometer (Molecular Devices, UK). Bovine 




together and concentrated using Vivaspin 6 Ultrafitration tubes (Sartorius, UK). A size exclusion 
chromatography column (Superdex 75 100 cm) was used to separate the pooled sample of proteins. 
Fractions were collected at a rate of 1 mL/min using 20 mM TRIS.HCI (pH 7.6). As soon as protein 
peaks emerged (280 nm), they were immediately placed on ice to prevent protein denaturation. SDS-
PAGE was again used to analyse the fractions and those containing the purified protein of interest 
were again pooled and concentrated before storing at -80°C before further use. 
2.2 SDS-PAGE 
SDS-PAGE was used to analyse the proteins contained within each 1 mL fraction that was 
collected from columns. Proteins were denatured using reducing sample treatment buffer (RSTB) 
[10% (w/v) SDS, 10% (v/v) b-mercaptoethanol, 1% (w/v) bromophenol blue, 50% (v/v) glycerol and 
stacking buffer, nanopure water] and heated at 90°C for 10 minutes. Samples were loaded (30µL) 
into precast gradient (4-15%) Mini-PROTEANâ TGXÔ gels (Biorad, UK) alongside the dual colour 
protein ladder (Precision Plus Biorad, UK) and resolved using a Mini-Protean II apparatus (Biorad, 
UK). Gels were immersed in a staining solution [0.1% (w/v) Coomassie Brilliant blue R250 
(ThermoScientific, UK), 10% (v/v) acetic acid, 40% (v/v) methanol and 50% (v/v) deionized water]) 
for 1 hour on a plate shaker, washed 3x with deionised H20 for 5 minutes and destained [10% (v/v) 
acetic acid, 40% (v/v) methanol and 50% deionized water] for 3 hours or until protein bands became 
clear.  
2.3 Fluorogenic assays 
Metalloprotease activity was analysed using the fluorogenic substrate, DQÔ gelatin 
(ThermoScientific, UK). A range of concentrations of CA2 (1, 2, 5, 10 and 15 µg/mL) were added to 
a black 96 well-plate in triplicate along with PBS as a negative control and whole C. atrox venom as 
a positive control. The DQ gelatin (10 µg/mL in PBS) was added to each well. The 96-well plate was 
placed on a plate shaker for five minutes, incubated and read at 10, 30, 60 and 120 minutes using a 
FLUOstar OPTIMA (BMG Labtech, Germany) spectrofluorimeter. Metalloprotease activity was 
measured at an excitation wavelength of 485 nm and emission wavelength of 520 nm. In addition to 
testing for metalloprotease activity, effect of treatment with marimastat, batimastat, zinc chloride and 
calcium chlorides (12.5, 25, 50 and 200 µM) as well as EDTA at three concentrations (25, 50 and 200 




To determine PLA2 activity an EnzChek™ Phospholipase A2 Assay Kit (ThermoFisher Scientific, 
UK) was used in accordance to the manufacturer’s instructions. CA2 was diluted to 2 µg/mL in PBS 
and treated in duplicate with chlorides MMP inhibitors and EDTA in 96 well black plates and incubated 
at 37°C. Readings were taken after 10, 30 and 60 minutes of incubation by FLUOstar OPTIMA (BMG 
Labtech, Germany) spectrofluorimeter using an excitation wavelength of 485 nm and emission 
wavelength of 520 nm.  
 
2.4 Mass Spectrometry analaysis 
CA2 was subject to tryptic digestion and mass spectrometry using a gel slice containing the 
purified CA2 from SDS-PAGE and was analysed by Alta Bioscience (Birmingham, UK). The trypsin 
digestion was performed using 10 µL of sample (purified protein band from SDS-PAGE) and 40 µL 
of 100 mM ammonium bicarbonate (pH 8), added to 50 µL of 10 mM dithiothreitol (DTT) and incubated 
at 56°C for 30 minutes. The sample was then cooled to room temperature and cysteines alkylated 
with the addition of 50 µL 50 mM iodoacetamide and mixed and incubated at room temperature in the 
dark for 30 minutes. 25 µL of trypsin gold (Promega, Southampton, Hampshire, UK, 6 ng/µL) was 
subsequently added to the sample and left to incubate overnight at 37°C overnight. An UltiMate® 
3000 HPLC series (Dionex, Sunnyvale, CA USA) was used for peptide separation and concentration. 
Samples were trapped on uPrecolumn Cartridge Acclaim PepMap 100 C18, 5 µM, 100A 300um i.d. 
x 5mm (Dionex, Sunnyvale, CA USA) and separated in Nano Series™ Standard Columns 75 µm i.d. 
x 15 cm, packed with C18 PepMap100, 3 µm, 100Å (Dionex, Sunnyvale, CA USA). A gradient from 
3.2% to 44% solvent B (0.1% formic acid in acetonitrile) for 30 minutes was used. Peptides were 
eluted directly (~ 300 nL min-1) via a Triversa Nanomate nanospray source (Advion Biosciences, NY) 
into an LTQ Orbitrap Elite mass spectrometer (ThermoFisher Scientific, Germany). The mass 
spectrometer alternated between a full FT-MS scan (m/z 380 – 1800) and subsequent collision-
induced dissociation (CID) MS/MS scans of the eight most abundant ions. The data-dependent 
scanning acquisition was controlled by Xcalibur 2.1 software. Survey scans were acquired in the 
Orbitrap at a resolution of 120,000 at m/z 400 and automatic gain control (AGC) 1 x 106. Precursor 
ions were isolated and subjected to CID in the linear ion trap with AGC 1 x 105. Collision activation 
for the experiment was performed in the linear trap using helium gas at normalized collision energy 
to precursor m/z of 35% and activation Q 0.25. The precursor isolation window was 2 m/z and only 




referenced against the Uniprot database using Sequest algorithm (Thermo fisher PD 1.4). Variable 
modifications were deamidated (N and Q), oxidation (M) and phosphorylyation (S, T and Y). 
Carbamidomethyl (C) modification was for fixed modification. The precursor mass tolerance was 10 
ppm and the MS/MS mass tolerance was 0.8 Da. Two missed cleavage was allowed and were 
accepted as a real hit protein with at least two high confidence peptides. 
2.5 Fibrinogenolytic assay 
A solution containing CA2 (0.1 mg/mL) or venom (0.1mg/mL), fibrinogen (1 mg/mL) and PBS 
was prepared and incubated at 37°C. Samples (50 µL) were taken at time intervals of 0, 10, 30 and 
60 minutes and then again after 12 hours and immediately mixed with 25 µL of RSTB before dry 
boiling at 90°C for 10 minutes. Each sample was then analysed by SDS-PAGE to determine their 
digestion pattern.  
2.6 Human blood collection and platelet preparation 
Blood samples from healthy volunteers were obtained in accordance to the approved procedures 
by the University of Reading Research Ethics Committee and the platelets were prepared as 
described previously [25,26]. Blood was collected using venipuncture into vacutainers containing 
3.2% (w/v) citrate. For the preparation of platelet-rich-plasma (PRP), blood samples were centrifuged 
at 102 RCF for 20 minutes at 20 °C. PRP was rested for 30 minutes before use at 30 °C in a water 
bath (Clifton, UK) in a 50 mL falcon tube. For isolated/washed platelets (WP), the PRP was carefully 
retrieved from the LP4 tubes using a transfer pipette and placed into a 50 mL falcon tube, after adding 
3 mL acid citrate dextrose (ACD, sodium citrate 2.5% (w/v), 2% glucose, 1.5% citric acid) and 10 µL 
prostacyclin (PG12, stock 125 µg/mL in Ethanol) and mixed gently by inversion and centrifuged at 
1413 RCF. After this 1 mL of modified tyrodes-HEPES buffer (with 5 mM glucose) and 150 µL of ACD 
was added to the platelet pellet which was then resuspended with 24 mL of 37°C tyrodes. A further 3 
mL ACD and 10 µL prostacyclin was added and the falcon tube gently inverted. Finally, the platelets 
were spun once more at 1413 RCF for 10 minutes at 20 °C, the supernatant was discarded, and the 
platelets were resuspended in modified tyrodes-HEPES buffer. Platelet-poor plasma (PPP) was 






2.7 Platelet aggregation 
A stock solution of 0.5 µg/mL cross-linked collagen-related peptide [CRP-XL, from Professor 
Richard Farndale (University of Cambridge, UK)] was used as a positive control and PBS as a 
negative control in platelet aggregation assays using an optical aggregometer (Chrono-log model 
700). Two concentrations of CA2 and venom (3 and 10 µg/mL) were tested from three separate 
donors. After incubating the platelets with CA2/venom for five minutes, CRP-XL was added and 
aggregation traces were used to calculate inhibition. 
2.8 Haemolytic Assay 
Human erythrocytes were collected from the dense red blood cells found in the bottom of 
vacutainers following centrifugation for collection of PRP. These erythrocytes were then mixed with 
an equal volume of PBS, mixed and centrifuged at 1413 RCF for 2 minutes, the supernatant was 
discarded. This was repeated three times. Haemolytic activity was measured using these washed 
human erythrocytes (10%) suspended in PBS. The erythrocytes were then treated with 2.5  µg/mL of 
CA2 or the whole venom. Triton X-100 detergent (1%)  was used as a positive control and PBS as a 
negative control. Samples were centrifuged at 1413 RCF for two minutes and 50 µL of supernatant 
was dispensed into a 96-well plate and the absorbance (at 540 nm) was measured using a 
spectrophotometer (Emax precision plate reader, UK).  Samples from the erythrocyte CA2/venom 
mixtures were incubated at 37°C and haemolysis was measured after 6, 12, 24 and 48 hours. 
2.9 Blood clotting assay 
 Untreated (without any anti-coagulants) whole human blood was mixed with CA2, whole 
venom or PBS in glass cuvettes. The solutions were then gently mixed once a minute until clotting 
was apparent. This was again done in three donors. 
2.10 Lactate Dehydrogenase (LDH) cytotoxicity assay   
An LDH cytotoxicity assay was used to determine whether CA2 had any cytotoxic effects on 
platelets. An LDH Cytotoxicity Assay Kit (ThermoFisher UK) was used in accordance to the 
manufacturer’s instructions. Briefly, human PRP was incubated at 37°C for 30 minutes prior to 
incubation with different concentrations of venom protein or a vehicle control (deionised water) for 
five minutes. The substrate mix from the kit was added to the platelets and incubated for another 30 




and 650 nm using Fluostar Optima s (BMG Labtech, Germany) Spectrofluorimeter. Absorbance was 
measured in triplicates using platelets obtained from three individual donors.   
 
2.16 Statistical analysis 
All statistical analysis was performed using GraphPad Prism V.7.00 statistical software.   
3. Results   
3.1 Purification of P-I SVMP 
With the aim of purifying a P-I SVMP from C. atrox venom, we deployed a two-dimensional 
chromatography approach. Initially, 50 mg of whole C. atrox venom was applied to a cation-exchange 
(HiTrap, SP HP) chromatography column (Figure 1A). Following the analysis of acquired fractions by 
SDS-PAGE (Figure 1B), the fractions containing a protein of semi-purified protein of approximately 
the correct (23kDa) molecular weight (6-9) were further separated by gel filtration (Superdex-75) 
chromatography (Figure 1C). The selected fractions were analysed by SDS-PAGE (Figure 1D) and 
fractions with the protein of interest (67-70) were further run through the same gel filtration column to 
remove any impurities (Figure 1E-F). After these three stages of chromatography, a pure protein with 
a molecular weight of approximately 23 kDa was isolated (fractions 74-77) which we henceforth refer 
to as CA2 (denoting the second SVMP that we have isolated from the venom of C. atrox).  
3.2 Mass spectrometry of CA2 
The purified protein was then analysed by mass spectrometry using the peptides resulting 
from tryptic digestion (Figure 1G). Mascot analysis of the sequences confirmed the high sequence 
similarity (52.2% coverage) of isolated protein to atroxase, a 23kDa SVMP from the venom of C. atrox 
[27]. Although CA2 is likely to be atroxase, we are unable to conclude this in the absence of complete 
sequence for CA2. However, these data confirm that the purified protein is an SVMP with a molecular 





Figure 1. Purification and characterisation of CA2. A, 50 mg of whole C. atrox venom 
was fractionated using a cation exchange column chromatography and the collected 
fractions were analysed by SDS-PAGE (B). C, a chromatogram showing the gel filtration 
chromatography of fractions 6 to 9 collected from the cation exchange column. D, SDS-
PAGE analysis of fractions resulting from the gel filtration chromatography. E, the 
chromatogram from the second run of gel filtration chromatography for selected fractions 
from the previous step, and SDS-PAGE analysis showing the purified protein (F). G, tryptic 
digested peptides from the purified protein were analysed by mass spectrometry and found 
to show 52.2% similarity to atroxase (mass spectrometry-identified peptide sequences are 





3.3 Fibrinogenolytic and collagenolytic activities of CA2 
A range of functional assays were employed to determine the functions of CA2 compared to 
the whole venom. Fluorogenic substrates were used to assess the ability for CA2 to digest gelatin 
(polymerised collagen) (Figure 2A & B) and a PLA2-specific substrate (Figure 2C). CA2 exhibited 
strong collagenolytic activity and no PLA2 activity. This data suggests that CA2 is an SVMP and free 
of enzymatic PLA2 impurities. One of the natural substrates for SVMPs, fibrinogen, was also 
incubated with CA2, before the digestion pattern was analysed by SDS-PAGE (Figure 2D). The 
results showed high specificity for the Aa chain of fibrinogen, digesting this within 10 minutes although 
over a longer time CA2 also began to degrade the Bb band and g bands.  
3.5 CA2 exerts cytotoxic activity  
In order to assess whether CA2 has any cytotoxic effects on different cell types, we performed 
LDH cytotoxicity assays using platelets, whole blood and erythrocytes. Using the production of lactate 
dehydrogenase as a marker for platelet cytotoxicity, we found CA2 to be cytotoxic to platelets only at 
the highest concentration tested, 12.5 µg/mL (Figure 2E), similarly it caused mild haemolysis but only 
after five hours of incubation at 2.5 µg/mL (Figure 2F). This suggests it is able to cleave some element 
of the plasma membrane causing cell lysis. 
3.4 Batimastat and marimastat inhibit CA2 
After confirming that CA2 is an SVMP, we utilised MMPIs, batimastat and marimastat to 
deduce the inhibitory properties of these compounds on CA2. We used the fluorogenic substrate, DQ 
gelatin, to analyse whether these compounds reduce the SVMP activity of CA2. Marimastat (Figure 
3A & B) and batimastat (Figure 3C & D) caused almost complete inhibition of SVMP activity of both 





Figure 2. Functional characterisation of CA2. The SVMP activity of purified SVMP, CA2 
(A) or the crude/whole venom (B) using a fluorogenic substrate, DQ gelatin. PLA2 activity of 
whole venom (CV), bee venom (positive control) and CA2 using enzcheck PLA2 substrate 
(C). D, SDS-page analysis of fibrinogen digestion by CA2 from 0 – 720 minutes. The 
cytotoxicity (E) of CA2 and whole venom as found via the measurement of lactate 
dehydrogenase release and ability for CA2 and whole venom to lyse red blood cells (F). 
Data were analysed in Graphpad Prism and represent mean +/- S.D. (n=3). The P-values 
shown are as calculated using one-way ANOVA followed by Tukey’s post hoc multiple 
comparisons test. For this, the proteins were compared to negative control values, and all 
the values were normalised using a blank and positive control. (*P ≤ 0.05, ** P ≤ 0.01, *** P 






Figure 3. Effect of matrix metalloprotease inhibitors on collagenolytic activity of CA2 
and whole venom. The inhibitory effect of marimastat on CA2 (A) or whole venom (B) and 
batimastat on CA2 (C) and whole venom (D), the protein or venom were treated with the 
inhibitors before the addition of a fluorogenic substrate, DQ-gelatin. Data were analysed in 
Graphpad Prism and represent mean +/- S.D. (n=3). The P-values shown are as calculated 
using one-way ANOVA followed by Tukey’s post hoc multiple comparisons test. For this, the 
proteins were compared to positive control values, and all the values were normalised using 






3.6 Chlorides have differing effects on metalloprotease activity  
As zinc-dependent proteases rely heavily on free calcium for catalysis, metal chlorides can affect their 
ability to cleave a substrate. Varied concentrations of both zinc and calcium chloride were utilised to 
assess how they would modulate the SVMP activities of CA2 and whole venom. It was found that 
while zinc chloride significantly reduced the SVMP activity seen in both the whole venom and CA2 
(Figure 4A & 4B), calcium chloride potentiated their SVMP activities (Figure 4C & 4D). These data 
confirm that CA2 is an SVMP which is relying on calcium ions for their activity.  
3.7 Metal chelators inhibit the activity of CA2 
A metal chelator (EDTA) was then employed to assess its ability to inhibit the activities of the SVMPs 
present in whole venom as well as CA2. The fluorogenic assay described previously for SVMPs was 
performed with the addition of ethylenediaminetetraceticacid (EDTA - a divalent cationic chelator) in 
order to determine its impact on CA2 activity. The metalloprotease activity of both whole venom and 
CA2 was strongly inhibited by EDTA (Figure 4E & 4F).  These data corroborate this enzyme as a 
metalloprotease, given EDTA is a metal chelator and would inhibit via the chelation of zinc found in 
SVMPs which is essential to their catalytic activity.  
3.8 CA2 inhibits platelet aggregation  
Platelets were isolated from fresh human whole blood in the forms of platelet rich plasma and 
isolated platelets. These two preparations allowed us to see the effects of CA2 on platelets both 
directly, using isolated platelets and any indirect effects that could be a result of the enzyme on other 
plasma proteins using platelet-rich plasma. In platelet-rich plasma CA2 had little or no effect (Figure 
5B) but in washed platelets CA2 had a statistically significant inhibitory effect (Figure 5A). The whole 
venom caused a strong activation in isolated platelets (Figure 5C) which was lesser in PRP (Figure 
5D). The activation could be the result of cell lysis while the inhibition is likely to be a result of cleavage 






Figure 4. Effects of chlorides and a chelator on whole venom and CA2. Two chlorides, 
zinc chloride [on CA2 (A) whole venom (B)] and calcium chloride [on CA2 (C) or whole 
venom (D)] were used to assess their inhibitory or potentiatory effects as well as a metal 
chelator, EDTA [on CA2 (E) whole venom (F)]. Data were analysed in Graphpad Prism and 
represent mean +/- S.D. (n=3). The P-values shown are as calculated using one-way 
ANOVA followed by Tukey’s post hoc multiple comparisons test. For this, the proteins were 
compared to positive control values, and all the values were normalised using negative and 





Figure 5. Effects of CA2 on platelets. The effect of CA2 on washed platelets (A) and 
platelet rich plasma (B) and whole venom on washed platelets (C) and platelet rich plasma 
(D). Representative aggregation traces and data demonstrate the impact of CA2 on cross-
linked collagen related peptide (CRP-XL)-induced human platelet aggregation. Data were 
analysed in graphpad prism and represent mean ± S.D. (n = 3). The p values shown are as 
calculated by One-way ANOVA followed by post hoc Tukey’s test using GraphPad Prism 





SVMPs play important roles in the overall pathophysiology of viper envenoming by inducing local 
and systematic haemorrhage along with tissue damage, which is primarily attributed to their potential 
to degrade BM components in blood capillaries [28-31]. SVMPs activate two key coagulation factors; 
Factor X and prothrombin to exhibit their procoagulant effects [9,17,29-33]. SVMPs exhibit activities 
through activation of zymogens, coagulation factors and precursors of integrins or receptors [29], 
rendering blood uncoagulable [34]. This is due to their ability to cleave fibrinogen into fibrinopeptides 
without the induction of clotting [35]. The venom contains two different types of fibrinogenolytic 
enzymes; those that cleave the Aa chain of fibrinogen and those which cleave both the Aa and the 
Bb chain [34,36]. The time course assay illustrated that CA2 primarily cleaved the Aa chain, and 
cleavage of the Bb chain occurred much more slowly (30 minutes later), whilst the g chain remained 
almost intact (Figure 2D).  
Given that SVMPs both directly [37] and indirectly [38] mediate local tissue damage, inhibition of 
these enzymes would reduce the local tissue damage typically associated with viper bites [28]. CA2 
was treated with commercially available matrix metalloproteinase inhibitors (MMPIs), batimastat and 
marimastat, which have already had promising research done into their use in vivo for snakebite 
envenomation [22-24]. Figure 3 (A-D) show both whole venom and CA2 enzyme activity were almost 
entirely inhibited when subjected to the MMPIs. There is a high degree of structural and functional 
homology between SVMPs and their matrix-based relatives (MMPs) [28]. This suggests that 
substrate/inhibitor interactions between these subfamilies are likely to be analogous [28]. Marimastat 
is a hydroxamic acid derivative designed to exert broad-range MMP inhibition by mimicking the 
cleavage site of collagen substrates [28]. Although these MMPi’s are likely to inhibit all SVMP 
domains, the additional domains found in P-II, P-III and P-IV SVMPs could potentially be unaffected 
despite inhibition of the protease domain, they may continue to exert anti-platelet or other effects. 
Antivenom on the other hand is likely to contain antibodies capable of binding all of these domains 
as well as the metalloprotease domain. Antivenom is made up of large immunoglobulins which, even 
when administered rapidly, struggle to reach the local bite-site in time to prevent tissue damage. 
Multiple injections of these smaller MMPIs have been suggested [39], however the repercussions 
from inhibiting MMPs occurring naturally in the body are yet to be fully elucidated although effects on 




SVMPs are zinc-containing endopeptidases [28] that are dependent on the presence of zinc [41] 
and calcium ions [42] to ensure enzymatic activity and stability as shown in Figure 4C-4F. The use of 
EDTA showed this metal chelator can abrogate entirely the collagenolytic activity of these enzymes 
(Figure 4A-4B), though the use of such broad-range metal chelators in vivo raises questions as to 
unwanted effects on endogenous metal-dependent physiology. Both whole venom and CA2 
demonstrated a haemolytic effect on red blood cells (Figure 2F). It is likely that the mechanism of 
action for haemolysis for whole venom is similar to other species of Crotalidae and largely PLA2 
dependent [43], though SVMPs have the potential to lyse red blood cells via the hydrolysis of the 
many membrane proteins responsible for transport and adhesion of the cell, or somehow interacting 
with the underlying skeletal proteins such as spectrin [44].  
The purification and characterisation of CA2 further demonstrates the breadth of SVMPs 
inhibited by MMPis and EDTA. The reality of their use on victims of SBE and the long-term damage 
associated with their use is yet to be elucidated, but with frequent amputations and long-term muscle 
damage as a result of viper bites it seems likely these small molecular therapeutics (SMT) are the 
lesser of two evils. The development of a drug able to inhibit SVMPs while leaving endogenous MMPs 
to function is the long term goal, but such specificity is likely to take time and amputations are 
occurring on a daily basis [45]. If morbidity is to be reduced to the same extent as the WHO intend to 
reduce mortality, SVMPs are a target in need of immediate inhibition [46]. The purification of individual 
venom components allows us to see their unadulterated effect and by comparison to the whole 
venom, this study somewhat highlights the contradictory nature of venoms; with CA2 inhibiting platelet 
aggregation while whole venom activates, or lyses platelets. In order to fully disentangle the web of 
effects that is found within a venom, each thread must first be understood. This study showed that 
the major P-I SVMP in C. atrox, has a range of effects, including inhibition of platelets and proteolytic 
effects, all of which are likely to be prevented by the SMTs currently being discussed as an adjunctive 
treatment for SBE [47]. 
 
Acknowledgments: This work received no external funding. 
References 
 
1. Hifumi, T.; Sakai, A.; Kondo, Y.; Yamamoto, A.; Morine, N.; Ato, M.; Shibayama, 




and treatment. Journal of Intensive Care 2015, 3, 16, doi:10.1186/s40560-015-0081-
8. 
2. Williams, D.; Gutierrez, J.M.; Harrison, R.; Warrell, D.A.; White, J.; Winkel, K.D.; 
Gopalakrishnakone, P.; Global Snake Bite Initiative Working, G.; International 
Society on, T. The Global Snake Bite Initiative: an antidote for snake bite. Lancet 
2010, 375, 89-91, doi:10.1016/S0140-6736(09)61159-4. 
3. WHO. Neglected tropical diseases. Availabe online: 
http://www.who.int/neglected_diseases/diseases/en/ (accessed on  
4. White, J. Bites and Stings From Venomous Animals: A Global Overview. 
Therapeutic Drug Monitoring 2000, 22, 65-68. 
5. Williams, D.; Gutiérrez, J.M.; Harrison, R.; Warrell, D.A.; White, J.; Winkel, K.D.; 
Gopalakrishnakone, P. The Global Snake Bite Initiative: an antidote for snake bite. 
The Lancet 2010, 375, 89-91, doi:https://doi.org/10.1016/S0140-6736(09)61159-4. 
6. Kasturiratne, A.; Wickremasinghe, A.R.; de Silva, N.; Gunawardena, N.K.; 
Pathmeswaran, A.; Premaratna, R.; Savioli, L.; Lalloo, D.G.; de Silva, H.J. The 
Global Burden of Snakebite: A Literature Analysis and Modelling Based on Regional 
Estimates of Envenoming and Deaths. PLOS Medicine 2008, 5, e218, 
doi:10.1371/journal.pmed.0050218. 
7. Williams, H.F.; Vaiyapuri, R.; Gajjeraman, P.; Hutchinson, G.; Gibbins, J.M.; 
Bicknell, A.B.; Vaiyapuri, S. Challenges in diagnosing and treating snakebites in a 
rural population of Tamil Nadu, India: The views of clinicians. Toxicon 2017, 130, 
44-46. 
8. Vaiyapuri, S.; Vaiyapuri, R.; Ashokan, R.; Ramasamy, K.; Nattamaisundar, K.; 
Jeyaraj, A.; Chandran, V.; Gajjeraman, P.; Baksh, M.F.; Gibbins, J.M. Snakebite and 
its socio-economic impact on the rural population of Tamil Nadu, India. PloS one 
2013, 8, e80090. 
9. Takeda, S.; Takeya, H.; Iwanaga, S. Snake venom metalloproteinases: Structure, 
function and relevance to the mammalian ADAM/ADAMTS family proteins. 
Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 2012, 1824, 164-
176, doi:https://doi.org/10.1016/j.bbapap.2011.04.009. 
10. Sunagar, K.; Undheim, E.A.B.; Scheib, H.; Gren, E.C.K.; Cochran, C.; Person, C.E.; 
Koludarov, I.; Kelln, W.; Hayes, W.K.; King, G.F., et al. Intraspecific venom 
variation in the medically significant Southern Pacific Rattlesnake (Crotalus oreganus 
helleri): Biodiscovery, clinical and evolutionary implications. Journal of Proteomics 
2014, 99, 68-83, doi:https://doi.org/10.1016/j.jprot.2014.01.013. 
11. Fry, B.G.; Winkel, K.D.; Wickramaratna, J.C.; Hodgson, W.C.; Wüster, W. 
Effectiveness of snake antivenom: species and regional venom variation and its 
clinical impact. Journal of Toxicology: Toxin Reviews 2003, 22, 23-34. 
12. Pla, D.; Sanz, L.; Sasa, M.; Acevedo, M.E.; Dwyer, Q.; Durban, J.; Pérez, A.; 
Rodriguez, Y.; Lomonte, B.; Calvete, J.J. Proteomic analysis of venom variability 
and ontogeny across the arboreal palm-pitvipers (genus Bothriechis). Journal of 




13. Modahl, C.M.; Mukherjee, A.K.; Mackessy, S.P. An analysis of venom ontogeny and 
prey-specific toxicity in the Monocled Cobra (Naja kaouthia). Toxicon 2016, 119, 8-
20. 
14. Juckett, G.; Hancox, J.G. Venomous snakebites in the United States: management 
review and update. American family physician 2002, 65, 1367-1374. 
15. Williams, H.F.; Layfield, H.J.; Vallance, T.; Patel, K.; Bicknell, A.B.; Trim, S.A.; 
Vaiyapuri, S. The Urgent Need to Develop Novel Strategies for the Diagnosis and 
Treatment of Snakebites. Toxins 2019, 11, 363. 
16. Calvete, J.J.; Fasoli, E.; Sanz, L.; Boschetti, E.; Righetti, P.G. Exploring the venom 
proteome of the western diamondback rattlesnake, Crotalus atrox, via snake venomics 
and combinatorial peptide ligand library approaches. Journal of proteome research 
2009, 8, 3055-3067. 
17. Gutiérrez, J.M.; Rucavado, A. Snake venom metalloproteinases:Their role in the 
pathogenesis of local tissue damage. Biochimie 2000, 82, 841-850, 
doi:https://doi.org/10.1016/S0300-9084(00)01163-9. 
18. Fox, J.W.; Serrano, S.M.T. Structural considerations of the snake venom 
metalloproteinases, key members of the M12 reprolysin family of metalloproteinases. 
Toxicon 2005, 45, 969-985, doi:https://doi.org/10.1016/j.toxicon.2005.02.012. 
19. Rundhaug, J.E. Matrix metalloproteinases and angiogenesis. Journal of cellular and 
molecular medicine 2005, 9, 267-285. 
20. Jabłońska-Trypuć, A.; Matejczyk, M.; Rosochacki, S. Matrix metalloproteinases 
(MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a 
target for anticancer drugs. Journal of enzyme inhibition and medicinal chemistry 
2016, 31, 177-183. 
21. Arias, A.S.; Rucavado, A.; Gutiérrez, J.M. Peptidomimetic hydroxamate 
metalloproteinase inhibitors abrogate local and systemic toxicity induced by Echis 
ocellatus (saw-scaled) snake venom. Toxicon 2017, 132, 40-49, 
doi:https://doi.org/10.1016/j.toxicon.2017.04.001. 
22. Rucavado, A.; Escalante, T.; Gutiérrez, J.M.a. Effect of the metalloproteinase 
inhibitor batimastat in the systemic toxicity induced by Bothrops asper snake venom: 
understanding the role of metalloproteinases in envenomation. Toxicon 2004, 43, 
417-424. 
23. Rucavado, A.; Escalante, T.; Franceschi, A.; Chaves, F.; León, G.; Cury, Y.; Ovadia, 
M.; Gutiérrez, J.M. Inhibition of local hemorrhage and dermonecrosis induced by 
Bothrops asper snake venom: effectiveness of early in situ administration of the 
peptidomimetic metalloproteinase inhibitor batimastat and the chelating agent 
CaNa2EDTA. The American journal of tropical medicine and hygiene 2000, 63, 313-
319. 
24. Escalante, T.; Franceschi, A.; Rucavado, A.; Gutiérrez, J.M.a. Effectiveness of 
batimastat, a synthetic inhibitor of matrix metalloproteinases, in neutralizing local 
tissue damage induced by BaP1, a hemorrhagic metalloproteinase from the venom of 




25. Vaiyapuri, S.; Ali, M.S.; Moraes, L.A.; Sage, T.; Lewis, K.R.; Jones, C.I.; Gibbins, 
J.M. Tangeretin Regulates Platelet Function Through Inhibition of Phosphoinositide 
3-Kinase and Cyclic Nucleotide Signaling. Arteriosclerosis, Thrombosis, and 
Vascular Biology 2013, 33, 2740-2749, doi:doi:10.1161/ATVBAHA.113.301988. 
26. Vaiyapuri, S.; Hutchinson, E.G.; Ali, M.S.; Dannoura, A.; Stanley, R.G.; Harrison, 
R.A.; Bicknell, A.B.; Gibbins, J.M. Rhinocetin, a venom-derived integrin-specific 
antagonist inhibits collagen-induced platelet and endothelial cell functions. The 
Journal of biological chemistry 2012, 287, 26235-26244, 
doi:10.1074/jbc.M112.381483. 
27. Willis, T.W.; Tu, A.T. Purification and biochemical characterization of atroxase, a 
nonhemorrhagic fibrinolytic protease from western diamondback rattlesnake venom. 
Biochemistry 1988, 27, 4769-4777, doi:10.1021/bi00413a028. 
28. Howes, J.M.; Theakston, R.D.; Laing, G.D. Neutralization of the haemorrhagic 
activities of viperine snake venoms and venom metalloproteinases using synthetic 
peptide inhibitors and chelators. Toxicon 2007, 49, 734-739, 
doi:10.1016/j.toxicon.2006.11.020. 
29. Kini, R.M.; Koh, C.Y. Metalloproteases Affecting Blood Coagulation, Fibrinolysis 
and Platelet Aggregation from Snake Venoms: Definition and Nomenclature of 
Interaction Sites. Toxins 2016, 8, 284, doi:10.3390/toxins8100284. 
30. Siigur, J.; Tõnismägi, K.; Trummal, K.; Aaspõllu, A.; Samel, M.; Vija, H.; Subbi, J.; 
Kalkkinen, N.; Siigur, E. Vipera lebetina Venom Contains All Types of Snake Venom 
Metalloproteases. Pathophysiology of Haemostasis and Thrombosis 2005, 34, 209-
214, doi:10.1159/000092426. 
31. Tasoulis, T.; Isbister, G.K. A Review and Database of Snake Venom Proteomes. 
Toxins (Basel) 2017, 9, doi:10.3390/toxins9090290. 
32. Matsui, T.; Fujimura, Y.; Titani, K. Snake venom proteases affecting hemostasis and 
thrombosis. Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular 
Enzymology 2000, 1477, 146-156, doi:https://doi.org/10.1016/S0167-
4838(99)00268-X. 
33. Kini, R.M.; Rao, V.S.; Joseph, J.S. Procoagulant Proteins from Snake Venoms. 
Pathophysiology of Haemostasis and Thrombosis 2001, 31, 218-224, 
doi:10.1159/000048066. 
34. Pandya, B.V.; Rubin, R.N.; Olexa, S.A.; Budzynski, A.Z. Unique degradation of 
human fibrinogen by proteases from western diamondback rattlesnake (Crotalus 
atrox) venom. Toxicon 1983, 21, 515-526, doi:https://doi.org/10.1016/0041-
0101(83)90129-0. 
35. Kim, C.H.; McBride, D.W.; Raval, R.; Sherchan, P.; Hay, K.L.; Gren, E.C.K.; Kelln, 
W.; Lekic, T.; Hayes, W.K.; Bull, B.S., et al. Crotalus atrox venom preconditioning 
increases plasma fibrinogen and reduces perioperative hemorrhage in a rat model of 





36. Pandya, B.V.; Budzynski, A.Z. Anticoagulant proteases from western diamondback 
rattlesnake (Crotalus atrox) venom. Biochemistry 1984, 23, 460-470, 
doi:10.1021/bi00298a010. 
37. Gutierrez, J.M.; Rucavado, A. Snake venom metalloproteinases: their role in the 
pathogenesis of local tissue damage. Biochimie 2000, 82, 841-850. 
38. Bernardoni, J.L.; Sousa, L.F.; Wermelinger, L.S.; Lopes, A.S.; Prezoto, B.C.; 
Serrano, S.M.T.; Zingali, R.B.; Moura-da-Silva, A.M. Functional Variability of 
Snake Venom Metalloproteinases: Adaptive Advantages in Targeting Different Prey 
and Implications for Human Envenomation. PLOS ONE 2014, 9, e109651, 
doi:10.1371/journal.pone.0109651. 
39. Williams, H.F.; Mellows, B.A.; Mitchell, R.; Sfyri, P.; Layfield, H.J.; Salamah, M.; 
Vaiyapuri, R.; Collins-Hooper, H.; Bicknell, A.B.; Matsakas, A., et al. Mechanisms 
underpinning the permanent muscle damage induced by snake venom 
metalloprotease. PLOS Neglected Tropical Diseases 2019, 13, e0007041, 
doi:10.1371/journal.pntd.0007041. 
40. Zhu, W.-H.; Guo, X.; Villaschi, S.; Nicosia, R.F. Regulation of vascular growth and 
regression by matrix metalloproteinases in the rat aorta model of angiogenesis. 
Laboratory Investigation 2000, 80, 545. 
41. Jagadeesha, D.K.; Shashidhara murthy, R.; Girish, K.S.; Kemparaju, K. A non-toxic 
anticoagulant metalloprotease: purification and characterization from Indian cobra 
(Naja naja naja) venom. Toxicon 2002, 40, 667-675, 
doi:https://doi.org/10.1016/S0041-0101(01)00216-1. 
42. Gong, W.; Zhu, X.; Liu, S.; Teng, M.; Niu, L. Crystal structures of acutolysin A, a 
three-disulfide hemorrhagic zinc metalloproteinase from the snake venom of 
Agkistrodon acutus11Edited by R. Huber. Journal of Molecular Biology 1998, 283, 
657-668, doi:https://doi.org/10.1006/jmbi.1998.2110. 
43. Rael, E.D.; Rivas, J.Z.; Chen, T.; Maddux, N.; Huizar, E.; Lieb, C.S. Differences in 
fibrinolysis and complement inactivation by venom from different northern 
blacktailed rattlesnakes (Crotalus molossus molossus). Toxicon 1997, 35, 505-513, 
doi:https://doi.org/10.1016/S0041-0101(96)00139-0. 
44. Mohandas, N.; Gallagher, P.G. Red cell membrane: past, present, and future. Blood 
2008, 112, 3939-3948, doi:10.1182/blood-2008-07-161166. 
45. Chippaux, J.-P. Estimate of the burden of snakebites in sub-Saharan Africa: a meta-
analytic approach. Toxicon 2011, 57, 586-599. 
46. Williams, D.J.; Faiz, M.A.; Abela-Ridder, B.; Ainsworth, S.; Bulfone, T.C.; 
Nickerson, A.D.; Habib, A.G.; Junghanss, T.; Fan, H.W.; Turner, M., et al. Strategy 
for a globally coordinated response to a priority neglected tropical disease: Snakebite 
envenoming. PLOS Neglected Tropical Diseases 2019, 13, e0007059, 
doi:10.1371/journal.pntd.0007059. 
47. Bulfone, T.C.; Samuel, S.P.; Bickler, P.E.; Lewin, M.R. Developing Small Molecule 
Therapeutics for the Initial and Adjunctive Treatment of Snakebite. Journal of 





4.4 The detection of snake venom serine proteases using a peptide-
based approach 
Harry F. Williams1, Harry J. Layfield1, Rufaida Ahamed1, Andrew B. Bicknell2, Steven Trim3 
and Sakthivel Vaiyapuri1 
1School of Pharmacy, University of Reading, Reading, United Kingdom 
2School of Biological Sciences, University of Reading, Reading, United Kingdom 




Conclusion of this chapter 
In order for future therapeutics including small molecular inhibitors such as 
batimastat/marimastat to be of real use and administered only when of net benefit to victims, 
diagnostical methods need to be developed. The future of diagnostics will undoubtedly, to 
some extent have to mirror therapeutics, with tools to indicate the administration of each 
suggested therapeutic. Here we develop a method for the identification of conserved regions 
in a protein family, from which to have peptides synthesised and specific antibodies to be 
developed for potential use in the diagnosis and indication of toxin-specific treatments. Such 
toxin-specific diagnostic platforms will empower clinicians to be able to treat victims of 
snakebite with confidence and pave the way for more specific treatment strategies. 
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General contribution (80%) 
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- Analysis and interpretation of data 
- Writing of the manuscript 
- Preparation of the figures 
 
Experimental contribution 
Figure 1 Collected sequence data, aligned sequences, assisted in identifying appropriate 
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Snakebite envenomation (SBE) is a priority neglected tropical disease associated with 
mortality and morbidity of epic proportions and this is primarily concentrated in developing 
nations. One of the best methods to improve snakebite treatment is by developing robust 
diagnostic tools. Notably, improving diagnostical methods is essential to guide more specific 
and prompt treatments, as well as giving indication to the need for appropriate pre-hospital 
management for certain snake bites. Snake venom serine proteases (SVSPs) are 
predominantly present in viper venoms, and they share several structural features. Hence, we 
sought to identify the well conserved regions among SVSPs and utilise them for the detection 
of snake venoms towards developing a diagnostic test. Using a sequence and structural 
analysis, we have identified specific regions (at the N- and C-terminal ends) common to 
SVSPs. These regions were then modified to improve their stability and immunogenicity, and 
synthesised into unique region peptides (URPs) and used to raise antibodies in sheep. One 
site enzyme-linked immunosorbent assays (ELISA) were then used to analyse their specificity 
to a range of different snake venoms, those indicating the likely presence of serine proteases 
in the venom and consequential associated haemotoxic pathologies. This method effectively 
identified a range of venoms, with a preference for vipers over elapids, as would be expected 
given the low abundance of SVSPs in non-viper venoms. However, these antibodies were 
unable to detect venoms in two-site immunoassays which may be due to poor antibody binding 
or issues related to the stearic hindrance on 3D structures of SVSPs. 
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1. Introduction  
Snakebite envenomation (SBE), a recently reinstated priority neglected tropical disease 
[1] is estimated to kill up to 125,000 people annually [2, 3] and cause permanent muscular, 
psychological and financial issues to millions of people living predominantly in the poorest 
areas of the world [4, 5]. The high mortality and morbidity arise in part from the difficulties 
associated in treating this disease, which can vary hugely in its nature depending on the 
species [6], locality [7] and age [8, 9] of the offending snake, as well as the quantity of venom 
injected, correct diagnosis and treatment of bite. Therefore, a diagnostic kit capable of 
differentiating between SBE and dry bites would be pivotal in the indication of treatment and 
transitioning to more case-specific treatments. 
Snake venoms are largely made up of enzymatic and non-enzymatic proteins and 
peptides, each of which has a different effect or range of effects on the human body [10]. 
Medically important snakes are generally found in two main families; Elapidae (elapids), a 
family with venoms composed mainly of smaller, more neurotoxic proteins such as 
phospholipase A2 (PLA2) and three finger toxins, and Viperidae (vipers), a family with 
generally larger venom components that attack the cardiovascular system, such as snake 
venom serine- and metalloproteases (SVSPs and SVMPs respectively) [11]. SVSPs are one 
of the most abundant families in viper venoms, making up approximately 15% of viper venoms 
[12], although ranging from nearly 60% in Crotalus horridus [13] to less than 1% in Bothrops 
colombiensis [14]. This is in contrast to elapids, where this protein family is virtually absent, 
with a few exceptions including Notechis scutatus [15] and most of the other Australian elapids 
[16] along with some species from the Bungarus genus [17] although SVSPs make up less 
than 6% of the venom in most of these cases.  
SVSPs are well documented to affect haemostasis in a number of ways, including via pro-
coagulant effects; e.g. ‘thrombin-like’ fibrinogen clotting enzymes, factor V activators, and 
platelet activators as well as anticoagulant effects: e.g. fibrinolytic, plasminogen and protein 
C activating enzymes [18, 19]. The snake venom ‘thrombin-like’ enzymes (SVTLEs) typically 
cleave fibrinogen (causing them to be called ‘venombins’), preferentially releasing either 
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fibrinopeptide A (subdivided as ‘venombins A’) or fibrinopeptide B (‘venombins B’) or both 
(‘venombins AB’), hence promoting coagulation via the conversion of fibrinogen to 
fibrinopeptides, which are essential to the formation of clots [20]. The SVTLEs differ from 
thrombin in their general inability to activate coagulation factor XIII, the lack of all the exosites 
present on the surface of thrombin, release of mostly a single fibrinopeptide, and the 
consequential lack of crosslinking formed by these fibrin monomers leads to the rapid 
dispersal of unstable and dangerous clots [21]. Other SVSPs occasionally activate coagulation 
factor V, a part of the prothrombinase complex which activates prothrombin to generate 
thrombin and are consequently procoagulant [22]. As well as the ‘thrombin-like’ enzymes, 
there are also ‘kallikrein-like’ SVSPs which release bradykinin from plasma kininogen, thus 
dilating blood vessels and consequently altering the blood pressure [23]. Some SVSPs also 
have effects on platelets, inducing platelet aggregation via the cleavage of protease activated 
receptors (specifically PAR1 & PAR4) [24].  
Some of the anticoagulatory SVSPs are documented to activate protein C [25], which then 
deactivates factor Va and VIIIa with consequential anticoagulatory effects. Certain SVSPs are 
anticoagulatory, capable of activating the zymogen plasminogen, to form plasmin, an 
endogenous serine protease which degrades fibrin clots [20] as well as directly fibrinolytic 
SVSPs such as ancrod . The angiotensin degrading (and reduction to vasoconstriction) activity 
of some SVSPs [26] contributes to the hypotension and vascular shock seen particularly in 
viper envenomation.  
Snakebite envenomation is a medical emergency, and it is generally the cardiovascular 
system (in bites from vipers – in part due to SVSPs) or the nervous system (in bites from 
elapids) that are the primary concern in saving a victim’s life. Being able to discern which 
snake family has caused the bite, and indeed whether venom has been injected, would allow 
the victims to seek prompt hospital treatment and empower the clinicians to initiate appropriate 
treatment without waiting for the onset of clinical symptoms.   
Antivenoms, the animal-derived immunoglobulins are the only available treatment for SBE. 
These are either monovalent when raised against a single venom, or polyvalent, when raised 
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against multiple venoms [27]. Most antivenoms are polyvalent and consequently only a 
fraction of the antibodies will be specific for the venom of offending snake. Being able to 
diagnose the species responsible for a bite would accelerate more specific treatment regimes, 
increasing the number of monovalent antivenoms being produced and reduce the wasteful 
injection of polyvalent antivenoms composed largely of redundant immunoglobulins. After 
hospitalisation, clinicians rely on seeing the actual snake specimen or an account of the snake 
as well as any local symptoms surrounding the bite site, and the traditional 20-minute whole-
blood clotting test (WBCT20) [10]. However, there is a significant incidence of “dry-bites”, 
where a victim is bitten by a venomous snake, but no venom is injected [28], therefore the 
making of decisions based on a victims account and bitemarks alone can be flawed. By the 
time symptoms are in evidence, such as severe swelling, internal bleeding, myoglobinuria, 
ptosis, haematuria, breathing difficulties, etc, the patient’s condition may have become critical, 
therefore an assay enabling the rapid assessment of envenomation and identification of the 
species responsible, would not only save lives, but could trigger a paradigm shift in the 
treatment and management of SBE.  
Despite clear recognition that we are in need of better snakebite diagnostics [29], 
advances in this field have been almost non-existent. The commonwealth serum laboratory 
snake venom detection kit (CSL-SVDK) is still, after over three decades the only available 
product in this field, the use of which is limited to Australasia. The CSL-SVDK relies on the 
enzyme-linked immunosorbent assay (ELISA) principle, which is relatively slow, and not 
without some difficulties involved in its use. The currently accepted technique for a simple 
point of care device giving rapid diagnosis is the lateral flow assay (LFA) and, in both India 
and Taiwan, the applications of LFA devices for SBE have been explored in scientific research 
[30, 31]. These are based on the use of monovalent and polyvalent antibodies respectively 
and seem able to identify the snake or snakes responsible for a bite within a very narrow range 
and are only of real use in these specific countries. However, in the future when more toxin 
specific treatments become available [32, 33] diagnostical devices able to detect individual 
toxins rather than species may be of greater use. Here, we identify, design and develop 
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antibodies for two unique regions found on viper venom serine proteases (unique region 
peptides – URPs) for use in detecting this group of enzymes in venoms, with a hope for uses 
in clinical diagnostics in the future. We used a sequence-structure-function and phylogenetic 
analysis to identify these peptides and screened the ability for corresponding antibodies to 
detect a range of different venoms. 
2. Methods 
In order to determine if SVSPs would be beneficial in developing a diagnostic method for 
SBE, URPs were designed based on viper venom serine proteases and antibodies were 
raised against these URPs in sheep to be used in the detection of these proteins in clinical 
samples from snakebite victims, and consequently corroborate envenomation from species 
containing these proteins. 
2.1 Peptide design 
The URPs were designed based on multiple sequence analysis previously carried out 
using 196 SVSP sequences [34] available on PubMed (https://www.ncbi.nlm.nih.gov/protein/). 
The basic local alignment search tool (BLAST) (https://blast.ncbi.nlm.nih.gov/Blast.cgi) was 
used in order to compare the sequences of all the proteins matching our search term “snake 
venom serine protease” and sequences were aligned using Clustal Omega [35]. Following the 
removal of signal and activation peptides, the mature protein sequences were compared 
between the SVSPs, as well as other protein families (including human serine proteases e.g. 
trypsin) to minimise cross reactivity with other groups. Highly conserved regions on these 
proteins were located at the N-terminal and C-terminal ends, and two URPs were designed: 
VIGGDECNINEHR (N-terminus/B) and KGNTDATCPP (C-terminus/A). The A-URP was 
slightly altered and the first alanine was exchanged for a lysine in order to increase solubility 
and provide a moiety that is amenable to modification. Similar sequence alignments can be 
seen in Vaiyapuri et al. (2012) [35], Ullah et al. (2018) [25] and Serrano & Maroun (2005) [20]. 
The crystal structures of the original SVSPs (available on Protein data bank 
https://www.rcsb.org/) were then viewed in PyMOL [36] in order to ensure that the conserved 
regions identified would be on the protein’s surface and freely accessible for antibodies. These 
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peptides were then slightly modified by adding a lysine to the A-URP to improve stability and 
solubility before being custom-synthesised by Sigma Aldrich (Merck, UK). 
2.2 Antibody production 
The URPs were conjugated to a carrier protein; maleimide activated keyhole limpet 
haemocyanin (KLH) in order to increase their immunogenicity. This carrier protein can bind to 
more than 200 haptens per KLH molecule, which increases the half-life of the URP and 
immunogenicity of the peptide by eliciting T helper and B cell responses, improving antibody 
production, yield and affinity. The KLH conjugation was achieved by mixing the maleimide 
activated KLH with the peptide at a molar ratio of 1:200 in phosphate buffered saline (PBS) 
(0.01 M phosphate buffer, 0.0027 M potassium chloride and 0.137 M sodium chloride, pH 7.4). 
After incubating at room temperature for sixty minutes, the solution was run through a PD-10 
column (GE Healthcare, UK) in order to desalt and remove the EDTA. The desalted peptide-
KLH conjugates were stored in -80°C freezer until further use.    
2.3 Immunisation of sheep 
The procedures used for immunisation and antibody production were approved by the 
British Home Office in accordance with the Animal (Scientific Procedures) Act 1986. Two 
sheep were injected with 50 µg of peptide-KLH conjugate each month via intradermal 
injections using GERBU P as an adjuvant as a scheduled immunisation programme for seven 
months. Before immunising, 10 mL of blood was taken from each sheep, the serum from which 
acted as a pre-immune serum control. Two weeks after each injection (with the exception of 
the first immunisation) approximately 500 mL (calculated based on the weight of the animal) 
of blood was taken from each sheep. The blood was allowed to clot overnight and the serum 
was then separated from any remaining blood cells and debris by centrifugation at 4000 RCF 
for 10 minutes at room temperature.  
2.4 Immunoglobulin G (IgG) precipitation 
Sodium sulfate was slowly added to the serum up to 18% under stirring conditions over 
60 minutes. The serum was then centrifuged at 5000 RCF for 30 minutes at room temperature. 
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The supernatant was discarded and the pellet was suspended in PBS. The suspension was 
then dialysed against 0.1% (w/v) saline overnight, followed by PBS for 3 hours before storing 
the IgG at -20°C prior to affinity purification. 
2.5 Affinity purification of URP-specific antibodies 
Following precipitation, the antibodies were selectively purified by using URP-specific 
affinity chromatography. Two columns were prepared by coupling each of the two URPs (2 
mg)  used for immunisations to UltralinkÒ Iodoacetyl resin as per the manufacturer’s 
instructions (Pierce, UK) [37]. Briefly, the lyophilised peptide (1 mg/mL) was dissolved in 
coupling buffer (50 mM Tris/5 mM EDTA pH 8.5) and was immediately added to Ultralink 
iodoacetyl gel prewashed with coupling buffer and incubated for 30 minutes at room 
temperature. After washing the unbound peptides with coupling buffer, non-specific binding 
sites were blocked using 50 mM b-mercaptoethanol in coupling buffer. The column was then 
washed again thoroughly with the coupling buffer before use. Alternating between high and 
low pH five times using 50 mM sodium acetate/20% (v/v) acetonitrile pH 6 and pH 3.5. 
After washing the resin with PBS, dialysed antibodies from 50 mL of serum were diluted 
in 1L PBS and slowly applied to the column via siphon. The column was then washed again 
with PBS, followed by 0.5 M sodium acetate and 50 mM sodium acetate/20% acetonitrile pH 
6. Fractions of 1 mL were then eluted using 50 mM sodium acetate/20% acetonitrile pH 3.5 
directly into saturated sodium bicarbonate to promptly neutralise the acid. The fractions 
containing proteins were identified using Pierce Bradford Coomassie protein reagent 
(Thermofisher, UK) and those containing proteins were pooled and quantified using direct UV 
at 280 nm. 
2.6 One-site enzyme-linked immunosorbent assay (ELISA)  
To determine the immune response of the sheep and analyse the specificity of antibodies 
produced to different venoms, one-site ELISAs were carried out: a 96-well microtitre plate was 
coated with either 100 µL 0.1 M sodium bicarbonate to act as a blank control or 100 µL of the 
URPs (100 ng/mL) (to monitor immune response) or venoms (1µg/mL)  (to analyse the cross 
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reactivity of antibodies to different venoms) diluted in 0.1 M sodium bicarbonate and incubated 
overnight at 4 °C. The plate was then blocked with 200 µL of assay buffer [1% (w/v) BSA in 
0.05% (v/v) PBS-Tween20] for one hour. Following washing four times using 0.05% PBS-T 
with a plate washer (Denley Wellwash 4 Mk 2, USA), 100 µL of either diluted serum (1/500 for 
monitoring immune response) or affinity purified IgG (at 1 µg/mL for cross reactivity analysis) 
diluted in assay buffer were added to the wells, and the plate was then incubated for a further 
two hours at room temperature. Following four further washes 100 µL (0.5 µg/mL) of rabbit 
anti-sheep horseradish peroxidase (Invitrogen, UK) were added and incubated at room 
temperature for one hour. The plate was then washed four more times before adding 200 µL 
of 3,3’,5,5’-Tetramethylbenzidine (TMB) substrate (Europa Bioproducts, UK) and incubating 
at room temperature for approximately 15 minutes or until the colour developed. The reaction 
was then stopped using 50 µL of 0.5 M HCl. The level of absorbance was measured at 450 
nm using a microplate reader (EMax precision plate reader, UK). 
2.7 Antibody biotinylation 
The affinity purified antibodies were biotinylated as per the manufacturer’s instructions. 
Briefly, EZ Link N-hydroxysuccinimido biotin (NHS-biotin) (ThermoFisher, UK) was dissolved 
in dimethyl sulfoxide (DMSO) and subsequently added to IgG in PBS at a 20 ´ molar excess. 
NHS-biotin is an ester of biotin which reacts readily with primary amine groups, forming amide 
bonds and labelling the antibody with biotin allowing for fast and specific detection with 
streptavidin, a high affinity binding partner for biotin. After mixing in the dark at room 
temperature for two hours, the unbound biotin was quenched using ethanolamine. The 
unbound biotin/ethanolamine was then removed using a G-10 desalting column (GE 
Healthcare, UK), and the desalted biotin-IgG conjugates were stored at -20 °C after 
quantification by measuring the absorbance at 280 nm by spectrophotometry. 
2.8 Two-site/Sandwich ELISA 
The 96-well microtitre plates were coated with the capture (non-biotinylated) antibody 
(5 µg/mL) (for either A & B URPs) for 16 hours at 4 °C, before blocking for one hour with assay 
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buffer before washing. Following this 100 µl of venoms were added (in a range of 2 – 20 µg 
per well) and incubation for up to 5 hours at room temperature. After further washing, 
biotinylated detection antibodies were added (1 µg/mL) and incubated for two hours at room 
temperature. Following washing four times with PBS-T, streptavidin-HRP conjugate (0.5 
µg/mL) was added and incubated for one hour at room temperature prior to washing a further 
four times with PBS-T. TMB (250 µL) was then added to each well and the plate was then 
incubated until the development of colour (up to one hour). The reaction was stopped using 
0.5 M HCl and the absorbance was read at 450 nm using ELISA reader. 
2.9 Immunoblotting analysis  
The venoms (30µg) from various snakes were dissolved in PBS and then mixed with 
reducing sample treatment buffer [10% (w/v) SDS, 10% (v/v) b-mercaptoethanol, 1% (w/v) 
bromophenol blue, 50% (v/v) glycerol and stacking gel buffer (0.5 M tris, 0.4% (w/v) SDS pH 
6.8)] and heated at 90°C for 10 minutes before being subjected to SDS-PAGE using 4-20% 
pre-made gels (Bio-Rad, UK). The proteins were then transferred from the gel to 
polyvinylidene difluoride (PVDF) membranes by semi-dry transfer system (Bio-Rad, UK) at 15 
V (constant) for 90 minutes. The membrane was then blocked in 5% (w/v) BSA/PBS-T for 60 
minutes at room temperature. After blocking, the membrane was incubated for 16 hours with 
URP-specific antibodies (0.25 µg/mL) in 5% BSA/PBS-T. The membrane was then washed 
six times in 0.05% PBS-T before incubating with anti-sheep HRP (0.2 µg/mL) diluted in 5% 
BSA/PBS-T for one hour. The membrane was then washed six times again before adding 
Pierce™ ECL Western Blotting Substrate (Thermo Scientific™, UK) and imaging using an 
ImageQuant LAS 4000 mini (GE Healthcare, UK). 
2.10 Statistical analysis 
All the data analysed were normalised, and statistical significance was calculated using 
GraphPad Prism 7 software [38]. One-way ANOVA was carried out before performing a post 




3.  Results 
3.1 Peptide design 
The sequences of 196 SVSPs were previously aligned [34] and used in this study in 
order to identify the conserved regions for use in the development of two URPs (a subset 
shown in Figure 1). The signal (18 amino acids) and activation (6 amino acids) peptides are 
cleaved upon secretion of venom through the fangs, this activates the zymogenic, inactive 
form of enzymes found in the venom primary duct via proteolytic enzymes found in the 
secondary venom duct prior to injection into the prey or victim [39]. These signal and activation 
peptides from the SVSP sequences were consequently removed and the mature sequences 
were realigned before two highly conserved regions among viper SVSPs were identified; one 
at the N-terminus end: VIGGDECNINEHR (henceforth A-URP: highlighted in red in line 1 in 
Figure 1) the other at the C-terminus end: KGNTDATCPP (henceforth B-URP: highlighted in 
blue in line 241 in Figure 1). We ensured the regions contained sulfhydryl groups (cysteines) 
in order for conjugation to both maleimide activated KLH and the iodoacetyl gel resin that is 
required for affinity purification and added a lysine to the A-URP to increase solubility. In 
addition, the structure of a number of SVSPs were analysed using PyMOL [36] to ensure the 
URPs were on the exterior of the protein’s 3D structure and freely accessible for antibody 
binding (Figure 2). 
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Figure 1. Multiple sequence alignment used to identify conserved regions within viper 
venom serine proteases. The sequences of several SVSPs (including vipers and elapids) 
were aligned in order to identify the conserved regions from which to design peptides for use 
in the production of antibodies. Highlighted regions show areas used to design the peptides: 
in red VIGGDECNINEHR (N-terminus/B) and in blue KGNTDATCPP (C-terminus/A). Snake 
species and accession numbers of SVSPs: DA: Deinagkistrodon acutus (Q9I8X1), PM: 
Protobothrops mucrosquamatus (XP_015671555), TS: Trimeresurus stejnegeri (Q91516), 
EC: Echis coloratus (ADI47560), VA: Vipera ammodytes ammodytes (AMB36345), CA: 
Crotalus atrox (AUS82485), GU: Gloydius ussuriensis (Q8UVX1), AP: Agkistrodon piscivorus 
(AUS82476) and SC: Sistrurus catenatus edwardsi (ABG26968). All the FASTA sequences 





Figure 2. 3D structure of ACC-C (Accession number: P09872), a protein C activating 
venom serine protease from Agkistrodon contortrix contortrix with the unique region 
peptides highlighted in blue (A-URP) and red (B-URP). PyMOL was used to analyse the 
3D structure of venom serine proteases and ensure that the unique regions we identified 
were available on the outer surface of the proteins and consequently accessible for antibody 
binding. Here one example from the southern copperhead, Agkistrodon contortrix contortrix 
is shown. 
 
3.2 Immune response to the URPs 
Over the course of five months, sheep were immunised with 50 µg of KLH-peptide (URP) 
conjugates and the serum was collected at regular intervals. Using one-site ELISAs, the 
immune response was monitored using diluted serum (1/100). From the results shown in 
Figure 3, the A-URP (C-terminus end) appeared to be mildly less immunogenic when 
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compared to the B-URP (N-terminus end). Although it is not entirely clear on the reasons for 
the slightly poorer immune response from the A-UPR, this could be partially due to the slightly 
smaller size compared to the B-URP: 10 amino acids for the A-URP compared with 13 amino 
acids for B-URP. Added to which, the B-URP also has a greater abundance of antigenic amino 
acids which can be associated with improved responses (lysine, arginine, glutamic acid, 
aspartic acid, glutamine, asparagine, etc [40]).	 
. 
 
Figure 3. Immune responses against A-URP (C-terminus) and B-URP (N-terminus) of 
snake venom serine protease. Blood was taken from sheep every four weeks and the serum 
was used in one-site enzyme linked immunosorbent assays (ELISA) to monitor immune 
responses to these antigens. High binding microtitre plates were coated in a single 
concentration of URPs (1 µg/mL), before being washed and then incubated with different 
concentrations of sheep serum. The unbound serum was washed off prior to the addition of 
anti-sheep IgG antibodies conjugated to horseradish peroxidase (HRP). All unbound HRP was 
then washed off and a HRP substrate (tetramethylbenzidine) was added allowing the 
quantification of binding by measuring the absorbance of the product. Data were analysed in 
























3.3 Standard curves using Crotalus atrox venom 
In order to gauge the detection limits of URP-specific antibodies to detect a venom in 
one-site ELISA, C. atrox venom (as a best example) at concentrations from 20 µg/mL to 10 
ng/mL was coated onto a high binding plate, before following the one-site ELISA protocol 
outlined as above. Figure 4 shows the differences in sensitivity between the two URP-specific 
IgGs. B-URP specific antibodies are more sensitive to C. atrox venom than the A-URP 
antibodies. The A-URP antibodies stop detecting at approximately 80 ng/mL, while the B-URP 
antibodies detect (though to a very low degree) all the way down to 10 ng/mL. These 
differences could in part, be due to the length, immunogenicity and antigenicity of the peptide.  
 
Figure 4. Standard curves for URP-specific antibodies using Crotalus atrox venom. 
One-site enzyme-linked immunosorbent assay (ELISA) was used to determine the detection 
limits of antibodies raised against KLH-conjugated unique region peptides (URPs) based on 
viper venom serine proteases. High binding microtitre plates were coated in different 
concentrations of Crotalus atrox venom, before being washed and then incubated with URP 
antibodies. The unbound antibodies were washed off prior to the addition of anti-sheep IgG 
antibodies conjugated to horseradish peroxidase (HRP). All unbound HRP was then washed 
off and a HRP substrate (tetramethylbenzidine) was added allowing the quantification of 
binding by measuring the absorbance of the product. Data were analysed in Graphpad Prism 
and represent mean +/- S.D. (n=3). 
 


































3.3 Immune reactivity against venoms in one-site ELISA  
After production and purification of IgG from sheep immunised against URPs based 
on two different regions of SVSPs, a range of snake and invertebrate venoms were screened 
for their ability to be detected by these antibodies using one-site ELISA. The antibodies raised 
against the A-URP (Figure 5A) were able to detect most viper venoms screened, to a 
significant level, although certain species of Elapidae, notably Dendroaspis polylepis, were 
also detected to a lower extent. However, the responses obtained were considerably lower 
than the URPs used. Notably, the B-URP detected all vipers to a much higher level (Figure 
5B), although D. polylepis was also detected to a significant level but to a smaller extent. 
These URPs generally seem to favour species from the subfamily Crotalinae over Viperinae, 
with Atheris squamigera, Bitis gabonica rhinoceros and Echis carinatus seeing the lowest 
levels of detection from within the vipers. One possible cause for the poorer A-URP antibodies 
is the two proline residues which can undergo cis/trans isomerisation reducing peptide purity 



















Figure 5. Specificity of URP antibodies to different viper (red) and elapid (blue) venoms. 
One-site enzyme-linked immunosorbent assay (ELISA) was used to determine the binding 
affinity of antibodies from sheep immunised with custom made KLH-conjugated peptides 
(URPs) to different snake venoms. High binding microtitre plates were coated in venoms (20 
µg/mL), before being washed and then incubated with URP antibodies. The unbound 
antibodies were washed off prior to the addition of anti-sheep IgG antibodies conjugated to 
horseradish peroxidase (HRP). All unbound HRP was then washed off and a HRP substrate 
(tetramethylbenzidine) was added allowing the quantification of binding by measuring the 
absorbance of the product. It shows the binding affinity of antibodies raised against peptides 
designed based on two conserved sequences in viper venom serine proteases, one at the C-
terminus end (A) and the other at the N-terminus end (B). Data were analysed in Graphpad 
Prism and represent mean +/- S.D. (n=3). The P-values shown are as calculated using one-
way ANOVA followed by Tukey’s post hoc multiple comparisons test. For this, the purified 
antibodies were compared to blank values, and all the values were normalised using a blank 
control. (*P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 and **** P ≤0.0001). 
 
 
3.4 Immunoblotting to assess venom proteins being bound by these antibodies  
Immunoblotting was undertaken in order to visualise the individual protein bands which 
the antibodies bind to in some elapid and viper venoms. Figure 6 shows the differences in 
binding between the A-URP IgG and B-URP IgG. Both antibodies bind well to proteins of 
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approximately 30 kDa in Agkistrodon, Crotalus and Daboia russelii venoms, however much 
lesser bands are seen in Echis carinatus. The two elapid venoms used, Bungarus fasciatus 
and Naja naja were also bound to by a much lesser extent, although a band representing a 
small protein of less than 10 kDa is bound in N. naja venom. 
 
Figure 6. Immunoblots showing venom proteins bound to A-URP (A) and B-URP (C) 
antibodies and a silver stained gel (B). Venoms were treated with reducing sample 
treatment buffer and boiled at 90 °C for 10 minutes. These were then analysed by 10% SDS-
PAGE at 150V for 45 minutes. The proteins were then transferred to a PVDF membrane 
before incubation with biotinylated IgG (0.25 µg/mL). The membrane was then washed before 
the addition of streptavidin-HRP (0.1 µg/mL). This was then washed again before a 
chemiluminescent substrate was used to visualise the areas where the antibodies had bound. 
B, a gel of crude venoms was silver stained by first fixing [40% (v/v) methanol, 10% (v/v) 
Acetic acid] then sensitising [5% (w/v) sodium thiosulphate, 6.4% (w/v) sodium acetate, 30% 
ethanol (v/v)] before priming with 2.5% (v/v) silver nitrate and developing [6.125% (w/v) 
sodium carbonate, 0.04% (v/v) formaldehyde]. In all images: lane 1, Agkistrodon piscivorus 
leucostoma, 2, Agkistrodon contortrix laticinctus, 3, Crotalus basilicus, 4, Crotalus atrox, 5, 




The development of snakebite diagnostics would allow clinicians the world over to have a 
reliable method by which to determine whether a patient has become envenomed and 
potentially in the future, quantify the amount of venom and individual toxins present in the 
circulation of victims. Instead of relying on clinical experience with snakebites, which not all 
clinicians have, using a robust diagnostic method, they can corroborate snakebite 
envenomation and validate the treatment with an expensive and sometimes dangerously 
immunogenic drug, antivenom. By producing antibodies against specific venom proteins for 
diagnostic applications, these proteins, and consequently the whole venoms or similar species 
or family members, may be detected in biological fluids of snakebite victims. This study 
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demonstrates a novel peptide-based approach to produce toxin-specific antibodies. These 
can be used in diagnostical devices to deduce the snake species inflicting a bite and go on to 
direct treatment regimes. 
The peptide-specific approach allows specific proteins to be targeted, based on 
published details about their sequences. This allows the diversity of species detected to be 
somewhat pre-determined and specific taxa to be targeted. This can however be impeded by 
unexpected sequence homology to other proteins, causing binding and detection to other 
proteins. The antibodies raised against the two URPs designed and detailed in this study 
showed a level of specificity for snake venoms which are typically more associated with SVSP 
contents, predominantly members of Viperidae with their characteristic haemo-/coagulotoxic 
venoms. The A-URP IgG gave a lower level of detection in ELISA relative to the B-URP, with 
both detecting both viper and elapid venoms, the B-URP also showed a more statistically 
significant preference for viper venoms. Notably, the highest detection was observed with 
Dendroaspis polylepis venom, a venom known to be devoid of SVSPs [41] is intriguing. The 
detection of D. polylepis venom to such a degree by both peptides may be due to the ATCP 
section of the A-URP sequence, which is also found in various adrenergic (accession number: 
P80495.1) and muscarinic toxins (~7 kDa, Accession number: P80494.1) in D. polylepis 
venom. Likewise, a similar GDRCN (compared to GDECN in B-URP) is found in various 
proteins in D. polylepis venom such as Calciseptine (~7 kDa, Accession number: P22947.1). 
The binding in ELISA to a small protein in Elapid venoms is corroborated by the low molecular 
weight band seen in N. naja venom via western blotting. The lack of SVSPs previously found 
in D. polylepis venom is likely to be based on a small potentially captive bred population and 
limited specimens. It could be that our source of venom is from a lineage with SVSPs in the 
venom. Venoms from multiple species should therefore be analysed, along with the protein 
content to determine the reliability of this SVSP absence.  
Western blotting indicated these antibodies show a far greater preference for proteins 
in viper venoms, found in the 25 – 35 kDa range, which is consistent with reported molecular 
weights of SVSPs. Though several bands below the 10 kDa mark are present for both vipers 
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and elapids, this is particularly prominent in the A-URP, which again is likely to be due to short 
homologous regions found in other toxins. 
Similarly several venoms such as Bitis species known to be rich in SVSPs, where 
these proteins comprise more than 20% of the venom showed very low levels of detection 
[42]. For the A-URP IgG, Echis carinatus, a species for which SVSPs make up between 2 – 
5% of the venom was non-significant, along with Atheris squamigera which also has a low 
percentage of SVSPs in its venom [43].  
In contrast to the A-URP antibodies, the antibodies against B-URP detected all viper 
venoms to a significant level as well as only one elapid venom again, D. polylepis, detecting 
several venoms to a level even greater than the peptide (used as a positive control). In line 
with the results from the A-URP, the least well detected species were E. carinatus and A. 
squamigera, although both detected to a high level of significance with the B-URP IgG. This 
improved specificity for SVSP-containing venoms could be due to the increased length of the 
B-URP (13 amino acids compared to just 10 for the A-URP). This larger B-URP also appears 
to be more conserved, with fewer SVSPs having substitutions in this region compared to the 
A-URP. Although these antibodies were produced based on the peptides with linear 
sequences, the ELISAs have confirmed that they can detect proteins in the native state in 
whole venoms. The slightly larger size could potentially give rise to an extra epitope and a 
wider variety of antibodies to be produced.  
Despite experimenting with extreme variations in conditions, a two-site ELISA using 
the A and B IgG was not achieved. Proteins as large as full IgG (150 kDa) binding to SVSPs 
(~30 kDa) are also in danger of steric hindrance, as such large molecules could prevent both 
capture and detection antibodies accessing respective binding sites at the same time. 
Attempts to incorporate these same antibodies into a lateral flow device have also failed, 
suggesting the fundamental issues with the suitability of antibodies for LFA and 3D structure 
of SVSPs could be a problem. This issue has the potential to be overcome by the use of 
antibody fragments (Fab/F(ab)2) or raising the capture antibody off the plate surface using 
anti-sheep antibodies, although this would introduce more cross reactivity.  
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The antibodies detailed herein were purified against the original URPs, however future 
work could attempt antibody purification using whole venoms. This could have the benefit of 
reducing the number of redundant ‘wrap around’ antibodies. These are antibodies which could 
target the ends of the URPs, wrapping around the ends of the peptides rather than the entire 
length of the hapten and are consequently unlikely to bind properly to the native SVSPs. This 
method could, however, also reduce specificity, with antibodies being given the opportunity to 
bind any proteins found in the venom used for purification. Another possible solution is the 
use of longer URPs, with potential increases to the number of epitopes and consequentially 
better detection and possibilities for a two-site assay. Increases in reactive epitopes have been 
linked to sensitivity improvements [44] and would undoubtedly have an effect on the outcome 
of a two-site assays. Although the diversity of serine proteases detected might be reduced 
due to the lesser sequence homology seen outside the unique regions used for these 
peptides.  
The standard curves further show the lower specificity of the A-IgG but were only done 
against one venom and could look different for each venom. The relatively poor detection 
limits may also suggest detection from clinical samples such as blood or plasma would not be 
versatile, these limits would be unlikely to detect SVSPs in victims of SBE suffering only mild 
envenomation, though in some venoms this could be sufficient for detrimental effects. 
Despite the lack of success in converting promising one-site antibodies into a two-site 
assay, the peptide-based approach shows much promise. The ability to detect specific toxins 
using synthetic peptides overcomes many of the limitations of using whole venoms and 
proteins, such as cross-reactivity and purity issues.  
Snakebite treatment is on the cusp of moving into toxin-specific therapeutics, rather 
than the broad spectrum polyvalent antivenoms currently available. Small molecular 
therapeutics are available for snake venom PLA2 [45] and metalloproteases [46], monoclonal 
human antivenoms have been produced against dendrotoxins [32] but alternative therapies 
for the SVSP-induced effects are still not advancing. The URP epitopes described here may 
also hold the ability for the broad-scale neutralisation of SVSPs: such specific epitopes holding 
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the key to neutralising an entire family of toxic venom proteins has implications in terms of a 
specific and efficacious therapeutic against serine-protease rich snake venoms and bites. 
These URPs could be used to develop human monoclonal antibodies, nanobodies or in the 
discovery of SVSP specific alternative binding scaffolds. 
At the forefront of improving therapeutics of SBE are reliable diagnostics with which to 
corroborate envenoming and justify the administration of any future treatments. The potential 
for adverse reactions, even with future treatments, is still there, and eliminating unwarranted 
and potentially harmful administration of antivenoms is essential. Methods such as that 
described here could give reliable, toxin-specific diagnostics and could form the primary 
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Conclusion of this chapter 
The identification of toxin-specific peptides and raising of toxin-specific antibodies using such 
peptides shows one way in which a diagnostical method can be developed. An alternative 
method is to purify the toxin itself from whole snake venom. In this chapter we use purified 
snake venom metalloproteases to raise antibodies and assess the range of detection possible 
with these antibodies. The conserved nature of these proteins mean a wide range of viper and 
elapid venoms can be detected with these antibodies, and once developed into a lateral flow 
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Abstract  
Snakebite envenoming (SBE) is an affliction which primarily effects the impoverished people of the 
rural tropics. Over 100,000 people are estimated to be killed via SBE annually and it is only in 2019 
that health authorities worldwide have realised the severity of the situation. Improvements to the 
treatment of this disease are primarily focussed on toxin-specific approaches, however such 
methods will require better diagnostical tools capable of identifying toxins actually present in the 
blood of snakebite victims. Since our approach using snake venom serine proteases was not 
successful in developing a two-site ELISA for the detection of snake venoms in clinical samples, 
here we have used snake venom metalloproteases as a target for the identification of venoms as 
these are larger proteins and more abundant in viper venoms compared to serine proteases. In this 
chapter, we report the purification of a P-I and a P-III metalloprotease from the venom of Crotalus 
atrox, the western diamondback rattlesnake, and production of antibodies against these in sheep. 
These have then been used in the detection of metalloproteases in a range of venoms using enzyme-
linked immunosorbent assays (ELISA) before being applied to lateral flow assay devices and used 
in clinical samples obtained from snakebite victims. This method shows promise in the detection of 
venoms in plasma, but currently faces sensitivity issues which need to be improved before such a 
device can be used by medical professionals in improving the diagnosis and future treatment for 
SBE. Overall, it appears that snake venom metalloproteases may be a potential candidate for the 
development of diagnostic tools for viper venoms.  




After decades of neglect, snakebite envenoming (SBE) is finally being taken seriously by the 
World Health Organisation [1]. SBE alongside cholera, yellow fever, Chagas’ disease, Leishmaniasis 
and many others, is recognised by the World Health Organisation as a neglected tropical disease 
(NTD) [2] and has recently been made a WHO priority. It affects predominantly impoverished people 
in the tropics, inhabitants of rural communities far from western medicine and hospital facilities. 
Hence, these victims frequently rely on herbal/traditional medicines and consequently die without 
any official record of snakebite as the cause. The mortality and morbidity from this disease is 
consequently expected to be hugely greater than current numbers suggest [3]. From estimates, 
deaths could match those from many of the other NTDs combined [4], and recent estimates suggest 
snakebite induced mortality could be as high as 94,000 every year [5].  
A large part of the snakebite problem stems from the diversity of venomous snakes across 
the world. Venomous snakes are mainly distributed in two families of strictly venomous snakes: 
Elapidae (elapids: include cobras, kraits, mambas and sea snakes) and Viperidae (vipers: include 
rattlesnakes, puff adders and saw-scaled vipers) as well as two families with both venomous and 
non-venomous species: Colubridae and Lamprophiidae [6-8]. Venomous snake species are thought 
to number more than 600 [9], approximately 20% of the total number of snakes worldwide and 
therefore snakebite is far from synonymous with envenomation, although this can be difficult to 
determine. Deaths from SBE come almost exclusively via the bites of vipers and elapids. These 
families while both potentially deadly, have very different venoms. Viper venoms being composed 
typically of haemotoxic serine  [10-12] and metalloproteases [13, 14] along with other minor 
components while elapid venoms are typically more neurotoxic relying on non-enzymatic nerve-
binding PLA2s [15] and three-finger toxins to paralyse victims [16, 17].  
A venomous snakebite should be treated as a medical emergency, and it is generally the 
cardiovascular system (in bites from vipers) and nervous system (in bites from elapids) that are of 
primary concern in saving a victim’s life. Elapid bites can lead to flaccid paralysis and respiratory 
failure [6, 18] while bites from vipers can lead to hypovolemic shock and kidney or heart failure along 
with severe local tissue damage [19, 20]. Being able to discern which snake family has caused the 
138
bite, and indeed whether venom has been injected (dry bites are commonplace), would allow 
appropriate pre-hospital care to be given. The use of PLA2 inhibitors such as varespladib [21, 22] or 
acetylcholinesterase inhibitors such as neostigmine or atropine in cases of elapid bites [23-25]; and 
in viper bites, the debatable administration of fresh frozen plasma when coagulopathy is suspected 
[26-28] and use of matrix metalloprotease inhibitors such as batimastat to reduce the effects of 
SVMPs – muscle damage and haemotoxicity [29, 30] are all currently being investigated for treating 
snakebite victims. Again for such treatment, the identity of the offending snake should be confirmed 
using a proper diagnostic device/method.  
Antivenom is still, over a century after its first development, the only treatment for SBE [31]. It is 
made up of polyclonal antibodies, raised against a single venom (monovalent) or multiple venoms 
(polyvalent) in large mammals, typically horses [32]. The majority of antivenom is polyvalent, and 
therefore a large proportion of the antivenom delivered will not only be specific to the offending 
snake. Better diagnostical methods of SBE could therefore allow monovalent antivenoms to be used, 
reduce adverse reactions and prevent the wastage of non-specific immunoglobulins. The delivery of 
antivenom is usually based on the victim’s account of the snake, examination of the bitten area, 
presenting symptoms and the 20-minute whole-blood clotting test [6]. However, there is a significant 
incidence of “dry-bites”, where a victim is bitten by a venomous snake, but no venom is injected [33], 
therefore making decisions based on a victims account and bitemarks is flawed, and waiting until 
symptoms start to show is commonly practised, despite the additional time between the bite and 
antivenom administration causing significant endangerment to the victim. By the time symptoms are 
in evidence crucial time is wasted, hence, making rapid accurate assessment of envenomation is 
critical in the improvement of SBE treatment. In cases of dry bites, the victims may still go to hospital 
and be treated for SBE, which not only wastes expensive and valuable antivenom, but puts 
themselves in a position to suffer the side effects of antivenom, including type III hypersensitivity, 
anaphylaxis, and pyrogenic reactions [6]. The ability to diagnose the presence of envenomation 
categorically would therefore not only stop the unnecessary use of antivenom, but minimise the 
adverse effects and treatment cost as well. 
It has been well established that not all the components in a venom are toxic or associated 
with the clinical symptoms. Therefore, toxin-specific treatment approaches are currently under 
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development. The production of monoclonal antibodies (mAbs) and small molecule inhibitors to 
target specific venom components [34] is currently being investigated by several researchers. This 
would supersede the antiquated polyclonal plasma-derived therapy that is currently the only option 
for victims of snakebite. In order for these future therapies to be of proper use, improvements must 
first be made to the diagnosis of SBE. A snakebite victim or their relative is unlikely to be able to 
ascertain conclusively the offending snake species, and even if they are able to identify the species, 
the huge intraspecific variability in venom composition observed based on the ontogeny [35], 
geographic location [36, 37], habitat type [38] as well as distinct sexual dimorphism in venom 
composition in some species [39] make clinical suppositions as to the nature of venom unwise. 
Assumptions made based solely on species have caused a “clinician’s nightmare” with the Southern 
Pacific Rattlesnake, Crotalus oreganus helleri [38]. A more case-specific treatment regimen would 
be possible given the mAb, small molecular inhibitors, anti-toxin libraries and improved diagnostics 
that the future strives to bring us. 
Currently, the development of diagnostics for snakebite has been slow. Notably, the 
commonwealth serum laboratory snake venom detection kit (CSL-SVDK) is the only commercially 
available product in this field, and is only suitable for venomous genera present in Australiasia. 
Despite its first production in 1988, and various problems relating to cross-reactivity with saliva of 
non-venomous species [40], it is still considered to be a “globally unique tool in snakebite 
management”  [41] and is used as standard procedure across Australia. Australia is estimated to 
suffer just 2-4 deaths from snakebite annually [5], yet the technology that has aided the country in 
minimising deaths, is yet to be available in the areas that really need it: South Asia and sub-Saharan 
Africa.  
There has been some research into the use of gold nanoparticle-conjugated venom-based 
antibodies in lateral flow assays for the detection of snakebites [42, 43]. These enable incredibly 
rapid detection of venoms, faster than the CSL-SVDK which relies on enzyme-linked immunosorbent 
assays (ELISA) and requires more time to acquire results. They have so far relied on antibodies 
raised against individual snake species (monovalent antivenom), and are therefore of little use at a 
global scale, although at a local level they have the potential to revolutionise the treatment of SBE. 
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Here, we use a novel sequence-structure-function approach to develop a family level 
diagnostical device specifically for most of the medically important vipers. Based on previous 
analyses, we have identified SVMPs as a good target for viper venom detection as these proteins 
are the most abundant in viper venoms [8]. Hence, by purifying and raising antibodies against a P-I 
and P-III metalloprotease from the venom of the western diamondback rattlesnake, Crotalus atrox, 
we assessed the ability of these antibodies to detect a range of different viper and elapid venoms 
via one-site and two-site ELISA. Later, a combination of suitable antibodies was used for the 





Lyophilised Crotalus atrox venom was purchased from Sigma Aldrich (UK). The whole 
venoms used in the ELISAs were provided by Venomtech Limited (UK).  
 
2.2 Protein purification 
The whole C. atrox venom (50 mg) was dissolved in 20 mM Tris·HCl pH 7.6, and centrifuged 
at 5000 x g for 5 minutes. The supernatant was then applied to either a 1 mL Sepharose Q HP anion 
exchange column (henceforth CA1 though previously named CAMP [44]) or a 1 mL Sepharose SP 
HP cation exchanger (protein named CA2) and eluted using 1 M NaCl/20 mM Tris·HCl pH 7.6 via a 
gradient up to 60%. The fractions with proteins (based on the absorbance) were analysed by SDS-
PAGE using standard methods [44] and the fractions containing the protein of interest were then 
pooled and concentrated using Vivaspin centrifugal filters before being applied to a superdex 75 gel 
filtration chromatography column. The collected fractions were analysed by SDS-PAGE and the 
fractions with the protein of interest were concentrated (same as above) before once again being 
applied to a superdex 75 column to reduce contaminanting proteins. After identifying fractions with 
CA1 (~50 kDa SVMP) and CA2 (~23 kDa SVMP) in pure form, they were dialysed before dilution to 
requisite concentrations for immunising the animals. 
2.3 Production of antibodies 
Solutions containing 50μg (500 μL of 100 μg/mL in PBS)  of the purified proteins were injected 
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into sheep via intradermal injections using GERBU P as the adjuvant (500 μL). This procedure was 
carried out in accordance with British Home Office regulations. Immunisations were repeated on a 
monthly basis and ten weeks after the first injection, 250 ml of blood was collected, allowed to clot, 
and serum was then separated from cellular debris by centrifugation at 4000 RCF for 10 minutes. 
This serum was then precipitated by gradual addition of sodium sulfate (up to 18%), before 
centrifugation at 4000 RCF for 10 minutes and resuspension in PBS. This was then filtered through 
syringe filters (0.45 µm) and diluted 1: 10 in PBS before affinity purification against the whole venom. 
 
2.4 Preperation of affinity column with venom 
Crude C. atrox venom (10 mg) was dissolved in 1 mL sepharose coupling buffer (0.1 M 
NaHCO3/0.5 M NaCl pH 8.3-8.5). Cyanogen bromide-activated-sepharose 4B resin (Sigma Aldrich, 
UK) was then swelled in cold 1 mM HCl for 1 hour, after which the supernatant was discarded and 
an empty column was packed with this sepharose-venom conjugate. The column was then washed 
with deionised water and then sepharose coupling buffer before adding the dissolved whole venom. 
These were incubated at room temperature in a roller mixer for two hours. The unbound venom was 
then washed away using sepharose coupling buffer and unreacted groups were quenched using 0.2 
M glycine. Blocking buffer was then removed by five alternate washes with coupling buffer followed 
by 0.1 M acetate buffer, containing 0.5 M NaCl, pH 3.5. The column was then equilibrated with PBS 
and stored at 4°C in 0.05% (w/v) sodium azide. 
 
2.5 Affinity purification of antibodies 
After applying 1 L of the diluted antibodies to the column over 10 hours, the column was 
equilibrated with 20 mL PBS, followed by 10 mL 500 mM sodium acetate buffer pH 8 and 50 mM 
sodium acetate buffer/20% acetonitrile(v/v) pH 6. The fractions of 1 ml were then collected manually 
using 50 mM sodium acetate buffer/20% acetonitrile (v/v) pH 3.5 to elute the IgG into saturated 
sodium bicarbonate buffer which was used to neutralise the pH, which was assessed using litmus 
pH paper. The fractions containing IgG were identified using Coomassie Plus (Bradford) assay 
reagent (ThermoFisher, UK). These fractions were then pooled, dialysed, and concentrated before 
the protein content was estimated by UV spectrophotometry (280 nm). The antibodies were then 
aliquotted and stored at -80 °C prior to use. 
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2.6 Biotinylation of antibodies 
N-hydroxysuccinimidobiotin (NHS-biotin) was dissolved in dimethyl sulfoxide (DMSO) before 
being used to label the purified IgG. NHS-biotin was added to the affinity purified IgG (in PBS) at a 
20 x molar excess. After mixing in the dark for two hours at room temperature, ethanolamine was 
used to quench any unbound biotin. Unbound biotin/ethanolamine was then removed via a PD-10 
desalting column, and the resulting biotin-IgG conjugate was stored at -20°C after protein 
quantification by direct measurement of O.D at 280 nm by UV spectrophotometry.  
2.7 One-site ELISA 
To assess the range of venoms these antibodies were able to cross react with, one-site 
ELISAs were carried out: 96-well high-binding microtitre plates (Corning, UK) were coated with either 
100 µl of 0.1 M sodium bicarbonate to act as a blank control or 100 µl of a range of venoms (10 
µg/mL) in 0.1 M sodium bicarbonate and incubated overnight at 4°C. The plates were then emptied 
and blocked with 200 µl of assay buffer [0.5% BSA (w/v) in PBS/0.05% (w/v) tween-20 (PBS-T)] for 
one hour. Following washing four times using a plate washer (Denley Wellwash 4 Mk 2, UK) and 
wash buffer (0.05% PBS-T (v/v)), 100 µl of toxin-specific IgG (250 ng/mL) in assay buffer was added 
to the wells, and the plate was then incubated for a further one hour at room temperature. Following 
further washing (4 times), 100 µl of rabbit anti-sheep horseradish peroxidase conjugated IgG (250 
ng/mL) was added and incubated at room temperature for one hour. The plate was then washed 
four more times with wash buffer before adding 200 µl of 3,3’,5,5’-Tetramethylbenzidine (TMB) 
substrate (Europa Bioproducts, UK) and incubating at room temperature for 15 minutes or until the 
colour developed. The reaction was then stopped using 50 µl of 0.5 M HCl. Absorbance was 
measured at 450 nm using a microplate reader (EMax precision plate reader, UK).  
2.8 Two-site ELISA 
High-binding microtitre plates were coated with a capture (un-labelled with biotin) antibody 
(5 μg/mL) overnight and blocked using assay buffer for one hour following this. A range of different 
venoms (100 μl of 10 µg/mL venoms) were then added and incubated for 2 hours at room 
temperature. After further washing, biotinylated detection antibodies (0.5 μg/mL) were added and 
incubated for two hours. After washing four times, 100 μL of streptavidin-HRP conjugate (0.5 μg/mL)  
was added and after 30 minutes washed off. TMB was then added and incubated until the 
143
development of colour (approximately 15 minutes). The reaction was stopped using 0.5 M HCl and 
the absorbance was read at 450 nm using a microplate reader.  
2.9 Synthesis of colloidal gold 
 Gold nanoparticles of approximately 40 nm were prepared for use in lateral flow assays in 
collaboration with UBIO PLC (Cochin, India). Briefly, gold chloride solution [0.01% HAuCl4 (v/v)] was 
boiled in the dark for five minutes. Trisodium citrate (2 mL of 1% Na3C6H5O7) was then added with 
continuous stirring and the solution was boiled until a blue and then dark red colour was produced. 
The solution was then stabilised at room temperature and stored at 4 °C while protected from light 
using foil coated glassware. 
2.10 Colloidal gold probe preparation 
The CA1 and CA2 antibodies purified previously were diluted to 2 µg/mL in 0.1 M citrate 
buffer, pH 6.8 and added to a solution of the colloidal gold nanoparticles synthesised previously. The 
solution was stirred for 60 minutes to allow conjugation, BSA was then added (up to 0.02%) to 
stabilise the conjugates. A resuspension buffer (0.01% BSA (w/v) , 0.001% sodium azide (v/v), 
10mM sodium phosphate pH 7.5) was then used to dilute the solution before the application of 
conjugates onto the conjugate pad (at 60 µg/mL) and drying by dehumidification for 30 minutes. 
These were then stored in azide (0.02% (w/v) at 4 °C before use in conjugate pad in lateral flow 
assay (LFA) development. 
2.11 Preparation of LFA devices 
The CA1 or CA2 capture (unlabelled) antibodies (2 mg/mL) were coated in test lines on the 
nitrocellulose membrane and goat anti-mouse antibodies (Whatmann, India) were coated as control 
line (2 mg/mL). The strips were then blocked with 0.02% BSA (w/v) in PBS before being dried by 
dehumidification. A commercially available glass fibre conjugate pad was prepared and coated in 
gold-antibody conjugates (both CA antibodies and gold conjugated mouse antibodies for control) 
mixed with conjugate spray buffer (0.01% (w/v) BSA, 0.05% (w/v) sodium azide, 0.01% (w/v) 
sucrose, 10mM sodium phosphate, pH 7.5) before drying by dehumidification. After assembly in 
appropriate plastic cassettes, the kits were assessed using dilutions of respective antigens, a range 
of venoms and plasma samples obtained from snakebite victims. Assembled kits were stored at 
room temperature away from sunlight and humidity. 
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2.12 Ethical statement and blood collection 
TCR multispecialty hospital research ethics committee approved the procedures for blood 
collection from snakebite victims. Human blood was obtained from patients in vacutainers with 3.2% 
(w/v) sodium citrate as an anti-coagulant and spun at 3000 RCF for 5 minutes. Plasma was then 
separated and stored at -20 °C until testing with LFA. 
2.13 Statistical analysis 
All data were first normalised before calculating statistical significance using GraphPad Prism 7 
software [45]. One-way and two-way ANOVAs (based on the data) were carried out before 
performing a post hoc Dunnett’s multiple comparisons test in order to calculate the statistical 
significance.  
3. Results 
3.1 Immune responses to CA1 and CA2 metalloproteases 
 Sheep were injected once every four weeks with either whole CA1 (Group III SVMP) or CA2 
(Group I SVMP) in order to produce antibodies specific for these two SVMPs. Despite CA1 being 
nearly double the molecular weight of CA2, both proteins generated a similar immune response 
which steadily increased during the first 8 weeks (Figure 1). After this point, the immunse response 
appears to plateau. 
 
Figure 1: Sheep immune responses against purified metalloproteases: CA1 and CA2. Blood 
was taken from sheep every four weeks and the serum was used in one-site enzyme linked 
immunosorbent assays (ELISA) to monitor immune responses to the purified CA1 and CA2. The 
O.D values measured by spectrophotometry indicate the level of antibody binding and indicate the 
immune response over the 20 week immunisation schedule. Data were analysed in Graphpad Prism 
and represent mean +/- S.D. (n=3). 















3.2 Specificity of toxin-specific IgG against a range of venoms using one-site ELISA 
To ascertain the cross-reactivity of these antibodies to different venoms arrays of viper and 
elapid venoms were used, and detected using different combinations of antibodies. One-site ELISAs 
demonstrated that these antibodies detect a wide range of venoms, but are generally more viper 
specific, cross reacting to a lesser degree with elapid venoms. In one-site assays (Figure 2), CA1 
antibodies show statistically significant cross reactivity with almost all the venoms (less specificity 
towards elapid venoms compared to vipers) used, while CA2 antibodies show a slightly greater 
specificity for viper venoms. Unsurprisingly Crotalus atrox, the snake from which these proteins 
originated is detected to the greatest degree, along with the purified proteins.  
 
 
Figure 2: Specificity of CA1 (A) and CA2 (B) antibodies to different viper and elapid venoms 
by one-site ELISA. After affinity purification of toxin-specific IgG (CA1 and CA2), one-site ELISAs 
were carried out in order to assess their specificity against a range of venoms. High binding microtitre 
plates were coated with a range of different venoms in sodium bicarbonate buffer before washing, 
blocking with BSA and the addition of CA1 or CA2 antibodies. The unbound antibodies were then 
washed off before the addition of anti-sheep-HRP conjugate. Followed by further washing, trimethyl 
benzidine (TMB) was added and the level of absorbance was measured at 450 nm by spectrometry. 
Data were analysed in Graphpad Prism and represent mean +/- S.D. (n=3). The P-values shown are 
as calculated using one-way ANOVA followed by Tukey’s post hoc multiple comparisons test. For 
this, the purified antibodies were compared to blank values, and all the values were normalised using 
a blank control. (*P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 and **** P ≤0.0001). 
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3.3 Specificity of toxin-specific antibodies against a range of different venoms using two-site ELISA  
Following one-site ELISA, CA1 and CA2 antibodies were biotinylated for use in two-site ELISA in 
order to determine their specificity without non-specific cross reactivity that was observed in one-site 
ELISA against elapid venoms. A range of venoms were screened using two-site ELISA and toxin-
specific antibodies in different configurations: CA1 as both capture and detection antibody (CA1-
CA1); CA1 as capture and CA2 as detection (CA1-CA2); CA2 as both capture and detection antibody 
(CA2-CA2) and CA2 as capture with CA1 as detection antibody (CA2-CA1).  In contrast to the one-
site assays, in two-site assays, there was much more specific binding of CA1 and CA2 for viper 
venoms, with very few elapid venoms being detected at a significant level (Figure 3). Detection does 
not differ significantly between the different genders (male and female) and morphologies (albino 
and normal) of C. atrox (Figure 3A-3D), although the closely related Crotalus basilicus is detected 
to a much lesser extent as are Agkistrodon species and Bothriechis schlegelii (Figure 3A-3D). The 
other members of Crotalinae (the pit vipers) including Bothrops atrox, B. asper and Sisturus miliarius 
barbouri are all well detected. The Viperinae species: Montivipera xanthina, Bitis arietans, Echis 
carinatus, E. pyramidum leakeyi and Atheris squamigera are all also detected to a much lower but 
still significant level. All the elapid venoms only showed a very small degree of binding and most of 
these were insignificant. Due to minimising significant elapid detection and maximising vipers 
detected to significant level the CA1-CA2 combination was employed in further experiments.  
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Figure 3. Two-site ELISA showing specificity of different combinations of CA1 and CA2 
antibodies to different viper (red) and elapid (blue) venoms: CA1-CA1 (A), CA1-CA2 (B), CA2-
CA1 (C) and CA2-CA2 (D) combinations were used. After affinity purification of toxin-specific IgG, 
two-site ELISAs were carried out in order to assess their specificity for a range of different venoms. 
High binding microtitre plates were coated with capture (as specified above) antibodies in sodium 
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bicarbonate before washing and the addition of different venoms (10 µg/mL). For detection, 
biotinylated CA1 or CA2 antibodies were then added. These were then washed off before the 
addition of streptavidin-HRP conjugate. Following further washing, colorimetric visualisation using 
trimethyl benzidine (TMB) was developed and measured the absorbance at 450 nm in a microplate 
reader. Data were analysed in Graphpad Prism and represent mean +/- S.D. (n=3). The P-values 
shown are as calculated using one-way ANOVA followed by Tukey’s post hoc multiple comparisons 
test. For this, the purified antibodies were compared to blank values, and all the values were 
normalised using a blank control. (*P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 and **** P ≤0.0001). 
 
3.3 Detection of venom in spiked whole blood and urine samples by two-site ELISA 
After assessing the ability for different combinations of CA1 and CA2 antibodies to detect a range 
of venoms in assay buffer, one combination (CA1-CA2) was then used to assess their ability to 
detect venoms in urine and plasma samples which had been spiked with venoms. The use of more 
complex mediums (biological fluids) decreased almost all the cross reactivity that was observed 
previously with elapid venoms in urine, although almost all viper venoms were clearly detected. In 
whole blood, slightly more detection of elapid venoms was seen when compared to urine but none 







Figure 4: Two-site ELISA showing the detection of different viper (red) and elapid (blue) 
venoms in urine (A) and whole blood (B). After purification of toxin-specific antibodies, two-site 
ELISAs were carried out in order to assess their specificity for a range of different venoms in 
biological samples such as urine and blood. High binding microtitre plates were coated with CA1 
capture antibodies (10 µg/mL) in sodium bicarbonate buffer before washing and the addition of 
different venoms (10 µg/mL) spiked in either human urine or whole blood. For detection, biotinylated 
CA2 antibodies were then added (0.5 µg/mL). These were then washed off before the addition of 
streptavidin-HRP conjugate. These were again washed off before colorimetric visualisation using 
trimethyl benzidine (TMB) and measuring absorbance at 450 nm in a microplate reader. Data were 
analysed in Graphpad Prism and represent mean +/- S.D. (n=3). The P-values shown are as 
calculated using one-way ANOVA followed by Tukey’s post hoc multiple comparisons test. For this, 
the purified antibodies were compared to blank values, and all the values were normalised using a 














3.4 Optimisation of ELISA using toxin-specific antibodies for the detection of Indian ‘big four’ 
snake venoms 
Given the extremity of the SBE in India, particularly with the ‘big four’ snakes (Russell’s viper, 
Indian cobra, Indian krait and saw-scaled viper), the toxin-specific antibodies were then assessed to 
determine their ability to detect these species venoms. Higher concentrations (1 and 2 µg/mL) of 
detection antibodies allowed detectability of ‘big four’ snake venoms, and some degree of detection 
in both urine and blood using all antibody concentrations (Figure 5). At both concentrations 1 µg/mL 
(Figure 5A) and 2 µg/mL (Figure 5B) and in both blood (Figure 5C) and urine (Figure 5D) the 
combination of CA1-CA1 gives the highest level of detection. In assay buffer Naja naja goes 
undetected then interestingly absorbance increases significantly in blood and urine. Likewise, Echis 
carinatus has the highest detection in buffer, but in blood and urine Daboia russelii does. 
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Figure 5: Two-site ELISA showing the ability of toxin-specific antibodies for the detection 
of the Indian ‘big four’ snake venoms: Indian Krait (Bungarus caeruleus), Russell’s viper 
(Daboia russelii - Indian and Pakistani origin), Saw-scaled viper (Echis carinatus) and 
Indian Cobra (Naja naja). Different concentrations of capture and detection antibodies were 
used until specific concentrations for the detection of these species’ venoms were identified. 
Concentrations of 1 µg/mL (A) and 2 µg/mL (B) were found to improve the detection of these 
species, and a concentration of 2 µg/mL was then used in both blood (C) and urine (D) spiked 
with venoms. Data were analysed in Graphpad Prism and represent mean +/- S.D. (n=3). The 
P-values shown are as calculated using one-way ANOVA followed by Tukey’s post hoc multiple 
comparisons test. For this, the purified antibodies were compared to blank values, and all the 





3.5 Lateral flow assays for the detection of snakebite envenomation in clinical samples 
After optimising and analysing the cross reactivity of these CA antibodies using one- and two-
site ELISAs, the most effective pairing on antibodies (CA1-CA2) were applied to lateral flow assay 
devices in order to work in a point of care setting and were trialled on snakebite patient samples. 
The LFA device was optimised used venoms in buffer and then spiked plasma before being tested 
on patient samples. In total 32 samples were tested, of which three were healthy human plasma 
controls (all of which gave negative results). In this different configuration and using clinical samples, 
detection proved broader than in ELISA, with samples from individuals thought to be bitten by Indian 
cobras, Naja naja, also giving positives, suggesting this LFA could have the potential to work as an 
SVMP detection device for elapids also. However, the strips were specific to snakebite with control 
samples from healthy human plasma showing no positives and those from a centipede bite also not 
giving results associated with SBE. Daboia russelii envenomed victim samples gave a high rate of 
detection with just two of 23 victim samples giving negative results (Figure 5C). This could be 
attributable to dry or mild bites, or juvenile snakes injecting a venom dose below the detection limit 
of the device. 
 
Figure 5: Lateral flow assay using CA1-CA2 antibodies on plasma samples from victims of 
envenomation (n=32: control=3, Echis carinatus=2, Daboia russelii=23, Naja naja=3, 
centipede=1). The CA antibodies were tried in various embodiments and found to respond most 
successfully in LFA configuration with the CA1-CA2 combination. These were then conjugated to 
gold nanoparticles before use in LFA devices. These were then used with 30  µl of plasma samples 
from victims of envenomation and compared to a clinicians prediction of offending snake species 
using description of snake combined with presence of bite marks, blistering, ptosis and blood clotting 
time. A, control showing plasma from non-envenomed individual. B, lack of test line seen with 
plasma from victim of centipede envenomation (n=1). C, Lack of test line seen with false negative 
for Daboia russelii envenomation (n=1). D, solid line seen with heavy Russell’s viper envenoming 
(n=5). E, fainter band seen with majority of snakebite envenomings (n=21) F, example of much 
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fainter band given by one sample from Russell’s viper patient (n=1).  The devices detected 




SBE is a brutal affliction, for which medical professionals have virtually no diagnostical devices 
and only one, sometimes dangerous, treatment option. A universal venom detection kit would allow 
clinicians the world over to have a reliable method by which to qualify whether a patient has become 
envenomed. In the future, the same method will be used, in conjunction with emerging devices [46] 
to also quantify the amount of venom or specific toxins present in the circulation of victims. This 
would reduce accountability on the clinicians part, speed up the treatment and direct more specific 
treatments as and when they become available. Instead of relying on experience with treating 
snakebites, clinicians would have a device with which to validate further treatment with an expensive 
and sometimes dangerously immunogenic drug: anti-venom. By producing antibodies specific for 
certain venoms/toxic proteins, these proteins, and consequently venoms containing these proteins, 
can then be detected in biological samples from victims, dictating toxin-specific treatments, thereby 
ensuring a need and efficacy of the treatment.  
In this study we purified two metalloproteases from Crotalus atrox, in order to raise and purify 
antibodies for use in diagnosing SBE. SBE currently suffers from a chronic lack of reliable methods 
of affirming envenomation. Despite being from the same species and family of proteins, CA1 and 
CA2 are heterogeneous proteins: CA1 is a P-III SVMP, containing disintegrin-like as well as cysteine-
rich domains as well as the metalloprotease domain and CA2, as a P-I SVMP and has just the 
metalloprotease domain. Using a Basic Local Alignment Search Tool (BLAST) analysis of their 
sequences shows that the sequence for CA1 (the larger SVMP) covers 51% of the sequence of CA2 
and a much higher 68% are positives meaning the sequence is made up of either identical or similar 
amino acids. This somewhat explains the similarities in their detection of the different species, 
although the disintegrin-like and cysteine-rich domains could be expected to lead to greater 
differentiation, as these regions may contain a range of different epitopes. 
The ELISA work ascertained that these SVMP-specific antibodies are successful in detecting 
most members of Crotalinae, the subfamily containing Crotalus atrox along with the most closely 
related species including some true vipers. Surprisingly, relatively poor reactivity (still highly 
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significant) with C. basiliscus was observed despite being closely related and its venom being 
composed of nearly 70% SVMPs [47]. Additionally, despite Crotalus atrox being evolutionarily more 
distant from Bothrops than Agkistrodon and Bothriechis, Bothrops species are detected to a much 
greater extent: seemingly SVMPs are well conserved within these genera despite more evolutionary 
distance [48], this may be attributable to similarities in preys. 
Through ELISAs in assay buffer, many true vipers (members of Viperinae) were also detected 
to a significant level but to a much lesser extent than the Crotalids and very few elapids were 
detected. Upon switching the buffer to human fluids (urine and blood) almost all cross reactivity with 
elapid venoms and most significant detection of Viperinae was also removed (although minor 
detection was still observed), possibly in part due to better blocking of the plate with plasma proteins. 
Slightly improved specificity could also be due to any especially cross reactive antibodies binding to 
plasma proteins rather than venom proteins or capture antibodies. While an incredibly valuable tool 
in vitro, in a clinical setting ELISA is relatively complicated and time consuming, requiring a minimum 
of approximately 20 minutes to get results and giving somewhat qualitative results when compared 
to LFA which can deliver results in a matter of minutes and gives a binary result, minimising 
confusion for clinicians.  
Translating these antibodies into an LFA configuration enabled the detection of Russell’s 
viper, Daboia russelii, and saw-scaled vipers, Echis carinatus, as well as all three cases of an elapid 
bite from the Indian cobra, Naja naja. Although N. naja venom does have a small metalloprotease 
content of around 1% [49], these are likely to show high homogeneity to viper SVMPs. BLAST 
analysis of SVMPs from Naja atra (Atragin, accession: D3TTC2) and Naja mossambica 
(Mocarhagin, accession: Q10749) against CA1 gave 58% and 44% coverage of identities 
respectively (72% and 63% positives - identical and similar amino acids combined). Therefore, the 
ability for these antibodies to detect venoms from Naja is possible (despite results from ELISA), only 
unlikely given the very low percentage found in N. naja venom [49]. This percentage is likely to vary 
based on a range of factors such as locality, age and possibly gender and the South Indian 
phenotype could possibly express a larger percentage of SVMPs, though published percentages 
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vary little and those between 1.45% in Pakistan [50] and 0.85% in Rajasthan/Gujurat and 0.86% in 
Sri Lanka have been reported [51]. 
At the initial antibody concentrations used (0.5 µg/mL), few species from Viperinae and 
Elapidae were detected (Figure 3 & 4), but by increasing antibody concentrations in ELISA, and 
using an alternative platform (LFA) these more distantly related snake species and venoms were 
also detected (Figure 5). Although this study eventually yielded an LFA device with such high cross 
reactivity it was unable to differentiate between vipers and elapids. Further optimisation, and raising 
of antibodies in two different species could overcome these hurdles.  
The major pitfall in assessing the LFA’s reliability is reliance on a clinician’s expert opinion to 
corroborate or refute the LFA results. Based on the local effects and other symptoms, description of 
snake or actual snake - in the case that the offending snake was killed and brought to hospital - 
clinicians can sometimes have a good idea of the offending snake. However, there are cases of 
these being very wrong and fear in victims can trigger misleading symptoms causing the 
administration of anti-venom in non-venomous bites, which can result in unnecessary anaphylaxis 
[52]. Even when correctly identifying the snake as a venomous species, the hugely varied levels of 
envenomation from dry bite to the near emptying of venom ducts into a victim cause a huge range 
of symptoms and pathologies to result. Therefore, the use of molecular techniques such as PCR-
aided DNA sequencing to corroborate a clinician’s interpretation of a bite in evaluating point of care 
devices would be beneficial. This has already been reported using DNA found on swabs from the 
bite site and comparing this with morphological identification of dead snakes [53]. The next 
generation of lateral flow devices will no doubt include multiple strips, each denoting a particular 
taxon, toxin or treatment type, whether the treatment be monovalent antivenoms of small molecule 
therapeutics. Whatever the future of snakebite therapeutics hold, diagnostic are in dire need of 
improvement as a priority. 
While the differential identification between viper and elapid SBE proved unreliable via the 
current prototype LFA device, the presence of SVMPs in victim samples seems to be correctly 
implied. What is required is an accurate venom profile of the South Indian N. naja phenotype and 
sequencing of its SVMPs. A larger sample size including a larger range of species would aid in the 
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assessment of breadth of species detected and specificity for venoms with high SVMP content. The 
ability for this device to detect SVMPs could act as indication for rapid administration of SVMP-
specific drugs or small molecule inhibitors such as batimastat/marimastat or other future treatments 
and significantly reduce SVMP-induced muscle damage and necrosis [8]. The negative effects of 
these broad spectrum metalloprotease inhibitors on angiogenesis [54] mean a definite indication is 
required before such potentially detrimental drugs are administered, and an LFA device such as that 
described here would be preferential than waiting for symptoms to develop. As novel, toxin-specific 
treatments become available, indicative diagnostics will become essential and a similar degree of 
specificity to respective treatments seems sensible. LFA devices currently provide the most rapid 
option for this and rapidity of treatment is essential when it comes to SBE-induced morbidities. As 
and when treatments become approved and available, similar devices also need to be developed in 
such a manner.  
SBE continues to take an unnecessarily large toll on the underpriveliged people of the tropics, 
this is hoped to be halved by 2030 by the WHO, but bold ideas will have to deliver approved 
diagnostic and therapeutic products if this is ever to become a reality. 
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5. General Discussion 
 
Snakebite envenoming (SBE) is perhaps the most toxicologically complex issue that a 
human can experience and one of the most difficult pathological complications humanity has 
ever attempted to overcome. A rapid and unexpected injection of a constantly evolving and 
highly diverse cocktail of hundreds of toxins and enzymatic proteins cause both rapidly deadly 
systemic neurotoxicity and coagulotoxicity as well as amputation-worthy local effects 
sometimes leading to lifetime sequelae. Overall, SBE is associated with detrimental effects on 
virtually every aspect of human physiology. The impossibility of appropriately solving this 
medical emergency has prevented any major breakthroughs in treatment for over a century. 
We are now seeing the true severity of the epidemiology associated with SBE and this thesis 
has added to the field in a number of small ways. 
5.1 Main findings of this thesis 
Snakebite envenomation is in urgent need of improvements to both diagnosis and treatment 
of bites. The diversity of toxins involved and consequential range of underlying 
pathophysiologies make improving upon current treatments difficult and this is further hindered 
by a lack of diagnostic methods (Williams et al., 2019a). Clinicians are somewhat powerless 
in treating victims, with no way to corroborate envenomation but waiting for symptoms to 
develop, and even then usually have just one treatment option, polyvalent antivenoms, which 
they appreciate do little to abrogate the local effects and morbidity associated with bites 
(Williams et al., 2017). A number of different venom components all work synergistically to 
worsen the state of victims. For example, the production of toxic, methaemoglobin is the result 
of a large range of venoms, this increases both hypoxia and oxidative stress (Williams et al., 
2018) which then further exacerbates tissue damage and is likely to impair muscle 
regeneration, which relies on a healthy blood supply. One of the main enzymes causing 
delayed muscle regeneration are the snake venom metalloproteases, these enzymes cause 
haemorrhaging and degrade the basement membrane hindering the ability for satellite cells 
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to regenerate (Williams et al., 2019b). Matrix metalloprotease inhibitors batimastat and 
marimastat are suggested therapeutics for these SVMP-induced pathologies and have shown 
efficacy in vitro against a P-I metalloprotease. These also inhibit endogenous proteins 
however and require careful diagnosis before administration – as should all future therapeutics 
with any potential to worsen a victim’s state with improper administration. Diagnostic 
approaches based on identifying conserved toxin sequences and the production of synthetic 
peptides or the purification of toxins from whole venom can both serve in raising toxin-specific 
antibodies with which to diagnose and more efficaciously treat snakebite envenoming. Such 
diagnostical platforms are required if clinicians are to be able to use the next generations of 
antivenom therapeutics and generally improve our understanding of the underlying 
pathophysiology with SBE. 
5.2 Limitations of the studies 
Snakebite envenomation is concentrated in the rural tropics where people are unequipped for 
regular contact with venomous snakes. This aspect of SBE means that, unlike diseases 
manifested in wealthier nations, it has undergone relatively little research, and the full scale of 
the epidemiology is still relatively unknown (Habib and Brown, 2018; Ralph et al., 2019; 
Chippaux, 2017; Mohapatra et al., 2011; Vaiyapuri et al., 2013). While the major systemic 
effects leading to mortality such as the neurotoxicity (causing death by paralysis) and 
haemotoxicity (causing death by hypovolemic shock) are fairly well studied, the lesser effects 
which contribute hugely to the morbidity are still very poorly understood (Habib et al., 2015; 
Williams et al., 2011; Snow et al., 1994). Research around SBE therefore suffers from a 
massive hole in the knowledge base required to gather a complete picture of the effects taking 
place. One significant unknown surrounds the different aspects leading to hypoxia and how 
significant this hypoxia is on the necrosis and damage local to the bite site. Unfortunately, 
basic information such as the volume of venom injected by different snake species and 
systemic concentrations of venom in the blood are all but unknown. Predictions can be made 
based on yields from milking venomous snakes (Hill and Mackessy, 1997; de Roodt et al., 
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1998) combined with average blood volumes found in humans. However, this does not take 
into account the colocalization of certain venom components with tissues surrounding the local 
bite site, the higher concentrations of venom found closer to the bite site, reduced injection of 
venom by snakes in laboratory settings and the much smaller venom injections given by 
snakes following recent feeding alongside many other variables. Therefore, suitable 
concentrations for studying the effects of venoms are hard to agree upon and vary hugely in 
within the field. The varied nature of venoms both inter- and intraspecifically, by ontogeny, 
diet, gender, size and habitat (Williams et al., 2019a) all lead to such disparity in venoms which 
are all considered to be the same when from the same species, mean replicating studies is 
somewhat impossible unless using the exact same pooled venom sample. These cause great 
issues in diagnosis as well as making all generalisations most unwise when it comes to the 
conclusions. 
 The variations from one venom to the next mean data indicating a low level of 
proteases are not necessarily accurate and the actual venom may be much richer in these 
than suggested (Pla et al., 2019). The numerous proteins found in venoms (frequently with 
several heterogenous proteins of the same molecular weight being found in one venom) make 
using SDS-PAGE a precarious procedure. The presence of multiple proteins of a similar 
molecular weight to haemoglobin, fibrinogen and many other endogenous proteins, make 
using techniques such as SDS-PAGE to display proteolysis somewhat inconclusive.  
The incredibly rapid and potent collagenolytic activity by SVMPs mean their effect on muscles 
can be too destructive to allow scientific deconstruction of the full processes. With isolated 
myofibres, we found denuding of the basement membrane and hypercontraction of the fibres 
to take place so rapidly at higher concentrations that only the lowest concentration could be 
analysed for proliferative effects and effects on migration speed could only be studied over 
the first 24 hours (before hypercontraction had taken place) (Williams et al., 2019b). The lack 
of in vivo work with the small molecular therapeutics suggested therein and tested in vitro also 
add to reduced impact of this work.  
163
 
Using synthetic peptides to mimic regions of whole proteins was proven to work in single site 
format but failed in two site formats. This suggests steric hindrance is preventing binding in 
some way. Despite this lack of evolution into a format of realistic use, this chapter does portray 
a methodology by which others can develop epitope specific antibodies and detect specific 
toxins. Using whole proteins caused a lack of specific detection, and the detection of such a 
broad range of species that it may be of limited use in the real world. 
5.3 Potential synergism between methaemoglobin production and myotoxicity 
Some of the effects of SBE appear to be well understood, for example the post- and 
pre-synaptic neurotoxicity which are generally associated more with elapid bites, however, 
despite intense studies still have a number of unanswered questions (Ranawaka et al., 2013). 
Direct haemolysis of venom is a well-known function of cytotoxic phospholipase A2 (PLA2) 
(Gutiérrez et al., 2017), but the consequential oxidation of the haemoglobin released from 
lysed erythrocytes has previously only been mentioned briefly and primarily only in a few 
viperids (Meléndez-Martínez et al., 2017; Sharma et al., 2015). The ability for elapid venoms 
devoid of L-amino acid oxidases (LAAO) to also produce methaemoglobin challenges the 
assumption that this is always an LAAO-mediated event and far more broad ranging than 
previously described (Williams et al., 2018). This adds a new level of hypoxia to the challenges 
of SBE pathologies and additional complications to exacerbate envenomation effects. The 
lack of oxygen associated with methaemoglobinaemia is likely to starve cells and organs 
already in dire need of nutrients, thus exacerbating an already potentially critical condition and 
further delaying muscle regeneration in myotoxic envenomations (Moseley et al., 1999). The 
inability for methaemoglobin to bind oxygen, combined with the stronger binding of 
haemoglobin to oxygen when the ferrous (Fe2+) ions of haem are oxidised to the ferric (Fe3+) 
state shifts the oxygen dissociation curve to the left and causes hypoxia as well as increased 
lactic acid production (Darling and Roughton, 1942; Banimahd et al., 2016).  
 In addition to having this effect on haemoglobin, this oxidative effect is also 
likely to occur in myoglobin due to sharing high structural homology. Myoglobin is closely 
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related to haemoglobin and is an oxygen storage protein found specifically in muscles (Davies, 
1990). By oxidising myoglobin, venoms would eradicate the muscular oxygen supply provided 
by healthy myoglobin, thereby intensifying the extensive muscle damage already seen with a 
large number of snake venoms (Gutiérrez and Ownby, 2003; Williams et al., 2019b; Gutiérrez 
et al., 1995). The myotoxicity associated with SBE is also complex, with a range of 
components carrying out compounding effects. The phospholipid destruction associated with 
enzymatic PLA2 (Gutiérrez and Ownby, 2003) and pore formation by non-enzymatic PLA2 can 
cause systemic myotoxicity and acute kidney injury due to build-up of myoglobin in renal 
tubules (Sitprija and Sitprija, 2012). This release of myoglobin (and possibly metmyoglobin) 
into the vasculature following extensive venom-derived muscle damage is likely to worsen the 
hypoxia and oxidative stress caused by methaemoglobin production. Certain myotoxins can 
also cause acute skeletal muscle degeneration which due to the lack of disruption to the 
basement membrane (BM), is associated with relatively unimpeded regeneration due to the 
vasculature and extra-cellular matrix being relatively unaffected (Gutiérrez and Ownby, 2003). 
In contrast, venoms containing snake venom metalloproteases (SVMPs), have clearly shown 
their ability to cleave vasculature and BM components thereby hindering regeneration 
(Gutiérrez et al., 2018). The added negative consequence on the speed of migration and 
proliferation of satellite cells that we have shown adds yet another level of complexity to the 
problem surrounding the treatment of SBE-associated muscular damage (Williams et al., 
2019b) and suggests rapid treatment may be the only way to prevent toxin longevity in 
muscles along with the BM and vascular destruction associated with this family of enzymes.  
The SVMP-induced effects of snake venoms have the proposed treatment with matrix 
metalloprotease inhibitors (Arias et al., 2017; Rucavado et al., 2004; Rucavado et al., 2000), 
which undoubtedly inhibit the collagenolytic effects of these proteases and are likely to reduce 
haemorrhaging. This reduction in haemorrhaging may have the added benefit of increasing 




The negative connotations of these inhibitors on endogenous proteins first requires 
careful consideration and better diagnostics are necessary to reduce the misuse of such 
potentially detrimental drugs in the treatment of SBE. Likewise, the use of melatonin in the 
reduction of hypoxia and toxic methaemoglobin build up requires careful diagnosis to ensure 
effects associated with melatonin administration will not exacerbate the specific 
envenomation.  
5.4 The necessity for treatments based on thorough diagnosis 
The immediate administration of small molecular therapeutics such as the matrix 
metalloprotease inhibitors batimastat/marimastat or metal chelators such as EDTA, have 
proven to inhibit SVMPs both in vitro and in vivo (Arias et al., 2017; Rucavado et al., 2004; 
Rucavado et al., 2000; Escalante et al., 2000) and we have shown a P-I metalloprotease to 
also be inhibited by these compounds (Williams et al., in preparation). It is a fair assumption 
to think all SVMPs, given their high sequence homogeneity, conserved active site and zinc 
dependence will be similarly affected by these compounds. The SVMP induced 
haemorrhaging, fibrinogenolytic activity, anti-platelet activity and delayed muscle regeneration 
are all likely to be prevented by these compounds. The question is at which point the 
administration of these compounds lose their merit and actually become detrimental? Within 
hours after envenomation the tissue damage and myotoxicity that these compounds aim to 
prevent will have already taken place. Administration after such a time may primarily have 
negative consequences: the prevention of angiogenesis - the formation of new vessels is 
necessary to replace venom-induced vasculature damage and muscle regeneration; 
morphogenesis and tissue repair. It is therefore of merit to develop a diagnostic tool to give 
sufficient indication for administration of such a drug in field or pre-hospital settings. There are 
similar concerns with melatonin administration and despite reducing oxidative stress, adding 
to hypotension in certain bites would undoubtedly worsen the victims state – development of 




 The detection of snake venom components and corroboration of SBE has become a 
necessity. The large number of venom proteins show at least some level of similarity to 
endogenous proteins (SVSPs and endogenous serine proteases; SVMPs and matrix 
metalloproteases; PLA2 etc). Therefore, inhibitors broad ranging enough to inhibit all of a 
family of venom proteins are also likely to unnecessarily inhibit these endogenous proteins 
too, causing unknown damage. Therefore, thorough verification of envenoming and the 
presence of toxins is absolutely necessary before such administration takes place. Methods 
of developing appropriate diagnostic devices have been described in this thesis (Williams et 
al., in preparation, Williams et al., in preparation) and devices using such methods need 
immediate production to not only enable future therapies to be correctly administered, but 
antivenom to be used only in victims of SBE, not in dry and non-venomous bites. Diagnostical 
tools will also enable much needed accuracy in epidemiology of snakebites to be improved 
and clinicians to feel empowered in their confident administration of a potentially life-changing 
treatment – both in terms of debt and hypersensitivity. 
5.5 Future Work 
We have described a way in which to assess haemoglobin oxidation, however, fractionation 
and reassessment of the oxidising ability of specific toxins is required to identify the proteins 
responsible for this effect in LAAO-devoid venoms. The inhibition of such effects using 
antioxidants needs to be studied in more detail and the negative effects of melatonin need to 
be weighed up against its ability to ameliorate the associated hypoxia. The added burden of 
this effect in relation to neurotoxicity and coagulotoxicity needs to be quantified in order to 
appraise the need to address this frequently ignored side-effect of SBE. Myoglobin also needs 
to be assessed for its ability to be oxidised by various venoms and amelioration of the effects 
on both myoglobin and haemoglobin by melatonin need to be quantified. One fairly simple and 
non-invasive way of assessing whether venom oxidises myoglobin would be to compare the 
urine of those suffering myoglobinuria as a result of SBE with urine from someone suffering 
myoglobinuria from physical trauma. Using full wavelength scans as we described herein, the 
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two samples could be assessed for their myoglobin peaks which occur at 540 nm and 580 nm 
(compared with a single peak at 628 nm for metmyoglobin (Schenkman et al., 1997)). 
The in vitro efficacy of MMPIs in the inhibition of SVMPs reported elsewhere has been 
corroborated, although the true effects of these under in vivo settings over an extended period 
is yet to be studied and will no doubt cast a shadow over what the snakebite community has 
hailed as a panacea for the SVMP-induced morbidities. What are the side-effects and long-
term implications of MMPi use in snakebite victims? 
There are still no snakebite diagnostical devices commercially available to indicate and direct 
treatment outside of Australasia. Future work needs to address this as a priority. Antivenoms 
themselves can quite simply be made into lateral flow devices instantly indicating the merit of 
that antivenom, preventing unnecessary adverse reactions and wastage of a medicine which 
is already in dangerously short supply (Habib and Brown, 2018). More specific devices can 
then be built upon this initial diagnostical platform. The use of specific toxins, or toxin-specific 
peptides has shown some promise towards developing diagnostic devices using toxin-specific 
antibodies. Further tweaking and optimisation is required if they are ever going to be of used 
in a clinical setting in order to improve the specificity and accuracy. Monovalent antivenom for 
use in such diagnostical devices around the world needs to be made available and diagnostics 
need greater heed taken of them before treatments become approved and available with no 
way of indicating them except the onset of symptoms – by which time the merit of 
administration is, while still essential, reduced. 
5.6 Conclusion 
A full understanding of the true complexity of SBE, with the secondary, as well as primary 
effects of each component being fully understood is potentially beyond the scope of humanity. 
The further we study each component the more functions and secondary effects become 
evident. There remain many mysteries to uncover, hidden in the infinite toxicological profile of 
snake venoms worldwide, but efforts need to concentrate on the major venom components. 
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Improvements to both therapeutics and diagnostics are a necessity if we are to meet the 
halving of SBE mortality by 2030 put forward by the WHO. We cannot allow another century 
passing where animal-derived immunoglobulins are the only acceptable treatment for a 
disease that promises to be only worsen in the future.  
Improvements are urgently needed to the treatment and diagnosis of snakebite (Williams et 
al., 2019a). It kills more than many of the other neglected tropical diseases combined and has 
far greater complexity in terms of improving treatment. 
The dramatic morbidity associated with SBE is seen worst in India where clinicians 
struggle to treat snakebite effectively due to a large range of challenges including a lack of 
diagnostics and available therapeutics (Williams et al., 2017). Despite there being suggested 
treatments for the oxidative stress (melatonin) and local tissue damage (varespladib and 
MMPis) these need thorough study and proper diagnostic options before administration to all 
those presenting symptoms of snakebite. 
The presentation of a snakebite does not automatically indicate SBE, and assumptions 
based on species can highlight holes in the science. For example, methaemoglobin production 
was previously associated with only viper venoms but we found to be a secondary effect of 
elapid venoms also (Williams et al., 2018). This can exacerbate the oxidative stress and 
hypoxia, which in turn impacts on other venom-induced complications, including potential 
further delays to muscle regeneration. The effect seen with haemoglobin may even have 
similar impacts on myoglobin – causing even greater harm through further extension to the 
hypoxic conditions. 
The hypoxia from oxidative stress and haemorrhagic ischaemia combines with the 
destruction of muscular basement membranes by snake venom metalloproteases (SVMP) to 
affect satellite cell function and persist within muscles for over ten days to cause prolonged 
effects and delayed regeneration (Williams et al., 2019b). Methaemoglobin production is likely 
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to exacerbate this, not only effecting blood supply, but potentially also oxygen stored in 
myoglobin.  
Treatment of these SVMP-effects include matrix metalloprotease inhibitors such as 
batimastat/marimastat and metal chelators such as EDTA and were here found all able to 
inhibit the collagenolytic effects of one such SVMP (Williams et al., in preparation). The use 
of such drugs would potentially speed up muscle regeneration and reducing the 
haemorrhaging and hypoxia associated with these enzymes. Diagnostical tools are 
compulsory to prevent unnecessary and potentially dangerous administration of such drugs. 
For the diagnosis of SBE, two methods are outlined: 1. Using multiple sequence 
alignment and 3D structures of proteins, toxin specific peptides have been designed and used 
to produce snake family-specific antibodies (Williams et al., in preparation), steric hindrance 
may prevent these specific antibodies ever being of use commercially however; 2. Antibodies 
raised against purified proteins have been used in the detection of a wide range of venoms 
and may give indication for further treatment (Williams et al., in preparation). 
 Together, these experimental chapters highlight the complexity of snakebite 
envenomation and the future of therapies based on diagnosis. There are compounding and 
synergistic factors to consider; hypoxia from the production of radicals and toxic molecules 
such as methaemoglobin act to further impede tissue regeneration from the directly cytotoxic 
effects of certain proteins. Certain compounds have been suggested to ameliorate the local 
tissue damage, hypoxia and even neurotoxicity, but without a thorough understanding of the 
venomous snakebites which they serve to treat and those they could further exacerbate it is 
hard for these therapeutics to be taken forwards. This requires diagnostics to be improved 
allowing the offending snake or toxins present in the venom to be ascertained. This will not 
only allow administration of appropriate drugs but improve research into snakebite 
envenomation, with effects unequivocally associated with diagnosed species or toxin group 
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How long have you been treating snake bites? 
How many snake bite patients do you see in a month? In a year? 
In which month of the year do you receive most cases? Is this stable over the years? 
What questions do you ask the victim or their relatives when they arrive? 
What is the first treatment you give? 
How important is it to know the identity of the snake? 
If the snake is unknown how do you treat? 
How long after the bite do patients arrive at the hospital? 
What are the effects of this delay? 
Do you use polyvalent anti-venom? Or mono valent for specific snake?  
Who is the supplier of anti-venom to your hospital? 
How much does it cost for a vial? How many do you normally use to treat the victim? 
Do you use any other treatments for snake bite? 
What would be the minimum and maximum costs to treat a snake bite victim? 
Have you seen any extreme cases so far? 
Can you describe what these were and how you treated them? 
Have you seen anything which you would consider a medical miracle following a snake bite? 
Have you seen any unusual envenomation effects? 
Did you treat this effect successfully? 
What is the percentage of snake bite victims who die in the hospital? 
Is that because of their time delay to reach the hospital? 
Do people die because of increased blood pressure and heart rate due to the threat?  
Has anybody died because the snake was misidentified and treatment was given for the wrong 
snake? 
What would you advise the victims after treatment? 
175
How long do they normally stay in the hospital? 
Would you be happy to show us the snake bite statistics recorded in your hospital? 
Would you be happy to show us any extreme case reports? 
Is there any snakebite victim admitted in your hospital now? 
Can we meet them for a short interview? 
What you think about the current treatments for snake bites? 
How do you think we can improve the treatments? 
What would you suggest researchers should investigate as a priority to treat snake bites better? 
Do you think the government should take any specific actions in the treatments or in the prevention 
of snake bites? What would that be? 
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Ruthenium-conjugated chrysin 
analogues modulate platelet 
activity, thrombus formation 
and haemostasis with enhanced 
efficacy
Divyashree Ravishankar1, Maryam Salamah1, Alda Attina1, Radhika Pothi1, Thomas M. 
Vallance1, Muhammad Javed1, Harry F. Williams1, Eman M. S. Alzahrani1, Elena Kabova1, 
Rajendran Vaiyapuri2, Kenneth Shankland1, Jonathan Gibbins3, Katja Strohfeldt1, Francesca 
Greco1, Helen M. I. Osborn1 & Sakthivel Vaiyapuri1
The constant increase in cardiovascular disease rate coupled with significant drawbacks of existing 
therapies emphasise the necessity to improve therapeutic strategies. Natural flavonoids exert 
innumerable pharmacological effects in humans. Here, we demonstrate the effects of chrysin, a natural 
flavonoid found largely in honey and passionflower on the modulation of platelet function, haemostasis 
and thrombosis. Chrysin displayed significant inhibitory effects on isolated platelets, however, its 
activity was substantially reduced under physiological conditions. In order to increase the efficacy of 
chrysin, a sulfur derivative (thio-chrysin), and ruthenium-complexes (Ru-chrysin and Ru-thio-chrysin) 
were synthesised and their effects on the modulation of platelet function were evaluated. Indeed, Ru-
thio-chrysin displayed a 4-fold greater inhibition of platelet function and thrombus formation in vitro 
than chrysin under physiologically relevant conditions such as in platelet-rich plasma and whole blood. 
Notably, Ru-thio-chrysin exhibited similar efficacy to chrysin in the modulation of haemostasis in mice. 
Increased bioavailability and cell permeability of Ru-thio-chrysin compared to chrysin were found to be 
the basis for its enhanced activity. Together, these results demonstrate that Ru-thio-coupled natural 
compounds such as chrysin may serve as promising templates for the development of novel anti-
thrombotic agents.
Cardiovascular diseases (CVDs) are collectively regarded as the number one killer worldwide, and notably, 
thrombosis is responsible for the majority of CVD-associated mortalities and morbidities1, 2. Platelets (small 
circulating blood cells) play indispensable roles in haemostasis by preventing excessive blood loss upon vascular 
damage through blood clotting. However, inappropriate activation of platelets leads to thrombosis (formation of 
blood clots within blood vessels) under pathological conditions such as the rupture of atherosclerotic plaques3. 
Thrombosis reduces the blood supply to vital organs such as the heart and brain resulting in heart attacks and 
strokes, respectively. Hence, targeting platelets has been proven to be effective in the prevention and treatment 
of CVDs (primarily heart attacks and strokes)4, 5. While the currently used anti-platelet drugs such as aspirin and 
clopidogrel demonstrate efficacy in many patients, they exert undesirable side effects such as bleeding complica-
tions and are ineffective in others5. Therefore, the development of safer, more effective therapeutic strategies for 
the prevention and treatment of thrombotic diseases is a pressing priority.
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The direct relationships between dietary components and cardiovascular health have been established over 
the last few decades even though their underlying molecular mechanisms are not well understood6–9. Although 
several genetic factors account for the development of CVD risks in multiple settings10, dietary components 
form an essential part of the disease progression. While a number of dietary molecules such as lipids are respon-
sible for the development of CVDs, many small molecules including flavonoids that are present in various plant 
products exert beneficial effects in the prevention of such diseases11, 12. Individuals who consume diets with low 
levels of saturated fatty acids together with a substantial amount of fruits and vegetables have been shown to have 
reduced development of CVD risks13, 14. In particular, a number of dietary flavonoids such as quercetin15, tangere-
tin16, nobiletin17, luteolin and apigenin have been shown to exhibit inhibitory effects in platelets by modulating 
diverse signalling cascades18. However, several challenges are associated with using dietary components for the 
prevention and treatment of diseases. Some of these include malabsorption, poor bioavailability of desired com-
pounds in the blood stream, poor metabolic stability as well as reduced lipophilicity to readily cross the cell mem-
branes19–22. Specific chemical modifications (e.g. addition of sulfur groups23) to the fundamental structures of 
dietary flavonoids have been shown to improve their hydrophobic nature and enhance their biological activities. 
Indeed, all the natural flavonoids share a basic template structure which can be modified by the specific addition 
of various functional groups, affording a diverse array of biological activities18, 22.
In recent years, the therapeutic applications of organometallic complexes have been considered for numer-
ous pathological conditions24–27. For example, cisplatin, a platinum-based FDA-approved anti-cancer drug has 
substantially increased the survival rate of patients with testicular cancer28 and it is being widely used to treat dif-
ferent types of cancer29. The success of cisplatin, as well as the occurrence of dose-limiting side effects stimulated 
significant research in this area. Ruthenium-based organometallics are a very promising class of therapeutic com-
pound, with two specific candidates, NAMI-A and KP1019 having entered clinical trials30, 31. There are three spe-
cific properties which make ruthenium an interesting metal for drug development: its range of oxidation states, its 
ability to mimic iron binding under physiological conditions and its low toxicity compared to platinum32. Hence, 
we hypothesised that ruthenium-based complexes of flavonoids may offer greater efficacy in target cell types by 
overcoming the problems associated with the natural flavonoids. In this study, we report the design, synthesis, 
chemical characterisation and biological evaluation of novel ruthenium complexes of chrysin, a natural flavonoid 
present in honey, honeycombs, propolis and passionflowers, as well as its synthesised thioflavone derivative for 
the modulation of platelet function, in vitro thrombus formation and haemostasis.
Results
Synthesis and chemical characterisation of the ruthenium complexes of chrysin and thio-chry-
sin. Similar to a recent study33, our initial experiments confirmed the inhibitory effects of chrysin in the acti-
vation of washed platelets in a concentration-dependent manner. Due to the limited knowledge of chrysin in 
the modulation of platelet function, thrombosis and haemostasis, this flavonoid was selected as a starting point 
for the chemical synthesis and biological evaluation of derivatives with additional chemical features in order 
to achieve enhanced platelet inhibitory effects under physiological conditions. In order to determine the rela-
tive potency of flavones versus thioflavones, thio-chrysin was chemically synthesised as reported by us previ-
ously23. New methods were then developed in order to access the novel ruthenium-chrysin (Ru-chrysin) and 
ruthenium-thio-chrysin (Ru-thio-chrysin) complexes. Chrysin and thio-chrysin were initially deprotonated 
prior to reacting with the commercially available bis [dichlorido (η6-p-cymene)] ruthenium(II), as shown in 
the scheme (Fig. 1A). Optimisation of synthesis was performed to ensure efficient deprotonation of the phenolic 
hydroxyl group adjacent to the carbonyl residue prior to the addition of the organometallic reagents. Table S1 
displays the range of conditions used with different bases and molar equivalents (eq.) of NaOMe (1.05 eq. to 2.00 
eq.) to synthesise Ru-chrysin. Product isolation proved to be difficult in the presence of Hünig’s base, triethyl 
amine, or DBU. Reactions with 1.10 eq., 1.25 eq. and 2.00 eq. of NaOMe yielded a mixture of products with 
the starting material (chrysin) being the primary contaminant. Purification of Ru-chrysin from these mixtures 
through recrystallisation was unsuccessful. 1H NMR spectroscopic analysis of the reaction mixtures revealed 
a positive correlation between the percentage of uncomplexed chrysin and an increased molar equivalent of 
NaOMe. This indicated that the excess amount of NaOMe might be affecting the hydrolysis of the bis [dichlori-
do(η6-p-cymene)] ruthenium(II) reagent thus leading to a higher percentage of uncomplexed chrysin. Finally, 
complete conversion of chrysin to Ru-chrysin was achieved in the presence of 1.05 eq. of NaOMe with 0.55 eq. 
of bis [dichlorido(η6-p-cymene)] ruthenium(II). The product Ru-chrysin was purified by recrystallisation from 
EtOAc:CHCl3 (9:1 v/v) and was isolated in a yield of 75%.
The conditions used for preparing Ru-chrysin (1.05 eq. of NaOMe with 0.55 eq. of bis [dichlori-
do(η6-p-cymene)] ruthenium(II)) yielded the Ru-thio-chrysin product but with a higher percentage of uncom-
plexed starting material, thio-chrysin. As illustrated above, an increased quantity of NaOMe was not beneficial in 
achieving a complete reaction conversion and therefore the synthesis of Ru-thio-chrysin was attempted with 0.90 
eq. of bis [dichlorido (η6-p-cymene)] ruthenium(II) and 1.05 eq. of NaOMe. This reaction successfully yielded 
Ru-thio-chrysin and purification was achieved by recrystallisation from EtOAc:CHCl3 (9:1 v/v) which resulted in 
access to the pure material in 65% yield. The loss of one proton in the 1H NMR spectra of Ru-chrysin (Figure S1A) 
versus chrysin, and Ru-thio-chrysin (Figure S2) versus thio-chrysin, from the hydroxyl groups of chrysin and 
thio-chrysin, respectively, confirmed the formation of Ru-complexes. A range of further chemical characterisa-
tion methods including 13C-NMR spectroscopic analysis (Figure S1B), mass spectrometry and elemental analysis 
confirmed the formation of the Ru-complexes. Furthermore, the crystal structures of Ru-chrysin (Fig. 1B) and 
Ru-thio-chrysin (Fig. 1C) were solved from powder X-ray diffraction data (Figure S3, Table S2) using DASH34, 35  
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Ru-chrysin and Ru-thio-chrysin display enhanced effects in platelet-rich plasma compared 
to washed platelets. To determine the effects of chrysin and thio-chrysin and their Ru-complexes in the 
modulation of platelet activation, aggregation assays were performed using cross-linked collagen-related pep-
tide (CRP-XL) as a platelet agonist, by optical aggregometry. Firstly, to determine the effects of chrysin and 
its derivatives on isolated platelets, aggregation assays were performed using human washed platelets (devoid 
of plasma proteins and other blood cells). Chrysin inhibited CRP-XL (0.5 µg/mL)-induced aggregation in 
washed platelets in a concentration-dependent manner (Fig. 2A and B). A concentration of 6.25 µM chrysin 
displayed approximately 80% reduction in CRP-XL (0.5 µg/mL)-induced platelet aggregation. The addition of 
a thiol group to chrysin did not affect its inhibitory effects (Fig. 2C and D). While Ru-Cl failed to affect platelet 
aggregation in washed platelets (Figure S4A), Ru-chrysin (Fig. 2E and F) and Ru-thio-chrysin (Fig. 2G and H) 
inhibited CRP-XL-induced platelet aggregation in a concentration-dependent manner. The overall effects 
of Ru-thio-chrysin were significantly better than Ru-chrysin at least at lower concentrations such as 6.25 µM, 
although higher concentrations resulted in similar effects. Together, these data demonstrate that the chemical 
modifications of chrysin did not affect its overall inhibitory activities in human washed platelets.
Plasma proteins such as albumin have been shown to bind small molecules including flavonoids and affect 
their bioavailability to target cells36. Therefore, to determine the effects of various concentrations of chrysin and 
its derivatives in the presence of plasma proteins, aggregation assays were performed using human platelet-rich 
plasma (PRP) and 0.5 µg/mL CRP-XL. In contrast to the results obtained with washed platelets, chrysin displayed 
reduced inhibitory effects on platelet aggregation in PRP. A concentration of 100 µM chrysin displayed around 40% 
reduction in platelet aggregation upon activation with 0.5 µg/mL CRP-XL, whilst the lower concentrations such as 
6.25 µM and 12.5 µM did not exhibit significant effects (Fig. 3A and B). Thio-chrysin displayed similar inhibitory 
effects compared to chrysin in platelet aggregation (Fig. 3C and D). As with washed platelets, Ru-Cl failed to show 
any inhibitory effects in PRP (Figure S4B). While Ru-chrysin did not significantly affect the platelet aggregation at 
the concentrations of 6.25 µM and 12.5 µM (Fig. 3E and F), Ru-thio-chrysin displayed a significant effect at lower 
concentrations including 6.25 µM compared to the control (Fig. 3G and H). In addition, Ru-thio-chrysin exhib-
ited significantly more inhibitory effects compared to the respective concentrations of native chrysin. These data 
demonstrate that although chrysin exhibited enhanced inhibitory effects on platelet activation in washed platelets, 
Figure 1. Synthesis scheme and molecular structures for Ru-chrysin and Ru-thio-chrysin. (A) Schematic 
diagram represents the synthesis of Ru-chrysin and Ru-thio-chrysin from chrysin and thio-chrysin, respectively 
via reaction with bis [dichlorido (η6-p-cymene)] ruthenium(II). The molecular structures of Ru-chrysin (B) and 
Ru-thio-chrysin (C) were determined by X-ray diffraction studies. The hydrogen bonds are not shown in the 
figures to enhance the clarity of the molecular images. The symbols C, O, Cl, S and Ru represent carbon, oxygen, 
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it failed to show similar levels of effects in PRP. However, Ru-chrysin and Ru-thio-chrysin displayed enhanced 
inhibitory effects on platelets even in PRP. The Ru-complex of thio-chrysin appeared to be more effective than 
others in the modulation of platelet activation in the presence of plasma proteins.
Figure 2. Effects of chrysin and its derivatives in washed platelet aggregation. Human washed platelets were 
incubated with a vehicle control [0.1% (v/v) DMSO] or different concentrations of chrysin (A,B), thio-chrysin 
(C,D), Ru-chrysin (E,F) and Ru-thio-chrysin (G,H) for 5 minutes prior to the addition of 0.5 µg/mL CRP-XL 
and the platelet aggregation was monitored for 5 minutes by optical aggregometry. The aggregation traces shown 
are representative of three separate experiments. The maximum aggregation obtained with vehicle control at 
5 minutes was taken as 100% to calculate the level of aggregation for chrysin and its derivatives-treated samples. 
Cumulative data represent mean ± S.D. (n = 3). *Indicates significance with respect to controls and p values 
shown (*p < 0.05, and ***p < 0.001) are as calculated by one-way ANOVA using Graphpad Prism.
180
www.nature.com/scientificreports/
5Scientific RepoRts | 7: 5738  | DOI:10.1038/s41598-017-05936-3
Figure 3. Impact of chrysin and its derivatives on platelet activation in platelet-rich plasma. Human platelet-
rich plasma was treated with vehicle control [0.1% (v/v) DMSO] or a range of concentrations of chrysin (A,B), 
thio-chrysin (C,D), Ru-chrysin (E,F) and Ru-thio-chrysin (G,H) for 5 minutes prior to the addition of 0.5 µg/
mL CRP-XL in an optical aggregometer. The platelet aggregation was monitored for 5 minutes. The traces shown 
are representative of three separate experiments. The maximum aggregation obtained with vehicle control 
at 5 minutes was taken as 100% to calculate the level of aggregation for chrysin and its derivatives-treated 
samples. Cumulative data represent mean ± S.D. (n = 3). *Indicates significance with respect to controls and 
#indicates significance with respect to the respective chrysin concentrations, p values shown (**,##p < 0.01 and 
***,###p < 0.001) are as calculated by one-way ANOVA using Graphpad Prism.
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Chrysin and its derivatives affect inside-out signalling to integrin αIIbβ3. Since chrysin and its 
derivatives affected platelet aggregation, we hypothesised that they may affect inside-out signalling to integrin 
αIIbβ3, as this plays a critical role in the affinity modulation of this integrin and its subsequent binding to fibrin-
ogen in order to facilitate platelet aggregation3. Hence, the level of fibrinogen binding on the platelet surface 
was measured as a marker for inside-out signalling to integrin αIIbβ3 using human PRP and FITC-labelled 
anti-fibrinogen antibodies by flow cytometry. Similar to aggregation assays, Ru-thio-chrysin showed significantly 
enhanced inhibitory effects on fibrinogen binding to the platelet surface upon activation with 0.5 µg/mL CRP-XL 
(Fig. 4A). While the concentration of 6.25 µM Ru-thio-chrysin showed around 15–20% inhibition, it inhibited the 
fibrinogen binding levels by almost 90% at 100 µM concentration. Notably, Ru-thio-chrysin (at concentrations of 
more than 12.5 µM) and Ru-chrysin (at concentrations of more than 25 µM) displayed significantly more effects 
compared to the respective concentrations of chrysin. Chrysin and thio-chrysin displayed similar inhibitory 
effects. Similar to the aggregation data, these results further emphasise the increased potential of Ru-complexes 
in exerting their target effects under these conditions.
Outside-in signalling driven by integrin αIIbβ3 is affected by chrysin and its deriva-
tives. Following fibrinogen binding, integrin αIIbβ3 triggers signalling into the platelets in order to induce 
clot retraction and promote wound healing. This also represents a late downstream signalling event in the platelet 
activation process37. To determine whether chrysin and its derivatives affect outside-in signalling by integrin 
αIIbβ3, a clot retraction assay was performed. The human platelets (PRP) were treated with different concentra-
tions of chrysin, thio-chrysin, Ru-chrysin and Ru-thio-chrysin prior to the addition of thrombin and initiation 
of clot formation and subsequent retraction. At three hours, the clot obtained with the vehicle control [0.1% (v/v) 
DMSO] retracted to around 50 mg. Although chrysin did not show significant effects, its derivatives substan-
tially inhibited the clot retraction process as the clot weights remained at more than 100 mg (Fig. 4B). Similar 
to other platelet functional assays, Ru-thio-chrysin displayed superior effects in comparison to native chrysin. 
Figure 4. Chrysin and its derivatives inhibit inside-out and outside-in signalling in platelets. (A) human 
platelet-rich plasma was treated with vehicle [0.1% (v/v) DMSO] or diverse concentrations of chrysin, thio-
chrysin, Ru-chrysin and Ru-thio-chrysin for 5 minutes prior to the addition of 0.5 µg/mL CRP-XL and 
incubation of 20 minutes at room temperature. The level of fibrinogen binding (as a marker for inside-out 
signalling to integrin αIIbβ3) was quantified using FITC-labelled anti-human fibrinogen antibodies by flow 
cytometry. The level of fluorescence obtained with vehicle control was taken as 100% to calculate the extent 
of inhibition in chrysin and its derivatives-treated samples. R represents ‘resting’ platelets. Cumulative data 
represent mean ± S.D. (n = 4). (B) human platelet-rich plasma was treated with vehicle (V) [0.1% (v/v) DMSO] 
or 50 µM of chrysin (C) or its derivatives, thio-chrysin (Tc), Ru-chrysin (Ru-c) and Ru-thio-chrysin (Ru-tc) 
for 5 minutes. Following incubation, clotting was initiated by the addition of 1 U/mL thrombin and the clot 
retraction was monitored for three hours. The remaining clot weight at three hours was measured to analyse 
the extent of retraction process. The image shown on the right is representative of four separate experiments. 
*Indicates significance with respect to controls and #indicates significance with respect to the respective chrysin 
concentrations; p values shown (*,#p < 0.05, **,##p < 0.01 and ***,###p < 0.001) are as calculated by one-way 
ANOVA using Graphpad Prism.
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Interestingly, thio-chrysin displayed significant inhibitory effect in clot retraction, suggesting that the chemical 
modification of 4-C=O (carbonyl) to 4-C=S (thiocarbonyl) may influence integrin αIIbβ3-mediated outside-in 
signalling. Together, these data establish a role for chrysin derivatives in the modulation of outside-in signalling 
by integrin αIIbβ3 in human platelets.
Effects of chrysin and its derivatives on granule secretion in platelets. Platelets primarily contain 
two types of granules (α- and dense granules) and the activation of platelets releases the granule contents to the 
external environment, where they play important roles in the stimulation of additional platelets and their recruit-
ment to the growing thrombus38. To establish whether chrysin and its derivatives affect α-granule secretion in 
platelets, the level of P-selectin on the platelet surface upon activation with 0.5 µg/mL CRP-XL was measured as a 
marker for α-granule secretion using human PRP and PECy5-labelled anti-P-selectin antibodies by flow cytom-
etry. CRP-XL-induced α-granule secretion was inhibited significantly by Ru-thio-chrysin at the concentrations 
of 12.5 µM and above, with approximately 80% inhibition being achieved at 100 µM concentration (Fig. 5A). 
Ru-chrysin and thio-chrysin significantly affected platelet granule secretion at the concentrations of 25 µM and 
above. However, chrysin affected α-granule secretion only at a minimum concentration of 50 µM in platelets. 
Only Ru-thio-chrysin displayed more inhibitory effects on α-granule secretion compared to chrysin at concen-
trations from 12.5 µM in PRP.
Based on the above data, chrysin and Ru-thio-chrysin were selected to distinguish their modulatory effects on 
dense granule secretion and other platelet functions. ATP secretion was measured as a marker for dense granule 
secretion in washed platelets upon activation with 0.5 µg/mL CRP-XL in the presence and absence of different 
concentrations of chrysin and Ru-thio-chrysin using a luciferin-luciferase luminescence assay (Fig. 5B). Both 
chrysin and Ru-thio-chrysin significantly inhibited dense granule secretion at the concentrations tested (6.25–
100 µM) with 100% inhibition observed at 100 µM concentration of both. These data demonstrate that chrysin 
and its derivatives significantly affect platelet granule secretion, which may influence the subsequent functions 
of platelets.
Figure 5. Chrysin and its derivatives affect granule secretion in platelets. (A) human platelet-rich plasma was 
treated with vehicle [0.1% (v/v) DMSO] or diverse concentrations of chrysin, thio-chrysin, Ru-chrysin and 
Ru-thio-chrysin for 5 minutes prior to the addition of 0.5 µg/mL CRP-XL and incubation of 20 minutes at room 
temperature. The level of P-selectin (as a marker for α-granule secretion) was quantified using PECy5-labelled 
anti-human P-selectin antibodies by flow cytometry. The level of fluorescence obtained with vehicle control was 
taken as 100% to calculate the extent of inhibition in chrysin and its derivatives-treated samples. R represents 
‘resting’ platelets. Cumulative data represent mean ± S.D. (n = 4). (B) human washed platelets were mixed with 
luciferin-luciferase reagent for two minutes followed by incubation with a vehicle control [0.1% (v/v) DMSO] 
or different concentrations of chrysin (i) or Ru-thio-chrysin (ii) for another 5 minutes. Platelets were then 
activated with 0.5 µg/mL CRP-XL and the ATP release was monitored for 5 minutes by lumi-aggregometry. 
The traces shown are representative of three separate experiments. The maximum ATP release obtained with 
vehicle control was taken as 100% to calculate the level of inhibition in chrysin and Ru-thio-chrysin treated 
samples (iii). Cumulative data represent mean ± S.D. (n = 3). *Indicates significance with respect to controls 
and #indicates significance with respect to the respective chrysin concentrations; p values shown (*p < 0.05, 
**p < 0.01 and ***,###p < 0.001) are as calculated by one-way ANOVA using Graphpad Prism.
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Chrysin and Ru-thio-chrysin do not affect platelet adhesion under static conditions. Integrins 
αIIbβ3 and α2β1 play critical roles in platelet adhesion to different matrix proteins such as fibrinogen and col-
lagen, respectively. To determine whether chrysin and Ru-thio-chrysin directly influence platelet adhesion by 
affecting the functions of integrins αIIbβ3 and α2β1, the static platelet adhesion assay was performed on col-
lagen, CRP-XL (a selective ligand for GPVI that is used to differentiate the binding effects of collagen to GPVI 
and integrin α2β1) and fibrinogen-coated surfaces using human PRP in the presence and absence of various 
concentrations of chrysin and Ru-thio-chrysin. Moreover, to determine the linear impact of these compounds on 
integrin αIIbβ3, integrilin (4 µM), an antagonist for integrin αIIbβ3 was also used in this assay prior to the treat-
ment with different concentrations of chrysin and Ru-thio-chrysin. Chrysin and Ru-thio-chrysin did not affect 
platelet adhesion to collagen, CRP-XL or fibrinogen both in the presence and absence of integrilin (Figure S5). 
These data suggest that chrysin and Ru-thio-chrysin may not directly affect the functions of αIIbβ3 and α2β1 on 
the platelet surface.
Effects of chrysin and Ru-thio-chrysin in the modulation of calcium signalling in plate-
lets. Platelets contain a dense-tubular system to store calcium, and the activation of platelets allows the mobili-
sation of calcium from stores to the cytoplasm. Similarly, a substantial amount of calcium is also pumped from the 
external milieu into the cytoplasm during platelet activation. The elevated levels of calcium play major roles includ-
ing the intracellular reorganisation of cytoskeleton to allow platelet spreading and subsequent thrombus forma-
tion39. Based on the above results achieved in washed platelets and PRP, chrysin and Ru-thio-chrysin were tested 
to evaluate their effects on the modulation of calcium mobilisation. Chrysin displayed greater inhibitory effects 
on calcium mobilisation than Ru-thio-chrysin in washed platelets compared to the control (Fig. 6Ai and Aii). 
However, Ru-thio-chrysin exhibited significantly greater effects in PRP compared to chrysin at a concentration of 
100 µM (Fig. 6Bi and Bii). Similar to other assays performed using PRP, Ru-thio-chrysin showed enhanced reduc-
tion in calcium mobilisation in platelets with around 60% obtained at 100 µM. Together, these results demonstrate 
the impact of chrysin and Ru-thio-chrysin in the modulation of calcium mobilisation in platelets.
Chrysin and Ru-thio-chrysin negatively regulate PI3K/AKT and Src signalling in plate-
lets. Calcium mobilisation is associated with phosphoinositide 3-kinase (PI3K) signalling in platelets39. 
Protein kinase B (AKT) is a downstream effector of PI3K and a key marker for the PI3K/AKT signalling pathway. 
A recent study has demonstrated the inhibitory effects of chrysin on the phosphorylation of AKT33. In addi-
tion, chrysin has been reported to inhibit focal adhesion kinase (FAK) activation33, which plays a key role in 
downstream signalling of integrins (outside-in signalling) that leads to platelet spreading40 as well as Src kinases 
that are critical initiators of integrin signalling and platelet activation41. Therefore, to determine whether chrysin 
and Ru-thio-chrysin share similar molecular targets in platelets, the phosphorylation of AKT at S473, FAK at 
Y397 and Src at Y527 (inhibitory site) was measured using resting and 0.5 µg/mL CRP-XL activated platelets 
in the presence and absence of different concentrations of chrysin and Ru-thio-chrysin by immunoblot anal-
ysis. The vehicle [0.1% (v/v) DMSO]-treated samples displayed a notable level of phosphorylation of AKT and 
FAK upon activation with CRP-XL, however, chrysin and Ru-thio-chrysin inhibited their phosphorylation in a 
concentration-dependent manner (Fig. 6C). Similarly, chrysin and Ru-thio-chrysin had a significant impact on 
the dephosphorylation of Src at Y527, which is an essential phenomenon for the activation of platelets. Together 
these data suggest that chrysin and Ru-thio-chrysin may share similar molecular targets in platelets, and their 
inhibitory effects on Src may directly or indirectly influence other signalling pathways that render the inhibition 
of platelet function.
Chrysin and Ru-thio-chrysin inhibit thrombus formation under arterial flow conditions. Platelet 
activation under arterial flow conditions culminates in the formation of thrombus at the damaged blood ves-
sels and thereby reducing the blood supply to target tissues. Here, the effects of chrysin and Ru-thio-chrysin 
on thrombus formation under arterial flow conditions on collagen-coated surface were tested. DiOC6-labelled 
whole human blood treated with vehicle control or 100 µM chrysin or Ru-thio-chrysin was perfused over 
collagen-coated surfaces of Vena8 biochips and thrombus formation was monitored for 10 minutes under arte-
rial flow conditions (20 dynes/cm2). The control sample showed notable level of thrombus formation over a 
10 minutes period (Fig. 7A). Chrysin inhibited the thrombus growth and volume by around 50% compared to the 
control (Fig. 7B and C). Notably, Ru-thio-chrysin at a concentration of 100 µM significantly reduced the number 
of thrombi, rate of thrombus formation and volume with approximately 75% inhibition achieved at this concen-
tration. These data corroborate the effects of Ru-thio-chrysin in whole blood (in the presence of plasma proteins 
and other blood cells), whereas chrysin did not exhibit similar effects.
Chrysin and Ru-thio-chrysin affect haemostasis in mice. To determine the effects of Ru-thio-chrysin 
in comparison to native chrysin in the modulation of haemostasis under physiological conditions in mice, a 
tail-bleeding assay was performed as described previously16. Mice were anaesthetised prior to infusing the vehicle 
control or chrysin or Ru-thio-chrysin (final concentration of 25 µM) through femoral arteries. Following five 
minutes incubation, 1 mm of tail tip was dissected and the bleeding time was monitored. Chrysin-infused mice 
displayed extended bleeding time (average of 901 seconds) compared to the control group (average of 445 sec-
onds) (Fig. 7D). Ru-thio-chrysin extended the bleeding time in mice to an average of 1096 seconds, although 
these effects do not significantly differ from chrysin. These data illustrate that Ru-thio-chrysin and chrysin affect 
haemostasis with similar efficacy in mice.
Ru-thio-chrysin possesses enhanced bioavailability. Similar to other natural flavonoids, chrysin dis-
played prominent inhibitory effects in isolated platelets but their inhibitory effects were reduced under physiolog-
ical conditions when PRP or whole blood were used. We hypothesised that the inhibitory effects of chrysin were 
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reduced due to greater binding to plasma proteins such as albumin and hence, poor bioavailability, and reduced 
lipophilicity in order to cross cell membranes. To determine the binding ability of chrysin and Ru-thio-chrysin 
to human serum albumin (HSA), the HSA binding assay was performed using TRANSILXL HSA binding kit 
according to the manufacturer’s instructions. The binding affinities (Kd) of chrysin and Ru-thio-chrysin were 
determined to be 1.93 µM and 1.40 mM, respectively. Moreover, the fraction bound to plasma (fb) was found to 
be 99.7% for chrysin and <29.6% for Ru-thio-chrysin. These data confirm that chrysin possesses greater binding 
affinity towards plasma proteins, primarily albumin, than Ru-thio-chrysin.
To determine the level of uptake of chrysin and Ru-thio-chrysin in platelets, mass spectrometry-based 
analysis was performed. Washed human platelets were treated with chrysin or Ru-thio-chrysin (100 µM) for 
5 minutes and the unbound compounds were washed prior to the quantification of the amount of chrysin and 
Ru-thio-chrysin present in platelets by LC-MS (Orbitrap, C8 column, Solvent system: 0.1% formic acid in water 
and 0.1% formic acid in acetonitrile). The uptake of Ru-thio-chrysin in platelets was found to be at 8.38 ± 1.07 µM 
whereas chrysin was found to be at 6.86 ± 0.27 µM as determined using standard curves (Figure S6). This indi-
cates that Ru-thio-chrysin, which possesses higher hydrophobicity (CLogP = 7.94 as predicted using Chemdraw 
Figure 6. Chrysin and its derivatives influence the calcium mobilisation and phosphorylation of various 
signalling proteins in platelets. Fluo4 AM-dye labelled human washed platelets (Ai,Aii) and platelet-rich plasma 
(Bi,Bii) were treated with vehicle control (V) [0.1% (v/v) DMSO] or different concentrations of chrysin (C) or 
Ru-thio-chrysin (Ru-tc) for 5 minutes prior to the addition of 0.5 µg/mL CRP-XL and monitoring of calcium 
mobilisation for three minutes by flourimetry. The calcium traces (Ai and Bi) shown are representative of three 
separate experiments. The maximum fluorescence obtained with each sample was converted into percentages 
to calculate the level of calcium mobilisation obtained with vehicle and chrysin or Ru-thio-chrysin treated 
samples. Cumulative data (Aii and Bii) represent mean ± S.D. (n = 3). *Indicates significance with respect 
to controls and #indicates significance with respect to the respective chrysin concentrations; p values shown 
(**,##p < 0.01 and ***p < 0.001) are as calculated by one-way ANOVA using Graphpad Prism. (C) Human 
washed platelets were treated with vehicle control or different concentrations of chrysin or Ru-thio-chrysin 
for 5 minutes prior to the addition of 0.5 µg/mL CRP-XL and incubation for another 5 minutes. The platelets 
were lysed and used for immunoblot analysis to detect the level of AKT phosphorylation at residue S473, FAK 
phosphorylation at Y397 and phosphorylation of Src at Y527. The level of 14-3-3ζ protein was detected as a 
loading control. The cropped images of the blots shown here are representative of three separate experiments. 
The uncropped full length blots are presented in Supplementary Information (Figure S8).
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16.0 software) than chrysin (CLogP = 3.04), has greater cellular permeability in platelets. These data confirm that 
the increased inhibitory effects observed for Ru-thio-chrysin are, indeed, due to its reduced binding to plasma 
proteins, greater bioavailability, and enhanced cell permeability when compared to chrysin.
Chrysin and its synthetic derivatives display no cytotoxic effects in platelets. In order to exam-
ine whether the native chrysin and its synthetic derivatives exert any cytotoxic effects in platelets at the concen-
trations used in this study, the lactate dehydrogenase (LDH) assay was performed using PRP. While the positive 
control displayed maximal effects in platelets, chrysin and its synthetic derivatives did not show significant cyto-
toxic effects in platelets at the concentrations used in this study (i.e. between 6.25 and 100 µM) (Figure S7). These 
data confirm that the inhibitory effects of chrysin and its synthetic derivatives presented in this study were not 
due to the cytotoxic effects of these molecules.
Discussion
In this study, the effects of chrysin and its chemical derivatives on the modulation of platelet function, in vitro 
thrombus formation and haemostasis were determined. Similar to a number of other dietary flavonoids such 
as quercetin42–44, tangeretin16, nobiletin17, luteolin and apigenin18, chrysin also exhibited inhibitory effects in 
various platelet functions. Chrysin affected CRP-XL-induced platelet aggregation, inside-out signalling to inte-
grin αIIbβ3, granule secretion and integrin αIIbβ3 mediated outside-in signalling in platelets. Notably, chrysin 
reduced thrombus formation in vitro in human blood under arterial flow conditions and extended bleeding time 
in mice. Recently, Liu et al. (2016)33 reported the anti-platelet properties of chrysin and its possible molecular tar-
gets in platelets. Chrysin has concentration-dependently inhibited platelet activation induced by various platelet 
Figure 7. Differential effects of chrysin and Ru-thio-chrysin in the modulation of thrombus formation under 
arterial flow conditions and haemostasis in mice. DiOC6-labelled human whole blood was treated with vehicle 
control [0.1% (v/v) DMSO] or 100 µM chrysin or Ru-thio-chrysin for 5 minutes prior to the perfusion over 
collagen-coated Vena8 biochips. Thrombus formation was monitored by capturing Z-stack fluorescent images 
at every 30 seconds over 10 minutes by fluorescence microscopy. The images shown (A) at different time points 
and traces (B) are representative of three separate experiments. (C) The mean fluorescence intensity obtained 
with vehicle control (V) at 10 minutes was taken as 100% to calculate the level of inhibition in chrysin (C) and 
Ru-thio-chrysin (Ru-tc)-treated samples. Data represent mean ± S.D. (n = 3). *Indicates significance with 
respect to control and #indicates significance with respect to the respective chrysin concentration; p values 
shown (***,###p < 0.001) are as calculated by one-way ANOVA using Graphpad Prism. (D) The effects of 
vehicle control [0.1% (v/v) DMSO] or 25 µM of chrysin (C) or Ru-thio-chrysin (Ru-tc) in the modulation of 
haemostasis were analysed by tail bleeding assay in mice. Data represent ± S.D. (n = 8 mice in each group). The 
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agonists including collagen, thrombin, U46619 and ADP. In addition, chrysin was found to inhibit the phospho-
rylation of numerous signalling proteins such as Syk, PLCγ2, AKT, PKC, ERK1/2, FAK, GSK3β and FCγRIIa 
consistent with the ability of flavonoids to inhibit kinase signalling. Together the previous study concluded that 
chrysin is involved in the modulation of platelet function by inhibiting inside-out signalling to integrin αIIbβ3 
and outside-in signalling driven by the same integrin molecule33. Similarly, in the present study, chrysin was 
found to affect CRP-XL-induced inside-out signalling to integrin αIIbβ3 and phosphorylation of selective signal-
ling molecules such as AKT, FAK and Src. In addition, chrysin was previously reported to affect platelet function 
via inhibition of cyclooxygenase activity and reduction of cAMP levels possibly by inhibiting adenylate cyclase45. 
These results indicate that chrysin is likely to have several molecular targets in platelets and thereby it modulates 
diverse functions of platelets enabling it to control thrombosis and haemostasis.
In general, dietary flavonoids have been shown to affect platelet function by acting as pro-oxidants in order to 
induce the production of nitric oxide (NO) (a potent inhibitor of platelet function through the elevation of cGMP)46, 
antioxidants by inhibiting reactive oxygen species (ROS) production, binding to cell surface receptors and affecting 
the integrity of the plasma membrane18, 47. Notably, a number of flavonoids have been shown to directly act as power-
ful inhibitors of numerous kinases (primarily tyrosine kinases) involved in diverse signalling pathways in platelets18, 48. 
In addition, flavonoids such as apigenin, genistein, luteolin and quercetin have also been shown to inhibit TXA2 
receptor on platelet surface and affect its signalling. Therefore, by using a range of cellular targets, dietary flavonoids 
enrich the anti-platelet properties. Hence, flavonoids act as templates for the design and synthesis of therapeutically 
valuable compounds with specific cellular targets, and they provide a basis to determine the molecular relationships 
between numerous cell surface receptors, intracellular signalling proteins and dietary components18.
Interestingly, several studies have highlighted the potential hindrances of using dietary flavonoids as ther-
apeutically valuable compounds for the treatment and prevention of diseases. Some of these include poor bio-
availability, enhanced binding to plasma proteins and decreased hydrophobicity/ lipophilicity to cross the cell 
membranes22, 36. Therefore, several researchers have attempted to chemically modify the natural flavonoids in 
order to overcome these issues23, 49. The previous studies published on the anti-platelet effects of chrysin have 
mainly used washed platelets to evaluate the functions of chrysin in platelets33, 45. In the present study, although 
chrysin inhibited platelet function significantly on isolated platelets, a substantial reduction in the effects of chry-
sin in platelets was observed when PRP and whole blood were used in experiments. These data indicate the poten-
tial binding of chrysin to plasma proteins in PRP and also other blood cells such as leukocytes and red blood cells 
in whole blood, and internalisation in these cell types. The addition of sulfur groups to flavonoids has previously 
been shown to improve their hydrophobicity and biological effects23. Therefore, the present study was initiated in 
order to synthesise chemical derivatives of chrysin with enhanced anti-platelet effects by reducing their binding 
to plasma proteins and increasing their bio-availability. Initially, thio-chrysin was synthesised by replacing an 
oxygen molecule with a sulfur group in the basic structure of chrysin. A parallel comparison of thio-chrysin with 
native chrysin revealed no significant differences in their inhibitory effects when washed platelets or PRP were 
used in platelet aggregation assays.
In recent years, organometallic complexes have been widely considered as valuable compounds for a number 
of pathological conditions including cancer27. Indeed, platinum-based chemical agents such as cisplatin, car-
boplatin and oxaliplatin are being used as effective drugs in the treatment of solid tumours e.g. for testicular 
and other cancer types28, 50. Due to increased associated toxicity, lack of selectivity and side effects such as nerve 
damage, nausea and hair loss of platinum-based drugs, a focus on other transition metals such as ruthenium, 
titanium, rhodium and iridium has been initiated24, 30, 50–53. In order to understand the roles of ruthenium-based 
flavonoid complexes in the modulation of platelet function, for the first time, in this study we synthesised 
Ru-chrysin and Ru-thio-chrysin complexes and determined their effects on the modulation of platelet func-
tion. Interestingly, both complexes showed enhanced inhibitory effects in platelets in comparison to chrysin 
and thio-chrysin under physiological conditions such as in PRP and whole blood, although they exerted slightly 
reduced effects in washed platelets. A comparison of chrysin and Ru-thio-chrysin in thrombus formation under 
arterial flow conditions using whole blood has revealed the significance of ruthenium-based complexes in the 
modulation of platelet function under physiological conditions. Ru-thio-chrysin substantially reduced thrombus 
growth and volume, whilst chrysin at the same concentration only exhibited moderate reduction in thrombus 
volume. Notably, Ru-thio-chrysin showed similar effects in the modulation of haemostasis in mice compared 
to native chrysin. It appears that the combination of ruthenium with thio-chrysin exerts 10–25% greater effects 
compared to Ru-chrysin complex.
Since ruthenium is able to achieve several oxidation states (II, III and IV) at low energy levels under physi-
ological conditions and interact with a range of biomolecules, it may facilitate efficient interaction of the small 
molecule present in the complex with its molecular targets, including targets that would normally be inaccessible 
for small molecules on their own24, 50. In addition, since ruthenium belongs to the same group within the periodic 
table as iron, ruthenium is known to mimic the nature of iron molecules, and therefore it has been shown to bind 
transferrin and thereby enhance the bioavailability of small molecules to a greater extent54–57. Furthermore, some 
ruthenium-based organometallic complexes have displayed enhanced stability in water and air50, which may be 
beneficial to exert prolonged effects of the target small molecule including chrysin. While the small molecules 
present in the ruthenium complexes bind to the target site, ruthenium may enhance its target-specific activi-
ties. Overall, ruthenium tends to have less severe side effects but enhanced biological properties compared to 
platinum-based drugs50. In line with these observations, our results demonstrate that Ru-thio-chrysin exhibits 
reduced binding ability to plasma proteins, and increased cell permeability in comparison to native chrysin. In 
addition, Ru-thio-chrysin shares similar molecular targets to chrysin in platelets indicating that the mechanisms 
through which they inhibit platelet function are unlikely to be changed. Interestingly, Ru-thio-chrysin displayed 
similar effects to chrysin in the modulation of haemostasis in mice and there were no toxic effects observed in 
platelets with the concentrations of Ru-complexes used in this study.
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Together with the numerous advantages of organometallic complexes, the results of this study demonstrate the 
importance of using ruthenium-based organometallic complexes in the development of novel anti-platelet agents 
for the prevention and treatment of thrombotic diseases. Preliminary analysis of signalling cascades in this study 
suggests that chrysin and Ru-thio-chrysin are likely to have similar targets in platelets. However, further studies 
are underway to determine the specific targets of chrysin and its ruthenium-complexes in platelets. In addition, 
the stability of the complexes in biological systems, their circulating plasma concentrations upon oral uptake and 
the nature of metabolites they produce in platelets must be determined.
Methods
Synthesis of ruthenium-chrysin derivatives (Ru-chrysin and Ru-thio-chrysin). 
 a) Synthesis of chlorido [(5-oxo-κO)-7-hydroxy-(2-phenyl)-4H-chromen-4-onato-κO] (η6-p-cymene)ruthe-
nium(II) (Ru-chrysin)
To a solution of chrysin (0.10 g, 0.39 mmol) and NaOMe (0.02 g, 0.41 mmol, 1.05 eq.) in anhydrous meth-
anol (10 mL), [Ru(η6-p-cymene)Cl2]2 (0.13 g, 0.21 mmol, 0.55 eq.) in anhydrous dichloromethane (10 mL) 
was added under argon atmosphere. The reaction mixture was heated at reflux for 18 h and then the solvent 
was evaporated in vacuo. The obtained residue was dissolved in warm chloroform:methanol [9.0:1.0 v/v] 
(15 mL) and the solution was filtered to remove NaCl (by product) and other insoluble impurities. The 
solution was then concentrated (2–3 mL) and the compound was precipitated by the addition of EtOAc. 
The precipitated compound was filtered and recrystallized from EtOAc:CHCl3 (9:1 v/v) to obtain the pure 
product (Ru-chrysin) as an orange red solid (0.15 g, 75%). The obtained compound was suitable for X-ray 
diffraction studies.
m.p: 258–260 °C; 1H NMR: (DMSO-d6, 400 MHz) 1.28, 1.30 (6H, 2 × s, 2 × CH3cym), 2.16 (3H, s, CH3, cym), 
2.89–2.91 (1H, m, CHcym), 5.37 (2H, d, J = 8.0 Hz, H-2cym, H-3cym), 5.65 (2H, d, J = 8.0 Hz, H-5cym, H-6cym), 
5.99 (1H, s, H-6), 6.05 (1H, s, H-8), 6.94 (1H, s, H-3), 7.54–7.58 (3H, m, H-3′,4′,5′), 8.01 (2H, d, J = 8.0 Hz, 
H-2′,6′), 10.29 (1H, s, OH); 13C NMR: (DMSO-d6, 100 MHz) δ 17.55 (CH3cym), 22.02 (2 × CH3cym), 30.44 
(CHcym), 77.88 (C3), 82.54 (C8), 86.30 (C10), 90.06 (C9), 96.68 (C6), 98.12 (C3cym, C5cym), 102.41 (C2cym), 
104.02 (C1’), 105.81 (C6cym), 126.22 (C3′, C5′), 129.27 (C2′, C6′, C4′), 130.52 (C1cym), 131.95 (C4cym), 
158.09 (C2), 159.71 (C5), 167.76 (C7), 177.07 (C = O); m/z (FTMS + ESI): Observed as M-Cl (C25H23O-
4Ru) requires 489.0634, found 489.0645. Elemental analysis: C25H23O4ClRu, Calculated: C-57.31%, 
H-4.42%, Cl-6.77%, Ru-19.29%; found: C-57.44%, H-4.25%, Cl-6.74%, Ru-19.31%. X-ray crystal 
structure obtained.
 b) Synthesis of chlorido [(5-oxo-κO)-7-hydroxy-(2-phenyl)-4H-chromen-4-thionato-κS] (η6-p-cymene)
ruthenium(II) (Ru-thio-chrysin)
To a solution of thio-chrysin (0.10 g, 0.37 mmol) and NaOMe (0.02 g, 0.39 mmol, 1.05 eq.) in anhydrous 
methanol (10 mL), [Ru(η6-p-cymene)Cl2]2 (0.20 g, 0.33 mmol, 0.90 eq.) in anhydrous dichloromethane 
(10 mL) was added under argon atmosphere. The reaction mixture was heated at reflux for 18 h and then 
the solvent was evaporated in vacuo. The obtained residue was dissolved in warm chloroform:methanol 
[9.5:0.5 v/v] (15 mL) and the solution was filtered to remove NaCl (by product) and other insoluble impu-
rities. The solution was then concentrated (2–3 mL) and the compound was precipitated by the addition of 
EtOAc. The precipitated compound was filtered and recrystallized from EtOAc:CHCl3 (9:1 v/v) to obtain 
the pure product (Ru-thio-chrysin) as a reddish brown solid (0.13 g, 65%). The obtained compound was 
suitable for X-ray diffraction studies.
m.p: decomposes at 270 °C; 1H NMR: (DMSO-d6, 400 MHz) 1.21, 1.23 (6H, 2 × s, 2 × CH3, cym), 2.07 (3H, 
s, CH3cym), 2.71–2.74 (1H, m, CH, cym), 5.31–5.68 (2H, H-2cym, H-3cym), 6.21, 7.41 (2H, H-5cym, 
H-6cym), 6.36 (1H, s, H-6), 6.39 (1H, s, H-8), 7.52–7.64 (3H, m, H-3′,4′,5′), 7.89 (1H, s, H-3), 8.14, 8.16 (2H, 
d, J = 8.0 Hz, H-2′,6′), 10.47 (1H, s, OH); 13C NMR: Couldn’t be obtained. m/z (FTMS + ESI): Observed as M-Cl 
(C25H23O3RuS) requires 505.0406, found 505.0407. Elemental analysis: C25H23O3ClRuS, Calculated: C-55.60%, 
H-4.29%, Cl-6.58%, Ru-18.72%; S-5.94% found: C-55.73%, H-4.16%, Cl-6.56%, Ru-18.71%, S-6.00%. X-ray 
crystal structure obtained.
X-ray diffraction analysis and structure determination for Ru-chrysin and Ru-thio-chrysin. 
Powder X-ray diffraction data for Ru-chrysin and Ru-thio-chrysin were collected on a Bruker D8 Advance (Cu 
Kα1, λ = 1.54056 Å) diffractometer operating in capillary transmission mode. The diffractometer was equipped 
with a LynxEye detector. Monochromatic Cu Kα1 is achieved with the use of a curved Johansson type primary 
monochromator. Furthermore, an 8 mm detector aperture slit and a metal knife edge collimator were used to 
minimise air scattering.
Both samples were lightly ground prior to packing into a 0.5 mm borosilicate capillary, and the data collection 
was carried out at room temperature (ca. 293 K). The powder diffraction data were indexed with DICVOL9158 
and solved using the simulated annealing (SA) approach implemented in DASH 3.3.234. Previously solved 
crystal structures were used to derive the starting models used in the SA optimisation; the CSD reference code 
BENZAX59 was used for the Ru-coordinated cymene moiety whilst the dihydroxyflavone ligand was derived from 
the CSD reference code RAMGOB0160. Both crystal structures were subsequently refined with TOPAS (Bruker, 
Germany). Further crystallographic information and CIF files are given in Table S2 and Table S3, respectively. The 
final Rietveld fits to the powder diffraction data are shown in Figure S3.
Human platelet preparation, aggregation assays and immunoblotting. The preparation of human 
platelets and aggregation assays were performed using standard protocols as described by us previously15, 16. 
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Briefly, human blood was collected in 3.2% citrate containing vacutainers via venepuncture from healthy, 
aspirin-free individuals with informed consent in accordance with the methods approved by the University of 
Reading Research Ethics Committee. All methods were performed in accordance with the relevant institutional 
and national guidelines and regulations. Blood samples were centrifuged at 102 g for 20 minutes at room tem-
perature to separate the PRP, which was used in aggregation, flow cytometry, static platelet adhesion, calcium 
mobilisation and clot retraction assays. For the preparation of washed platelets, 50 mL of blood samples were 
mixed with 7.5 mL of ACD (acid citrate dextrose) (20 g/L glucose, 25 g/L sodium citrate and 15 g/L citric acid) and 
centrifuged at 102 g for 20 minutes at room temperature. The PRP was carefully aspirated from the other blood 
cells prior to mixing with 3 mL of ACD and centrifuging at 1413 g for 10 minutes at room temperature. The result-
ing platelet pellet was re-suspended in modified Tyrodes-HEPES buffer (2.9 mM KCl, 134 mM NaCl, 0.34 mM 
Na2HPO4.12H20, 1 mM MgCl2, 12 mM NaHCO3, 20 mM HEPES, pH 7.3) and washed by centrifuging again at 
1413 g for 10 minutes. The resulting platelet pellet was suspended in modified Tyrodes-HEPES buffer at a density 
of 4 × 108 cells/mL for aggregation, dense granule secretion, cellular uptake studies and calcium mobilisation 
assays. Human platelet aggregation was performed using CRP-XL as an agonist in the presence and absence of 
various concentrations of chrysin and its synthetic derivatives by optical aggregometry. A vehicle control [DMSO 
at a concentration of less than 0.1% (v/v)] was included in all the experiments. Dense granule secretion in plate-
lets was determined by measuring the ATP release using the luciferin-luciferase reagent by lumi-aggregometry 
(Chrono-Log, USA). SDS-PAGE and immunoblotting analysis were performed using standard protocols16. The 
rabbit anti-phospho-specific antibodies for human AKT pS473, FAK pY397 and Src pY527 were obtained from 
Abcam, UK and rabbit anti-human 14-3-3ζ (Santa Cruz Biotechnology, USA) was used to detect protein 14-3-3ζ 
as a loading control in immunoblot assays. The Cy5-conjugated goat anti-rabbit IgG (Life technologies, UK) was 
used as the secondary antibody.
Flow cytometry based assays. Fibrinogen binding (a marker for platelet inside-out signalling to integrin 
αIIbβ3) and P-selectin exposure (a marker for α-granule secretion) were measured by flow cytometry (Accuri 
C6, BD Bioscences, UK). The platelets (PRP) were treated with a vehicle control [0.1% (v/v) DMSO] or with dif-
ferent concentrations of chrysin and its synthetic derivatives prior to activation with CRP-XL (0.5 µg/mL). The 
levels of fibrinogen binding and P-selectin exposure were measured using FITC-labelled anti-human fibrinogen 
antibodies (Dako, UK) and PECy5-labelled CD62P antibodies (BD Biosciences, UK), respectively. The median 
fluorescence intensity was used to assess the levels of fibrinogen binding and P-selectin exposure on the platelet 
surface. The level of fluorescence obtained with the vehicle control was taken as 100% when compared with the 
treated samples.
Intracellular calcium mobilisation. The intracellular calcium levels in platelets were measured using 
Fluo-4 AM calcium-sensitive dye by spectrofluorimetry. The PRP or washed platelets pre-incubated with 
Fluo-4 AM were treated with a vehicle control [0.1% (v/v) DMSO] or appropriate concentrations of chrysin or 
Ru-thio-chrysin prior to activating with 0.5 µg/mL CRP-XL and measuring the fluorescence continuously for 
3 minutes using an excitation wavelength of 485 nm and emission at 510 nm by a Fluostar Optima spectrofluorim-
eter (BMG Labtech, Germany). Data were analysed by calculating the maximum level of calcium released in each 
sample.
Clot retraction. PRP (200 µL) was mixed with 5 µL of red blood cells and the final volume was made to 
950 µL with modified Tyrodes-HEPES buffer in the presence and absence of various concentrations of chrysin or 
its synthetic derivatives. Clot formation was initiated by adding 1 U/mL (50 µL) thrombin. A glass capillary was 
placed in middle of the tube and the clot retraction was observed over a period of 3 hours at room temperature. 
Clot weight was measured as a marker for clot retraction after 3 hours.
In vitro thrombus formation. Human citrated blood [labelled with DiOC6 (Sigma Aldrich, UK)] was 
incubated with vehicle [0.1% (v/v) DMSO] or 100 µM of chrysin or Ru-thio-chrysin for 5 minutes and perfused 
over collagen coated Vena8 BioChips (Cellix Ltd, Ireland) at a shear rate of 20 dynes/cm2. Z-stack images of 
thrombi were obtained every 30 seconds for up to 10 minutes using a Nikon eclipse (TE2000-U) microscope 
(Nikon Instruments, UK). The median fluorescence intensity and thrombus volume were calculated by analysing 
the images using ImageJ.
Tail bleeding assay. The University of Reading Local Ethical Review Panel and the British Home Office 
approved the tail-bleeding assay performed in this study. All methods were performed in accordance with the 
relevant guidelines and regulations. In brief, C57BL/6 mice (9 weeks old; Envigo, UK) were anaesthetized using 
ketamine (80 mg kg−1) and xylazine (5 mg kg−1) administered via intraperitoneal route 20 minutes prior to the 
experiment and placed on a heated pad (37 °C). The vehicle control [0.1% (v/v) DMSO] or 25 µM Chrysin (C) or 
Ru-thio-chrysin (Ru-tc) was injected via femoral artery 5 minutes prior to the dissection of 1 mm of tail tip using 
a scalpel blade. The tail tip was placed in sterile saline at 37 °C and the time to cessation of bleeding was measured 
up to 20 minutes.
Platelet uptake of chrysin and Ru-thio-chrysin. Washed human platelets were treated with chrysin or 
Ru-thio-chrysin (100 µM) for 5 minutes and the platelets were then washed twice with modified Tyrodes-HEPES 
buffer by centrifugation at 1413 g for 10 minutes to remove unbound flavonoids. The compounds taken up by the 
platelets were extracted with methanol (400 µL). The methanol extract was dried using vacuum centrifugation 
and reconstituted in 200 µL of methanol for mass spectrometry (LC-MS) analysis. The concentration of chrysin 
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HSA binding assay. HSA binding assay was performed using TRANSILXL binding kit (Sovicell, Germany) 
according to the manufacturer’s protocol. Briefly, 15 µL of 16x concentration of chrysin or Ru-thio-chrysin was 
added (to obtain a final concentration of 50 µM) to a column of 8 wells of the room temperature equilibrated 
TRANSIL assay plate containing varying amount of HSA immobilised silica beads. The plate was then incubated 
on a plate shaker at 100 g for 12 minutes followed by centrifugation for 10 minutes at 750 g. The supernatant 
(100 µL) was analysed by LC-MS to determine the affinity of chrysin and Ru-thio-chrysin based on the concen-
tration of the free compounds in the supernatant. The Kd values for chrysin and Ru-thio-chrysin were calculated 
according to the instructions and algorithms supplied by the manufacturer (Sovicell, User Guide TRANSIL PPB 
binding kit V2.01, 2017).
Static platelet adhesion assay. Micro titre plates (96 well) were coated with 1 µg/100 µL/well of fibrino-
gen, collagen or CRP-XL followed by incubation at 4 °C for overnight. Following the removal of unbound pro-
teins/peptide, the wells were blocked with 1% bovine serum albumin in modified Tyrodes-HEPES buffer for 
1 hour. The plates were then washed three times with modified Tyrode’s-HEPES buffer prior to adding human 
PRP (1 × 108 cells/mL, 50 µL/well) and incubated at room temperature for 1 hour. Non-adhered platelets were 
discarded and then the wells were washed with modified Tyrodes-HEPES buffer. Citrate lysis buffer (100 µL/well) 
was added and incubated for 1 hour at room temperature. Finally, 100 µL of 2 M NaOH was added to all the wells 
to stop the reaction and the absorbance was measured at 405 nm using a Fluostar Optima spectrofluorimeter 
(BMG Labtech, Germany). Experiments were performed both in the absence and presence of integrilin (4 µM) 
(an antagonist for integrin αIIbβ3).
LDH cytotoxicity assay. The LDH cytotoxicity assay was performed using the LDH Cytotoxicity Assay 
Kit (Pierce, Thermo Fisher, UK) according to the manufacturer’s instructions. In brief, the PRP was incubated 
at 37 °C for 30 minutes. The vehicle [0.1% (v/v) DMSO] or different concentrations of chrysin and its synthetic 
derivatives were added to the PRP and incubated for 5 minutes. Following incubation, the reaction mixture (pro-
vided in the kit) was added to the PRP and incubated for 30 minutes. The reaction was then stopped using a stop 
solution provided in the kit. The absorbance of the mixture was measured at 490–650 nm using a Fluostar Optima 
spectrofluorimeter (BMG Labtech, Germany). Results provided represent duplicate absorbance measures from 
three separate donors.
Statistical analysis. The data obtained in this study are represented as mean ± S.D. The statistical sig-
nificance between the controls and chrysin or its derivatives-treated samples was determined using one-way 
ANOVA. The data obtained from tail bleeding assay were analysed using a non-parametric Mann-Whitney test. 
All the statistical analyses were performed using GraphPad Prism 7 software (GraphPad Software Inc., USA).
Note. CCDC deposition number for Ru-chrysin: 1495422 and Ru-thio-chrysin: 1495423.
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Platelets are anucleated blood cells that participate in a wide range of physiological and pathological functions. Their major role is
mediating haemostasis and thrombosis. In addition to these classic functions, platelets have emerged as important players in the
innate immune system. In particular, they interact with leukocytes, secrete pro- and anti-inflammatory factors, and express a
wide range of inflammatory receptors including Toll-like receptors (TLRs), for example, Toll-like receptor 4 (TLR4). TLR4,
which is the most extensively studied TLR in nucleated cells, recognises lipopolysaccharides (LPS) that are compounds of the
outer surface of Gram-negative bacteria. Unlike other TLRs, TLR4 is able to signal through both the MyD88-dependent and
MyD88-independent signalling pathways. Notably, despite both pathways culminating in the activation of transcription factors,
TLR4 has a prominent functional impact on platelet activity, haemostasis, and thrombosis. In this review, we summarise the
current knowledge on TLR4 signalling in platelets, critically discuss its impact on platelet function, and highlight the open
questions in this area.
1. Introduction
Platelets are small, anucleated, and short-lived blood cells
with a range of important functions beyond their classical
roles in haemostasis [1–3]. The function of platelets in
haemostasis has been well documented and is linked to their
capacity to respond to the damaged endothelium [4–6]. Fol-
lowing vessel damage and initial activation, platelets secrete a
wide variety of small molecules and proteins from intracellu-
lar granules in order to activate and recruit more circulating
platelets and immune cells, such as leukocytes [4]. In addi-
tion to these secretion events, platelets undergo dramatic
shape changes that enable them to cover the site of injury
and prevent bleeding [4]. Thrombosis (blood clot formation)
mediated by platelets occurs in the arteries under pathologi-
cal conditions and significantly obstructs the blood flow to
major organs such as the heart and brain resulting in heart
attacks and strokes, respectively [7]. In addition to their
physiological functions, platelets can be involved in different
pathological conditions, for example, in atherosclerosis [8, 9].
If the atherosclerotic plaque ruptures, the exposure of the
subendothelial matrix and release of procoagulatory matrix
proteins, such as collagen, are sufficient to initiate the forma-
tion of a thrombus (blood clot) at this site [4, 10]. Thrombus
poses a significant systemic risk because it is formed in a
narrowed blood vessel and so has the potential to completely
occlude the vessel and trigger a myocardial infarction or
ischaemic stroke [10].
Platelets also have pivotal roles in the innate immune
system, which includes cells that combat general infections
(e.g., neutrophils), and is responsible for the eradication of
pathogens to protect the body from infection [11, 12]. During
the immune response, platelets have been shown to interact
with and respond to many species of Gram-positive and
Gram-negative bacteria through different receptors [13, 14].
Moreover, platelets are capable of internalising specific types
of bacteria and viruses although the function of this phenom-
enon is poorly understood [15, 16]. The ability of platelets to
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participate in such a wide range of functions and their ability
to synthesise certain new proteins despite lacking a nucleus
have generated significant scientific interest [2, 3, 17].
In addition, platelets play a role in the development of
disseminated intravascular coagulation (DIC), a common
complication observed in patients with sepsis [18–20]. Dur-
ing DIC, platelets are activated and form smaller thrombi
in the microvasculature or aggregates that are sequestered
in organs such as the lungs. Together, this leads to thrombo-
cytopenia, a reduction in the number of circulating platelets.
Mild thrombocytopenia is defined as less than 1.5× 1011
platelets per litre of blood compared to between 1.5 and
4.0× 1011 in healthy individuals, but more severe thrombocy-
topenia is defined as less than 0.5× 1011 platelets per litre [6,
20, 21]. Furthermore, it has been discovered that platelets can
promote the formation of neutrophil extracellular traps
(NETs) which have cytotoxic actions on host cells beyond
their beneficial antibacterial effects [22].
Notably, conditions such as sepsis and DIC have been
suggested to be linked to several platelet receptors, especially
Toll-like receptor (TLR) 4 [8, 18, 22, 23]. In human nucleated
cells, especially in professional antigen-presenting cells, the
binding of a ligand to TLR1, 2, 4, 5, 6, 7, 8, 9, and 10 results
in the activation of the so called myeloid differentiation
factor-88- (MyD88-) dependent pathway, whereas TLR3
activates the MyD88-independent pathway [12, 23, 24].
In contrast to most TLRs which signal exclusively through
one of the two pathways, TLR4 is able to activate both
MyD88-dependent and MyD88-independent signalling
[12, 24].
Platelets contain all of the proteins (e.g., MyD88 and
interferon regulatory factor 3 (IRF3)) that are required for
signal transduction through TLR4 and so at first glance it
would appear that platelets utilise the same mechanisms as
in nucleated cells [2, 25]. However, as we will explain in more
detail in the subsequent sections, this cannot be the case as
both the MyD88-dependent and the MyD88-independent
pathways culminate in the activation and nuclear transloca-
tion of transcription factors, and this step would not be appli-
cable in anucleated cells like platelets [2, 12, 26]. Before
examining the evidence for the TLR4 signalling pathways in
platelets, it is worth reviewing the pathways in nucleated cells
for use as a benchmark.
2. TLR4 Signalling in Nucleated Cells
2.1. TLR4 Ligands. Lipopolysaccharide (LPS) is a component
of Gram-negative bacterial cell membranes and a powerful
ligand for TLR4 [27, 28]. LPS is composed of a lipid Amoiety
(responsible for the molecule’s interactions with TLR4),
the core oligosaccharide, and the O-antigen polysaccharide
[27, 29, 30]. The lipid A moiety is localised in the outer
cell membrane and is formed from a 1,4-bis-phosphorylated
diglucosamine molecule linked to variable acyl chains (e.g.,
six chains in Escherichia coli LPS) [27, 29]. The phosphate
groups and acyl chains of LPS are important for interactions
with TLR4, and alterations in these can shift the molecule
from being an agonist to an antagonist [27, 31]. LPS may
not be the only ligand for TLR4 as damage-associated
molecular patterns (DAMPs), such as high-mobility group
box 1 (HMGB1) and heat shock proteins (HSPs), have also
been suggested to be capable of inducing activation through
this receptor [12, 32].
Although the immunogenic region of LPS is inside the
bacterial cell membrane, it is capable of eliciting an immune
response due to the presence of lipopolysaccharide-binding
protein (LBP) [27, 29, 33]. LBP is a soluble protein that is
synthesised by hepatocytes and found in the blood [28, 33].
It is capable of binding to areas rich in LPS (e.g., LPS
aggregates and Gram-negative bacterial membranes) and
promotes the exposure of the molecule’s hydrophobic
regions [34]. Subsequent to this, LPS monomers, via a pro-
cess facilitated by albumin, can associate with CD14 (cluster
of differentiation 14), a high affinity, horse shoe-shaped,
glycosylphosphatidylinositol- (GPI-) anchored membrane
protein [28, 31, 33–35]. CD14 forms a dimer with the
dimerisation interface at the C-terminal end and LPS-
binding pockets at the N-terminal end [33]. The transfer
of LPS to TLR4 and the breakdown of LPS aggregates
(micelles) into monomers are mediated by CD14 [28, 31,
33, 36]. Albumin can bind LPS, and other hydrophobic
molecules, via hydrophobic interactions between domain
III (on albumin) and the fatty acid chains of LPS [34].
Furthermore, albumin is capable of transferring LPS to
TLR4 on its own although this requires approximately 10-
fold higher concentrations of LPS compared to CD14 [34].
2.2. TLR4 Receptor. Similarly to CD14 (the molecule respon-
sible for transferring LPS to TLR4), the ectodomains of TLR4
are horse shoe-shaped due to the presence of several leucine-
rich repeats (LRRs) [33, 37]. Like other type I membrane-
spanning proteins, the membrane-spanning domain of
TLR4 is comprised of a single helix that serves to link the
intracellular and extracellular domains [31]. The intracellular
domain of TLRs contains a Toll/IL-1 receptor (TIR) domain
common to all of the adaptor protein molecules involved at
this stage of signalling [1, 31].
For signalling via TLR4 to occur, TLR4 requires hetero-
meric association with myeloid differentiation factor 2
(MD-2) [38, 39] (Figure 1). MD-2 is required because TLR4
does not bind LPS directly [27]. This is exemplified by
the ability of human MD-2 to bind LPS in the absence of
TLR4 [31]. MD-2 is constitutively associated with TLR4
through an interaction in the central region of TLR4 and
may be responsible for the recognition of different LPS
chemotypes [33, 39].
TLR4 has been detected on the plasma membrane and in
intracellular compartments (such as the early endosome) of
both nucleated cells and platelets [24, 40, 41]. In addition,
TLR4 is capable of internalisation, as has been shown follow-
ing prolonged exposure to LPS [24, 40–42]. The mechanisms
behind the internalisation of TLR4 differ between cell types
and may be required for MyD88-independent signalling
[40, 43]. The intracellular forms of TLRs are not inactive as
may be expected for an internalised extracellular receptor
but are capable of recognising ligands (such as LPS) in endo-
somes, lysosomes, and endolysosomes [12, 43, 44]. Notably,
plasma membrane localisation of TLR4 requires HSP
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90 kDa βmember 1 (gp96) and protein associated with TLR4
(PRAT4A) acting as chaperones [44, 45]. Moreover, MD-2
has been reported to play a role in TLR4 localisation at the
plasma membrane as its absence traps TLR4 in the Golgi
apparatus [38].
2.3. TLR4 Activation. In order to activate the TLR4 signalling
pathway, two receptor complexes need to dimerise to bring
together the intracellular TIR domains (Figure 1) [31]. LPS
and MD-2 (constitutively bound) binding to TLR4 is
required for the TLR4 complex dimerisation to take place
[27]. This dimerisation occurs due to the formation of a
dimerisation domain that incorporates a hydrophobic patch
on TLR4 and one of the acyl chains of LPS [33]. The remain-
ing acyl chains are hidden in the hydrophobic cavity of MD-2
[27]. Ectodomain dimerisation leads to an interaction
between the two intracellular domains of the TLR4 mono-
mers [31]. This builds a platform onto which the intracellular
signalling complexes can be formed [33]. At this stage, the
two pathways diverge but there is still disagreement about
what happens during this step [31].
2.4. The MyD88-Dependent Pathway. For the MyD88-
dependent pathway, the TIR domain-containing adaptor
protein (TIRAP), also known as MyD88 adaptor-like (Mal)
protein, interacts with the TIR domain of the receptor
enabling it to recruit MyD88 to the plasma membrane [31].
TIRAP presence at the plasma membrane is mediated by its
phosphatidylinositol-4,5-bisphosphate- (PI(4,5)P2-) binding
domain [43, 46]. It has been suggested that TIRAP may bind
to TLR4’s TIR domain using complementary charge distribu-
tions because of the observation that charges differ between
TLR3 (cannot bind TIRAP) and TLR4 and TLR2 (can or only
bind TIRAP, resp.). However, the exact details and structures
involved during this binding have not been determined, par-
tially due to the lack of a crystal structure for the TIR domain
of TLR4 [31]. Once TIRAP has bound to the receptor, it
recruits MyD88 via an interaction between their respective
TIR domains [43, 46, 47].
MyD88 contains a death domain (DD) at its N-terminal
end, which is crucial for the subsequent signalling cascade
as it enables the construction of a large multimeric complex
called the Myddosome (Figure 2) [47]. The Myddosome is
formed of six MyD88, four interleukin- (IL-) 1 receptor-
associated kinase 4 (IRAK4), and four IRAK1/2 molecules,
all of which contain DDs, arranged in a single-stranded
left-handed helix [24, 47]. As shown in Figure 2, this helix
has multiple levels with the first two levels comprised solely
of MyD88, IRAK4 is found in the third level, and IRAK1/2
is found in the fourth level [47]. Following assembly, IRAK4
undergoes an activating autophosphorylation process
thereby enabling it to phosphorylate, and activate, IRAK1/2






Figure 1: Structure of TLR4/MD-2 ectodomains, in a
heterotetrameric form, as seen from (a) or (b). The TLR4
molecule (green) is constitutively bound to MD-2 (magenta), and
the TLR4∗ (cyan) molecule is constitutively bound to MD-2∗
(yellow). Dimerisation interfaces form between TLR4 and MD-2∗
and vice versa. Images were created by adapting the structure of







Figure 2: Structure of the Myddosome showing the protein death
domains (DD). The Myddosome is formed of six MyD88
molecules, four IRAK4 molecules, and four IRAK1/2 molecules
arranged in a single-stranded helix. MyD88 occupies the two
layers closest to the plasma membrane whereas IRAK4 and
IRAK1/2 form the two subsequent layers. The image was created




from the Myddosome and triggers polyubiquitination of
tumour necrosis factor (TNF) receptor-associated factor
(TRAF) 6 [47, 48]. TRAF6 interacts with TRAF-activated
kinase 1 (TAK) and IRAK1/2, and this complex in turn inter-
acts with NF-κB essential modulator (NEMO) to stimulate
the activating phosphorylation of IκB kinase- (IKK-) β and
the degradation of IκB [24, 49–51]. Degradation of IκB and
the release of inhibition on NF-κB permit it to translocate
into the nucleus and enhance expression of proinflamma-
tory cytokines including TNFα and IL-1β [44, 50, 51]. The
MyD88-dependent signalling downstream of LPS stimula-
tion is dependent on TLR4 remaining at the plasma mem-
brane as inhibition of internalisation increases NF-κB
activity [52].
Activation of mitogen-activated protein kinases
(MAPKs) downstream of MyD88 and TAK1 is also involved
in TLR4-mediated responses in nucleated cells [44, 48].
MAPKs include a range of proteins including extracellular
signal-regulated kinase (ERK) 1 and 2, c-Jun N-terminal
kinase (JNK) 1 and 2, and p38 [48]. These kinases are capable
of activating the transcription factor, activator protein 1
(AP-1) [48]. This part of the MyD88-dependent pathway
is dependent on the downregulation of TRAF3, via ubiqui-
tination by cellular inhibitor of apoptosis (cIAP), near the
plasma membrane where it has a negative regulatory role
[48]. A summary of all the signalling pathways in nucleated
cells is shown in Figure 3.
2.5. The MyD88-Independent Pathway. TRIF-related adaptor
molecule (TRAM) is responsible for recruiting TIR domain-
containing adaptor-inducing interferon-β (TRIF) in the
MyD88-independent pathway [31]. Signalling through this
pathway occurs following specific internalisation of the
TLR4-MD-2 heterotetramer, its bound ligand, and CD14
[53–55]. The protein responsible for the internalisation
(clathrin or caveolin) of TLR4 varies between cell types
and with time although dynamin and CD14 are always
necessary [40, 43, 52, 55]. Whereas CD14 is only required
at low concentrations of LPS for MyD88-dependent path-
way signalling (with other proteins such as albumin capa-
ble of transferring LPS to MD-2), CD14 is always
necessary for MyD88-independent signalling [34, 55, 56].
As internalisation of TLR4 occurs, the decrease in PI(4,5)P2
in the local area leads to a weakening of the interaction
between TLR4 and TIRAP and thus propagates the break-
down of the Myddosome [24, 43]. Interestingly, endocytosis
of TLR4 does not appear to be dependent on TLR4-
mediated signalling, with cells lacking TIRAP, MyD88,
TRAM, or TRIF retaining the capacity to internalise the
receptor [55]. This has been suggested to be a result of phos-
pholipase Cγ2 (PLCγ2) and spleen-associated tyrosine
kinase (Syk) activation in a CD14-dependent and TLR4-
independent manner [55].
Upon internalisation, TLR4 enters the endosome, a
region of the cell where TRAM and TRAF3 are present and
from where MyD88-independent signalling can begin [24,
43, 48, 55]. When recruited to the TLR4-TRAM-TRIF com-
plex by TRIF, TRAF3 is polyubiquitinated thus stimulating
the activation of TRAF family member-associated NF-κB
activator- (TANK-) binding kinase- (TBK-) 1 and IKKε
[48]. TBK1 and IKKε are then free to phosphorylate IRF3,
which is activated upon phosphorylation and dimerisation
and stimulates the production of type I interferons [48, 56].
3. TLR4 Signalling in Platelets
3.1. Platelet Activation upon Vascular Damage. The response
of platelets to “classical” agonists and the subsequent activa-
tion in haemostasis have been well defined [4–6]. During vas-
cular injury, there is exposure of the subendothelial matrix
and proaggregatory proteins, such as von Willebrand factor
(vWF) and collagen, to the flow of blood. vWF is immobi-
lised on collagen, and its association with GPIb-V-IX, a large
glycoprotein (GP) complex, represents the initial interaction
between platelets and the damaged vessel. This interaction
slows down the platelets enabling them to interact with the
exposed collagen via GPVI and platelet activation to ensue
[57–59]. Binding of collagen to GPVI promotes an intracellu-
lar signalling cascade involving tyrosine kinase-mediated
(e.g., Syk) activation of PLCγ2. The degradation of
PI(4,5)P2 by PLCγ2 into diacylglycerol (DAG) and inositol
1,4,5-trisphosphate (Ins(1,4,5)P3, also known as IP3) induces
indirect activation of protein kinase C (PKC) [59].
Platelet activation induces shape change and modulation
of integrin αIIbβ3 affinity to allow the formation of a platelet
plug with fibrinogen used as a bridging molecule to sur-
rounding platelets [5, 6]. Integrin activation is critical for a
successful aggregation response. In resting platelets, integrin
αIIbβ3 is in a low affinity state but a conformational change
during platelet activation enables high-affinity binding of
ligands. PKC activation has a key role in modulating integrin
αIIbβ3 affinity [59, 60].
Furthermore, activation of platelets leads to degranula-
tion and the secretion of adenosine diphosphate (ADP)
and the synthesis and release of thromboxane A2 (TxA2),
resulting in the activation of more platelets and recruit-
ment of them to the thrombus [57–59]. Moreover, pro-
thrombin is cleaved into thrombin following interactions
involving tissue factor, factor VIIa, and factor Xa on the
activated platelet surface. Thrombin is able to activate
platelets through a cleavage of a region in the extracellular
domains of protease-activated receptors (PARs) 1 and 4.
Together, these agonists activate more circulating platelets
and thus stimulate the formation of a platelet plug to seal
the damaged region [5–7].
3.2. TLR4 Expression in Platelets. The presence of TLR4 on
platelets is not disputed, and it was first identified on mouse
and human platelets using flow cytometry by Andonegui
et al. [36]. In addition, the same research group demon-
strated that TLR4 displays functional effects in platelets.
Furthermore, the discovery was backed up independently
by Cognasse et al. in the same year, also through flow
cytometry-based experiments [41]. Other research groups
have also confirmed the presence of TLR4 on platelets
through immunoblot analysis [42, 61, 62]. The amount of
TLR4 expressed on the surface of platelets is variable, and
an intracellular pool has also been identified [30, 41, 42].
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A big difference in TLR4 signalling between platelets and
nucleated cells is that although platelets contain the intra-
cellular signalling proteins required for TLR signalling
(Figure 4), they do not have all of the necessary extracellular
components (e.g., CD14) [2, 63, 64]. Membrane-bound
CD14 is absent in platelets; however, this problem is
overcome by high levels of soluble CD14 in the plasma















































































Figure 3: Summary of intracellular TLR4 signalling pathways in nucleated cells. LPS is transferred to CD14 (or albumin), via a process
involving LBP and albumin, which transfers LPS to TLR4:MD-2 to complete the heterotetramerisation. There are two major signalling
pathways, namely, the MyD88-dependent and -independent pathways, for TLR4 signalling. In the MyD88-dependent pathway, TIRAP (or
Mal) enables MyD88 binding to TLR4 and formation of the Myddosome, which contains MyD88, IRAK4, and IRAK1/2. The kinases
found at the base of the Myddosome activate TRAF6 and TAK1 followed by the activation of NEMO and its associated kinases. IKKβ
stimulates the degradation of inhibitory IκB, which leads to nuclear translocation of NF-κB and transcription of proinflammatory genes.
In addition, TAK1 activates JNK1/2, ERK1/2, and p38, which can then stimulate the transcription factor AP-1. In the MyD88-
independent pathway, following CD14-dependent internalisation into the endosomes, TRAM and TRIF are recruited to TLR4 before
activating TRAF3. Activation of TRAF3 activates TBK1 and IKKε, which phosphorylate and activate the transcription factor IRF3 that
stimulates the transcription of anti-inflammatory cytokines.
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at low concentrations of LPS whilst responses at higher
concentrations are not affected. Moreover, the requirement
for higher concentrations of LPS could prevent NET forma-
tion in response to minor bacterial infections, thus protecting
against unwarranted endothelial damage [22]. Furthermore,
the absence of membrane-bound CD14 may also have an
impact on MyD88-independent signalling which requires
CD14 for the endocytosis of TLR4 and LPS [55]. The loss
of CD14 caused by “washing” platelets appears to reduce
the magnitude of the response to LPS although a response
is still present [63, 66, 67].
3.3. TLR4 Activity in Platelets. A strong piece of evidence for
TLR4 activity in platelets comes from experiments conducted
by Clark et al. They demonstrated that high concentrations of
LPS led to an interaction between platelets and neutrophils
that stimulated the formation of NETs [22]. The researchers
also linked this activity to sepsis, a disease that is commonly
associated with platelet TLR4 [19]. This was achieved by
determining the production of NETs in the blood samples
of sepsis patients [22]. It is unclear whether it was the LPS
in the blood or another substance that stimulated this





























































































Figure 4: Summary of intracellular TLR4 signalling in platelets. Although the individual steps of the MyD88-dependent pathway have been
observed, signalling in its entirety downstream of TLR4 has not been confirmed. Similar to nucleated cells, the proteins required for signalling
through MyD88-dependent and -independent pathways are present in platelets but it is currently unclear how they mediate their effects.
Signalling downstream of MyD88 can also be mediated by cGKI. The presences of TLR4, MyD88, IRAK1, TRAF6, TAK1, JNK, MAPK,
IκBα, NF-κB, TRIF, TRAF3, TBK1, IKKε, and IRF3 have all been confirmed by immunoblot analysis [2, 25]. Question marks (?) denote
aspects of the pathway that have not been confirmed.
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a TLR4-dependent manner are also released into the blood
during sepsis, for example, HMGB1 [22, 32]. Similarly, fur-
ther evidence for the role of platelet TLR4 is provided by the
observation that the levels of soluble cluster of differentiation
40 ligand (sCD40L) are raised following treatment of platelets
with LPS [63, 66–69]. This is important because platelet
α-granules are the largest source of sCD40L, and CD40L is
involved in inflammatory responses elucidated by the endo-
thelium and immune cells [1, 68–70]. Increases in sCD40L
levels have been suggested to directly involve TLR4 [69].
Many attempts have been made to characterise the
responses of platelets to LPS and other TLR4 agonists
although there have been conflicting results. Evidence from
different studies agree that exposure of platelets to LPS stim-
ulates the release of tumour necrosis factor- (TNF-) α, a mol-
ecule that is produced downstream of the MyD88-dependent
pathway in nucleated cells [42, 50, 71]. Although platelets
lack genomic DNA, they still contain mRNA transcripts
that can be processed and spliced following stimulation
of platelets by LPS or thrombin [63, 72]. Transcripts that
are affected include IL-1β (a proinflammatory cytokine)
and cyclooxygenase-2 (produces a platelet agonist, TxA2)
[63]. In addition, IL-1β mRNA has been shown to be
spliced in platelets in a TLR4-dependent manner with JNK
and protein kinase B (PKB) (found downstream of the
MyD88-dependent pathway) activity increasing during splic-
ing [65]. Furthermore, splicing of IL-1β was diminished in
the presence of JNK or PKB inhibitors. However, the mech-
anism of action has not yet been elucidated [65]. Platelet
shape change as a result of actin filament formation has also
been suggested [63]. A comprehensive examination of
cytokine release from platelets after treatment with LPS
was conducted by Cognasse et al. [30]. They demonstrated
that the expression of CD63 and release of sCD40L and
platelet-activating factor 4 (PAF4) were increased; release
of regulated upon activation, normally T-expressed, and
presumably secreted (RANTES), angiogenin and platelet-
derived growth factor- (PDGF-) AB were decreased (along
with TLR4 expression); meanwhile, there was no change
in the expression of soluble P-selectin, epidermal growth
factor (EGF), transforming growth factor β (TGFβ), or
IL-8 [30]. Upregulation of P-selectin following LPS expo-
sure is controversial with evidence both for [32, 61, 63]
and against [26, 30, 66].
3.4. The Role of MyD88 in Platelets. It is unclear whether the
traditional TLR4 pathways are responsible for all the effects
mediated by TLR4 ligands on platelet function. MyD88−/−
mouse platelets have been used to demonstrate that this
protein is necessary for the effects of LPS in enhancing
aggregation and granule secretion in platelets. Some effects
downstream of MyD88 have also been shown to be mediated
by the cyclic guanosine monophosphate- (cGMP-) mediated
signalling pathway [61].
In contrast, one research study demonstrates that there
is virtually no role for MyD88 in modulating platelet func-
tion during Gram-negative (Klebsiella pneumoniae) bacte-
rial infection [71]. Differences in responses were observed
in systemic MyD88−/−mice compared to the controls;
however, these differences could not be recovered by
transfusing wild-type platelets into the MyD88−/− mice.
Furthermore, some changes in the secretion of TNFα
and monocyte chemoattractant protein-1 (MCP-1) were
observed that could be the result of deletion of platelet
MyD88, thus suggesting that signalling to NF-κB is still
intact and functioning [71].
The results of this study are somewhat limited for several
reasons. For example, the observed effects were not shown to
be mediated by TLR4 as competitive antagonists, blocking
antibodies for TLR4, and platelets derived from TLR4-
deficient mice were not used in their experimental settings.
Furthermore, this study did not use pure LPS (or other
potential TLR4 ligands), but rather whole Klebsiella pneumo-
niae bacteria, which means that other bacterial components
or exotoxins may have been able to influence cellular activi-
ties. More specifically, there was no investigation into the
success of the platelet transfusions as the recipient mice were
not depleted of their platelets and transfused platelets may
have been sequestered in organs such as the lungs and spleen.
The possibility of adaptive mechanisms in the MyD88-
deficient mice was not investigated either; nor was an alterna-
tive signalling pathway suggested. Nevertheless, this study
highlights the necessity for further research in order to con-
firm the significance of MyD88 in TLR4-mediated signalling
in platelets.
3.5. Priming Platelets. There is evidence suggesting that LPS
(and therefore TLR4-mediated signalling) has a “priming”
role in platelets. LPS on its own is unable to induce aggrega-
tion in washed platelets, but it can potentiate agonist-induced
aggregation responses. This was elucidated through the use
of classical agonists such as collagen and thrombin [14, 26,
61]. Despite washed platelets being used, sCD14 was still
detectable on platelets via flow cytometry [61]. Similar
results have been obtained with platelet-rich plasma (PRP)
using agonists such as adenosine diphosphate (ADP) [63].
The response was mediated by TLR4 as demonstrated
through the use of TLR4−/− mouse platelets [61]. An intrigu-
ing observation from this was that the different bacterial
strains of LPS tested had different potencies [61]. This
has also been observed with the LPS from Rhodobacter
sphaeroides demonstrating its ability to act as a competi-
tive TLR4 antagonist [63]. This priming behaviour in
platelets is also supported by studies using NF-κB and
IKKβ inhibitors [26, 73, 74].
The identification of TLR4:MyD88 coupling to the
cGMP-dependent pathway is important as this pathway
stimulates platelet aggregation from a subthreshold concen-
tration of an agonist (0.02U/mL of thrombin) [75]. Thus,
there is a precedent for TLR4 to have a priming role in plate-
let aggregation. The response to cGMP-analogues was
biphasic with an initial stimulatory response followed by an
inhibitory response [75]. An interesting point to consider is
that whilst cGMP-dependent kinase I (cGKI) inhibition
affected aggregation and secretion to low agonist concentra-
tions (excluding ADP), there was no effect on calcium
mobilisation [76] and TLR4 is also incapable of modulat-
ing calcium mobilisation [77]. cGKI has been proposed to
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be involved positively in the Gi-pathway, and so activation of
cGKI could help amplify platelet responses in a similar man-
ner to the P2Y12 receptor [76].
3.6. NF-κB in Platelets. Given that platelets lack a nucleus, it
may appear that the presence of a signal transduction path-
way that culminates in transcription factor activation would
have no role in platelet function. This initially prompted
some researchers to claim that TLR4 and its downstream
signalling proteins in platelets were relics left over from
their formation by megakaryocytes. Furthermore, certain
experiments concluded that there were no responses medi-
ated by TLR4 with specific bacterial species, lending support
to this argument [78]. Other concerns arose from different
LPS chemotypes derived from diverse bacterial species hav-
ing diverse potencies when it comes to elucidating a response
[61, 63, 66, 79]. NF-κB, however, appears to have a role in
platelet function, suggesting a nongenomic role, especially
when the ability of NF-κB inhibitors to reduce the proaggre-
gatory effects of TLR4 is considered [26, 80].
Notably, IKKβ is involved in the phosphorylation of sol-
uble N-ethylmaleimide-sensitive factor attachment protein
receptors (SNAREs), particularly synaptosomal-associated
protein 23 (SNAP23), and thus, IKKβ has an important role
in granular secretion [73]. Phosphorylation of SNAREs is
known to occur downstream of PKC when thrombin is used
as an agonist [73]. This is relevant because IKKβ is found
downstream of both this classical agonist pathway and the
MyD88-dependent pathway, suggesting a mechanism by
which TLR4 activation could lead to the secretion of granules
that has been shown in some studies [32, 51, 73]. Further
investigations have revealed that IKKβ activity occurs down-
stream of TAK1, found in the MyD88-dependent pathway
[25]. This evidence points towards the ability of the
MyD88-dependent pathway to promote SNARE complex
formation and may explain some of the “priming” activity
induced by TLR4 ligands. However, it is unclear whether
IKKβ directly phosphorylates SNAP23 or whether it occurs
due to the activation of NF-κB. It has been shown that NF-
κB activity is involved in modulating dense and α-granule
secretion upon activation with low agonist doses by using
inhibitors of IκBα phosphorylation and ubiquitination (to
indirectly inhibit NF-κB activity) [74, 80]. Moreover, NF-
κB inhibition decreases binding of platelets to fibrinogen
[80]. This suggests that NF-κB is responsible for modulating
secretion in this case although one of the inhibitors used is
likely to directly inhibit IKKβ. Inhibition of aggregation has
also been seen to be mediated by NF-κB inhibitors down-
stream of TLR4, suggesting that TLR4 and NF-κB activity is
connected in platelets [26].
3.7. Other Ligands. Although LPS has been the predominant
ligand mentioned in this review, other ligands have also been
suggested to bind to TLR4; however, this area is highly con-
troversial [9, 67, 81, 82]. HMGB1 is one such possible ligand
and has been shown to have effects in platelets in an auto-
crine and paracrine manner [32]. With a presence in the
plasma and on NETs, the DNA-binding protein released
from dead/dying cells or activated immune cells has
opportunities to interact with platelets in many conditions,
for example, sepsis [22, 32, 83, 84]. HMGB1 has been
reported to elicit similar responses in platelets compared to
LPS, including the priming effects. These effects were also
shown to involve TLR4, MyD88, and cGKI although there
is not yet clear evidence indicating exactly how these proteins
relate. ERK was another protein that had a change in its
activity as a result of treatment with HMGB1 dependent on
the presence of TLR4 [32]. HMGB1 has also been shown to
have a role in tumour metastasis in a mechanism involving
TLR4 [84]. Platelets are known to aid in cancer metastasis
by forming protective thrombi around metastasising cells
[85], and subsequent experiments by Yu et al. demonstrated
that deletion of TLR4 in mice led to fewer metastatic tumours
[84]. However, evidence from nucleated cells exists implying
that HMGB1 acts solely as a TLR ligand-binding protein
(e.g., LPS) and potentiates signalling through TLRs (alarmin
effect) [86, 87]. Thus, the effects observed in the studies might
be due to the binding of HMGB1-LPS colligation to TLR4
[87]. Moreover, recent studies have shown that, instead of
direct binding to TLR4, HMGB1 directly exerts effects (such
as activation of NF-κB andMAPKs) on cells through binding
to the receptor for advanced glycosylation end-products
(RAGE) [88].
Another ligand that has been suggested to alter platelet
activity in a TLR4-dependent manner is cellular fibronectin
[9]. It has been shown that cellular fibronectin can modify
platelet activity in a similar manner to LPS by potentiating
aggregation induced by low doses of thrombin and increasing
phosphorylation of NF-κB and IKKα/β [9]. Furthermore, it
was shown that the presence of TLR4 in mouse platelets
significantly increased thrombus growth when treated with
cellular fibronectin [9]. These findings suggest a possible
effect of cellular fibronectin that may be mediated in a
TLR4-dependent manner.
Histones have also been proposed to be ligands for TLR4
and are found in the blood during sepsis following release
from neutrophils or necrotic cells [89–92]. They are impor-
tant for the organisation of DNA in nucleated cells and, like
HMGB1, appear in NETs [93]. Histones (especially H4) have
interactions in the blood, and they have been reported to
have a role in chemokine production in whole blood, platelet
aggregation, and also thrombocytopenia in mice [89, 93].
However, these studies concluded that it was monocytes,
and not platelets, that were responsible for the TLR4-
dependent production of cytokines (even though histone
H4 did associate with platelets) whereas the impact of
TLR4 on histone-induced aggregation and thrombocytope-
nia was not examined [89, 93]. In contrast, it has been shown
that histones can stimulate P-selectin exposure and thrombin
generation on platelets in a TLR2- and TLR4-dependent
manner [81].
Additionally, HSP60, a cell-stress marker, has been
proposed to trigger TLR4-mediated signalling in a vascular
smooth muscle cell line, with implications in atherosclerosis.
However, the effects of this protein have not been tested on
platelets despite an increased expression of HSP60 on endo-
thelial cells in sheer stress environments [94, 95]. Serum
amyloid A (SAA) is a potential ligand for TLR4 that is
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released, primarily from the liver, during an inflammatory
response [96, 97]. Platelets have been shown to adhere to
SAA in an integrin αIIbβ3-dependent manner; however, it
has not been determined whether or not this integrin is solely
responsible for this behaviour as the research was conducted
before the discovery of TLR4 on platelets [97]. Further
research is required to determine whether these proposed
ligands are having an effect due to direct binding to TLR4
or if it is the result of a more complex interaction, as has been
suggested for HMGB1 [87].
4. TLR4 Signalling in Platelets: What Is
Still to Discover?
Although many studies have linked TLR4 activity in platelets
to immune responses, there have not been many studies to
explore the signalling pathways downstream of TLR4 or
MyD88 [26, 32, 61]. This is of particular interest as this
receptor, with so many potential ligands and possible func-
tions, operates through a pathway that classically results in
gene transcription, but this end result is not achievable due
to the lack of a nucleus in platelets. Moreover, the presence
of all the signalling proteins in the pathways has been con-
firmed [2, 25] but whether the entirety of each pathway is
functional, in platelets, has not been elucidated. Currently,
individual steps of the MyD88-dependent pathway have
been seen but not tied together downstream of TLR4. The
MyD88-independent pathway in platelets also lacks consid-
erable amounts of detail, including study of its activity. Fur-
thermore, platelet TLR4 expression levels have been linked
to more severe disease states in inflammatory responses [8,
9, 81, 84, 98–101]. This obviously makes TLR4 an interesting
receptor to target for the prevention and/or treatment of
cardiovascular diseases. However, it is challenging due to
the important contribution of TLR4 to innate immunity.
Determination of the effector proteins involved and their
responses may lead to the discovery of novel pathways
downstream of TLRs and present TLR4 as a novel therapeu-
tic target for the treatment of cardiovascular diseases and
other pathological settings such as inflammatory disease.
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SNAP23: Synaptosomal-associated protein 23
SNARE: Soluble N-ethylmaleimide-sensitive factor
attachment protein receptor
Syk: Spleen-associated tyrosine kinase
TAK1: TRAF-activated kinase 1
TBK1: TRAF family member-associated NF-κB acti-
vator- (TANK-) binding kinase 1
TGFβ: Transforming growth factor β
TIR: Toll/IL-1 receptor
TIRAP: TIR domain-containing adaptor protein
TLR: Toll-like receptor
TNF: Tumour necrosis factor
TRAF: TNF receptor-associated factor 3
TRAM: TRIF-related adaptor molecule
TRIF: TIR domain-containing adaptor-inducing
interferon-β
TxA2: Thromboxane A2
vWF: von Willebrand factor.
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Impact of specific functional groups 
in flavonoids on the modulation of 
platelet activation
Divyashree Ravishankar1, Maryam Salamah1, Angela Akimbaev1, Harry F. Williams  1,  
Dina A. I. Albadawi1, Rajendran Vaiyapuri2, Francesca Greco1, Helen M. I. Osborn1 &  
Sakthivel Vaiyapuri1
Flavonoids exert innumerable beneficial effects on cardiovascular health including the reduction of 
platelet activation, and thereby, thrombosis. Hence, flavonoids are deemed to be a molecular template 
for the design of novel therapeutic agents for various diseases including thrombotic conditions. 
However, the structure-activity relationships of flavonoids with platelets is not fully understood. 
Therefore, this study aims to advance the current knowledge on structure-activity relationships of 
flavonoids through a systematic analysis of structurally-related flavones. Here, we investigated a panel 
of 16 synthetic flavones containing hydroxy or methoxy groups at C-7,8 positions on the A-ring, with 
a phenyl group or its bioisosteres as the B-ring, along with their thio analogues possessing a sulfur 
molecule at the 4th carbon position of the C-ring. The antiplatelet efficacies of these compounds were 
analysed using human isolated platelets upon activation with cross-linked collagen-related peptide by 
optical aggregometry. The results demonstrate that the hydroxyl groups in flavonoids are important 
for optimum platelet inhibitory activities. In addition, the 4-C=O and B ring phenyl groups are less 
critical for the antiplatelet activity of these flavonoids. This structure-activity relationship of flavonoids 
with the modulation of platelet function may guide the design, optimisation and development of 
flavonoid scaffolds as antiplatelet agents.
Platelets are small circulating blood cells that play pivotal roles in the regulation of haemostasis upon vascular 
injury through blood clotting1,2. However, unnecessary activation of platelets within the vasculature leads to 
pathological conditions such as thrombosis, which results in blockage or reduction of blood flow to major organs 
including heart and brain instigating heart attack and stroke, respectively3,4. The currently used therapeutic 
options that involve the use of antiplatelet drugs such as clopidogrel, aspirin, and prasugrel are often linked with 
adverse side effects such as bleeding and are ineffective in some patients5–10. As cardiovascular diseases remain 
the leading cause of death worldwide11, the development of improved therapeutic strategies to prevent and treat 
thrombotic diseases remains a pressing priority.
Flavonoids, a group of polyphenolic plant metabolites, have been widely demonstrated to possess beneficial 
effects in the prevention of cardiovascular diseases12–14. Epidemiological and clinical studies have established a 
prominent link between the regular consumption of dietary flavonoids and decreased incidences of cardiovas-
cular diseases or their risk markers15–20. Flavonoids have also been recognised as modulators of platelet function 
and their inhibitory activities can be attributed to their ability to inhibit reactive oxygen species (ROS) produc-
tion21,22, modify cytoskeletal proteins such as actin and tubulin that mediate degranulation23,24, and to inhibit 
various kinases25–29 and receptors30,31 that play numerous roles in the regulation of platelet activation and throm-
bosis. The pharmacological potential of flavonoids is strongly related to their molecular structure, hence, the 
identification of key structural elements that are prerequisites for antiplatelet activity has provoked considerable 
interest in the area of drug discovery32,33. With a view to develop flavonoids as potential anti-thrombotic agents, 
some studies have been carried out to identify the key structural features governing the antiplatelet activity of 
flavonoids34. However, the current knowledge of structure-activity relationships (SARs) has mainly resulted from 
analyses involving different subclasses of natural flavonoids32,34. In order to translate flavonoids into potential 
molecular templates for drug design, a better understanding of the SAR of flavonoids, and a careful comparison of 
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substitution pattern within a flavonoid subclass is necessary. Hence, to gain greater insights into the SAR of flavo-
noids with human platelets, this study has focused on assessing the effect of methoxylation, 4-C=S substitution, 
and different B-ring substitutions using a series of 16 synthetic flavones on the antiplatelet activities.
Materials and Methods
Flavones. The synthetic flavones used in this study are grouped into four main classes namely; hydroxy fla-
vones with free –OH and 4-C=O, hydroxy 4-thioflavones with free –OH and 4-C=S, methoxy flavones with 
–OMe and 4-C=O and methoxy 4-thioflavones with–OMe and 4-C=S35. The hydroxy flavones include 7,8-dihy-
droxy-2-phenyl-4H-chromen-4-one (F-1), 7,8-dihydroxy-2(thiophen-2-yl)-4H-chromen-4-one (F-2), 2-(furan-
2-yl)-7-8,dihydroxy-4H-chromen-4-one (F-3) and 7,8-dihydroxy-2(pyridine-3yl)-4H-chromen-4-one (F-4). The 
hydroxy 4-thioflavones include 7,8-dihydroxy-2-phenyl-4H-chromen-4-thione (TF-1), 7,8-dihydroxy-2(thi-
ophen-2-yl)-4H-chromen-4-thione (TF-2), 2-(furan-2-yl)-7-8,dihydroxy-4H-chromen-4-thione (TF-3) and 
7,8-dihydroxy-2(pyridine-3yl)-4H-chromen-4-thione (TF-4). The methoxy flavones include 7,8-dimethoxy-2-
phenyl-4H-chromen-4-one (CYC-1), 7,8-dimethoxy-2-(thiophen-2-yl)-4H-chromen-4 (CYC-2), 2-(furan-2-yl)-
4H-chromen-4-one (CYC-3) and 7,8-dimethoxy-2-(pyridine-3-yl)-4H-chromen-4-one (CYC-4). The methoxy 
4-thioflavones include 7,8-dimethoxy-2-phenyl-4H-chromen-4-thione (TCYC-1), 7,8-dimethoxy-2-(thiophen-
2-yl)-4H-chromen-4-thione (TCYC-2), 2-(furan-2-yl)-7,8-dimethoxy-4H-chromen-4-thione (TCYC-3) and 
7,8-dimethoxy-2-(pyridine-3-yl)-4H-chromen-4-thione (TCYC-4). Stock solutions of these flavones were pre-
pared in dimethyl sulfoxide (DMSO) (100%) at 10 mg/mL concentration and the final required test concentra-
tions were obtained by appropriately diluting these stocks. The final concentration of DMSO in platelets was 
maintained at 0.1% (v/v), which did not affect their function.
Human blood collection. All the experiments in this study were conducted in line with the appropriate 
institutional and national guidelines and regulations. Human blood was collected by venepuncture from aspirin 
free, healthy volunteers into vacutainers containing 3.2% (v/v) citrate after obtaining their informed consent. The 
procedures and consent forms used in this study were approved by the University of Reading Research Ethics 
Committee.
Preparation of human isolated platelets. Human isolated platelets were prepared by adding 7.5 mL 
of ACD [(acid citrate dextrose) (20 g/L glucose, 25 g/L sodium citrate and 15 g/L citric acid)] to 50 mL of blood 
prior to centrifugation at 100 g for 20 minutes at room temperature. The Platelet-Rich Plasma (PRP) was removed 
using wide bore pipette tips and mixed with 3 mL of ACD and centrifuged at 1400 g for 10 minutes at room tem-
perature. The resulting platelet pellet was resuspended in modified Tyrodes-HEPES buffer (2.9 mM KCl, 134 mM 
NaCl, 0.34 mM Na2HPO4.12H2O, 1 mM MgCl2, 12 mM NaHCO3, 20 mM HEPES, pH 7.3) and centrifuged again 
at 1400 g for 10 minutes28. The final platelet pellet obtained was suspended in modified Tyrodes-HEPES buffer 
at a density of 4 × 108 cells/mL for aggregation assays and rested at 30 °C for 30 minutes before using in platelet 
functional assays.
Platelet aggregation assays. Platelet aggregation was performed using a platelet glycoprotein VI 
(GPVI)-selective agonist, CRP-XL (obtained from Professor Richard Farndale, University of Cambridge) in the 
presence or absence of a vehicle control [0.1% (v/v) DMSO] or different concentrations of flavone derivatives by 
optical aggregometry. Human isolated platelets (267 µL) taken in siliconised cuvettes were incubated with 3 µL of 
a vehicle control or various concentrations of flavone derivatives for 5 minutes at 37 °C. Following the incubation, 
30 µL of CRP-XL (0.5 µg/mL) was added to platelets and the level of aggregation was measured for 5 minutes at 
37 °C under constant stirring (1200 rpm). Data were analysed by calculating the percentage of maximum platelet 
aggregation at 5 minutes, and the level of aggregation obtained with the vehicle control was considered as 100% 
to quantify the impact of flavones on platelets.
Lactate dehydrogenase assay. The lactate dehydrogenase (LDH) assay was performed using a LDH 
Cytotoxicity Assay Kit (Pierce, Thermo Fisher) according to the manufacturer’s instructions. Briefly, to 50 µL of 
human isolated platelets, 1 µL of a positive control [1% (v/v) Triton-X 100, provided in the kit] or a vehicle control 
[0.1% (v/v) DMSO] or various concentrations of flavone derivatives were added and incubated for 30 minutes at 
37 °C. Then, 25 µL of the reaction mixture (provided in the kit) were added to the platelets and further incubated 
for 30 minutes in dark. Finally, the reaction was stopped by adding 25 µL of stop solution (provided in the kit). 
The absorbance was measured at 490 and 650 nm using a Fluostar Optima spectrofluorimeter (BMG Labtech, 
Germany). The level of LDH released with the positive control was considered as 100% to quantify the LDH 
release in flavone-treated samples.
Statistical analysis. The statistical significance between the vehicle controls and flavones-treated platelet 
samples was analysed by one-way ANOVA followed by Bonferroni post-hoc test. All the statistical analyses were 
performed using GraphPad Prism 7 (GraphPad Software Inc., USA).
Results
To determine the relationship between the specific functional groups in the structures of flavones and their 
antiplatelet activity, a series of hydroxy flavones, hydroxy 4-thioflavones, methoxy flavones and methoxy 
4-thioflavones containing different B-ring (Figs 1A, 2A, 3A & 4A) were used in this study. These 16 flavones were 
synthesised based on the molecular template of 7,8-hydroxy flavone to systematically determine the influence 
of hydroxyl (-OH), methoxy (-OMe) and 4-thiocarbonyl (4-C=S) groups as well as the effects of phenyl group 
and its bioisosteres such as thiofuran, furanyl and pyridinyl moieties as B-ring on platelet activation/function. 
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The synthesis of these compounds from our laboratories has been previously reported35 and the purities of com-
pounds were analysed by reverse phase HPLC, and they were found to be >95%.
In order to determine the SAR of flavones with human platelets, the effects of 16 selected synthetic flavones 
on CRP-XL-stimulated platelet aggregation were evaluated by optical aggregometery. Human isolated platelets 
were treated with a vehicle [0.1% (v/v) DMSO] or diverse concentrations of flavones (3.125, 6.25, 12.5, 25, 50 and 
100 µM) for 5 minutes prior to activation with 0.5 µg/mL CRP-XL for 5 minutes. None of the flavones exhibited 
activatory effects on platelets on their own, and the vehicle control containing 0.1% (v/v) DMSO did not affect 
platelet activation.
Flavones with phenyl B-ring. Hydroxy flavone (F-1) with free hydroxyls and carbonyl moiety significantly 
inhibited CRP-XL-stimulated platelet aggregation at lower concentrations such as 3.125, 6.25 and 12.5 µM but 
no significant inhibition was observed at concentrations higher than 12.5 µM. The hydroxy 4-thioflavone (TF-
1) showed significant inhibitory effects at all the concentrations tested. However, the methoxy flavone (CYC-1) 
inhibited the aggregation significantly only at 100 µM and the methoxy 4-thioflavone (TCYC-1) did not show any 
inhibitory effects at any of the concentrations tested (Fig. 1A–C).
Flavones with thiofuran B-ring. Hydroxy flavone (F-2) displayed a similar inhibitory trend to F-1 with 
significant inhibition at lower concentrations up to 12.5 µM, whereas the hydroxy 4-thioflavone (TF-2) and the 
methoxy flavone (CYC-2) inhibited aggregation only at 100 µM. The methoxy 4-thioflavone (TCYC-2) of this 
group was found to possess no inhibitory activity on platelet aggregation (Fig. 2A–C).
Figure 1. Effect of flavones with phenyl B-ring on human platelet activation. (A) Chemical structures of the 
flavones, F-1, TF-1, CYC-1 and TCYC-1. (B) Representative traces displaying the level of aggregation obtained 
when human isolated platelets were treated (for 5 minutes) with a vehicle control [0.1% (v/v) DMSO] or various 
concentrations of flavones, F-1, TF-1, CYC-1 and TCYC-1 (3.125–100 µM) and 0.5 µg/mL CRP-XL. (C) Bar 
graphs show the percentage of aggregation obtained in the presence and absence of different concentrations of 
flavones, F-1, TF-1, CYC-1 and TCYC-1. The data were normalised by considering the maximum aggregation 
observed for the vehicle control at 5 minutes as 100%, and the level of inhibition in flavone and its derivatives-
treated platelet samples was calculated accordingly. Cumulative data denote mean ± S.D. (n = 3). The p values 
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Flavones with furan B-ring. Hydroxy flavone (F-3) and hydroxy 4-thioflavone (TF-3) inhibited the 
CRP-XL-induced platelet activation at all the concentrations tested, however, the methoxy flavone (CYC-3) and 
the methoxy 4-thioflavone (TCYC-3) failed to inhibit the aggregation (Fig. 3A–C).
Flavones with pyridine B-ring. None of the flavones with a pyridine B-ring displayed inhibitory effects on 
CRP-XL-stimulated platelet aggregation (Fig. 4A–C) at concentrations up to 100 µM.
It is interesting to note the impact of altering the B-ring on the platelet activity among the same class of 
flavones. For hydroxy flavones (with –OH and 4-C=O), changing the phenyl group (F-1) to a thiofuran group 
(F-2) did not affect the inhibitory potential as both compounds elicited the inhibitory activity up to 12.5 µM. 
Consistent inhibition (~65–70%) across the tested concentrations (3.125–100 µM) was observed when the phenyl 
group was replaced with a furan group (F-3). In contrast, substitution of the phenyl group with a pyridine group 
led to a complete abolition of inhibitory activity in platelets (F-4). A similar trend was observed for the hydroxy 
4-thioflavones (with –OH and 4-C=S) when the B-ring phenyl group was replaced with its bioisosteres furan 
and pyridine. However, the substitution of thiofuran led to a reduction in the activity, for example, TF-2 showed 
~50% inhibition only at 100 µM (Fig. 2) where its phenyl analogue, TF-1 elicited ~50% inhibition at all the con-
centrations used (Fig. 1).
The influence of B-ring modifications was not conspicuous among the methoxy flavones (with –OMe and 
4-C=O) and methoxy 4-thioflavones (with –OMe and 4-C=S) as these two classes of flavones did not display 
any significant inhibitory activity on platelets in comparison to their hydroxyl analogues. Nevertheless, amongst 
the methoxy flavones, flavones with a B ring phenyl group (CYC-1) or thiofuran group (CYC-2) showed similar 
Figure 2. Effect of flavones with thiofuran B-ring on human platelet activation. (A) Chemical structures of the 
flavones, F-2, TF-2, CYC-2 and TCYC-2. (B) Representative traces showing the level of aggregation obtained 
when human isolated platelets were treated (for 5 minutes) with a vehicle control [0.1% (v/v) DMSO] or diverse 
concentrations of flavones, F-2, TF-2, CYC-2 and TCYC-2 (3.125–100 µM) and 0.5 µg/mL CRP-XL. (C) Bar 
graphs show the percentage of aggregation obtained in the presence and absence of various concentrations of 
flavones, F-2, TF-2, CYC-2 and TCYC-2. The data were normalised by considering the maximum aggregation 
observed for the vehicle control at 5 minutes as 100%, and the level of inhibition in flavone and its derivatives-
treated platelet samples was calculated accordingly. Cumulative data denote mean ± S.D. (n = 3). The p values 
displayed (*p < 0.05, **p < 0.01 and ***p < 0.001) are as analysed by one-way ANOVA using Graphpad Prism.
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activities with inhibition only at 100 µM. Methoxy 4-thioflavones (with –OMe and 4-C=S) did not exert any 
inhibitory effects on platelets.
To corroborate the above results, the effects of these flavones on another platelet activation marker, specifically 
fibrinogen binding (a marker for inside-out signalling to integrin αIIbβ3), were measured by flow cytometry. The 
results obtained from this experiment concur with the aggregation data where hydroxy flavones F-1 (at 3.125–
12.5 µM), F-2 (at 3.125–12.5 µM) and F-3 (at all concentrations tested), as well as thiohydroxy flavones TF-1 (at all 
concentrations tested), TF-2 (at 100 µM) and TF-3 (at all concentrations tested) significantly inhibited fibrinogen 
binding (Fig. S1), which is critical for subsequent platelet aggregation.
Finally, to determine whether the platelet inhibition observed was the result of a specific pharmacological 
effect of flavones rather than due to their cytotoxic effects, an LDH cytotoxicity assay was performed. For this, 
platelets were treated with a vehicle control [0.1% (v/v) DMSO] or diverse concentrations of flavones (3.125, 6.25, 
12.5, 25, 50 and 100 µM) and the release of LDH, a cytosolic enzyme, which is an indicator of cellular toxicity was 
measured. As shown in Fig. 5, a positive control showed the maximum level of cytotoxicity with a higher LDH 
release, whereas the flavones did not exert cytotoxic effects at the concentrations (3.125–100 µM) used. These 
observations suggest that the inhibitory effects of flavones demonstrated in this study were not due to their cyto-
toxic effects on platelets.
Figure 3. Effect of flavones with furan B-ring on human platelet activation. (A) Chemical structures of the 
flavones, F-3, TF-3, CYC-3 and TCYC-3. (B) Representative traces displaying the level of aggregation obtained 
when human isolated platelets were treated (for 5 minutes) with a vehicle control [0.1% (v/v) DMSO] or various 
concentrations of flavones, F-3, TF-3, CYC-3 and TCYC-3 (3.125–100 µM) and 0.5 µg/mL CRP-XL. (C) Bar 
graphs display the percentage of aggregation obtained in the presence and absence of diverse concentrations of 
flavones, F-3, TF-3, CYC-3 and TCYC-3. The data were normalised by considering the maximum aggregation 
observed for the vehicle control at 5 minutes as 100%, and the level of inhibition in flavone and its derivatives-
treated platelet samples was calculated accordingly. Cumulative data denote mean ± S.D. (n = 3). The p values 
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Discussion
Understanding the relationship between distinct functional groups within the structures of flavones and their 
influence on antiplatelet activity is critical for further development and modification of flavones in order to make 
them as more potent lead compounds for drug design. Such knowledge will aid in the development of improved 
therapeutic strategies for the prevention and treatment of cardiovascular disesaes, specifically thrombosis. In the 
present study, the analysis and comparison of the inhibitory activities of a series of 16 structurally-related syn-
thetic flavones on CRP-XL-stimulated human platelet activation highlighted the key structural features that are 
required for the inhibition of platelet function.
In general, comparison between different classes of flavones with the same B-ring moiety suggested that the 
hydroxy flavones (with free -OH groups) were more effective than their corresponding methoxy flavones (with 
-OCH3 group). This highlighted that hydroxy groups, which are hydrogen bond donors, are essential for their 
inhibitory activities in platelets and that methoxy groups with hydrogen bond accepting profiles are less effective 
in this regard. However, the study by Bojić et al.34 reports increased anti-aggregatory potencies of O-methylated 
derivatives in comparison to their hydroxy analogues. This disparity could possibly be due to the difference in 
the hydroxyl substitution pattern of the flavones studied which would affect the interaction with the molecular 
target. In addition, several previous studies reported the loss of biological activity of flavonoids upon complete 
methylation of their active hydroxy groups29,35,36. Together with these previous studies, our data suggest that 
hydroxy groups are a key descriptor for the biological activity of flavonoids. It is worth highlighting that the 
hydroxy flavones used in this study possess hydroxyl groups at the C-7,8 position as opposed to the C-5,7 posi-
tion in chrysin, a natural flavone that was previously reported to negatively modulate platelet activity37. When 
comparing the activity between chrysin and its 7,8-hydroxy analogue (F-1), it can be deduced that the position of 
the hydroxyl groups also influences platelet function as chrysin exhibited dose-dependent inhibition of platelet 
Figure 4. Effect of flavones with pyridyl B-ring on human platelet activation. (A) Chemical structures of the 
flavones, F-4, TF-4, CYC-4 and TCYC-4. (B) Representative traces showing the level of aggregation obtained 
when human isolated platelets treated (for 5 minutes) with a vehicle control [0.1% (v/v) DMSO] or various 
concentrations of flavones, F-4, TF-4, CYC-4 and TCYC-4 (3.125–100 µM) and 0.5 µg/mL CRP-XL. (C) Bar 
graphs show the percentage of aggregation obtained with flavones, F-4, TF-4, CYC-4 and TCYC-4. The data 
were normalised by considering the maximum aggregation observed for the vehicle control at 5 minutes 
as 100%, and the level of inhibition in flavone and its derivatives-treated platelet samples was calculated 
accordingly. Cumulative data denote mean ± S.D. (n = 3).
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activity (6.25–100 µM)38, whereas, 7,8- hydroxyl flavone showed inhibition only between 3.25–12.5 µM. Further 
studies are required to determine the reasons for the low inhibitory effects obtained from higher concentrations 
of hydroxyl flavones with phenyl and thiofuran B-rings.
Figure 5. Cytotoxicity profile of flavones in human platelets. Human isolated platelets were treated with a 
positive control, or a vehicle control [0.1% (v/v) DMSO] or various concentrations (3.125–100 µM) of flavones, 
F-1, TF-1, CYC-1 and TCYC-1 (A), F-2, TF-2, CYC-2 and TCYC-2 (B), F-3, TF-3, CYC-3 and TCYC-3 (C) 
and F-4, TF-4, CYC-4 and TCYC-4 (D) for 30 minutes and the release of LDH, a marker for cytotoxicity was 
measured at 490 and 650 nm using spectrofluorimeter. The LDH release attained with the positive control 
was considered as 100%, and the levels of LDH release for flavone-treated samples were calculated. The data 
represent mean ± S.D. (n = 3). Statistical significance was analysed by one-way ANOVA using Graphpad Prism.
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A number of previous studies have reported the significance of 4-C=O in the C-ring of flavonoids for anti-
platelet activities based on the comparison between flavonoids with and without 4-C=O32,34,39. In this study, 
the influence of modification of 4-C=O to 4-C=S was also evaluated. Indeed, the replacement of 4-C=O with 
4-C=S was well tolerated for flavones with free hydroxy groups (hydroxy flavones and hydroxy 4-thioflavones), 
however, no beneficial effects were observed for flavones with methoxy groups (methoxy flavones and methoxy 
4-thioflavones). It is interesting to note that the influence of 4-C=S was also found to be dependent on the B-ring 
functionality as moderate loss of inhibitory activity was observed upon the replacement of 4-C=O with 4-C=S 
for flavones with a thiofuran B-ring. This demonstrates that the systematic analysis of flavones through careful 
correlation of effect of each substitution with respect to other functional groups is important for better optimisa-
tion of these compounds as molecular templates for drug design and discovery.
Natural flavonoids contain a phenyl group as the B-ring, hence, previous reports have focused on the influ-
ence of the position of the B-ring and its hydroxylation patterns. The present study involving synthetic flavonoids 
allowed the determination of the effect of incorporating bioisosteres of the phenyl group. It was found that replac-
ing the phenyl group with a furan group was well tolerated for hydroxy flavones and hydroxy 4-thioflavones, 
whereas replacement of a phenyl group with a thiofuran group led to loss of inhibitory activities in platelets 
for hydroxy 4-thioflavones but was tolerated for hydroxy flavones. Conversely, replacement of the phenyl group 
with a pyridine group led to complete loss of inhibition in platelets. These observations suggest that the B-ring 
phenyl group is not critical for the antiplatelet activity, but the B-ring heteroatoms largely influence the activity. 
Furthermore, these observations suggest that the orientation and binding modes of the B-ring moieties might 
influence the interaction with their molecular targets. Hence, identification of the molecular targets for these fla-
vones, and careful optimisation of the nature of the B-ring could lead to more efficacious flavone scaffolds for the 
development of novel antiplatelet agents. Furthermore, the hydroxy flavones and thiohydroxy flavones showed 
significant inhibitory effects on fibrinogen binding, a key marker for platelet activation via inside-out signalling 
to integrin αIIbβ3. This suggests that these flavones specifically with free hydroxy groups may modulate distinc-
tive functions of platelets. The LDH cytotoxicity assay showed that these flavones are not cytotoxic to platelets at 
the concentrations tested and hence the inhibitory effects observed are due to their pharmacological effects on 
platelet function.
In conclusion, a panel of 16 structurally-related hydroxy flavones, methoxy flavones and their 4-thio ana-
logues were screened for their antiplatelet activity upon CRP-XL-induced activation in human platelets. SAR 
analysis of these flavones suggested that the free hydroxyl group is essential for antiplatelet activity. Moreover, the 
modification at 4-C=O to 4-C=S in the C-ring, and B-ring modifications of phenyl group into specific bioisostere 
such as furanyl group, are well tolerated without any significant loss of their inhibitory activities. The molecular 
targets and the impact of these synthetic flavones on specific signalling pathways in platelets were not investigated 
in this study. Since the natural flavonoids posses broad spectrum of binding affinities and inhibitory activities 
against numerous cellular targets, the synthetic flavones with higher specificity for selective targets may be ben-
eficial in achieving targeted effects. Therefore, further studies will be required to underpin the impact of these 
synthetic flavones with specific functional groups on various molecular targets in platelets. Together, the results 
obtained in this study with synthetic flavones enhance the current understanding of the SAR of flavones with 
human platelets and may aid in the design and development of novel anti-thrombotic strategies using flavones as 
potential molecular templates.
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Key Points
• LL37 primes platelet
function and augments
thrombus formation.
• LL37 mainly acts
through FPR2/ALX in
platelets.
Platelet-associated complications including thrombosis, thrombocytopenia, andhemorrhage
are commonly observed during various inflammatory diseases such as sepsis, inflammatory
bowel disease, and psoriasis. Despite the reported evidence on numerous mechanisms/
molecules that may contribute to the dysfunction of platelets, the primary mechanisms
that underpin platelet-associated complications during inflammatory diseases are not fully
established. Here, we report the discovery of formyl peptide receptor 2, FPR2/ALX, in
platelets and its primary role in the development of platelet-associated complications via
ligation with its ligand, LL37. LL37 acts as a powerful endogenous antimicrobial peptide,
but it also regulates innate immune responses. We demonstrate the impact of LL37 in the
modulation of platelet reactivity, hemostasis, and thrombosis. LL37 activates a range of
platelet functions, enhances thrombus formation, and shortens the tail bleeding time in
mice. By utilizing a pharmacological inhibitor and Fpr2/3 (an ortholog of human FPR2/ALX)–
deficient mice, the functional dependence of LL37 on FPR2/ALX was determined. Because the
level of LL37 is increased in numerous inflammatory diseases, these results point toward a
critical role for LL37 and FPR2/ALX in the development of platelet-related complications in
such diseases. Hence, a better understanding of the clinical relevance of LL37 and FPR2/ALX in
diverse pathophysiological settings will pave the way for the development of improved
therapeutic strategies for a range of thromboinflammatory diseases.
Introduction
Platelets play pivotal roles in the regulation of hemostasis; however, their unwarranted activation
under pathological conditions leads to the formation of blood clots (thrombosis) within the circulation,
which is a major cause of premature death.1-3 Platelets also play significant roles in the regulation of
innate immunity, inflammatory responses, and microbial infection.4,5 The activation of platelets during
inflammatory diseases induces the formation of blood clots or disseminated intravascular coagulation in
capillaries, resulting in the blockage of blood supply to tissues.6,7 Moreover, platelet activation results in
the aggregation and sequestration of platelets, instigating thrombocytopenia.8,9 Several mechanisms
that contribute to platelet dysfunction under inflammatory diseases have been reported10; however, the
primary molecular mechanisms that underpin platelet activation are not fully understood.
LL37 is the only cathelicidin known to be expressed in human cells.11 It acts as a powerful antimicrobial
peptide against bacteria,12 fungi,13 and viral particles14 and modulates innate and adaptive immune
responses predominantly through formyl peptide receptor 2 (FPR2/ALX).15,16 Despite detailed
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research on the roles of LL37 in the modulation of inflammatory
responses in various pathological settings,17,18 its effects in the
regulation of thrombosis and other platelet-related complica-
tions remained unknown for a long time. Because the level of
LL37 released during inflammation is significantly higher than
normal,19,20 understanding its critical functions in the modulation
of platelet reactivity will pave the way for determining fundamental
mechanisms underlying platelet-related complications in various
inflammatory diseases. Immediately prior to the submission of
this manuscript, Pircher et al21 demonstrated the ability of LL37
to prime circulating platelets and induce thromboinflammation.
Although they have established a significant functional impact of
LL37 in platelets, its actions via FPR2/ALX were not determined.
In this study, we report the effects of LL37 on a range of platelet
functional assays and establish its roles in the modulation of
platelet reactivity, thrombosis, and hemostasis. Moreover, by using
pharmacological tools and Fpr2/3-deficient mice, we have
established the functional dependence of LL37 on FPR2/ALX in
platelets.
Methods
The University of Reading Research Ethics Committee approved all
the experimental procedures using human blood from healthy
volunteers. The mouse strains of Fpr12/222 and Fpr2/32/223 on
a C57BL/6 background obtained from William Harvey Research
Institute (London, United Kingdom) and control C57BL/6 mice
from Envigo (United Kingdom) were used in this study. Detailed
methods for the preparation of platelets, immunoblotting, enzyme-
linked immunosorbent assay (ELISA), immunocytochemistry, in vitro
thrombus formation, tail bleeding, platelet aggregation, dense granule
secretion, platelet spreading, calcium mobilization, cytotoxicity and
flow cytometry-based assays, mass spectrometry, molecular docking,
and statistical analyses are provided in the supplemental Methods.
Results
Platelets store LL37 and release it upon activation
The expression of LL37 has been reported in several cell types
including neutrophils where it is mainly stored in granules.24,25 By
using immunofluorescence microscopy, we determined the pres-
ence of LL37 in human platelets (Figure 1A). Furthermore, resting
and cross-linked collagen-related peptide (CRP-XL) (a glycoprotein
VI [GPVI]-selective agonist) (1 mg/mL)–activated human platelets
were centrifuged, and the supernatant and pellet were used in
ELISA to determine the release of LL37 from platelets. In the resting
state, the level of LL37 was significantly higher in the pellet (15596
433 pM) compared with the supernatant (41 6 12 pM) (Figure 1B).
However, upon activation of platelets with CRP-XL, the presence of
LL37was significantly increased in the supernatant (14906581.7 pM)
compared with the pellet (59 6 7.6 pM). Similar results were
obtained upon the activation of platelets with collagen (acts via GPVI
and integrin a2b1) or TRAP-6 (acts via PAR1). To corroborate these
results, the release of LL37 in human platelet-poor plasma (PPP) or
platelet-rich plasma (PRP) was investigated by mass spectrometry.
The level of LL37 was stable and significantly increased in PRP
compared with PPP over 2 hours, indicating its release; by contrast,
the level of LL37 was significantly reduced in PPP (Figure 1C).
Together, these data confirm the presence of LL37 in platelets
(between picomolar and nanomolar concentrations) and its release
upon platelet activation.
LL37 augments thrombus formation and
affects hemostasis
To determine whether LL37 has a direct influence on thrombotic
complications during inflammatory diseases, its effects on thrombus
formation under arterial flow conditions were investigated.26,27
LL37 (10, 20, and 50 mM) significantly increased the thrombus
formation (Figure 1Di) and the mean fluorescence intensity in a
concentration-dependent manner (Figure 1Dii). The highest con-
centration of LL37 (50 mM) increased the thrombus intensity by
;70% compared with the vehicle-treated samples (Figure 1Diii).
Moreover, LL37 affected hemostasis in mice as determined by a tail
bleeding assay. A mean bleeding time of 370.8 6 46.6 seconds
was observed in the vehicle-treated group; however, the infusion
of LL37 significantly shortened the bleeding time to a mean of
225.2 6 18.8 seconds (Figure 1E).
LL37 induces platelet activation
To further determine the impact of LL37 in distinctive platelet
functions, additional assays were performed. Human isolated
platelets were treated with a vehicle or LL37 (5, 10, and 20 mM),
and the level of aggregation was monitored by optical aggregometry.
LL37 directly induced platelet aggregation in a concentration-
dependent manner, notably, 20 mM LL37 induced 100% aggrega-
tion (Figure 1F). In line with a recent study,21 in our experiments, LL37
failed to induce aggregation in human PRP (supplemental Figure 1).
Similarly, to determine whether LL37 influences inside-out signaling
to integrin aIIbb3 and a-granule secretion, the level of fibrinogen
binding and P-selectin exposure was measured respectively
using human isolated platelets and PRP by flow cytometry. LL37
increased the level of fibrinogen binding in human isolated
platelets (Figure 2Ai) and PRP (Figure 2Aii) in a concentration-
dependent manner. Similarly, the level of P-selectin exposure was
increased by LL37 in isolated platelets (Figure 2Bi) and PRP
(Figure 2Bii). Moreover, the ability of LL37 to induce plate-
let spreading on immobilized fibrinogen (Figure 2C) was
analyzed as a marker for integrin aIIbb3-mediated outside-in
signaling. LL37 (5, 10, and 20 mM) significantly increased the
number of adhered (Figure 2Ci) and spread (Figure 2Cii) platelets,
and the relative surface area (Figure 2Ciii) compared with their
controls. Furthermore, to assess the effects of LL37 in calcium
mobilization, intracellular calcium levels were measured in human
isolated platelets. LL37 induced calcium mobilization with a
maximum level achieved with 50 mM. The level of calcium release
obtained with 50 mM LL37 is similar to that obtained with CRP-XL
(1 mg/mL), although the initial kinetics of calcium release
appeared to be faster for LL37 (Figure 2D). These data confirm
that LL37 triggers distinctive platelet functions.
LL37 does not exhibit cytotoxic effects in platelets
A previous study28 reported the inhibitory effects of LL37 in platelets
at exceptionally high concentrations (0.1-1.2 mM). It has been shown
previously that LL37 exhibits cytotoxic effects in neutrophils and
monocytes at concentrations higher than 50 mM.29 To determine
whether the concentrations of LL37 used in this study (#50 mM)
exhibit any cytotoxic effects in platelets, lactate dehydrogenase
cytotoxicity assay was performed. The concentrations of LL37 used
here (1-50 mM) failed to exert any cytotoxic effects in human isolated
platelets, although 100 mM LL37 displayed significant toxicity
(Figure 2E). These results confirm that LL37 concentrations up to
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50 mM do not display any toxic effects in platelets, although higher
concentrations may exhibit cytotoxic effects.
LL37 activates platelets selectively through FPR2/ALX
Numerous studies indicate that LL37 acts primarily through
FPR2/ALX to exert its effects in immune cells.16,30,31 The expression
of FPR2/ALX in megakaryocytes and human and mouse platelets at
the transcript level has been reported previously.32,33 Here, the
presence of FPR2/ALX in human platelets remained unchanged in
resting and CRP-XL (1 mg/mL)–activated platelets as confirmed by
immunoblots (Figure 3Ai), although the activation increased the surface
level as determined by flow cytometry (Figure 3Aii). Moreover, the
presence of Fpr2/3 (an ortholog to human FPR2/ALX) in control, and its
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Figure 1. Presence of LL37 in platelets and its impact on thrombus formation, hemostasis, and platelet activation. (A) Human platelets were treated with primary
antibodies against LL37 and appropriate fluorescent-labeled secondary antibodies (purple) and phalloidin (green) and analyzed by confocal microscopy (magnification 3100;
bar represents 10 mm). Images shown are representative of 3 independent experiments. (B) the level of LL37 in resting and activated (1 mg/mL CRP-XL, 1 mg/mL collagen or
10 mM thrombin receptor activator peptide 6 [TRAP-6]) platelet pellets and supernatants (SNs) was measured by ELISA using LL37-selective antibodies. Data represent
mean 6 standard error of the mean (SEM) (n 5 5). (C) The stability/release of LL37 in human plasma was analyzed by mass spectrometry (liquid chromatography mass
spectrometry [LC-MS]). Graph represents the intensities of LL37 (100 mg/mL) spiked in PRP and PPP at different time points over 120 minutes. Control represents the
intensity of LL37 at 100 mg/mL (unspiked). Data represent mean 6 SEM (n 5 3). (D) The effects of LL37 in the modulation of thrombus formation. Human DiOC6-labeled
whole blood was preincubated with a scrambled peptide (SC) or LL37 (10, 20, and 50 mM) for 10 minutes prior to perfusion over collagen-coated (400 mg/mL) Vena8
Biochips. Images (i) (at 10 minutes) shown are representative of 3 separate experiments (magnification 310; bar represents 10 mm). Data (ii-iii) represent mean 6 SEM
(n 5 3). (E) The impact of LL37 (20 mM) on the modulation of hemostasis. C57BL/6 mice (10-12 weeks old) were anesthetized 20 minutes before the infusion of a scrambled
peptide or LL37 (20 mM) via femoral artery 5 minutes before the dissection of 1 mm of tail tip, and monitoring of time to cessation of bleeding. Data represent mean 6 SEM
(n 5 6 per group). (F) The effects of LL37 on platelet activation were measured by optical aggregometry using human isolated platelets. Data represent mean 6 SEM (n 5 6).
The statistical significance was established by 1-way analysis of variance (ANOVA) followed by Bonferroni’s correction in most of the experiments except the data shown
in panels B and E, which were analyzed by 2-tailed unpaired Student t test and nonparametric Mann-Whitney U test, respectively (*P , .05; **P , .01).
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To determine the functional dependence of LL37 on FPR2/ALX, the
binding of LL37 to the platelet surface was confirmed using a
fluorescently labeled LL37 (5-FAM-LC-conjugated LL37) by flow
cytometry. 5-FAM-LL37 (20 mM) displayed marked binding to the
surface of human platelets compared with a fluorescently labeled
scrambled LL37 (5-FAM-conjugated sc-LL37) (Figure 3Bi). Similarly,
LL37 (20 mM) binding was analyzed using platelets obtained from
control, Fpr1-, or Fpr2/3-deficient mice. The control and Fpr12/2
mouse platelets exhibited significant binding to 5-FAM-LL37 com-
pared with Fpr2/32/2 (Figure 3Bii). In addition to LL37, mCRAMP
(mouse ortholog of LL37) was also investigated for the binding to
mouse platelets, and indeed, the level of mCRAMP binding was
reduced in Fpr2/32/2 mouse platelets compared with the controls
(Figure 3Biii). The interactions between LL37 and FPR2/ALX were
examined by molecular docking analysis, which predicted that LL37
peptide forms prominent hydrogen bonds with key residues such as
Gln-89, Ser-182, Asn-285, and Gly-275 of FPR2/ALX that are
identified as crucial for receptor activation (Figure 3Biv; Table 1).
The functional dependence of LL37 on FPR2/ALX was analyzed by
using a range of platelet functional assays. The activatory effects of
LL37 (5-50 mM) were substantially reduced in Fpr2/32/2 mouse
platelets both in isolation (Figure 3Ci,Di) or whole blood
(Figure 3Cii,Dii) compared with the controls as analyzed by
fibrinogen binding and P-selectin exposure. Notably, the character-
ization of platelets obtained from Fpr2/32/2mice failed to display any
defects in size and number of platelets or the levels of major platelet
receptors such as GPVI (Figure 3Ei), glycoprotein Iba (GPIba)
(Figure 3Eii), aIIbb3 (Figure 3Eiii), and a2b1 (Figure 3Eiv) compared
with the control mouse platelets. To corroborate these results,
platelet functional assays were performed in the presence of a
selective FPR2/ALX antagonist, WRW4 (WRWWWW), in human
and mouse platelets. The addition of WRW4 (5 mM) in human
isolated platelets before activation with 20 mM LL37 inhibited platelet
aggregation by ;40% (Figure 3F). Similarly, the effects of LL37
(20 mM) on fibrinogen binding (Figure 3Gi) and P-selectin exposure
(Figure 3Gii) were significantly reduced in WRW4 (5 mM)–treated
mouse platelets. These data demonstrate the involvement of FPR2/
ALX in the regulation of LL37-mediated effects in platelets.
FPR2/ALX regulates normal platelet activation
To validate the importance of FPR2/ALX in the regulation of normal
platelet activation, further experiments were performed using human
isolated platelets in the presence or absence of WRW4. CRP-XL
(0.25 mg/mL)–induced platelet aggregation was significantly
reduced in the presence of WRW4 (2.5-20 mM). The inhibition of
FPR2/ALX with WRW4 (20 mM) reduced the platelet aggregation
by ;89% (Figure 4A). Similar results were obtained with adenosine
59-diphosphate (ADP)–induced platelet aggregation, wherein
WRW4 (20mM) inhibited 75% of aggregation (Figure 4B). Moreover,
dense granule secretion (evidenced by adenosine triphosphate
release) was significantly reduced in the presence of WRW4
(Figure 4C). The platelet activation was also assessed using whole
blood obtained from control and Fpr2/32/2 mice upon stimulation
with conventional platelet agonists such as CRP-XL, ADP, AY-NH2
(activates protease activated receptor, PAR4), and U46619, an
analog of thromboxane A2 by measuring the levels of fibrinogen
binding and P-selectin exposure. Similar to human platelets, the
activation of platelets obtained from Fpr2/32/2mice upon stimulation
with CRP-XL (Figure 4D), ADP (Figure 4E), AY-NH2 (Figure 4F),
and U46619 (Figure 4G) was significantly reduced compared
with the controls. Additionally, preincubation of human platelets
with WRW4 (1.25-20 mM) significantly decreased the number of
adhered (Figure 5Ai) and spread (Figure 5Aii) platelets, and the relative
surface area (Figure 5Aiii). The impact of Fpr2/3 on the modulation of
hemostasis in mice was determined by tail bleeding assay. A mean
bleeding time of 428.5 6 64.8 seconds was observed in the control
group; however, Fpr2/3-deficient mice significantly increased the
bleeding time to a mean of 1128 6 71.9 seconds (Figure 5B).
Together, these data emphasize the impact of FPR2/ALX on the
regulation of normal platelet function through a positive feedback
mechanism (may be through LL37), and thus the inhibition or deletion
of this receptor results in diminished platelet function in general.
FPR2/ALX exerts its effects through
cAMP-dependent signaling
FPRs are Gi-coupled receptors,34 which are known to inhibit adenylate
cyclase, reducing the level of cAMP, a known inhibitor of platelet
function. Therefore, the deletion of Gi-coupled receptor genes in mice
increases the basal cAMP levels in target cells.35,36 To investigate
whether the inhibition of FPR2/ALX in human or deletion of Fpr2/3 in
mouse platelets is influenced by the cAMP-dependent signaling, the
level of cAMP was quantified in platelets. The inhibition of FPR2/ALX
with WRW4 (20 mM) significantly elevated the cAMP levels com-
pared with the controls in human platelets (Figure 5Ci). Similarly,
resting Fpr2/32/2 mouse platelets exhibited elevated basal levels of
cAMP comparedwith the controls (Figure 5Cii). In order to corroborate
this data, we investigated the phosphorylation of the vasodilator-
stimulated phosphoprotein (VASP), a substrate for protein kinase
A that is involved in the regulation cAMP-mediated signaling. The
treatment of platelets with an FPR2/ALX-selective inhibitor, WRW4,
increased the phosphorylation of Ser157-VASP (Figure 5Di).
Similarly, Fpr2/32/2 mouse platelets demonstrated increased
phosphorylation of Ser157-VASP compared with control mouse
platelets (Figure 5Dii).
Discussion
LL37 is a powerful antimicrobial peptide that plays substantial roles
in the initiation of chemotaxis and subsequent inflammatory
Figure 2. The impact of LL37 on platelet activation, spreading, and calcium mobilization. (A) The level of fibrinogen binding was analyzed using fluorescein
isothiocyanate–conjugated fibrinogen antibodies by flow cytometry in human isolated platelets (i) or PRP (ii). (B) Similarly, the level of P-selectin exposure was measured in
human isolated platelets (i) or PRP (ii) using PECy5-labeled P-selectin antibodies. Data represent mean 6 SEM (n 5 3). (C) Platelet adhesion and spreading on immobilized
fibrinogen was analyzed using platelets treated with LL37 (5, 10, and 20 mM) by confocal microscopy (magnification 360; bar represents 10 mm). The number of adhered (i)
and spread (ii) platelets, and the relative surface area of spread platelets (iii) was determined via analyzing the images using ImageJ. Ten random fields of view were recorded
and analyzed for each sample. Data represent mean 6 SEM (n 5 3). (D) Ca21 mobilization was measured using Fluo-4 AM dye-loaded human isolated platelets upon
stimulation with LL37 by spectrofluorimetry. Data represent mean of maximum level of Ca21 6 SEM (n 5 4). (E) The cytotoxic effects of LL37 were measured in human
isolated platelets using a lactate dehydrogenase cytotoxicity assay kit. Data represent mean 6 SEM (n 5 4). The statistical significance was established by 1-way ANOVA
followed by Bonferroni’s correction (*P , .05; **P , .01; ***P , .001).
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responses in immune cells including monocytes,16 mast cells,37
eosinophils, and neutrophils.38 Moreover, the involvement of LL37
in the development of pathological conditions such as sepsis,
inflammatory bowel disease, psoriasis, and cystic fibrosis has been
previously reported, and hence, its therapeutic potential has been
analyzed in detail.39 LL37 has also been found to play a role in
the pathogenesis of atherosclerosis,40,41 wherein it leads to the
development of lesions and recruitment of inflammatory cells at the
site of injury.18 However, the role of LL37 in the modulation of
thrombosis and hemostasis has not been investigated until recently.
Immediately prior to the submission of this manuscript, a recent
study demonstrated the functional impact of LL37 in priming
platelets and inducing thromboinflammatory conditions, although
the molecular mechanisms that regulate such effects were not
fully established.21 However, in this study, we have investigated the
impact of LL37 in the modulation of platelet reactivity, thrombosis,
and hemostasis under physiological conditions and uncovered the
functional dependence of LL37 on FPR2/ALX in platelets.
The expression of LL37 has been reported in numerous cell types





































































































































































































Figure 3. Expression of FPR2/ALX in platelets and its influence on LL37-mediated platelet activation. The presence of FPR2/ALX was confirmed in human (Ai) and
mouse (Aiii) platelet lysates by immunoblot analysis using selective antibodies. The blots are representative of 3 separate experiments. The expression of FPR2/ALX on the
surface of resting or activated (1 mg/mL CRP-XL) human platelets was analyzed using FPR2/ALX-selective and fluorescent-labeled secondary antibodies by flow cytometry
(Aii). Data represent mean 6 SEM (n 5 4). The binding of LL37 to platelets was analyzed by flow cytometry. Human isolated platelets were incubated with 20 mM
5-FAM-LC-conjugated LL37 (FL-LL37) or scrambled LL37 (FL-scLL37), and the level of binding was analyzed by flow cytometry (Bi). Data represent mean 6 SEM (n 5 4).
Similarly, platelets obtained from control, Fpr2/32/2, and Fpr12/2 mice were analyzed with 20 mM 5-FAM-LC-conjugated LL37 or scrambled 5-FAM-LC-LL37 (Bii). Data
represent mean 6 SEM (n 5 7). Similarly, platelets obtained from control or Fpr2/32/2 mice were analyzed with 20 mM 5-FAM-conjugated mCRAMP or scrambled 5-FAM-
mCRAMP (Biii). Data represent mean 6 SEM (n 5 4). The interactions between LL37 and FPR2/ALX were analyzed through structural modeling and molecular docking
analysis (Biv). (C) The level of fibrinogen binding upon stimulation with LL37 in isolated platelets (i) or whole blood (ii) obtained from Fpr2/32/2 or control mice was analyzed by
flow cytometry. Data represent mean 6 SEM (n 5 10 for panel Ci; n 5 8 for panel Cii). (D) Similarly, the level of P-selectin exposure was analyzed using isolated platelets (i) or
whole blood (ii) from these mice. Data represent mean 6 SEM (n 5 10 for panel Di; n 5 13 for panel Dii). (E) The expression levels of major platelet receptors such as GPVI
(i), GPIba (ii), aIIbb3 (iii), and a2b1 (iv) in platelets obtained from Fpr2/32/2 and control mice were analyzed by flow cytometry using selective fluorescent-labeled antibodies.
Data represent mean 6 SEM (n 5 8 per group). (F) The effect of a selective inhibitor for FPR2/ALX, WRW4 (5 mM), on LL37-induced platelet activation was measured by
optical aggregometry. Data represent mean 6 SEM (n 5 3). (G) Mouse isolated platelets were stimulated with LL37 (20 mM) in the presence or absence WRW4 (5 mM),
and the level of fibrinogen binding (i) and P-selectin exposure (ii) were analyzed by flow cytometry. Data represent mean 6 SEM (n 5 4). The statistical significance was
calculated using 1-way ANOVA followed by Bonferroni’s correction in most of the experiments except for the data shown in panels Aii, B, and E-G, where a 2-tailed unpaired
Student t test was used (*P , .05; **P , .001; ***P , .0001).
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and monocytes.42 Because platelets are also derived from the
myeloid lineage,43 we hypothesized that platelets may possess
LL37, and indeed the presence of LL37 in platelets and its
release to the external milieu upon activation were confirmed in
this study. Similar to neutrophils, platelets may also contain LL37
in their granules and release it upon stimulation to increase its
concentration at the local environment and enhance the second-
ary activation of platelets toward augmentation of thrombosis.
A recent study21 also reported the elevated level of LL37 in
the microenvironment of arterial thrombi in human and mice.
Platelets are known to contain several antimicrobial peptides
and release them upon activation during microbial infection.44
Similarly, platelets may contribute to the release of LL37 upon
activation to support the microbial clearance, activation of in-
flammatory responses, and modulation of thrombosis and hemo-
stasis during pathological settings. Although the activation of
platelets during inflammatory diseases is inevitable because of the
presence of several molecules that activate platelets,45 here we
demonstrate LL37 as a major contributor to platelet activation and
thrombus formation.
Thrombosis and subsequent bleeding are associated with various
inflammatory diseases.46 Similarly, disseminated intravascular co-
agulation, thrombosis in the microvasculature, and sequestration
of platelets are some of the common clinical manifestations in
sepsis.47 The level of LL37 is significantly increased in psoriasis48
and sepsis49 patients compared with healthy individuals. In line
with thrombosis in vasculature, LL37 augmented in vitro thrombus
formation and shortened the bleeding time in mice. These data
demonstrate a fundamental function for LL37 in the modulation
of thrombosis and hemostasis. Similarly, LL37 induced platelet
aggregation, fibrinogen binding, granule secretion, adhesion,
spreading, and intracellular calcium mobilization in platelets. Pircher
et al21 also demonstrated the functional impact of LL37 on arterial
thrombosis and platelet granule secretion. In line with this previous
study, we also did not observe the ability of LL37 to induce platelet
aggregation in PRP, although it displayed aggregation in human
isolated platelets. Similarly, the previous study has failed to detect
a response for LL37 on integrin aIIbb3 activation and platelet
spreading on a fibrinogen-coated surface. In our study, however,
we demonstrate the ability of LL37 to increase fibrinogen binding
and platelet spreading. Surprisingly, the previous study failed
to detect integrin aIIbb3 activation. However, we have directly
measured the level of fibrinogen binding in isolated platelets,
PRP, and whole blood with a range of concentrations of LL37
(ie, up 50 mM), whereas they have measured PAC-1 binding in
isolated platelets using LL37 concentrations of only up to 5 mM.
It is unclear why these discrepancies occur between the
previously reported data and our results, although it may be
attributed in part to the differences in the methodologies used.
The concentrations used in this study (up to 50 mM) revealed
the activatory effects of LL37 in platelets. A recent study reported
the inhibitory effects of LL37 in platelets at concentrations between
0.1 and 1.2 mM.28 These concentrations are not only substantially
greater than those achievable in pathological conditions, but also
exert cytotoxic effects in several cell types29 including platelets
(Figure 2E) at 100 mM. However, in severe psoriasis, a median
concentration of 304 mM LL37 in psoriatic lesions has been
reported,48 which can exert cytotoxicity towards platelets at the
local sites and reduce the number of functional platelets. During
pulmonary infection, a concentration of 5 mM LL37 has been
detected.50 Notably, the normal plasma concentration of LL37 in
healthy individuals is suggested to be ;1.2 mM,51 which did not
exert any effects on platelets. The LL37 concentrations used in
this study are similar to those achievable during pathological
conditions, such as sepsis,49 and early stages of psoriasis. Hence,
the LL37 inhibitory effects previously reported in platelets may
well be because of cytotoxicity, although additional causes cannot
be excluded. This perspective was also reflected in the recent
study by Pircher et al.21 Together with the previous reports, our
data demonstrate that LL37 induces platelet activation at the
early stages of inflammatory diseases resulting in the initiation
of thrombosis and modulation of hemostasis. However, at concen-
trations of 100 mM and above, LL37 may exert cytotoxicity, reducing
the number and function of circulating platelets, which can ultimately
lead to bleeding complications. Together with the modulation of
thrombosis and hemostasis, LL37 may also induce other platelet-
related complications (eg, thrombocytopenia and inflammation)
during various inflammatory diseases where its level is elevated.
Notably, the previous study21 has demonstrated the impact of
LL37 in the augmentation of platelet-neutrophil interactions, cytokine
release, release of extracellular nucleosomes, and reactive oxygen
species.
LL37 has been reported to act mainly through FPR2/ALX in other
cell types,16,24 although additional receptors such as Toll-like
receptors, receptor tyrosine kinases, ligand-gated ion channel,
CCR3, P2Y11, and P2X7 were shown to bind this peptide.52 To
investigate the underlying molecular mechanisms through which
LL37 modulates platelet function, the effects of LL37 in human
platelets treated with WRW4 and platelets obtained from Fpr2/32/2
mice were analyzed. LL37-mediated activation was largely re-
duced by WRW4 and in platelets obtained from Fpr2/32/2 mice,
confirming the functional dependence of LL37 primarily on FPR2/
ALX. LL37 binding assays confirmed the substantial reduction in
the binding of LL37 to Fpr2/32/2 platelet surface compared with
Fpr12/2 and control mouse platelets. Additionally, we were able








Gly-3 (N) Arg-26 (NH2) 2.76
Ser-9 (OG) Glu-89 (OE1) 3.12
Ser-9 (O) Glu-89 (OE2) 2.61
Lys-10 (N) Glu-89 (OE2) 2.81
Ser-9 (OG) Asn-171 (ND2) 3.00
Gln-22 (NE2) Ser-182 (N) 3.20
Gln-22 (OE1) Ser-182 (OG) 2.91
Gln-22 (NE2) Ser-182 (OG) 3.14
Gln-22 (NE2) Ser-182 (OG) 3.18
Glu-11 (OE2) Gly-275 (N) 3.23
Lys-8 (NZ) Lys-276 (O) 2.53
Arg-7 (NH1) Asn-285 (OD1) 3.08
Arg-7 (NE) Asn-285 (OD1) 3.29
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to demonstrate that FPR2/ALX inhibition in human platelets or
deletion of Fpr2/3 gene in mice lead to the elevation of cAMP
levels, which is a major inhibitory molecule for platelet activation.
This indicates the involvement of cAMP-dependent signaling
pathways in the regulation of FPR2/ALX in platelets. Nevertheless,
the activation of platelets by LL37 through receptors other than
FPRs cannot be excluded, and further investigations will be












































































































































































































































































































































































Figure 4. Positive feedback regulation of FPR2/ALX in platelets. The effects of different concentrations of WRW4 on CRP-XL– (0.25 mg/mL) (A) or ADP-induced
(2 mM) (B) human platelet aggregation was analyzed by optical aggregometry. (C) The level of adenosine triphosphate (ATP) secretion in human platelets (PRP) treated with
WRW4 prior to activation with CRP-XL (0.25 mg/mL) was measured by lumi-aggregometry. The levels of fibrinogen binding (i) and P-selectin exposure (ii) were analyzed in
platelets obtained from control or Fpr2/32/2 mice upon stimulation with various concentrations of CRP-XL (D), ADP (E), AY-NH2 (F), or U46691 (G) by flow cytometry. Data
represent mean 6 SEM (n 5 3). P values shown are as calculated by 2-way ANOVA followed by Bonferroni’s correction in most of the experiments except for the data shown
in panels A-C, which were analyzed by 1-way ANOVA followed by Bonferroni’s correction (*P , .05; **P , .01).
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modulation of platelet function upon ligation with LL37. In-
terestingly, the recent study21 has reported that LL37 is partially
acting through the GPVI signaling pathway in platelets, but it does
not have any impact on G protein-coupled receptor–mediated
signaling specifically via FPR1 and FPR2/ALX using a single
concentration of pharmacological inhibitors (Boc-MLF and
WRW4) for these receptors. However, in the present study, we
report the presence of FPR2/ALX (a G protein-coupled receptor)
and its role in the regulation of LL37-mediated effects in platelets
using a range of concentrations of these pharmacological
inhibitors and platelets obtained from Fpr2/32/2 mice in multiple
experiments.
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A
Figure 5. Impact of FPR2/ALX in platelet spreading, hemostasis, and cyclic adenosine monophosphate (cAMP)–mediated signaling. (A) Platelet adhesion and
spreading on fibrinogen-coated glass surface was analyzed in the absence and presence of WRW4 (1.25, 2.5, 5, and 20 mM) by confocal microscopy (magnification 360;
bar indicates 10 mm). The number of adhered (Ai) and spread (Aii) platelets and the relative surface area of spread platelets (Aiii) were determined by analyzing the images
using ImageJ. Ten random fields of view were recorded for each sample. Data represent mean 6 SEM (n 5 3). (B) The impact of FPR2/ALX in the modulation of hemostasis
was analyzed using tail bleeding assay in control or Fpr2/32/2 mice. Data represent mean 6 SEM (n 5 8 in each group). (C) The level of cAMP in human isolated platelets
in the presence or absence of WRW4 (i) and control and Fpr2/32/2 mouse platelets (ii) was analyzed using a cAMP assay kit. Data represent mean 6 SEM (n 5 4). (D)
The phosphorylation of VASP at Ser-157 was analyzed in the presence of WRW4 (i) and in platelets obtained from Fpr2/32/2 mice (ii) by immunoblot analysis using selective
antibodies. The blots are representative of 3 separate experiments. P values shown are as calculated by 1-way ANOVA followed by Bonferroni’s correction in most of
the experiments except for the data shown in panels B-C, where a nonparametric Mann-Whitney U test and a 2-tailed unpaired Student t test were used, respectively
(*P , .05; **P , .01; ***P , .001).
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In conclusion, we demonstrate that LL37 is stored in platelets and
secreted upon activation. Similar to a recent publication,21 we also
report that LL37 promotes thrombus formation. LL37 induced a
range of platelet function such as platelet aggregation, inside-out
signaling to integrin aIIbb3 and outside-in signaling, granule
secretion, calcium mobilization, and shortened tail bleeding time
in mice. These effects were diminished in the presence of an
FPR2/ALX pharmacological inhibitor and in platelets obtained
from Fpr2/32/2 mice confirming the functional dependence of
LL37 primarily via this receptor in platelets. Additionally, we
demonstrate an instrumental role for FPR2/ALX in the positive
feedback regulation of platelet function, in which the deficiency
or blockade of this receptor impaired hemostasis and the normal
activation of platelets. The significant roles of LL37 and FPR2/
ALX in the modulation of thrombosis and hemostasis renders
them potential candidates for the exacerbation of platelet-related
complications and immune responses in numerous inflammatory
diseases where platelets play critical roles. Notably, the pres-
ence of FPRs in platelets opens up new avenues to investigate
the involvement of a multiplicity of FPR ligands in the modulation
of thrombosis, hemostasis, and other platelet-related compli-
cations during inflammatory responses. Based on the data
presented in this study, both LL37 and FPRs can act as potential
therapeutic targets for cardiovascular and a range of inflamma-
tory diseases.
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